https://biospectrumindia.com/rssfeed/bio-med/medical%20tools%20%26%20device medical tools & device https://biospectrumindia.com/news/91/28623/alcon-unveils-clareon-panoptix-pro-in-india-to-expand-advanced-cataract-surgery-portfolio.html https://biospectrumindia.com/news/91/28623/alcon-unveils-clareon-panoptix-pro-in-india-to-expand-advanced-cataract-surgery-portfolio.html Thu, 08 Oct 2026 20:58:52 +0530 Alcon has announced the launch of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in India. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilisation of any trifocal IOL. PanOptix Pro provides an unprecedented 94% light utilisation, compared to a theoretical maximum utilisation of 96% for diffractive optics. These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate. PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix. “As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,” said Amar Vyas, Country Head, Alcon India. “Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world’s most implanted trifocal IOL.” PanOptix Pro will be available for use with the Clareon Monarch® IV delivery system. ]]> https://biospectrumindia.com/news/91/28508/bpl-medical-technologies-and-aiims-delhi-partner-to-take-forward-ai-powered-mammography-technology.html https://biospectrumindia.com/news/91/28508/bpl-medical-technologies-and-aiims-delhi-partner-to-take-forward-ai-powered-mammography-technology.html Fri, 18 Sep 2026 17:36:00 +0530 BPL Medical Technologies and the All India Institute of Medical Sciences (AIIMS), New Delhi, have formalised the technology transfer of an artificial intelligence (AI) powered mammography technology, with BPL set to further develop and upgrade the technology for mammography equipment. The ceremony was held at AIIMS Delhi bringing together senior leadership from both institutions to mark the transfer and outline the next stage of work on the technology. As part of the agreement, BPL Medical Technologies, in collaboration with AIIMS, will work on further development of the AI technology to be deployed within mammography equipment. The work will focus on strengthening the role of AI in breast imaging and developing the technology further for clinical use. The initiative brings together AIIMS Delhi’s academic research and inputs with BPL’s capabilities in medical equipment development and manufacture to take the technology across the country, especially tier 2 and tier 3 regions. The technology transfer ceremony took place in the presence of Prof. Nikhil Tandon, Director, AIIMS New Delhi, and Ajay Jindal, Chief Financial Officer (CFO), BPL Technologies.  Going forward, BPL Medical Technologies will focus on developing the mammography AI technology and working towards its integration with mammography equipment. The company will also continue to foster and encourage industry-academia collaborations that lead to increased productivity of clinicians and create access to medical innovations. ]]> https://biospectrumindia.com/news/91/28467/fujifilm-india-installs-echelon-smart-mri-at-jansons-health-in-erode.html https://biospectrumindia.com/news/91/28467/fujifilm-india-installs-echelon-smart-mri-at-jansons-health-in-erode.html Sat, 12 Sep 2026 11:46:21 +0530 Fujifilm India has installed and commissioned the Echelon Smart MRI at Jansons Health in Erode, a medical diagnostics institution established to provide pathology and diagnostic services of global standards. The installation expands access to advanced MRI services in the region and supports clinicians in delivering accurate, efficient diagnoses closer to patients. The installation reflects the growing adoption of advanced imaging technologies beyond major urban centres. Designed for image quality, patient comfort, ease of operation and efficient clinical workflows, the system supports neurological, musculoskeletal, spine, abdominal and other advanced MRI examinations. The deployment marks a significant milestone for Fujifilm as the company’s first MRI installation equipped with DLR technology. Powered by Deep Learning, DLR reduces image noise while enhancing sharpness and clarity, supporting high-quality imaging with shorter scan times. These capabilities help produce detailed images across a broad range of applications and support confident clinical evaluation and informed diagnostic decisions. The centre’s existing imaging capabilities are supported by the Fujifilm low-dose Supria 32 CT system, designed to deliver fast, high-throughput examination while maintaining high image quality with optimised radiation dose. With high-speed scanning, it supports detailed clinical evaluation across a broad range of routine clinical applications while enabling efficient workflow and high patient throughput.    The Echelon Smart MRI supports brain and neurological, spine, musculoskeletal, abdominal and pelvic, angiographic and whole-body examinations. This clinical breadth enables healthcare providers to address diverse diagnostic requirements on a single advanced MRI platform.   ]]> https://biospectrumindia.com/news/91/28470/photonence-announces-india-launch-of-korean-aesthetic-treatment-volformer.html https://biospectrumindia.com/news/91/28470/photonence-announces-india-launch-of-korean-aesthetic-treatment-volformer.html Sat, 12 Sep 2026 12:06:41 +0530 Photonence, the Indian distribution partner of South Korean medical aesthetics company Classys, has announced the launch of Volformer in India. The new treatment combines two Classys technologies, Volnewmer and Ultraformer, to tighten and lift the skin from within, helping it appear firmer, smoother, and more youthful. The launch comes as Korean aesthetic technology gains ground in India. More patients are seeking advanced, non-invasive skin treatments that were once available only through cosmetic surgery. Classys operates in more than 80 countries, and its established Indian partner, Photonence, distributes technologies including Volnewmer, Ultraformer MPT, Ultraformer 3, Curas Hybrid, and Aquapure. “We have seen this opportunity growing for some time,” said Ashish Jha, Co-Founder and Director of Photonence. “Demand for advanced skin-tightening and body-contouring treatments is growing in India. Patients want access to the same non-invasive technologies available in Korea, the US and other global markets. Volformer is one of the advanced treatments we are now bringing to India.” India’s aesthetic dermatology market is projected to reach $383.79 million by 2032, growing at a compound annual growth rate of 16.34% from 2025 to 2032. Photonence believes this growth creates a strong opportunity to introduce combination treatments such as Volformer across India. As global companies increase their focus on India’s growing medical-aesthetics market, Photonence is positioning itself as a key partner for bringing advanced Korean technologies to the country. Volformer treatment is priced at approximately Rs 2.5 lakh in India. ]]> https://biospectrumindia.com/news/91/28413/fujifilm-india-strengthens-therapeutic-endoscopy-portfolio.html https://biospectrumindia.com/news/91/28413/fujifilm-india-strengthens-therapeutic-endoscopy-portfolio.html Wed, 02 Sep 2026 17:03:15 +0530 Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026.    India is witnessing a growing burden of gastrointestinal diseases, including digestive disorders and gastrointestinal cancers, driving greater demand for early diagnosis and minimally invasive treatment options.As therapeutic endoscopy becomes increasingly important in modern gastroenterology, healthcare providers are looking for technologies that not only deliver high-quality imaging but also help perform complex procedures with greater precision, efficiency and confidence.   Responding to these evolving needs, the new addition strengthens Fujifilm India's therapeutic endoscopy offering by combining advanced imaging, improved maneuverability and clinician-friendly workflow features to support more accurate diagnosis and treatment during complex gastrointestinal procedures.At the centre of the launch are the latest generation therapeutic GI scopes including gastroscopes, colonoscopes, duodenoscopes and therapeutic gastroscopes for third space procedures, designed to help clinicians perform advanced therapeutic procedures with greater ease.   Equipped with high-sensitivity CMOS imaging, enhanced bending capability and a dedicated therapeutic instrument channel, the new gastroscopes provide better access to difficult-to-reach areas while offering improved control during procedures. The slim therapeutic model further enables physicians to work comfortably in narrower anatomical spaces without compromising on therapeutic capability. Together, these innovations are designed to support more precise treatment while improving procedural efficiency.The therapeutic gastroscopes complement the ELUXEO 8000 Endoscopy System, which combines 4K-ready imaging with Fujifilm's latest image enhancement technologies to deliver brighter, sharper images and improved visualisation during both diagnosis and treatment. The system also introduces Amber-red Color Imaging (ACI), a new observation mode that helps clinicians identify subtle colour differences associated with blood, supporting greater confidence during therapeutic procedures.   Along with seamless compatibility across Fujifilm's endoscopy portfolio and an integrated workflow designed for busy endoscopy suites, the platform enables healthcare providers to perform procedures more efficiently while maintaining high standards of patient care. ]]> https://biospectrumindia.com/news/91/28357/luxid-enters-indias-hospital-technology-market-with-launch-of-vuear-glass.html https://biospectrumindia.com/news/91/28357/luxid-enters-indias-hospital-technology-market-with-launch-of-vuear-glass.html Sat, 22 Aug 2026 12:58:23 +0530 Bengaluru-based startup Luxid Tech has launched its VueAR Glass in India, marking the company’s entry into the country’s hospital technology market with an augmented-reality solution designed to improve patient counselling and support nursing workflows. The launch comes as Indian hospitals increasingly look for technology that can improve patient experience while helping healthcare professionals manage time and workload more efficiently. VueAR Glass focuses on two areas where technology can potentially make a practical difference — explaining complex medical procedures to patients and improving access to relevant information for nursing teams. Pre-surgery counselling requires doctors and healthcare professionals to explain procedures, treatment steps and recovery expectations to patients and their families. When robotic surgery is involved, explaining the technology can make the process even more detailed. VueAR Glass enables hospitals to create customised three-dimensional visual modules for different surgical procedures. Patients can use the glasses to view a visual representation of their procedure, understand the different stages of treatment and explore relevant anatomy from multiple perspectives. The second application of VueAR Glass is focused on nursing workflows, particularly in intensive care units (ICUs), where continuous monitoring of patients is essential. Weighing approximately 78 grams, VueAR Glass is designed to be lightweight for patient counselling and professional use. The device supports three-dimensional content and can connect with digital systems. Its VueAR software development kit (SDK) allows hospitals and technology partners to create customised counselling modules and data views based on specific procedures, departments and workflows. ]]> https://biospectrumindia.com/news/91/28308/kshipra-health-solutions-unveils-l3tx-red-light-therapy-cap-to-support-evidence-based-hair-restoration.html https://biospectrumindia.com/news/91/28308/kshipra-health-solutions-unveils-l3tx-red-light-therapy-cap-to-support-evidence-based-hair-restoration.html Fri, 14 Aug 2026 17:07:18 +0530 As hair loss concerns intensify among both men and women, people are increasingly seeking science-backed treatment options. Addressing this need, Mumbai-based Kshipra Health Solutions LLP has introduced L3Tx, a medical-grade LED Red Light Therapy Cap that supports hair regrowth while controlling intense hair fall by relying on clinically studied Low-Level Light Therapy (LLLT), also known as photobiomodulation. A brainchild of Kirtesh Jain and Utpal Limkar, Kshipra Health Solutions is envisioning making evidence-based, non-invasive hair restoration increasingly accessible by combining scientific innovation and patient-friendly technology, easing their use at home under a dermatologist’s guidance.  Using 120 medical-grade LEDs, the L3Tx Red Light Therapy Cap emits red light at a controlled wavelength of nearly 640 nm. The light energy treatment stimulates cellular activity within hair follicles. Relying on photobiomodulation, the therapy helps increase ATP (cellular energy) production, improves scalp circulation, reduces oxidative stress, and supports the natural hair growth cycle. Instead of replacing treatments suggested by dermatologists, L3Tx complements them given its wide-scale adaptability to therapies including Minoxidil, Finasteride, Platelet-Rich Plasma (PRP) and Growth Factor Concentrate (GFC). The L3Tx device is US FDA cleared and houses medical-grade LED technology supporting long-term use under professional guidance. Kshipra Health Solutions is working with dermatologists and hair restoration specialists to raise awareness around hair health, early diagnosis, and evidence-based treatments. Through education and innovation, the company aims to empower individuals to make informed decisions while advancing a more scientific approach to hair restoration. ]]> https://biospectrumindia.com/news/91/28261/depuy-synthes-to-establish-global-capability-centre-in-bengaluru.html https://biospectrumindia.com/news/91/28261/depuy-synthes-to-establish-global-capability-centre-in-bengaluru.html Fri, 07 Aug 2026 21:19:09 +0530 Johnson & Johnson's DePuy Synthes, a global leader in orthopaedics, has announced plans to establish a new Global Capability Centre (GCC) in Bengaluru. The centre will serve as a global engine for innovation, engineering, and enterprise services. The GCC will bring together technology, data, and business capabilities to advance clinical innovation and operational excellence for patients, surgeons, and healthcare partners around the world. DePuy Synthes is working to establish the centre which will host disciplines including software development, data & AI, enterprise applications, technology services, cybersecurity and more upon launch. "India is one of the fastest-growing markets in the world for orthopaedic care, and this investment deepens our long-term commitment to patients, surgeons, and colleagues here, " said Namal Nawana, Worldwide President, DePuy Synthes. Over the next 18–24 months, DePuy Synthes expects to build a team of approximately 500 professionals in Bengaluru, with room to grow as the centre matures. The centre will be led by Nicholas Parrotta, Chief Information Officer, DePuy Synthes, with support from experienced technology leaders who will support the planning, establishment and future operations of the centre, including: Jai Ganesh, Chief Technology Officer, DePuy Synthes will provide leadership for technology engineering, architecture, infrastructure, cybersecurity engineering, and digital platforms for DePuy Synthes. Nagaraj Bhat, GCC Leader, DePuy Synthes, will assist in the establishment of local operations and its leadership team. The centre is expected to be established in phases, with initial operational activities, including recruitment beginning in August 2026. ]]> https://biospectrumindia.com/news/91/28249/time-medical-international-ventures-announces-partnership-for-installation-of-inter-op-mri-suite.html https://biospectrumindia.com/news/91/28249/time-medical-international-ventures-announces-partnership-for-installation-of-inter-op-mri-suite.html Mon, 03 Aug 2026 17:14:05 +0530 Time Medical International Ventures (India), a wholly owned subsidiary of Fischer Medical Ventures and a global leader in advanced medical imaging solutions, has entered into a partnership with Parul Sevashram Hospital, Vadodara, to install its revolutionary DRIS–iMRI Medharanya Suite, an AI-enabled next-generation portable intraoperative MRI system. Time Medical has developed a revolutionary new variant of MRI imaging technology — DRIS–iMRI Medharanya, an AI-enabled, next-generation, portable and specialised MRI system integrating Augmented Reality (AR), Artificial Intelligence (AI), Machine Learning (ML), and Exoscope technologies. The intraoperative MRI platform is designed to transform intraoperative imaging by providing surgeons with real-time visualisation during complex neurosurgical procedures, enabling unprecedented precision, safety, and surgical control in procedures that traditionally rely on limited visual feedback. Time Medical International Ventures has entered into a partnership to install its first Modern Brain Suite: the DRIS–iMRI Medharanya system at Parul Sevashram Hospital, Vadodara. Through this upcoming partnership, the DRIS–iMRI Medharanya Suite is expected to strengthen the university's academic and clinical ecosystem, giving medical students, residents, and faculty at Parul University hands-on exposure to next-generation neurosurgical imaging technology. ]]> https://biospectrumindia.com/news/91/28160/optrascan-receives-us-fda-510k-clearance-for-digital-pathology-system.html https://biospectrumindia.com/news/91/28160/optrascan-receives-us-fda-510k-clearance-for-digital-pathology-system.html Mon, 20 Jul 2026 17:43:44 +0530 OptraSCAN, Inc., a California-headquartered digital pathology and image analysis company in which Molbio Diagnostics acquired a majority stake in 2025, has received US Food and Drug Administration (FDA) 510(k) clearance (K260755) for the OptraSCAN System. The clearance covers the integrated OptraSCAN System comprising the OS-Ultra Whole Slide Scanner, a color display monitor, and a workstation running the company’s ImagePath Image Management Software, including HER2 Image Analysis Software. Together, the system supports pathologists in the review and assessment of HER2 expression in clinical practice. HER2 assessment plays a critical role in breast cancer characterisation and therapeutic decision-making. As pathology laboratories worldwide continue to transition towards digitised workflows, image analysis technologies are increasingly adopted to support standardisation, reproducibility, and efficiency in pathology review processes. Commenting on the significance of the development for the global pathology community, Dr Reena Nakra, Chief Scientific Officer, Dr Lal PathLabs, said, “Digital pathology is becoming an increasingly important part of modern pathology. We have had the opportunity to work with OptraSCAN and regulatory milestones such as US FDA clearance provide additional confidence in the quality of its digital pathology platform and the clinical robustness of this technology. This milestone is an encouraging step forward for the continued adoption of digital pathology.” ]]> https://biospectrumindia.com/news/91/28086/low-rd-spending-constrains-medtech-innovation-in-india-exim-bank-study.html https://biospectrumindia.com/news/91/28086/low-rd-spending-constrains-medtech-innovation-in-india-exim-bank-study.html Wed, 08 Jul 2026 23:05:54 +0530 India’s medical devices industry stands at a critical juncture. While the country has made significant strides in manufacturing and exports, achieving technological self-reliance will require a shift from low-value production to innovation-led growth. Key findings from the Exim Bank Study, “Building Technological Capabilities in India’s Medical Devices Industry,” are as follows: Domestic manufacturing is gaining momentum- Production of medical and dental instruments more than doubled from Rs 162.6 billion in 2019–20 to Rs 348.7 billion in 2023–24 (21.0% CAGR), while production of irradiation, electromedical, and electrotherapeutic equipment rose from Rs 70.8 billion to Rs 113.9 billion (12.6% CAGR). Exports are growing but not reducing import dependence- Medical device exports increased from $4.7 billion in 2019 to $6.9 billion in 2024 (8.1% CAGR), outpacing global growth (7.7%). However, the trade deficit widened from $2.9 billion to $4.9 billion, reflecting continued reliance on imports. Technology gap remains the core challenge- Exports are concentrated in low- and medium-technology segments such as consumables (37.2%) and PPE (29.8%), while imports are dominated by medium-tech instruments and high-tech equipment. Low R&D spending further constrains innovation. Global market presence remains limited- India accounts for only ~1% of high-technology exports, 1.3% in low-tech, and 0.7% in medium-tech segments, indicating significant untapped potential. High-potential product opportunities identified- The study highlights 11 Product Champions ($1.4 billion India exports vs. $45 billion global market) where India has export competitiveness and exhibits strong global demand and 68 Underachievers ($3.7 billion vs. $576 billion globally), indicating substantial scope to expand exports in high-demand segments. Strategic roadmap aligned with National Medical Policy 2023- In line with the National Medical Devices Policy 2023 target of achieving a 10–12% global market share by 2047, the study outlines measures to build a technology-driven, high-value manufacturing ecosystem. Key policy recommendations include strengthening domestic production of critical components; improving MSME access to finance; scaling public–private R&D partnerships; upgrading testing and certification infrastructure; developing specialized medical devices clusters and med-tech parks; deepening industry–academia collaboration. Market expansion opportunities exist in high-growth markets such as Mexico, Brazil, Canada, Russia, Vietnam, Hong Kong, Saudi Arabia, and Singapore,  leveraging recently signed FTAs with Australia, UK, EU, EFTA, New Zealand, UAE, Oman among others, alongside digital and AI-driven innovation in product and services. ]]> https://biospectrumindia.com/news/91/27965/medtronic-introduces-breakthrough-pulseselect-cardiac-technology-in-india.html https://biospectrumindia.com/news/91/27965/medtronic-introduces-breakthrough-pulseselect-cardiac-technology-in-india.html Mon, 15 Jun 2026 16:06:26 +0530 Medtronic, a global leader in healthcare technology, has announced the launch of the PulseSelect™ system in India. The PulseSelect™ is a Pulsed Field Ablation (PFA) system designed to treat atrial fibrillation (AF), one of the most common heart rhythm disorders and a leading risk factor for stroke. Affecting over 7 million of the general population, its prevalence markedly increases with age. While AF affects millions of people in India, awareness, diagnosis, and treatment rates remain relatively low. Many patients experience intermittent or mild symptoms that often go unrecognized, leading to delayed diagnosis and treatment. Medtronic’s PulseSelect™ PFA system expands the company’s established atrial fibrillation portfolio, complementing its proven cryoablation technologies that are widely used around the world. Together, these therapies provide physicians with a comprehensive set of treatment options, enabling them to tailor care based on patient needs and procedural considerations while building on Medtronic’s long-standing clinical experience in AF management. Unlike traditional treatments such as radiofrequency ablation (which uses heat) or cryoablation (which uses extreme cold), pulsed field ablation uses short electrical pulses instead of thermal energy. Because it does not rely on heat or freezing, it is designed to reduce the risk of damage to nearby tissues. The procedure can also be performed relatively quickly, which may help lower the risk of complications and support a smoother recovery after treatment . The safety and effectiveness of this technology have been demonstrated in Investigational Device Exemption (IDE) clinical trials. Cryoablation remains a proven and effective therapy, while the introduction of the PulseSelect™ PFA system reflects Medtronic’s continued commitment to advancing innovative technologies that expand treatment options for physicians and the patients they serve. ]]> https://biospectrumindia.com/news/91/27923/biorad-medisys-unveils-quantino-20w-laser-system-for-kidney-stones-management.html https://biospectrumindia.com/news/91/27923/biorad-medisys-unveils-quantino-20w-laser-system-for-kidney-stones-management.html Tue, 09 Jun 2026 10:58:06 +0530 Pune-based medtech firm Biorad Medisys announced the launch of Quantino 20W Thulium Fiber Laser for kidney stone management at UROLITHOCON 2026, the annual conference of the Urolithiasis Section of the Urological Society of India (USI), recently held in Bengaluru. The launch comes at a time when kidney stone disease is emerging as a growing health concern across India. Studies suggest that nearly 12% of the Indian population is likely to develop kidney stones during their lifetime. The Quantino 20W Thulium Fiber Laser has been developed to support these evolving clinical needs. The compact system is designed for stone fragmentation procedures and expands Biorad Medisys' existing Quantino portfolio, which includes 40W and 75W platforms. Integrated with the company's Smart OR (Operation Room) ecosystem, the solution combines laser technology with visualisation, irrigation, suction and workflow management capabilities, helping clinicians perform stone procedures more efficiently while optimising operating room resources. Its compact footprint and lower power requirements make it particularly relevant for hospitals and urology centres looking to strengthen their stone management capabilities without significant infrastructure additions. ]]> https://biospectrumindia.com/news/91/27930/fujifilm-india-announces-first-installation-of-ai-powered-digital-mammography-system-at-nm-medical.html https://biospectrumindia.com/news/91/27930/fujifilm-india-announces-first-installation-of-ai-powered-digital-mammography-system-at-nm-medical.html Tue, 09 Jun 2026 22:19:45 +0530 Fujifilm India, a leader in advanced diagnostic imaging solutions, has announced the installation of its latest AI Powered Digital Mammography System, AMULET SOPHINITY at NM Medical, Mmbai. India’s healthcare ecosystem is witnessing a growing emphasis on preventive healthcare and early disease detection, particularly in women’s health. According to estimates from the Indian Council of Medical Research, National Cancer Registry Programme, breast cancer is projected to remain the leading cancer among women in India, with over 2.32 lakh cases estimated in 2025.   As timely screening continues to play a critical role in enabling early diagnosis and improving clinical outcomes, rising awareness, expanding access to diagnostic services, and increasing adoption of advanced imaging technologies are further accelerating the need for clinically reliable, patient-friendly, and workflow-efficient mammography solutions across healthcare institutions in the country.Designed with a strong focus on patient comfort, diagnostic precision, and workflow efficiency, AMULET SOPHINITY represents Fujifilm’s next-generation mammography platform built around the philosophy of “Sophisticated Features. Human Comfort.”   The system integrates advanced AI-enabled technologies, high-definition imaging capabilities, and ergonomically designed patient-centric features to support radiologists and technologists in delivering accurate, efficient, and comfortable breast imaging experiences.Further strengthening workflow efficiency and positioning accuracy, the system integrates Fujifilm’s REiLI Medical AI technologies, including Intelligent AEC for optimised dose management based on breast composition, Positioning MAP for reproducible positioning support, and AI-driven Positioning Analysis tools that assist technologists in continuously improving imaging quality and consistency.The AMULET SOPHINITY platform also features a compact, space-saving footprint through integrated system architecture, enabling easier deployment across high-throughput hospitals, diagnostic centres, and space-constrained imaging environments. Its streamlined workflow design, user-friendly operation console, and rapid quality control tools further support operational efficiency and reliable clinical performance. ]]> https://biospectrumindia.com/news/91/27901/bpl-medical-technologies-unveils-new-icu-ventilator-to-strengthen-critical-care-capabilities-in-hospitals.html https://biospectrumindia.com/news/91/27901/bpl-medical-technologies-unveils-new-icu-ventilator-to-strengthen-critical-care-capabilities-in-hospitals.html Wed, 03 Jun 2026 13:57:10 +0530 BPL Medical Technologies, India’s leading medical equipment brand with a 50-year legacy under the BPL Group, has announced the launch of the BPL Vent 300, a new ICU ventilator developed to support critical care teams with advanced respiratory management across adult, paediatric, and infant patients. The launch comes at a time when hospitals across India are continuing to invest in stronger ICU preparedness, patient monitoring, and dependable respiratory support systems. Designed for use in Intensive Care Units (ICUs), High Dependency Units (HDUs), emergency rooms, recovery centres, and step-down ICUs, the BPL Vent 300 combines advanced ventilation capabilities with a compact, clinician-friendly design. The ventilator features a high-performance turbine capable of delivering up to 240 L/min peak flow, enabling operation independent of central gas supply. It also comes equipped with a 12.1-inch full-touch display, lightweight build of nearly 9 kg, and supports invasive, non-invasive, and High Flow Nasal Cannula (HFNC) ventilation modes for adult, paediatric, and infant patients. The ventilator further integrates clinical support tools including lung protection and weaning assessment parameters such as P0.1, NIF, and RSBI, along with dynamic lung monitoring, lung recruitment manoeuvre support, PV Tool tracing, integrated nebulization, and auto leakage compensation during NIV therapy. To support hospital connectivity and uninterrupted care, the BPL Vent 300 offers WiFi, 4G, wired networking, HL7 protocol compatibility, USB data export, HDMI, RS232, nurse call interfaces, and an inbuilt lithium battery providing up to two hours of backup support during power interruptions. A 360-degree visual alarm system has also been incorporated to improve alarm visibility in busy ICU settings.   ]]> https://biospectrumindia.com/news/91/27844/us-based-medtech-firm-align-technology-to-open-multi-million-dollar-manufacturing-facility-in-hyderabad.html https://biospectrumindia.com/news/91/27844/us-based-medtech-firm-align-technology-to-open-multi-million-dollar-manufacturing-facility-in-hyderabad.html Mon, 25 May 2026 13:51:26 +0530 US-based Align Technology, Inc, a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, has announced plans to open a new manufacturing facility in Hyderabad, in 2027, create more than 300 direct jobs, and spend approximately $200 million in both capital and operational expense over the next several years. This new facility reflects Align’s strategy to get closer to customers and scale its operations to support high-growth markets like India, while strengthening its supply chain resilience and operational efficiency to drive shareholder value. Align’s Hyderabad manufacturing facility will complement Align’s existing footprint in Hyderabad, which includes its Global Capability Centre, the Align Innovation Centre, further reinforcing the city’s strategic importance within Align’s global operations network. It would mark the company’s first manufacturing presence in India and its fourth globally. The proposed facility is expected to commence operations in 2027 and be margin accretive in the first year. ]]> https://biospectrumindia.com/news/91/27788/abbott-introduces-first-of-its-kind-device-to-repair-leaky-tricuspid-valve-in-india.html https://biospectrumindia.com/news/91/27788/abbott-introduces-first-of-its-kind-device-to-repair-leaky-tricuspid-valve-in-india.html Mon, 11 May 2026 13:47:50 +0530 Abbott, a global healthcare leader, has announced the launch of the TriClip™ transcatheter edge-to-edge repair (TEER) system in India. This device is specifically designed for the treatment of tricuspid regurgitation (TR) or a leaky tricuspid valve. Delivered through a vein in the leg, TriClip's TEER technology works by clipping together a portion of the leaflets – or flaps of tissue – to repair the tricuspid valve and help blood flow in the right direction without the need for open-heart surgery. It leverages the technology and robust body of evidence from the MitraClip device, the minimally invasive option to repair leaky mitral valves, which occurs on the left (opposite) side of the heart. The TriClip has a specialised delivery system engineered for navigating the right side of the heart. On average, people who receive TriClip only need one day in the hospital before they recover and can return home. The tricuspid valve controls blood flow from the heart’s right atrium to the right ventricle. TR occurs when the valve doesn’t close properly, causing a leak and allowing the blood to flow backward in the heart. TR can force the heart to work harder, causing debilitating symptoms such as fatigue and shortness of breath. When left untreated, TR can lead to atrial fibrillation (irregular heartbeat) and heart failure. For those who continue to have symptoms or persistent TR despite treatment with medical therapy and are not considered good candidates for surgery, TriClip represents an option that can improve a person’s quality of life and reduce hospitalisations for heart failure. TR is increasingly being recognised as a common but under‑diagnosed heart valve condition in India, particularly among older adults and people with rheumatic heart disease, atrial fibrillation, pulmonary hypertension, or other valve disorders. Published reviews and echocardiography‑based data indicate that clinically significant TR is frequently seen in routine cardiac practice and often progresses over time when left untreated, highlighting the need to address this disease in India. ]]> https://biospectrumindia.com/news/91/27732/stryker-announces-launch-of-trident-ii-acetabular-system-in-india-for-hip-replacement-.html https://biospectrumindia.com/news/91/27732/stryker-announces-launch-of-trident-ii-acetabular-system-in-india-for-hip-replacement-.html Mon, 27 Apr 2026 00:00:00 +0530 Stryker, a global leader in medical technologies, has announced the launch of the Trident II Acetabular System in India. This advanced hip replacement solution is designed to support surgeons in addressing critical clinical challenges in total hip arthroplasty (THA), providing greater precision, improved stability and increased confidence.  Recognised as the most implanted acetabular shell in the Australian Orthopaedic Association National Joint Replacement Registry for 20 consecutive years. The Trident II system builds on the legacy that has defined Stryker’s Trident brand for more than two decades, paired with the latest additive manufactured Tritanium In-Growth Technology or PureFix HA. “Hip replacement surgeries are rising globally due to ageing populations and rising incidence of osteoarthritis and mobility-related disorders. With the launch of the Trident II Acetabular System, we reinforce our commitment to bringing clinically proven, innovation-led solutions to surgeons and their patients,” said Aman Rishi, Vice President & General Manager, India, Stryker. “By combining advanced materials, data-backed design and robotic-arm assisted capabilities, Trident II represents a significant step forward in hip replacement solutions.” Trident II is compatible with Mako SmartRobotics™ and designed to support a wide range of patient anatomies and surgical approaches. The Innerchange Locking Mechanism provides surgeons with intraoperative flexibility, including the use of Modular Dual Mobility constructs to improve joint stability and reduce dislocation risk. The system also incorporates Stryker’s X3 highly crosslinked polyethylene, developed using a patented sequential crosslinking process that enhances wear resistance and oxidation stability, contributing to long-term implant performance. ]]> https://biospectrumindia.com/news/91/27708/medtronic-launches-adaptive-deep-brain-stimulation-system-for-parkinsons-patients-in-india.html https://biospectrumindia.com/news/91/27708/medtronic-launches-adaptive-deep-brain-stimulation-system-for-parkinsons-patients-in-india.html Thu, 23 Apr 2026 00:00:00 +0530 Medtronic, a global leader in healthcare technology, has announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional DBS, in India to further improve quality of life of patients living with Parkinson’s disease. The prevalence of Parkinson's disease (PD) in India is roughly 10% of the global burden, which is a considerable public health concern. Treatment options like Deep Brain Stimulation exist which involve manual adjustment of stimulation levels throughout the day, usually managed by patients or caregivers. Medtronic’s aDBS technology is designed to adapt real time to changes in a patient’s condition or medication needs—helping deliver more consistent symptom management. The aDBS system uses BrainSense™ technology, which has been approved by the US Food and Drug Administration (FDA). Adaptive deep brain stimulation (aDBS) is designed to automatically adjust therapy based on changes in brain signals or patient activity. By responding in real time, it aims to provide more consistent symptom control, minimize side effects, and help extend the life of the implanted device’s battery. With India expected to witness a significant rise in Parkinson’s disease cases—projected to become the second-highest globally within the next five years—the introduction of the aDBS system comes at a critical time. Although there is currently no cure for conditions such as Parkinson’s disease, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson’s and other neurological disorders for more than three decades.  DBS uses a small, pacemaker-like device, placed under the skin of the chest, to send electronic signals to an area in the brain that controls movement.   ]]> https://biospectrumindia.com/news/91/27654/nihon-kohden-brings-globally-deployed-life-scope-e7-patient-monitor-to-india.html https://biospectrumindia.com/news/91/27654/nihon-kohden-brings-globally-deployed-life-scope-e7-patient-monitor-to-india.html Mon, 13 Apr 2026 00:00:00 +0530 Nihon Kohden India Private Limited, a wholly-owned subsidiary of Japan's Nihon Kohden Corporation, one of the world's largest manufacturers of medical electronic equipment, has announced the Indian launch of the Life Scope E7 (BSM-5700 series). An advanced multi-parameter patient monitoring system designed for use across critical care, emergency, operating room, and general ward settings.   The BSM-5700 series received Import License clearance from the Central Drugs Standard Control Organisation (CDSCO) in February 2026, marking the product's formal regulatory approval for the Indian market. The official India launch is scheduled for April 16, 2026. The BSM-5700 series is available in two display configurations. A 15.6-inch and a 12.1-inch high-resolution LCD touchscreen, allowing hospitals to deploy the appropriate variant based on ward and clinical setting requirements.   The system stores up to 120 hours of continuous patient trend data, full waveform disclosure for up to five parameters simultaneously, and up to 40,960 alarm history records, providing clinical teams with comprehensive retrospective data for patient review and audit. The Life Scope E7 is already deployed across hospitals in Europe, North America, South America, the Middle East, Southeast Asia and Africa. Its introduction in India represents the product's first entry into the South Asian market.   The Life Scope E7 is engineered to support patient monitoring across five key clinical environments: the Intensive Care Unit (ICU), Neonatal ICU (NICU), Emergency Room (ER), Operating Room (OR), and General Ward. The system integrates monitoring of ECG, SpO2, blood pressure (both non-invasive and invasive), body temperature, CO2, anaesthetic gases, and brain activity parameters including EEG and amplitude-integrated EEG (aEEG), eliminating the need for multiple standalone devices across different departments.   The platform incorporates several proprietary Nihon Kohden measurement technologies including cap-ONE, an ultra-compact mainstream CO2 sensor validated for both intubated and non-intubated patients. iNIBP, an algorithm that measures non-invasive blood pressure during cuff inflation for faster and less disruptive readings. PWTT (Pulse Wave Transit Time) triggers NIBP, which automatically initiates blood pressure measurement when a sudden pressure change is detected. SynECi18, which generates right ventricular and posterior wall data from a standard 12-lead ECG without any additional procedure or electrodes.   A distinguishing feature of the platform is its Human Machine Interface (HMI) design philosophy. The principle that the accuracy and usability of a monitoring system are only as strong as the technology connecting the patient to the device. Nihon Kohden develops its sensor technology, signal processing systems, and measurement modules in-house, rather than outsourcing them a manufacturing approach the company says ensures consistent signal accuracy and long-term product reliability.   The system also supports integration with third-party anaesthesia machines and ventilators, and connects to hospital Electronic Medical Record (EMR) systems using the HL7 data exchange protocol. The Life Scope E7 also employs certificate-based Net-9 encryption for all networked device communications, ensuring patient data transmitted across hospital networks meets current cybersecurity standards. ]]> https://biospectrumindia.com/news/91/27622/siemens-healthineers-announces-expansion-of-manufacturing-footprint-in-india.html https://biospectrumindia.com/news/91/27622/siemens-healthineers-announces-expansion-of-manufacturing-footprint-in-india.html Tue, 07 Apr 2026 00:00:00 +0530 Siemens Healthineers has announced the expansion of manufacturing footprint in India with the local production of the Artis one Edition X angiography system at company’s Bengaluru factory. The system will be manufactured alongside the facility’s existing portfolio of mobile C-arms, CT scanners, MRI systems, and digital radiography X-ray systems, further strengthening the company’s commitment to the Make in India initiative and to advancing access to innovative healthcare technologies across the country. With its advanced capabilities, Artis One Edition X empowers clinicians with enhanced imaging and workflow efficiency while supporting improved patient outcomes. It helps interventionalists perform procedures that restore blood flow and treat blockages in arteries and veins, thereby benefitting patients with conditions such as heart disease, kidney failure, and irregular heart rhythms. Additionally, India's cath lab density currently stands at just 1.5 to 1.75 per million people, underscoring the urgent need for accessible cardiac care infrastructure. This growing demand is evident in the widespread adoption of angiography systems across metropolitan hubs and tier 2/3 cities. Designed as a compact, low-maintenance, and versatile solution, Artis One Edition X enables healthcare providers to treat a greater number of patients efficiently while maintaining high clinical standards. The universal angiography system combines flexibility with advanced imaging features, making it the need of the hour for hospitals and healthcare providers looking to expand their interventional capabilities. ]]> https://biospectrumindia.com/news/91/27479/johnson-johnson-launches-new-tecnis-odyssey-next-gen-intraocular-lens-in-india.html https://biospectrumindia.com/news/91/27479/johnson-johnson-launches-new-tecnis-odyssey-next-gen-intraocular-lens-in-india.html Fri, 13 Mar 2026 00:00:00 +0530 Johnson & Johnson is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of TECNIS Odyssey IOL in India. The new full visual range IOL offers high-quality and continuous vision with unmatched range. This will allow patients to see clearly from far to near and in between, minimising their need for glasses. Built on the industry-leading TECNIS platform, combining advanced optics and proprietary materials, TECNIS Odyssey IOL offers consistently clear, high-contrast vision. TECNIS Odyssey is engineered for surgeon confidence as Freeform diffractive profile contributes to enhanced tolerance to residual refractive errors. 94% of patients were satisfied with their overall vision without glasses. Freeform diffractive profile contributes to a low incidence of bothersome visual disturbances. 93% of patients either did not report any visual disturbances. TECNIS Odyssey delivers superior low light contrast. 92% satisfaction with ability to see steps and curbs at night. With a variety of options for different visual needs and lifestyles, the TECNIS platform empowers more patients to find the right solution. This year marks the 25th anniversary of TECNIS innovation at Johnson & Johnson. “The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence. Its introduction in India expands access to advanced IOL technology designed to deliver high-quality, continuous vision across distances. Together with TECNIS PureSee, TECNIS Odyssey IOL elevates the strength and depth of our IOL portfolio, helping us meet the diverse needs of today’s aging population,” said Burzin Shahana, Country Manager, Surgical Vision India & South Asia, Johnson & Johnson. ]]> https://biospectrumindia.com/news/91/27473/zydus-expands-companion-diagnostics-portfolio-with-launch-of-ai-powered-continuous-glucose-monitor.html https://biospectrumindia.com/news/91/27473/zydus-expands-companion-diagnostics-portfolio-with-launch-of-ai-powered-continuous-glucose-monitor.html Thu, 12 Mar 2026 00:00:00 +0530 Zydus Lifesciences has announced its new offering companion diagnostics portfolio. The company will be launching DiasensTM and GlucoLiveTM, next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence-powered insights, and integrated remote care capabilities. The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real time. Zydus has partnered with Digicare Health Solutions (TatvaCareTM), a healthcare technology company to help the patients gain access to its proprietary, integrated care ecosystem GoodFlipTM to provide AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab booking, and a comprehensive medical record vault - all in a single mobile application.  Despite this burden, most glucose monitoring in India remains episodic - limited to periodic finger-prick tests or laboratory HbA1c checks every three to six months. Existing CGM devices in the Indian market predominantly rely on NFC technology, requiring patients to manually scan the sensor to retrieve readings. This creates gaps in data continuity, delays clinical intervention, and places the burden of vigilance entirely on the patient. DiasensTM and GlucoLiveTM will enable automatic streaming of glucose readings to the patient’s smartphone every three minutes - without manual scanning - ensuring uninterrupted capture, including overnight reading and in emergencies. Through TatvaCareTM’s GoodFlipTM app, AI analytics will detect trends, flags hypo-/hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights. A clinician dashboard will support remote monitoring, early intervention, and data-driven treatment adjustments.   ]]> https://biospectrumindia.com/news/91/27462/abbott-introduces-its-most-advanced-drug-eluting-stent-xience-skypoint-in-india.html https://biospectrumindia.com/news/91/27462/abbott-introduces-its-most-advanced-drug-eluting-stent-xience-skypoint-in-india.html Tue, 10 Mar 2026 00:00:00 +0530 Abbott, the global healthcare company, has announced the launch of XIENCE Skypoint in India. This is Abbott’s most advanced generation stent within the globally trusted XIENCE™ family of everolimus (drug)-eluting coronary stents (DES). The stent is designed to be more flexible, easier to guide through the heart’s arteries, including large vessels, and better suited for treating complex heart blockages. Tushar Sharma, general manager for Abbott’s vascular business in India and South Asia said, “The launch of XIENCE Skypoint in India represents an advancement for doctors treating cardiovascular disease, which remains a leading cause of mortality in India. Many patients today develop severe blockages earlier in life due to rising hypertension, diabetes, cholesterol, and lifestyle risks. This makes it essential to support doctors with stents that can safely reach difficult areas and treat a wide range of blockages. XIENCE Skypoint brings improvements with precision and strengthens our commitment to providing advanced heart treatments across the country.” Abbott has introduced newer generations of XIENCE, with the goal of providing physicians with access to the latest DES technology. With this launch, XIENCE Skypoint brings the broadest size matrix ever offered by the XIENCE family, supporting the treatment of long lesions while helping reduce the number of stents required per procedure. The platform also introduces 4.5 mm and 5.0 mm diameters, making it the only DES indicated for vessels up to 5.25 mm. This is especially important because real‑world patients at times have bigger or more varied artery sizes that need the right fit.      ]]> https://biospectrumindia.com/news/91/27431/aig-hospitals-unveils-south-indias-first-zap-x-gyroscopic-neuro-radiosurgery-platform.html https://biospectrumindia.com/news/91/27431/aig-hospitals-unveils-south-indias-first-zap-x-gyroscopic-neuro-radiosurgery-platform.html Fri, 06 Mar 2026 00:00:00 +0530 Hyderabad-based AIG Hospitals has announced the launch of the ZAP-X® Gyroscopic Neuro-Radiosurgery® Platform, the first installation of its kind in South India and only the second in the country, marking a major advancement in the treatment of brain tumours and complex neurological disorders. Designed exclusively for intracranial radiosurgery, ZAP-X enables doctors to treat brain lesions with extreme precision that too without open surgery, without incisions, and as a day-care procedure. The system delivers highly focused radiation beams with sub-millimeter accuracy, targeting tumors and abnormal tissues while sparing healthy brain structures. For patients, this means a completely non-invasive treatment that is painless, requires no hospital stay, and allows them to return to normal life quickly. Stereotactic radiosurgery has emerged globally as a safer alternative for carefully selected cases, and the introduction of ZAP-X at AIG Hospitals brings one of the world’s most advanced neuro-radiosurgical technologies to patients across South India.  One of the areas where ZAP-X is expected to make a particularly significant impact is in the treatment of brain metastases, tumours that spread to the brain from cancers elsewhere in the body, most commonly from the lung, breast, or melanoma. Prof. John R. Adler, renowned neurosurgeon, inventor of CyberKnife® and ZAP-X®, and one of the world’s foremost pioneers in radiosurgery, emphasised the broader potential of the technology adding “Radiosurgery has evolved tremendously over the past three decades, and ZAP-X represents the next generation of this field. While brain tumors remain a primary indication, the precision of this technology also opens up exciting possibilities in the treatment of functional neurological conditions such as trigeminal neuralgia, movement disorders, and now we are seeing trials to treat depression as well. The goal has always been to treat disease with surgical accuracy but without the invasiveness of traditional surgery. It is gratifying to see institutions like AIG Hospitals bringing this level of innovation to patients in India.”   ]]> https://biospectrumindia.com/news/91/27415/fujifilm-inaugurates-endoscopy-manufacturing-in-jodhpur.html https://biospectrumindia.com/news/91/27415/fujifilm-inaugurates-endoscopy-manufacturing-in-jodhpur.html Fri, 27 Feb 2026 00:00:00 +0530 Fujifilm India, a leader in advanced diagnostic imaging solutions, has announced the inauguration of endoscopy manufacturing in Jodhpur, Rajasthan. This marks an important milestone in the company’s endoscopy journey in India and reaffirms its commitment to the Government of India’s Make in India initiative.The Chief Guest at the inauguration was Gajendra Singh Shekhawat, Union Minister, Ministry of Culture and Tourism, Government of India, and Gajendra Singh Khimsar, Cabinet Minister, Ministry of Medical, Health & Family Welfare, Government of Rajasthan, joined as the Guest of Honour. Haruto Iwata, Managing Director, Fujifilm Asia Pacific and Koji Wada, Managing Director, Fujifilm India, along with various dignitaries from the healthcare fraternity and government institutions graced the occasion.The initiative is aligned with Fujifilm’s globally benchmarked Japanese quality and localisation standards, integrating advanced production processes, robust quality systems, and precision-driven practices.Under the national localisation framework, the initiative will support local manufacturing of advanced endoscopy systems designed to address the growing need for improved diagnostic accuracy and smoother endoscopic examinations. These systems are equipped with LED light sources that precisely control multi-coloured LED illumination, combined with advanced image processing technologies to deliver clearer and more clinically relevant images tailored to different diagnostic requirements. Key features include Blue Light Imaging (BLI), which enhances the visualisation of fine blood vessels and microstructures of the mucosal surface, and Linked Color Imaging (LCI), which emphasises subtle colour differences, particularly in red regions of the image, supporting physicians during endoscopic examinations.Fujifilm plans to consider progressively expanding the scope of Made in India offerings to support neighbouring markets, reinforcing India’s role as an emerging regional manufacturing and supply base within Fujifilm’s global healthcare network. ]]> https://biospectrumindia.com/news/91/27379/nit-rourkelas-stopbleed-receives-cdsco-approval-as-class-c-medical-device.html https://biospectrumindia.com/news/91/27379/nit-rourkelas-stopbleed-receives-cdsco-approval-as-class-c-medical-device.html Tue, 24 Feb 2026 00:00:00 +0530 In its effort to bring innovations from the lab to the real world, National Institute of Technology Rourkela (NIT Rourkela) spined out Startup Miraqules MedSolutions has received regulatory approval for commercial manufacturing and clinical deployment of its patented technology, a rapid nano-biopolymer hemostat, to transform emergency hemorrhage control. StopBleed®, the technology developed at NIT Rourkela, has received approval from the Central Drugs Standard Control Organisation (CDSCO) as a Class C medical device, marking a significant step in translating academic research into real-life-saving medical technology. The product facilitates for rapid control of severe bleeding arising from road accidents, gunshot wounds, blast injuries, industrial accidents, deep stab wounds, and other critical or life-threatening trauma situations. The developed innovation is an advanced bleeding control solution available in powder and pellet forms, designed to be used in trauma situations such as road accidents, military injuries, and emergency first-aid situations. With a shelf life of three years (at room temperature), it can be easily used by medical professionals and non-medical first-aid responders, making it suitable for emergency cases, which could lead to saving lives. Developed using nanofibrous aggregate technology, the product rapidly absorbs blood plasma while trapping blood cells within a high-surface-area fibrous mesh. This helps in accelerating the body’s natural clotting mechanisms and forms a strong hydrogel seal at the wound. This technology was originally patented by the Institute and developed in the Department of Biotechnology and Medical Engineering by Professor Devendra Verma and his research graduate, Sabir Hussain. Subsequently, the technology was transferred to the startup Miraqules MedSolutions, led by Hussain, for manufacturing, distribution, and field deployment.   ]]> https://biospectrumindia.com/news/91/27377/aiims-bhubaneswar-becomes-first-govt-institution-in-odisha-equipped-with-comprehensive-robotic-surgery-programme.html https://biospectrumindia.com/news/91/27377/aiims-bhubaneswar-becomes-first-govt-institution-in-odisha-equipped-with-comprehensive-robotic-surgery-programme.html Mon, 23 Feb 2026 00:00:00 +0530 Bringing about a paradigm shift in the healthcare landscape of Odisha and Eastern India, All India Institute of Medical Sciences (AIIMS) Bhubaneswar has successfully established a comprehensive liver transplant programme and commissioned a state-of-the-art surgical robotic system. Union Minister for Health and Family Welfare Jagat Prakash Nadda virtually inaugurated the Liver Transplant Unit and formally launched the Advanced Robotic Surgery System at the Institute. Aparajita Sarangi, Member of Parliament, Odisha and Punya Salila Srivastava, Union Health Secretary were also present on the occasion. The Institute has established a state-of-the-art Liver Transplant Operation Theatre and an advanced Intensive Care Unit equipped with modern medical technology. It has also set up a dedicated Liver Transplant Specialist Clinic for systematic follow-up and continuous post-transplant care. Referring to the commissioning of the Surgical Robotic System, the Union Minister said that AIIMS Bhubaneswar has become the first Government Medical Institute of Odisha to launch a comprehensive robotic surgery programme and this is a significant step towards innovation in public sector healthcare. The robotic surgery programme will initially cover urology, gynaecology, paediatric surgery and other specialties and will improve the accuracy of surgery, reduce bleeding, and reduce length of hospital stay. ]]> https://biospectrumindia.com/news/91/27359/hana-health-by-dss-imagetech-to-bring-world-first-automated-egg-freezing-technology-to-india.html https://biospectrumindia.com/news/91/27359/hana-health-by-dss-imagetech-to-bring-world-first-automated-egg-freezing-technology-to-india.html Thu, 19 Feb 2026 00:00:00 +0530 For the first time in India, couples seeking In Vitro Fertilisation (IVF) treatment for conception can rely on a globally preferred, automated egg-freezing technology to enable a successful pregnancy and the healthy birth of their child. Hana Health by DSS Imagetech, a market leader in Molecular Diagnostics, Life Sciences, and Biotechnology, has exclusively partnered with US-based Overture Life, a leading developer of automated IVF technologies and the first company to achieve live births from both robotic fertilization and robotic egg freezing, to bring to India their pioneering automated egg-freezing technology — DaVitri. Overture Life is the first company to achieve live births from both robotic fertilization and robotic egg freezing. The DaVitri platform is the first to receive regulatory clearance from major authorities in the US, UK and Europe that enables fertility clinics to standardise egg-freezing, one of the most technically demanding steps in IVF. This collaboration introduces automated vitrification platform, DaVitri, into routine clinical use in India, enabling clinics to standardise one of IVF’s most technically demanding steps, expand procedural capacity, and support embryologists amid the country’s rapidly growing fertility demand. In clinical evaluations, DaVitri has demonstrated measurable improvements in post-thaw embryo development compared with manual methods, while enabling small and large centralised laboratories to process significantly more procedures without increasing staffing. By reducing infrastructure requirements from millions of dollars to a fraction of that cost, it enables smaller clinics and satellite locations to offer advanced services that were previously out of reach. ]]> https://biospectrumindia.com/news/91/27288/shukra-pharma-receives-rs-600-cr-facility-from-yeida-to-advance-surgical-robotics-cancer-therapy.html https://biospectrumindia.com/news/91/27288/shukra-pharma-receives-rs-600-cr-facility-from-yeida-to-advance-surgical-robotics-cancer-therapy.html Thu, 05 Feb 2026 00:00:00 +0530 Shukra Pharmaceuticals has received a letter of intent from the Yamuna Expressway Industrial Development Authority (YEIDA) for 10 acres of land in the Medical Device Park, Sector 28, Greater Noida, with a planned investment of approximately Rs 600 crore. The facility will produce advanced surgical robotics and Boron Neutron Capture Therapy (BNCT) technology, an innovative treatment for complex cancer cases. The project is expected to generate over 900 direct and approximately 2,000 indirect employment opportunities, positioning India at the forefront of health innovation. Shukra Pharmaceuticals has also signed a Memorandum of Understanding (MoU) with Borns Medical Robotics Inc. to bring cutting-edge surgical robotics technology to India. The partnership, formalised at an event in New Delhi, will introduce the Veer Surgical Robot; an artificial intelligence (AI)-driven surgical platform designed to enhance precision, safety, and patient outcomes while making advanced healthcare technology accessible to millions of Indians.   The partnership will establish manufacturing and distribution capabilities in India, creating a robust ecosystem for robotic surgery. The collaboration aims to train surgeons, build infrastructure, and expand access to minimally invasive surgical options across tier-2 and tier-3 cities, where advanced healthcare technology has traditionally been limited. The first-ever human clinical trial of the Veer Surgical Robot evaluated its safety and efficacy across basic to advanced procedures, with results demonstrating excellent safety, precision, and clinical outcomes, establishing it as a reliable surgical platform. The findings from the trial have been published in leading international journals and reported to the CDSCO. The Veer Surgical Robot is expected to be deployed across leading hospitals beginning in Q2 2026, with plans to scale rapidly across the country. ]]> https://biospectrumindia.com/news/91/27279/forus-health-secures-cdsco-approval-for-ai-led-diabetic-retinopathy-screening-tool-.html https://biospectrumindia.com/news/91/27279/forus-health-secures-cdsco-approval-for-ai-led-diabetic-retinopathy-screening-tool-.html Wed, 04 Feb 2026 00:00:00 +0530 Bengaluru-based medtech firm Forus Health has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for its FH-POISE™ DRT (Diabetic Retinopathy Tools). FH-POISE™ (Precision Ocular Intelligence for Systemic & Eye Health) is Forus Health’s AI-powered retinal image analysis platform designed to support the detection and screening of ocular and systemic diseases using state-of-the-art algorithms. The approval enables FH-POISE™ DRT to be used as a screening tool to identify patients at risk of diabetic retinopathy, supporting earlier clinical evaluation and timely intervention to help prevent diabetes-related vision loss. The software uses deep learning models to assess retinal images and predict disease severity, allowing for more nuanced and clinically relevant screening outcomes. It has received CDSCO approval as Class C SaMD (Software as a Medical Device), one of the most stringent risk categories, with the approach validated on real-world retinal images, spanning a diverse demography, demonstrating suitability for real-world healthcare settings. India carries one of the world’s largest diabetes burdens. According to the International Diabetes Federation, approximately 89.8 million adults in India were living with diabetes in 2024, placing sustained pressure on the healthcare system.  “India’s challenge with diabetic retinopathy is not awareness alone, but scale,” said Chandrasekhar K., Founder and CEO, Forus Health, “Embedding reliable screening into routine diabetes care is essential if we are to prevent avoidable vision loss. Regulatory approval for FH-POISE™DRT enables technology-focussed screening closer to where patients already receive care, helping strengthen early detection while making better use of limited specialist capacity.” The broader economic impact of vision impairment further underscores the importance of early detection. Peer-reviewed studies estimate that vision impairment and blindness in India result in productivity losses exceeding Rs 11,000 crore annually, highlighting the societal cost of delayed diagnosis and treatment. With CDSCO approval in place, Forus Health plans to deploy FH-POISE™ DRT across hospitals, public health initiatives, and screening programs, aligned with India’s focus on preventive healthcare and digital health–enabled early diagnosis.   ]]> https://biospectrumindia.com/news/91/27258/wipro-ge-healthcare-unveils-made-in-india-ai-powered-breakthrough-in-mr-imaging.html https://biospectrumindia.com/news/91/27258/wipro-ge-healthcare-unveils-made-in-india-ai-powered-breakthrough-in-mr-imaging.html Sat, 31 Jan 2026 00:00:00 +0530 Wipro GE Healthcare, a leading global medical technology, diagnostics, and digital solutions innovator, has announced the launch of SIGNA™ Prime Elite, its latest MR imaging system, at the Indian Radiological and Imaging Association (IRIA) 2026 Annual Conference in Hyderabad.  Manufactured at Wipro GE Healthcare’s MDM facility - the company’s PLI factory, SIGNA™ Prime Elite is the latest addition to its pioneering ‘Made in India’ portfolio. The MR system combines advanced imaging intelligence with patient-centric design to deliver faster, more comfortable scans and improved diagnostic confidence. Compared to non-deep learning GE HealthCare scanners, SIGNA™ Prime Elite achieves up to 37% reduction in table time, enabling quicker throughput. AI-enabled workflow solutions further streamline MR exams, with AIR Touch™ automatically selecting optimal coil combinations, while AIR x™ applies ‘deep learning’ to detect anatomy and prescribe MRI slices — even in complex neurological and knee cases. Together, these tools eliminate sources of variation, improve reproducibility, and allow clinicians to focus on patients. Additionally, the MR system’s blanket‑like AIR™ Coils allow natural positioning and shorten preparation time, while a flared bore entrance with feet-first scanning adds clearance and headspace, easing exams for claustrophobic patients. Its compact footprint and lower 60 KVA power consumption make installation easier, enabling hospitals and diagnostic centers beyond major metros to offer advanced MR imaging and expand access to care. Additionally, with Intelligent Magnet Technology reducing helium use by up to 75%, the solution supports more sustainable operations while redefining the future of MR imaging. ]]> https://biospectrumindia.com/news/91/27250/amtz-expands-additive-manufacturing-coe-to-boost-indias-medtech-sector.html https://biospectrumindia.com/news/91/27250/amtz-expands-additive-manufacturing-coe-to-boost-indias-medtech-sector.html Thu, 29 Jan 2026 00:00:00 +0530 Strengthening India’s journey towards self-reliance in medical device manufacturing, the Advanced Additive Manufacturing Centre of Excellence (CoE) at Andhra Pradesh MedTech Zone (AMTZ) is set to expand its advanced manufacturing capabilities across plastics, metals and silicone-based medical components. The expansion builds on the Centre’s proven success in polymer and metal additive manufacturing, CNC precision machining and pilot-scale production, positioning AMTZ as a key enabler of high-precision, export-ready MedTech manufacturing in the country. To date, the facility has worked with over 20 startups and more than 35 industry partners, providing end-to-end support ranging from industrial design and rapid prototyping to machining, post-processing and low-volume production. Commenting on this integrated approach, Dr Jitendra Sharma, Founder CEO and Managing Director, Andhra Pradesh Medtech Zone said, “By combining additive manufacturing with precision machining, injection-moulded plastics, silicone component manufacturing, and advanced post-processing capabilities, the Centre of Excellence at AMTZ has created a strong platform for indigenous, scalable, and globally competitive medical device component production. This integrated model reduces import dependence, shortens manufacturing cycles, and accelerates innovation and commercialisation for the MedTech sector.” Aligned with national initiatives such as Make in India and Atmanirbhar Bharat, the Centre of Excellence is playing a pivotal role in strengthening domestic manufacturing while supporting export-oriented production. Its shared-access model lowers entry barriers for innovators and manufacturers, enabling them to leverage world-class facilities without heavy capital investment, while simultaneously addressing quality, scale and compliance requirements demanded by global markets. The Centre enabled the development of a manufacturing process for ultra-high molecular weight polyethylene (UHMWPE), a critical material used in joint replacements and orthopedic implants. This effort helped Nanoshel break a global supply duopoly and provide a domestic alternative, significantly reducing India’s dependence on imports estimated at nearly Rs 2,000 crore. Looking ahead, AMTZ plans to increase collaborations beyond current industry partners and continue building a skilled workforce in advanced manufacturing technologies. With this expansion, the Centre of Excellence is poised to play a defining role in positioning India as a global hub for medical device component manufacturing.   ]]> https://biospectrumindia.com/news/91/27228/lubrizol-plans-expansion-of-medical-device-manufacturing-capabilities-in-chennai.html https://biospectrumindia.com/news/91/27228/lubrizol-plans-expansion-of-medical-device-manufacturing-capabilities-in-chennai.html Tue, 27 Jan 2026 00:00:00 +0530 As part of its global expansion, Lubrizol, a Berkshire Hathaway company, is introducing new contract manufacturing capabilities in India, including a state-of-the-art medical manufacturing site in Chennai, Tamil Nadu, scheduled to open mid-2026. This new facility in Chennai, Tamil Nadu, will produce high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other devices for minimally invasive procedures. Leveraging Lubrizol’s advanced medical-grade thermoplastic polyurethane (TPU) and other biocompatible engineered polymers, the tubing produced is intended for minimally invasive device technologies, supporting applications in electrostimulation, cardiovascular, neurovascular, and beyond. Key capabilities include single and multi-lumen precision extrusion of TPU, Nylon, Pebax® and other engineered thermoplastics, tri layer tubing, balloon tubing, as well as braiding. “We are strengthening our presence in India with strategic investments in local manufacturing, R&D, and technical capabilities,” said Mittal Shah, Business Head at Lubrizol. “These investments address our customers’ need for biocompatible, high-performance materials and advanced solutions that enable medical device innovation in India and globally.” ]]> https://biospectrumindia.com/news/91/27098/iit-kharagpur-partners-with-intuitive-foundation-to-explore-use-of-ai-enabled-surgical-models.html https://biospectrumindia.com/news/91/27098/iit-kharagpur-partners-with-intuitive-foundation-to-explore-use-of-ai-enabled-surgical-models.html Sun, 21 Dec 2025 00:00:00 +0530 Indian Institute of Technology (IIT) Kharagpur has announced a new research programme in partnership with Intuitive Foundation, a non-profit organisation funded by Intuitive Surgical, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. The initiative aims to develop comprehensive digital models of surgical care that can underpin more reliable safety guidance, AI-enabled decision support, and responsible early-stage automation in future robotic-assisted procedures. Over time, these advancements are expected to help surgeons work with greater confidence and consistency, supporting better patient outcomes through more standardised and predictable surgical processes. To test these models, IIT Kharagpur will use the da Vinci Research Kit (dVRK), a non-clinical research platform built from retired da Vinci systems. The dVRK links digital models to physical robotic movements, enabling the development and testing of early automation modules using phantoms, synthetic tissues, and anatomical models. All testing will take place in controlled laboratory settings and will not involve human surgery. The work is guided by a multidisciplinary research team and supported by IIT Kharagpur’s long-standing collaboration with Nil Ratan Sircar Medical College and Hospital in Kolkata. By closely documenting cholecystectomy procedures (the surgical removal of the gallbladder) in real clinical settings, the researchers will gain practical insight into how surgeries unfold, helping them refine the digital models and identify where supportive tools could have the greatest impact.  The programme is expected to deliver two major outcomes. The first is a complete digital footprint of the surgical pathway, enabling AI-driven systems that combine diagnostic details, planned scenarios, intra-operative context, and recovery data to highlight safer techniques, flag deviations, and trace the sources of complications. The second is the responsible introduction of selective automation. Once the mapped workflows identify steps that are simpler, safer, and more repeatable, targeted automation modules can support surgeons during routine tasks and help them focus on higher-level decision-making. ]]> https://biospectrumindia.com/news/91/27067/aster-dm-healthcare-invests-rs-120-cr-to-establish-five-advanced-oncology-radiation-linac-centres-across-india.html https://biospectrumindia.com/news/91/27067/aster-dm-healthcare-invests-rs-120-cr-to-establish-five-advanced-oncology-radiation-linac-centres-across-india.html Mon, 15 Dec 2025 00:00:00 +0530 Aster DM Healthcare, one of the largest integrated healthcare providers in India, has announced a major CSR initiative with Rs 120 crore investment to establish five advanced Oncology Radiation LINAC Centres across India, dedicated to supporting underprivileged cancer patients. The first centre will be established in Wayanad, Kerala catering to the wider Malabar region, including neighbouring areas such as Gudalore and Gudalpet. The remaining centres will be developed in strategic locations including Bengaluru and other cities over the next three years, based on community needs and clinical feasibility. The programme aims to provide free and subsidised high-quality radiation therapy to cancer patients from economically weaker sections who are unable to afford or continue life-saving treatment. A few key highlights of the initiative include a fully equipped modern centre with linear accelerators and allied facilities. The treatment will be provided completely free or at highly subsidized rates for patients with low income or those who fall under the below poverty line. Priority will be given to patients who have discontinued therapy due to financial constraints. The centres will be part of Aster Volunteers; the flagship global CSR programme of Aster DM Healthcare focused on community health improvement and socio-economic development. ]]> https://biospectrumindia.com/news/91/27027/vtitan-launches-ai-powered-cardiac-monitor-vcardio.html https://biospectrumindia.com/news/91/27027/vtitan-launches-ai-powered-cardiac-monitor-vcardio.html Thu, 04 Dec 2025 00:00:00 +0530 vTitan Corporation, a MedTech company focused on innovative healthcare solutions, has announced the launch of vCardio, a single-lead, wearable point-of-care cardiac monitor. The device is entirely designed and manufactured in India, making vTitan one of the first companies in the country to deliver an end-to-end solution from hardware to cloud-based AI analytics in the health-tech space. vCardio has been engineered to provide smart, continuous monitoring for early detection of cardiac events and vigilant post-surgery care. With this launch, the company aims to make point-of-care services more accessible for patients and clinics. “The cardiac monitoring market faces a critical gap," said Prasad Maganti, CEO, vTitan. "There is an unmet need for point-of-care cardiac screening at ambulatory clinics, for continuous monitoring in pre-and-post-surgical step-down environments, and for prolonged home-based monitoring in cardiac risk patients. When we built vCardio, an edge-AI-enabled cardiac monitor, from ground up keeping clinical work flows in mind, , our aim was to meet this market need, and make cardiac care safer, smarter, and more accessible.” vCardio is a lightweight, compact point-of-care cardiac monitor designed for remote patient monitoring in homecare, geriatric care, and clinical settings. With Bluetooth connectivity, the device integrates seamlessly with the vCardio mobile app and software platform. Its lightweight construction ensures patient comfort during extended wear periods, supporting continuous monitoring throughout post-care recovery. The device employs AI-powered algorithms to detect and classify over 20 clinically significant cardiac arrhythmias in real-time as well as in the post-recording analysis of cardiac data over the course of a week. With clinically-validated accuracy, and beat-to-beat analysis, vCardio empowers healthcare professionals with faster, more precise rhythm insights, enhancing diagnostic confidence, streamlining clinical workflows, and improving patient outcomes.   ]]> https://biospectrumindia.com/news/91/27023/biomoneta-receives-us-fda-approval-for-air-decontamination-medical-device.html https://biospectrumindia.com/news/91/27023/biomoneta-receives-us-fda-approval-for-air-decontamination-medical-device.html Tue, 02 Dec 2025 00:00:00 +0530 Biomoneta, a Bengaluru-based healthtech company building advanced air-decontamination technologies, has announced that its flagship product Avata Rx, powered by its proprietary ZeBox® microbicidal technology, has received approval from the United States Food and Drug Administration (US FDA), marking the first time an Indian company has achieved FDA clearance in the air-decontamination category. Biomoneta enters the global arena at a time when the clean-air and infection-prevention sector is undergoing rapid transformation, with a combined global TAM spanning Healthcare Facilities ($15–20 billion), Consumer/Residential Air Purifiers ($17–20 billion), Commercial & Industrial HVAC Clean-Air systems ($50–60 billion), HVAC OEM clean-air modules ($20–30 billion), and Transportation IAQ solutions ($8–12 billion), and its FDA approval now positions the company to access regulated markets that require clinically validated air-decontamination technologies, unlocking significant global pathways for adoption. Avata Rx, powered by ZeBox®, delivers broad-spectrum microbicidal action that inactivates airborne bacteria (including multidrug-resistant strains), viruses, fungi, hardy spores, and even Mycobacterium tuberculosis, one of the most difficult airborne pathogens to eliminate and, having been independently validated across multiple testing environments, including a Department of Biotechnology–funded IISc study that demonstrated its ability to destroy over 10 million airborne SARS-CoV-2 viral particles within 5 minutes, it now stands as one of the most scientifically validated air-decontamination technologies globally. ]]> https://biospectrumindia.com/news/91/26970/samsung-launches-r20-ultrasound-system-in-india-by-redefining-general-imaging-with-next-gen-ai.html https://biospectrumindia.com/news/91/26970/samsung-launches-r20-ultrasound-system-in-india-by-redefining-general-imaging-with-next-gen-ai.html Mon, 24 Nov 2025 00:00:00 +0530 Samsung, India’s largest consumer electronics brand, has announced the launch of its super-premium, next-generation R20 ultrasound system for general imaging.   The R20 represents a major leap forward in general imaging, combining advanced artificial intelligence tools, superior image clarity, and an ergonomic design focused on clinician comfort and efficiency.   Built on Samsung’s state-of-the-art Crystal Architecture™, the R20 delivers exceptional image uniformity, resolution, and penetration across a wide range of general imaging applications. Its next-generation imaging engine, powerful GPU, and ultra-high-definition OLED monitor provide clinicians with remarkable visualization and diagnostic confidence in every scan.   The R20 is equipped with a comprehensive suite of AI-powered clinical and workflow enhancement tools that streamline complex procedures and automate repetitive tasks. Key technologies include:   Live LiverAssist – Detects a suspicious focal lesion during live ultrasound scan Live BreastAssist – Real-time detection of Breast lesions with BIRADS Classification and reporting. Auto measurement tools – AI-based automatic detection, measurement of internal structures with guided reporting for high consistency and maximum throughput Deep USFF – AI Based Deep Ultrasound Fat Fraction quantification with proven high correlation to the gold standard, i.e., MRI PDFF   “The R20 embodies Samsung’s commitment to advancing healthcare through intelligent innovation. With AI at its core and a focus on both image excellence and clinician comfort, the R20 is a paradigm shift in ultrasound technology helping doctors ensure detection of lesions during live scanning,” said Atantra Das Gupta, Head of HME Business, Samsung India.   ]]> https://biospectrumindia.com/news/91/26940/bpl-medical-technologies-partners-with-alpinion-to-introduce-x-cube-50-ultrasound-system-in-india.html https://biospectrumindia.com/news/91/26940/bpl-medical-technologies-partners-with-alpinion-to-introduce-x-cube-50-ultrasound-system-in-india.html Tue, 18 Nov 2025 00:00:00 +0530 Bengaluru-based BPL Medical Technologies has partnered with Korea's ALPINION Medical Systems to bring the X CUBE 50 from Korea to the Indian Market. This new-generation ultrasound imaging system sets higher standards for diagnostic precision and workflow efficiency in Indian healthcare settings. In routine diagnostic practice, clinicians often struggle with uneven image quality, repeated manual adjustments and fatigue from managing heavy patient loads, which can slow down procedures and affect the consistency of results. To overcome these limitations, the X CUBE 50 is built on ALPINION’s X+ Architecture. It brings together refined beamforming, high-sensitivity transducer technology, and advanced image optimization to deliver uniform, high-contrast images that support accurate and confident diagnoses across a range of clinical needs. By simplifying frequent tasks and minimizing operator effort, the system helps doctors work faster and more efficiently, even in demanding clinical settings. With the launch of the X CUBE 50, BPL Medical Technologies strengthens its commitment to providing advanced, reliable, and accessible diagnostic solutions that enhance clinical outcomes and support the evolving needs of healthcare professionals across India. Engineered for speed, comfort, and accuracy, the X CUBE 50 features a compact ergonomic design, a 21.5 inch Full HD monitor, and a 12.1 inch intuitive touchscreen for smooth operation and clear visibility from multiple angles. Intelligent workflow tools such as X+ Assistant, Power Preset, and Xpeed streamline routine scanning and reduce examination time, while automated measurements like Auto Biometry, Auto IMT, and Auto EF deliver consistent and reproducible results. This joint venture, utilizing an integrated imaging technology platform developed by ALPINION and supported by BPL's reliable network of services and local experience, introduces a highly customisable, high-quality, and affordable ultrasound solution for medical practitioners in India, thereby enhancing BPL's mission to deliver quality diagnostics and patient-based care.     ]]> https://biospectrumindia.com/news/91/26874/motorica-introduces-worlds-first-bionic-hand-prosthesis-powered-by-optical-sensors.html https://biospectrumindia.com/news/91/26874/motorica-introduces-worlds-first-bionic-hand-prosthesis-powered-by-optical-sensors.html Mon, 03 Nov 2025 00:00:00 +0530 Motorica, a global MedTech company specialising in assistive technologies and medical cybernetics, has unveiled Omni Hand, world’s first bionic hand prosthesis equipped with optical myography (OMG) sensors. The launch marks a major leap forward in human–technology interaction and intuitive prosthetic control. Moving beyond the limitations of traditional muscle-signal prosthetics, the Omni Hand leverages optical sensors to capture minute changes in tissue light transmittance caused by the movement of muscles and tendons. By interpreting these subtle variations in real time, the prosthesis translates even the smallest impulses into natural, precise motion. This breakthrough extends the benefits of advanced prosthetics to individuals with limited muscle activity, such as those recovering from electrical injuries, frostbite, or trauma, making intuitive and responsive control accessible to a wider spectrum of users. While optical sensing in prosthetics has long remained within the realm of research, Cyber Motorica has become the first company to translate this breakthrough into real-world use. The successful pilot rollout, with the first eight users already integrating Omni Hand into their daily lives, marks a significant step forward in practical adoption and user experience. With mass production planned for 2026, the company is poised to make advanced, intuitive prosthetic control accessible to users on a global scale. In 2025, Motorica opened its first office in New Delhi. In India, it already collaborates closely with over 25 clinics across key states, including Delhi NCR, Maharashtra, Karnataka, Uttar Pradesh, Tamil Nadu, as well as in several other regions nationwide. ]]> https://biospectrumindia.com/news/91/26806/medtronic-launches-avalus-ultra-surgical-valves-in-india.html https://biospectrumindia.com/news/91/26806/medtronic-launches-avalus-ultra-surgical-valves-in-india.html Tue, 14 Oct 2025 00:00:00 +0530 Medtronic plc has launched the Avalus Ultra™ Bioprosthesis valve, its next-generation surgical aortic heart valve, in India. Innovating on the strong foundation of the Avalus™ platform with 10 years of clinical experience, the Avalus Ultra valve was specifically designed to offer ease of use at implant and provides a durable circular foundation and reliable performance for future transcatheter aortic valve in surgical aortic valves (TAV-in-SAV) reinterventions to support patient lifetime management.   The low profile Avalus Ultra valve is designed to accommodate diverse patient anatomies. It offers a flexible sewing cuff for secure seating with minimal paravalvular leak (PVL) rates and replica sizers with simulated cuffs for precise sizing.  For valve-in-valve procedures, the platinum-iridium coil and tantalum badge enhance fluoroscopic visibility, supporting accurate placement and secure positioning within the anatomy during reinterventions. For patients undergoing heart valve surgery, the Avalus Ultra valve offers excellent durability with good clinical outcomes. The AOA tissue treatment technology is used across a suite of Medtronic valves to help drive durable valve replacements, encompassing over half a million patients for over 30 years. Backed by clinical studies, this innovation brings hope for a healthier future to thousands of Indian patients. Commenting on the launch, Prateek Tiwari, Senior Director, Neuroscience and Specialty Therapies at Medtronic India, said "The Avalus Ultra valve is designed to simplify implantation, enhance reliability, and provide clinicians with a solution that supports consistent, long-term outcomes for their patients. Every feature reflects Medtronic’s commitment to advancing cardiac care, equipping surgeons with precise and dependable tools, and helping them deliver care that is tailored to each patient’s needs. Our aim is to support clinicians at every step of the surgical journey to deliver on our Medtronic Mission to alleviate pain, restore health, and extend life.” ]]> https://biospectrumindia.com/news/91/26775/terumo-india-expands-interventional-cardiology-portfolio-with-launch-of-finecross-m3.html https://biospectrumindia.com/news/91/26775/terumo-india-expands-interventional-cardiology-portfolio-with-launch-of-finecross-m3.html Tue, 07 Oct 2025 00:00:00 +0530 Terumo India, the Indian arm of Japan's Terumo Corporation, has announced the launch of FineCross™ M3 Coronary Micro-Guide Catheter in India. The latest-generation catheter raises the bar for percutaneous coronary intervention (PCI), offering cardiologists enhanced crossing ability, guidewire support, and navigability in complex lesions that often hamper procedural success. With coronary artery disease (CAD) continuing to be the leading cause of death in India, and a rising proportion of patients presenting with complex lesions it highlights the urgent need for advanced interventional tools.  Addressing this challenge, FineCross™ M3 equips cardiologists to perform more efficient, predictable, and safer procedures, enhancing both clinical outcomes and procedural confidence. Commenting on the launch Shishir Agarwal, President and Managing Director, Terumo India said, “Innovation at Terumo India is always guided by enabling physicians to deliver the best possible care to patients. With the launch of FineCross™ M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects not only our commitment to strengthening cardiovascular care in the country, but also Our Promise "Unwavering commitment to patients” that lies at the heart of everything we do.” FineCross™ M3 integrates Terumo’s legacy of engineering excellence with new design enhancements that address real-world challenges in percutaneous coronary intervention (PCI). Adding perspective on the product’s clinical relevance, Nitin Stephen Abel, Senior Director, Terumo Interventional Systems, Terumo India said, “FineCross™ M3 represents more than just a product launch, it reflects our continued focus on advancing cardiovascular care in India in line with Terumo’s mission of contributing to society through healthcare. Through globally trusted innovations, we aim to empower physicians in delivering better patient outcomes and create a meaningful impact where it matters most.” The launch of FineCross™ M3 adds to Terumo India’s growing portfolio of advanced interventional solutions, further strengthening its role in shaping the future of cardiovascular care in the country. ]]> https://biospectrumindia.com/news/91/26773/abbott-launches-worlds-first-dual-chamber-leadless-pacemaker-system-in-india.html https://biospectrumindia.com/news/91/26773/abbott-launches-worlds-first-dual-chamber-leadless-pacemaker-system-in-india.html Mon, 06 Oct 2025 00:00:00 +0530 Abbott, a global healthcare company, has announced the launch of AVEIR™ dual chamber (DR) leadless pacemaker system - the first of its kind in the world. This tiny high-tech device helps the heart beat properly – without wires (leads) or surgical pockets used in traditional pacemakers. Until recently, leadless pacemakers could only support one chamber of the heart, because getting two separate devices to work together in sync was a major challenge. Abbott has changed that with its breakthrough implant-to-implant (i2i) technology. This innovation allows two tiny leadless pacemakers—one in the upper chamber (right atrium) and one in the lower chamber (right ventricle)—to communicate with each other in real time, beat by beat. For the first time, patients can benefit from true dual chamber leadless pacing, helping the heart beat more normally and synchronously—without the need for wires. The AVEIR DR leadless pacemaker system includes two tiny devices - AVEIR VR, which helps control the heartbeat in the lower chamber (right ventricle), and AVEIR AR, which supports the upper chamber (right atrium). Each of the two leadless pacemakers is roughly about one-tenth the size of a traditional pacemaker. Once implanted and paired, these devices communicate with each other on every heartbeat with the i2i technology. This tech utilises high-frequency pulses to relay messages through the naturally conductive characteristics of the body’s blood between each leadless pacemaker. This method uses far less battery power than inductive, radio frequency or Bluetooth® communication which are other alternatives used in implantable medical devices or traditional pacemakers. ]]> https://biospectrumindia.com/news/91/26753/medtronic-unveils-two-advanced-surgical-energy-generators-in-india.html https://biospectrumindia.com/news/91/26753/medtronic-unveils-two-advanced-surgical-energy-generators-in-india.html Tue, 30 Sep 2025 00:00:00 +0530 Medtronic, a global leader in healthcare technology, has announced the launch of two advanced surgical energy generators in India under the Valleylab™ FT10 series – the Valleylab™ FT10 Electrosurgical Generator (VLFT10FXGEN) and the Valleylab™ FT10  Vessel Sealing Generator (VLFT10LSGEN). Both devices are US FDA-approved and CE-marked, providing Indian hospitals with access to adaptive surgical technology designed to enhance precision, safety and efficiency in the operating room. This launch builds on the trusted Valleylab™ portfolio which for over 50 years has supported surgeons worldwide with reliable performance and improved patient outcomes. The Valleylab™ FT10 is a smart surgical device that helps doctors perform operations more safely and efficiently. It uses controlled energy to cut or seal tissue during procedures. What makes it special is its TissueFect™ sensing technology, which automatically adjusts the energy based on the type of tissue being treated. This means surgeons get more precise results, with less risk and faster recovery for patients. Operating rooms are highly dynamic environments with variability stemming from patient anatomy, disease states, comorbidities, equipment differences, surgical field conditions and team coordination. The Valleylab™ FT10 energy platform tackles these challenges by monopolar, bipolar and LigaSure™ technologies. Its advanced sensors and rapid processing capabilities enable algorithms to deliver energy consistently, adapting in real time to changing surgical conditions. This adaptability allows operating room teams to concentrate on the patient, perform procedures with greater confidence and achieve precise energy delivery. It also supports shorter surgery times, faster patient recovery and more efficient use of hospital resources. To support the launch, Medtronic will roll out comprehensive training and education programmes for surgeons and operating room staff at hospitals, ensuring seamless adoption of the Valleylab™ FT10 Family of Generators. ]]> https://biospectrumindia.com/news/91/26702/medisys-unveils-indigenous-next-gen-anaesthesia-and-neonatal-technologies.html https://biospectrumindia.com/news/91/26702/medisys-unveils-indigenous-next-gen-anaesthesia-and-neonatal-technologies.html Sat, 20 Sep 2025 00:00:00 +0530 Noida-based Medisys used the stage of Medicall Delhi at Bharat Mandapam to unveil Made in India, Patient First, next- generation of anaesthesia and neonatal technologies. These advanced and innovative solutions are designed to put patient safety, comfort, and faster recovery at the centre of critical care. The unveiling ceremony of new and innovative range of Anaesthesia and Neonatal Workstations was graced by renowned cardiologist and Padma Bhushan awardee Dr TS Kler. A large number of healthcare professionals, hospital administrators, and policymakers gathered at the Medisys’ launch of new range of solutions at Medicall to witness the company’s next chapter in patient-focused innovation.  “With our new range of anaesthesia workstations and neonatal equipments, our main objective is to strengthen patient safety, improve monitoring, and provide clinicians with a truly user-friendly support system,” said Piyush Gupta, CEO & Managing Director, Medisys, highlighting the company’s mission to elevate Indian medical technology to global standards. Flagship launches for safer, smarter care include COSMOS, a cutting-edge anaesthesia workstation with a 15-inch advanced interface and integrated patient monitoring for complete operating-theatre control; Medivent Grand, now featuring a 10-inch touchscreen that combines ease of use with trusted reliability for intensive care; Spectra, a compact 7-inch touch workstation bringing advanced features to a wide range of healthcare settings; and Excelsior Pro, an upgraded version of the popular Excelsior machine equipped with digital monitoring capabilities and enhanced safety features. The newly launched neonatology equipments vis-à-vis LED Phototherapy and Infant Wamer are also developed using all care and precision and with this Medisys shall strive to create a stronger place in NICU setups in hospitals with comprehensive neonatal range. The event also underpinned the transformation of Medisys from being known primarily as the manufacturing India’s first indigenous ventilator to a broader role as the leader in the medical technology innovation.   ]]> https://biospectrumindia.com/news/91/26698/stryker-expands-rd-footprint-in-india-with-new-facility-in-bengaluru.html https://biospectrumindia.com/news/91/26698/stryker-expands-rd-footprint-in-india-with-new-facility-in-bengaluru.html Thu, 18 Sep 2025 00:00:00 +0530 US-based Stryker, a global leader in medical technologies, has announced the expansion of its R&D presence in India with the opening of a new facility in Whitefield, Bengaluru.   Building on its existing 220,000 square-foot R&D campus in Gurgaon, the new 140,000 square-foot facility further strengthens Stryker’s footprint in the country. The new state-of-the-art facility brings together cross-functional teams and industry-leading lab infrastructure, uniquely blending next-generation capabilities in robotics, artificial intelligence (AI), digital innovation and product security.   Complementing this innovation hub, a medical experience center will deepen collaboration with healthcare professionals by showcasing solutions that help save lives and improve patient care, including ICU beds, stretchers, ambulance cots, and hospital and public-access AEDs (automated external defibrillators).   “We’re growing with purpose – expanding our capabilities to innovate, collaborate and deliver solutions that address the needs of our customers and patients worldwide,” said Ram Rangarajan, Vice President, Stryker Global Technology Center. “The advanced labs will allow us to work closely with healthcare professionals, unlock valuable insights, and accelerate innovation. With a strong focus on Digital and AI technologies, our new, state-of-the-art facility is designed to attract top talent, foster excellence, and drive sustained growth – all while remaining true to our mission of making healthcare better”.    The launch of the new facility in Bangalore builds on Stryker’s existing presence and reflects its continued commitment towards India’s dynamic ecosystem of research excellence, medical technology innovation and deep talent expertise. ]]> https://biospectrumindia.com/news/91/26676/medtronic-unveils-new-transcatheter-aortic-valve-evolut-fx-in-india.html https://biospectrumindia.com/news/91/26676/medtronic-unveils-new-transcatheter-aortic-valve-evolut-fx-in-india.html Sat, 13 Sep 2025 00:00:00 +0530 Medtronic, a global leader in healthcare technology, has launched its new transcatheter aortic valve, Evolut™ FX+, in India. The valve is designed to help improve treatment for patients with severe aortic stenosis, especially those who may need future coronary procedures. The Evolut FX+ TAVI system facilitates easier coronary access while maintaining the proven performance of the Evolut™ platform, based on CoreValve™ technology. It was approved by the Central Drugs Standard Control Organization (CDSCO) on June 10, 2025, paving the way for its launch in India. The main innovation of Evolut FX+ is its new frame with bigger windows to reduce frame interference while using guide catheters, especially during complex coronary procedures. The system continues to deliver the key advantages that clinicians have come to expect from previous Evolut valves. The system provides market leading valve performance including durable low gradients, which are important for long-term heart function. This makes it a strong alternative for patients at risk of coronary disease while supporting long-term treatment needs. The introduction of Evolut FX+ in India marks a significant advancement in transcatheter aortic valve therapy and reinforces Medtronic’s leadership in structural heart innovation. With enhanced coronary access and proven hemodynamic performance, the Evolut FX+ empowers physicians to deliver both immediate procedural success and sustained long-term care.  This milestone underscores Medtronic’s steadfast dedication to broadening access to advanced therapies and driving innovation in cardiovascular care and treatment across India.   ]]> https://biospectrumindia.com/news/91/26638/max-healthcare-partners-with-bapio-training-academy-to-focus-on-radiology.html https://biospectrumindia.com/news/91/26638/max-healthcare-partners-with-bapio-training-academy-to-focus-on-radiology.html Thu, 04 Sep 2025 00:00:00 +0530 Max Healthcare, one of the largest private sector healthcare services companies in India, and the BAPIO Training Academy (BTA), United Kingdom, have announced the signing of a strategic training agreement to advance medical education and capacity building in India, with a focus on radiology.  The partnership will focus on developing and implementing comprehensive capacity-building programmes designed to upskill and reskill medical professionals, including training students for the Fellowship of the Royal College of Radiology examination. The joint initiatives will leverage the expertise of both Max Healthcare and BTA to provide innovative training, facilitate knowledge transfer, and enhance diagnostic capabilities, ultimately leading to improved patient outcomes. Speaking on the partnership, Dr Sandeep Budhiraja, Group Medical Director, Max Healthcare, said, “This collaboration is a testament to our continuous pursuit of clinical excellence and our commitment to nurturing the next generation of healthcare leaders. The focused approach on radiology will undoubtedly strengthen our diagnostic capabilities and contribute significantly to the broader medical community in India.” Commenting on the partnership, Dr Parag Singhal, CEO of BAPIO Training Academy, added, “Our collaboration with Max Healthcare marks a significant milestone in our mission to deliver high-quality, impactful medical training. By combining our robust training methodologies with Max Healthcare’s extensive clinical infrastructure and expertise, we are poised to create unparalleled opportunities for healthcare professionals, especially in critical areas like radiology, which is crucial for modern healthcare delivery.” ]]> https://biospectrumindia.com/news/91/26633/foldax-announces-launch-of-tria-mitral-valve-in-india.html https://biospectrumindia.com/news/91/26633/foldax-announces-launch-of-tria-mitral-valve-in-india.html Wed, 03 Sep 2025 00:00:00 +0530 US-based Foldax® Inc., a leader in the development of innovative polymer heart valves, in conjunction with its local manufacturing partner Dolphin Life Science LLP, has announced the launch of the TRIA™ Mitral Valve in India, marking the first time a polymer heart valve has been made commercially available to patients anywhere in the world. Mitral valve disease is a concern in India, with rising surgical volumes and increased need for long-term treatment solutions. The TRIA™ Mitral Valve is positioned to offer a new option for patients seeking a durable solution without the lifestyle limitations of mechanical valves. As part of the launch, Foldax has initiated the Evolve™ Training & Certification Programme to ensure high-quality outcomes and surgeon preparedness. Physicians who complete training will be certified to implant the valve at participating hospitals. The TRIA Mitral Valve in the United States is limited to investigational use only, while it is approved for use in India by CDSCO. “We are honoured to work with India’s top cardiovascular surgeons and Dolphin Life Science to bring next generation medical solutions to the Indian population,” said Laxmikant Khanolkar, Senior Vice President of Foldax Asia and MEA. “This is the first in a series of heart valve solutions we intend to introduce into the market.” ]]> https://biospectrumindia.com/news/91/26594/samsung-india-to-transform-patient-centric-imaging-with-new-mobile-ct-technologies-portfolio.html https://biospectrumindia.com/news/91/26594/samsung-india-to-transform-patient-centric-imaging-with-new-mobile-ct-technologies-portfolio.html Tue, 26 Aug 2025 00:00:00 +0530 Samsung, India’s largest consumer electronics brand, in collaboration with NeuroLogica, a subsidiary of Samsung Electronics Co., Ltd., has announced the launch of its next-generation mobile CT product portfolio in India.  The newly introduced range includes CereTom® Elite, OmniTom® Elite, OmniTom® Elite PCD, and BodyTom® 32/64, each tailored to meet the diverse clinical needs of hospitals and specialty centres. By enabling adoption across hospitals of all sizes, including those in underserved regions, Samsung is set to help democratise access to advanced imaging in India.  “Samsung is taking a decisive step toward making advanced medical imaging more accessible, efficient, and patient-centric with the launch of the mobile CT solutions in India. These innovations are as much about technology as they are about empowering healthcare providers to bridge the care gap between metros and tier-2/3 cities. We believe this portfolio will strengthen India’s healthcare infrastructure, support clinical excellence across specialties, and play a crucial role in improving patient outcomes at scale,” said Atantra Das Gupta, Head of HME Business, Samsung India.  CereTom® Elite: 8-slice CT scanner with a 32cm patient opening and 25cm FOV, delivering efficient imaging supported by a 2-hour battery capacity.  OmniTom® Elite: Achieves 0.125mm x 80 slice reconstruction in UHR (Ultra High Resolution) mode, with a 40cm patient opening and 30cm FOV, ensuring versatility with a 1.5-hour battery capacity. Notably, it has transformed neurosurgical workflows, enabling complex procedures such as deep brain stimulation (DBS) to be completed in as little as 2 hours, compared to traditional timelines of 8-10 hours. Additionally, the OmniTom® Elite enables immediate post-operative scans directly in the operating room (OR).  OmniTom® Elite PCD: Incorporates photon counting detector (PCD) technology for superior image quality, enhanced differentiation, and advanced artifact reduction.  BodyTom® 32/64: 32/64-slice CT scanner with an 85cm patient opening and 60cm FOV, designed for comprehensive full-body imaging, equipped with a lithium polymer battery with up to 12-hour capacity in standby mode.   The portfolio is suited for a wide spectrum of clinical scenarios, enhancing precision and efficiency across diverse specialties. In neurosurgery, it enables intraoperative CT for surgical planning and verification; in emergency medicine, it provides rapid imaging for trauma and stroke diagnostics; interventional radiology teams benefit from CT-guided biopsies, ablations, and drainage procedures; in oncology, the systems support imaging for brachytherapy and tumour resection; and for paediatric imaging, they offer safe and efficient solutions tailored to the needs of children and neonates.  ]]> https://biospectrumindia.com/news/91/26561/gujarat-health-minister-inaugurates-advanced-radiotherapy-system-for-cancer-care-at-apollo-hospitals-in-ahmedabad.html https://biospectrumindia.com/news/91/26561/gujarat-health-minister-inaugurates-advanced-radiotherapy-system-for-cancer-care-at-apollo-hospitals-in-ahmedabad.html Thu, 21 Aug 2025 00:00:00 +0530 Gujarat Health Minister Rushikesh Patel inaugurated the cutting-edge Varian TrueBeam 3.0 Radiotherapy system at Apollo Hospitals, Ahmedabad, marking a significant leap forward in precision cancer treatment in Gujarat. The inauguration was attended by the hospital’s Radiation oncology team, other Oncologists and entire staff of oncology department.  The Varian TrueBeam 3.0 is a modern fully equipped most Advanced linear accelerator (LINAC) used for External beam radiotherapy for patients suffering from cancer. It delivers high-energy X-rays with exceptional accuracy, targeting tumours while sparing healthy surrounding tissues. For patients, this translates into faster treatment sessions, reduced side effects, and improved overall outcomes. Its ability to integrate advanced imaging with treatment also allows doctors to adapt therapy with greater precision for each individual case. Speaking at the event, Rushikesh Patel said, “Ahmedabad has emerged as a hub for advanced healthcare, with patients from across Gujarat and neighbouring states and countries seeking treatment here. Availability of advanced treatment facilities and clinical expertise of doctors further strengthens the city’s position as a centre for cutting-edge medical care and gives new hope to cancer patients.”  With this launch, Apollo Hospitals, Ahmedabad, has strengthened its role as a regional referral centre for advanced cancer care, blending cutting-edge technology with compassionate treatment. This was the first Radiation centre in corporate sector in Gujarat and has the highest number of Radiation treatment delivered to cancer patients with his experienced Team. ]]> https://biospectrumindia.com/news/91/26569/himachal-cm-inaugurates-states-first-robotic-assisted-surgery-facility-at-aimss.html https://biospectrumindia.com/news/91/26569/himachal-cm-inaugurates-states-first-robotic-assisted-surgery-facility-at-aimss.html Thu, 21 Aug 2025 00:00:00 +0530 Chief Minister (CM) Sukhvinder Singh Sukhu inaugurated Himachal Pradesh’s first robotic-assisted surgery facility at the department of urology, Atal Institute of Medical Super Specialities (AIMSS), at Chamiana in Shimla. The launch of this facility marks a significant step forward in strengthening the state’s surgical healthcare capabilities and expanding access to advanced healthcare technologies. The event was graced by Health Minister Dr (Col.) Dhani Ram Shandil and Minister for Rural Development Anirudh Singh, alongside senior officials from Health and Medical Education departments. The facility features the da Vinci Surgical System, a cutting-edge platform for minimally invasive procedures that enhances surgical precision, safety, and recovery. With this, AIMSS emerges as a pioneering hub for advanced surgical care in the region. Rohitt Mahajan, Vice President and General Manager, Intuitive India, said, “This initiative by the Himachal Pradesh government to bring robotic-assisted surgery into the public healthcare system is a significant step towards modernising healthcare facilities across the state and ensuring equitable access to advanced surgical care. This progress reflects the collaborative effort of government institutions and healthcare professionals to expand the reach of minimally invasive care not only in metros but across Tier-2 and Tier-3 cities as well." During the inauguration, Health Minister Dr (Col.) Dhani Ram Shandil highlighted that the facility will contribute to build a skilled surgical workforce and elevate the standard of care in the region. The state government is currently reviewing an implementation plan, under cabinet consideration, to expand robotic-assisted surgery services across other government medical institutions. This initiative is part of a broader plan by the state to strengthen surgical capabilities across government institutions through the phased installation of robotic surgical systems. In its initial phase, the project will cover key medical colleges, including the Atal Institute of Medical Super Speciality in Chamiyana, Dr. Rajendra Prasad Government Medical College in Tanda, Hamirpur Medical College, and Indira Gandhi Medical College (IGMC) in Shimla. To support this initiative, the government will initiate recruitment of specialist robotic surgeons to build a future-ready team capable of leading the expansion of advanced surgical care in Himachal Pradesh. ]]> https://biospectrumindia.com/news/91/26528/fortis-noida-acquires-medtronics-o-arm-intra-operative-x-ray-rechnology.html https://biospectrumindia.com/news/91/26528/fortis-noida-acquires-medtronics-o-arm-intra-operative-x-ray-rechnology.html Wed, 13 Aug 2025 00:00:00 +0530 In a major leap for advanced surgical care, Fortis Hospital Noida has become the first hospital in Noida to install the state-of-the-art ‘O-arm’ intra-operative X-ray system.   This breakthrough technology enables surgeons to visualise bones, implants -screws, plates, rods and catheters with high precision during surgery. Its highly enabled technological design enables the patient to be positioned within the circular scanner for a complete spine scan. This supports minimally invasive techniques, shorter operation times and significantly lower radiation exposure for both patients and medical teams. When used with neuro navigation, the system acts like a GPS inside the body and enables surgeons to place implants with 99.9 percent accuracy while reducing surgical trauma and recovery time. Smaller incisions and minimal muscle injury contribute to faster healing and a reduced risk of infection. Speaking about the new technology, Dr Rahul Gupta, Senior Director and HOD, Neuro and Spine Surgery, Fortis Hospital, Noida said, “The O-arm will greatly improve the accuracy and safety of surgeries. With advanced imaging and real time navigation, we can perform complex procedures with smaller cuts, less muscle damage, lower radiation exposure and quicker recovery time for patients. This pioneering technology significantly reduces surgery duration, lowers infection risks and enhances recovery outcomes. For patients, it means less pain, smaller scars and a quicker return to normal life. For surgeons, it offers unmatched clarity and confidence during critical procedures.” With this addition, Fortis Hospital Noida further strengthens its position as a leader in healthcare technology. Fortis Noida is already equipped with modular operation theatres, robotic surgery capabilities and high-definition imaging systems, enabling it to deliver excellent medical care to patients from across the region. ]]> https://biospectrumindia.com/news/91/26504/aarthi-scans-installs-indias-first-helium-free-1-5t-mri-from-siemens-healthineers-in-bengaluru.html https://biospectrumindia.com/news/91/26504/aarthi-scans-installs-indias-first-helium-free-1-5t-mri-from-siemens-healthineers-in-bengaluru.html Sun, 10 Aug 2025 00:00:00 +0530 Aarthi Scans and Labs, a leader in radiology and pathology, has achieved a significant milestone in sustainable medical imaging with the launch of India’s first helium-free 1.5 Tesla MRI system from Siemens Healthineers. The facility has introduced the Siemens Healthineers Magnetom Flow Plus at its newly opened centre in Whitefield, Bengaluru, marking a breakthrough in patient-friendly and environmentally responsible diagnostics. Traditional MRI systems consume thousands of litres of liquid helium, a non-renewable resource that is becoming increasingly scarce and expensive. The Magnetom Flow Plus transforms this approach by utilizing just 0.7L of helium in a completely sealed, zero-loss system. This breakthrough eliminates the need for regular helium refills and prevents any helium emissions into the atmosphere. This innovative solution positions Aarthi Scans at the forefront of sustainable healthcare, offering diagnostic centres a pathway to long-term efficiency while maintaining the highest standards of patient care and environmental responsibility. Founded in 1988 by V Govindarajan, Aarthi Scans and Labs is India's largest integrated diagnostics provider. With over 70 MRI scanners, 71 CT scanners, and 20 processing labs, Aarthi serves more than 8000 patients daily across cities like Chennai, Hyderabad, Mumbai, Delhi, Pune, Kolkata and Bengaluru.     ]]> https://biospectrumindia.com/news/91/26493/indias-first-advanced-3d-printing-hub-for-orthopaedic-implants-to-open-in-amtz.html https://biospectrumindia.com/news/91/26493/indias-first-advanced-3d-printing-hub-for-orthopaedic-implants-to-open-in-amtz.html Thu, 07 Aug 2025 00:00:00 +0530 In a landmark collaboration that spans three continents, OIC International (USA), Medi Mold, part of the Andhra Pradesh Medtech Zone (AMTZ) (India), and AddUp, a subsidiary of Fives Group (France) have announced a strategic partnership to establish India’s most advanced orthopaedic implant manufacturing facility powered by 3D printing and precision engineering. The facility will be housed within AMTZ, India's flagship medical device manufacturing park. This trilateral arrangement marks a decisive step toward transforming India into a global hub for high-performance orthopedic implants while aligning with the Indian government’s “Make in India” and medical self-reliance initiatives. OIC is launching a first-of-its-kind line of implants manufactured in India using advanced additive 3D technology, designed for both domestic and global markets. Developed with proprietary technology, these implants aim to significantly reduce post-surgery recovery time while delivering cutting-edge solutions at a fraction of the cost and can be produced on a mass scale, close to the delivery points. The first metal 3D printer from AddUp’s FormUp range will be installed at AMTZ, enabling rapid prototyping and market entry. This infrastructure, operated by Medi Mold, will ensure speed, flexibility, and efficiency in manufacturing — a vital combination for meeting the growing orthopaedic demand in India and abroad. Through this partnership, the coalition aims to address three fundamental challenges in orthopaedics: technology-led innovation, affordability and market access. The new facility will offer an integrated manufacturing platform for low-cost implants for public sector procurement, supporting government hospitals and healthcare schemes. Meanwhile, OIC will have the ability to support India’s fast-growing private healthcare market. ]]> https://biospectrumindia.com/news/91/26491/new-initiative-to-establish-south-indias-leading-robotic-cardiac-surgery-and-training-centre.html https://biospectrumindia.com/news/91/26491/new-initiative-to-establish-south-indias-leading-robotic-cardiac-surgery-and-training-centre.html Wed, 06 Aug 2025 00:00:00 +0530 As part of a major initiative to democratise access to advanced surgical technologies, Dr Sudhir Prem Srivastava, founding chairman of SSI group of companies, has signed a Memorandum of Understanding (MoU) to donate SSI Mantra Surgical Robotic System, India’s first and only indigenously developed robotic surgery system to the Sri Madhusudan Sai Institute of Medical Sciences and Research (SMSIMSR) in Chikkaballapur, Karnataka. The MoU signing ceremony, held at the SS Innovations International Headquarters in Gurugram, was graced by the esteemed presence of Sadguru Madhusudan Sai. This initiative aims to establish a world-class Robotic Cardiac Surgery Centre at SMSIMSR and develop the institution into South India’s premier training hub for robotic surgeries across multiple specialties, including adult and pediatric cardiac surgery, thoracic, general surgery, urology, gynecology, and head and neck surgery.  As part of the collaboration, Dr Srivasatava will support the first 100 robotic surgical procedures at SMSIMSR, cover the full maintenance costs of the SSI Mantra System for the next five years, and lead advanced training programs for cardiac and multi-specialty surgical teams at the institute, ensuring both immediate impact and long-term capacity building. This partnership not only strengthens equitable access to cutting-edge surgical care but will also accelerate knowledge exchange, clinical training, and joint research initiatives to expand the reach and efficacy of robotic surgery in India. ]]> https://biospectrumindia.com/views/91/26436/next-generation-surgical-robotics-stand-poised-for-global-revolution.html https://biospectrumindia.com/views/91/26436/next-generation-surgical-robotics-stand-poised-for-global-revolution.html Thu, 31 Jul 2025 00:00:00 +0530 In spite of the many advantages, surgical robotic platforms have drawbacks. Legacy surgical robots involve a large setup that consumes significant space in the operating room. The platforms are not mobile and cannot be transferred from one room to another after installation. Moreover, the instrument setup and positioning of conventional robotic surgical arms before the procedure require considerable effort, which subsequently increases the total operation time frame. The use of rigid instruments in these traditional surgical robotic platforms becomes extremely challenging in non-linear pathways and makes it difficult to reach anatomical areas such as the brain in a minimally invasive fashion. This has spurred the development of agile and state-of-the-art next-generation surgical robotic technology platforms, which have been built with unique designs, advanced instrumentation, analytics and visualisation technologies that address the limitations of conventional surgical robotic systems. Small footprint: Next-generation surgical robotic technology platforms have a smaller footprint that makes them easily accommodated in operating rooms without taking up much space. Moreover, these mobile platforms can be rapidly deployed in various operating rooms to facilitate higher utilisation. Shorter setup time: The unique configuration and minimal cable management of next-generation platforms ensure quick docking and setup, resulting in shorter operating room time frames for both surgeons and patients.  Ergonomic design: The robotic platforms’ console allows surgeons to be situated in an ergonomically comfortable position throughout the procedure. This helps reduce physical strain and the procedure-related burnout commonly observed among surgeons.  Multi-articulating and flexible instruments: These instruments aid in achieving optimal triangulation and easily maneuver through non-linear pathways in a patient’s body to reach the target site and effectively carry out a surgical procedure in hard-to-reach areas.  Motion control and anthropomorphic movements: The platforms provide high-precision motion control and anthropomorphic movements that are nearly identical to human hand movement while performing delicate surgeries. Haptic sensing: The ability of robotic systems to provide haptic feedback to surgeons allows them to feel the pressure/force exerted on the tissues or organs during surgery, both in and outside the field of view. Alerts are provided to surgeons if the pressure threshold is reached to prevent damage to the anatomical structures.  Multi-quadrant surgeries: The robotic systems offer a unique column architecture that facilitates its placement in any position around the patient, providing four-quadrant anatomical access to the surgical site. This enables greater accessibility to the patients’ anatomy for the surgeons without the need to frequently move the robotic platform.  Open platform architecture: The open-platform architecture of these systems enables seamless integration with existing technologies in the operating room ecosystem. This allows hospitals to maximise benefit from existing capital investments while providing surgeons access to devices and instruments of their preference.  Decreasing learning curve: The time required to train surgeons on the next-generation surgical robotic systems is significantly lower compared to conventional robotic platforms. This helps shorten the learning curve, enabling surgeons to learn the robotic-assisted procedures within days instead of months, typically required for traditional ones. Depending on the type or route of incision, the next-generation surgical robotic systems have been classified into multi-port, single-port, and robotic natural orifice surgery systems. Multi-Port Robotic Surgery Systems: These systems typically require multiple small ports or incisions to be carried out on the patients’ body to insert long surgical instruments for performing the procedures. These platforms feature haptic feedback that provide alerts to the surgeons if the pressure threshold is reached to prevent damage to the anatomical structures and deploy artificial intelligence (AI) to offer insights to the surgeons based on the accumulated procedural data.  For instance, in January 2025, SS Innovations International, Inc launched its made-in-India, Central Drugs Standard Control Organization (CDSCO) certified SSi Mantra 3 surgical robotic system (SSi Mantra 3) at Pune's Noble Hospital in India. The SSi Mantra 3 is a modular, multi-robotic arm system featuring open-faced ergonomic surgeon command center, a large 3D 4K monitor and has 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery. Single-Port Robotic Systems: The procedures carried out through single-port robotic systems require a single, small incisions in the patients’ body to reach target anatomical structures. The platforms provide high precision motion control and anthropomorphic movements that facilitate controlled motion and movements. The single-port robotic systems offer a unique column architecture that facilitates its placement in any position around the patient providing four-quadrant anatomical access to the surgical site. This enables greater accessibility to the patients’ anatomy for the surgeons without the need to frequently move the robotic platform.  For instance, Intuitive Surgical’s da Vinci SP surgical system features high precision motion control and anthropomorphic movements that allow surgeons exceptional flexibility and deep, narrow access to internal tissues and organs for performing challenging surgical tasks while filtering out tremors during instrument movements. Besides receiving US Food and Drug Administration (FDA) clearance and Conformité Européenne (CE) mark, the system has been approved for use in Japan and Korea for surgical procedures such as general surgeries, thoracic surgeries, urologic surgeries, and gynecological surgeries. Robotic Natural Orifice Surgery Systems: The robotic natural orifice surgery systems use the body’s natural orifices including mouth, anus, or vagina to perform incisionless surgery on patients. Anthropomorphic movements of the robotic arms and the use of multi-articulating and flexible instruments in these platforms aid in optimal triangulation and also enable them to circumvent non-linear pathways in the patients’ body to reach the target site and effectively carry out surgical procedure in hard-to-reach areas.  Israel-based Momentis Surgical Ltd has developed the Anovo robotic surgical platform, featuring miniature humanoid shaped robotic arms with anthropomorphic movements. This helps provide multi-planar flexibility, human-level dexterity and 360 degrees of articulation for performing challenging surgical tasks and avoiding obstacles in non-linear pathways within the body. The platform has received US FDA clearance for performing natural orifice transvaginal benign gynaecology procedures and single site, abdominal access ventral hernia repair.   The Way Forward  Developers of next-generation surgical robotic systems can focus on flexible payment models, shifting from the traditional upfront capital model to a managed service wherein the robot, all required instrumentation, and maintenance are bundled into an annual contract based on agreed procedure volumes, with the intent to reduce the lifetime cost of robotic surgery. This model will allow hospitals to tie costs to revenues, making robotic surgery viable for more healthcare facilities.  Next-generation surgical robotics companies need to create a customer-centred design process and work closely with surgeons and healthcare executives during their product development activities. Following a dynamic research loop - where client feedback is actively incorporated into refining the platforms’ functionality, can go a long way in developing surgical robotics systems that are closely aligned with customer needs.  Currently, surgical robots are restricted to inpatient settings at hospitals. However, an increasing number of surgical procedures are being performed in outpatient settings and ambulatory surgical centres, which currently do not have access to surgical robots. Deployment of next-generation surgical robotic technology platforms in these settings can help companies capture lucrative growth opportunities offered by the shift toward outpatient procedures.   Neeraj Nitin Jadhav, Senior Industry Analyst & Team Lead, TechVision, Frost & Sullivan ]]> https://biospectrumindia.com/news/91/26454/fujifilm-india-unveils-endoveda-to-revolutionise-clinical-reporting-in-gastroenterology.html https://biospectrumindia.com/news/91/26454/fujifilm-india-unveils-endoveda-to-revolutionise-clinical-reporting-in-gastroenterology.html Tue, 29 Jul 2025 00:00:00 +0530 Fujifilm India, a global leader in healthcare technology, has unveiled its latest innovation in endoscopy reporting, ENDOVEDA, at the Endocon 2025 conference in Jaipur. Developed entirely in India, ENDOVEDA marks a significant leap forward in digital documentation for endoscopic procedures, designed to support clinicians with advanced reporting tools and intuitive workflow. ENDOVEDA offers a comprehensive suite of features for endoscopic reporting, including Full HD 4k and UHD 4K  image capture, intelligent image enhancement, and a user-friendly interface. It ensures seamless integration with hospital systems (PACS/HIS), robust data security, and flexible reporting options. Backed by dedicated local and remote support, ENDOVEDA streamlines workflows and enhances diagnostic precision for healthcare professionals. ENDOCON 2025 at Jaipur, a premier platform for knowledge exchange in gastroenterology, served as the ideal venue for the introduction of ENDOVEDA. The event brought together key opinion leaders, clinicians, and industry experts to discuss advancements in interventional techniques and medical technologies. Dheeraj Chaudhari, Head of Endoscopy Systems Division, Fujifilm India, added, “ENDOVEDA™ reflects our understanding of what modern-day endoscopists require, a solution that not only captures high-quality images but also simplifies the reporting journey. Developed in close consultation with medical professionals, it supports seamless integration, personalization, and precision, all within a single platform. We believe ENDOVEDA will become an essential component in the endoscopy workflow and help set new standards for digital documentation in India.”   ]]> https://biospectrumindia.com/news/91/26395/aig-hospitals-brings-zap-x-gyroscopic-radiosurgery-to-south-india-for-brain-tumour-treatment.html https://biospectrumindia.com/news/91/26395/aig-hospitals-brings-zap-x-gyroscopic-radiosurgery-to-south-india-for-brain-tumour-treatment.html Wed, 16 Jul 2025 00:00:00 +0530 ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, has announced that AIG Hospital in Hyderabad, will acquire the ZAP-X® Gyroscopic Radiosurgery® platform. Reinforcing its commitment to patient-centric innovation, AIG Hospitals will become the first hospital in South India to offer this revolutionary brain tumour treatment. This advancement will empower AIG Hospitals’ neurosurgical team to deliver precision-focused care without the need for traditional open surgery, thereby redefining outcomes for patients with brain tumors and other intracranial conditions. Stereotactic Radiosurgery (SRS), widely accepted as an alternative to conventional brain surgery for many patients, is an incision-free outpatient procedure offering surgical-like precision with no anesthesia, and minimal recovery time. However, access to SRS has remained limited globally due to high infrastructure costs and radiation safety challenges. With ZAP-X, AIG Hospitals addresses these constraints while placing India on the global map of next-generation neurosurgical care. Developed by Dr John R. Adler, former Stanford professor of neurosurgery and radiation oncology, the ZAP-X platform is the world’s first vault-free radiosurgery system, enabling installation without the need for costly radiation-shielded rooms. It also eliminates reliance on traditional Cobalt-60 radioactive sources, using a modern linear accelerator to deliver biologically consistent and efficient radiation doses. ]]> https://biospectrumindia.com/news/91/26358/hyderabad-based-care-hospitals-installs-strykers-advanced-ai-powered-robotic-surgery-system.html https://biospectrumindia.com/news/91/26358/hyderabad-based-care-hospitals-installs-strykers-advanced-ai-powered-robotic-surgery-system.html Wed, 09 Jul 2025 00:00:00 +0530 In a ground-breaking move towards the future of precision medicine, CARE Hospitals, Hitech City in Hyderabad, has introduced artificial intelligence (AI)-powered Stryker Mako Robotic System, marking a new era in robotic joint replacement surgeries in Telangana.   The MACO Robo brings a new level of precision and personalisation in joint replacement procedures, marking a significant advancement in surgical outcomes and faster patient recovery.    Speaking at the launch, Arekapudi Gandhi, MLA, Serilingampally said, "The integration of such advanced AI-based robotic solutions in Telangana’s healthcare ecosystem showcases our state's progress in embracing next-gen medical technology. I commend CARE Hospitals for constantly pioneering innovations that improve patient outcomes and set new benchmarks in clinical excellence."   The Stryker Mako Robotic System, integrated with Artificial Intelligence, enhances surgical accuracy by enabling real-time decision-making, personalised surgical planning, and precision execution. This advanced system is particularly effective in total knee, partial knee and hip replacement surgeries, resulting in faster recovery, minimal post-op pain, and improved long-term outcomes.   Key Features of the AI-Assisted Robotic Surgery System include- AI-driven 3D CT-based surgical planning for patient-specific procedures; Real-time intra-operative robotic guidance with haptic feedback for enhanced precision; Minimal bone removal and reduced soft tissue damage; Improved implant positioning for better long-term outcomes; Faster recovery and reduced hospital stay.     ]]> https://biospectrumindia.com/news/91/26335/kaya-clinics-launches-globally-trusted-neo-elite-laser-treatment-across-india.html https://biospectrumindia.com/news/91/26335/kaya-clinics-launches-globally-trusted-neo-elite-laser-treatment-across-india.html Sat, 05 Jul 2025 00:00:00 +0530 Aerolase, a global technology leader in laser skin health, has taken a significant step forward in the Indian market with the launch of its US FDA-approved Neo Elite laser treatment in collaboration with Kaya, a leading dermatology chain clinic in India. The treatment will now be available across all Kaya clinics nationwide, signifying a major leap forward in non-invasive skincare for Indian consumers. As a pioneer in global skincare innovation, Aerolase is empowering Indian consumers by making advanced, research-driven treatments available and customisable for the diverse needs of Indian skin. Acne is one of the most common dermatologic conditions worldwide, with a global prevalence estimated at approximately 9–10% based on Global Burden of Disease (GBD) data. Traditional acne treatments, oral medications, creams, and hormone therapies require prolonged use. This has led to the rise in demand for non-invasive, effective solutions  with minimal or no  downtime and  discomfort. Underscoring the market need for this innovation, voiced Madhusudhan HK, Country Manager, Aerolase, "India’s dermatology and aesthetic market is among the fastest-growing globally, projected to grow at a CAGR of 10.11% from 2025 to 2032.  Aerolase’s collaboration with Kaya is perfectly timed to meet India’s rising demand by innovations such as 650 microsecond breakthrough technology for safer, customisable treatments. Within this rapidly advancing landscape, Neo Elite’s technology stands out by not    overheating surrounding skin or causing pigmentation issues. Its contactless design ensures optimal hygiene, making it ideal for those with acne-prone skin. The device effectively addresses active acne, post-inflammatory hyperpigmentation, and redness in the same session, minimizing the need for multiple treatments. Its versatility means it can treat a range of concerns, from teenage Acne to adult acne and postpartum breakouts, and can be safely integrated with existing skincare routines.” Aerolase has collaborated with Kaya to bring its advanced laser technology to a broader patient base. Supported by extensive global clinical evidence, Aerolase offers reliable, reproducible outcomes across 36 indications from aesthetic procedures to complex dermatological conditions. By integrating with Kaya’s wide-ranging expertise, the collaboration aims to enhance access to comprehensive, science-driven skin and beauty solutions.   ]]> https://biospectrumindia.com/news/91/26328/nethradhama-unveils-mysurus-first-coe-for-minimally-invasive-glaucoma-surgery.html https://biospectrumindia.com/news/91/26328/nethradhama-unveils-mysurus-first-coe-for-minimally-invasive-glaucoma-surgery.html Thu, 03 Jul 2025 00:00:00 +0530 Nethradhama Superspeciality Eye Hospital, Mysuru, has launched the city’s first dedicated Centre of Excellence (CoE) for Minimally Invasive Glaucoma Surgery (MIGS), offering new hope to people affected by one of India’s leading causes of irreversible blindness. Glaucoma affects nearly 11.9 million people across the country and is responsible for more than 12 percent of all blindness. “The newly introduced MIGS treatment at Nethradhama offers a modern, patient-friendly solution for those living with mild to moderate glaucoma,” said Dr Monica Anand, Senior Consultant, Phaco and Glaucoma, Nethradhama Mysuru. In addition to the iStent inject-W, the centre also offers excisional goniotomy using the Kahook Dual Blade. In this procedure, a small part of the eye’s natural drainage tissue, called the trabecular meshwork, is removed through a micro incision to help lower eye pressure. This is a safe and effective minimally invasive option for treating glaucoma. Since late 2024, Nethradhama Mysuru has performed more than 25 MIGS procedures, including both iStent inject-W and Kahook Dual Blade, making it the first hospital in the city to offer this advanced treatment. Patients have already reported better comfort, improved quality of life, and in several cases, complete freedom from glaucoma drops. Now in its 12th year, Nethradhama Mysuru has become known for consistently introducing first-in-city technologies and delivering comprehensive eye care under one roof. It was the first in Mysuru to offer bladeless robotic laser cataract surgery, advanced topography-guided laser correction for keratoconus, and is also NABH ECO accredited for patient safety and quality care. With the launch of the MIGS Centre of Excellence, Nethradhama is now setting a new benchmark for glaucoma care in Tier 2 India and transforming the way patients experience treatment and recovery. As part of its preventive care strategy, Nethradhama plans to conduct regular glaucoma awareness campaigns and early screening programs to help detect the condition before irreversible damage occurs. ]]> https://biospectrumindia.com/news/91/26293/ddmm-heart-institute-becomes-first-in-western-india-to-install-real-time-cardiac-view-recognition-ultrasound-system.html https://biospectrumindia.com/news/91/26293/ddmm-heart-institute-becomes-first-in-western-india-to-install-real-time-cardiac-view-recognition-ultrasound-system.html Thu, 26 Jun 2025 00:00:00 +0530 Nadiad’s Dharmsinh Desai Memorial Methodist Institute of Cardiology and Cardiovascular Surgery has announced the installation of an advanced artificial intelligence (AI)-enabled real-time cardiac view recognition ultrasound system at its centre. With this, the hospital is now the first in western India to have the innovative AI-enabled Acuson Origin ultrasound system by Siemens Healthineers. This technology reduces reliance on traditional Electrocardiogram (ECG) during echocardiography for patients, thereby enhancing patient experience and comfort.   Known for its state-of-the-art treatment facilities for patients with cardiac and vascular ailments, the hospital aims to provide world-class technology-driven solutions to their patients in and around the city. Although cardiovascular disease (CVD) is recognised as a major public health issue in India, access to cardiovascular care remains constrained, as reflected by the low rates of detection and treatment. Talking about the development, Dr Sanjeeth Peter, Director and Chief Cardiac Surgeon, DDMM Heart Institute, said, “With this cutting-edge technology, we are further empowering our team to diagnose and treat cardiovascular conditions with unparalleled precision and speed, ensuring the highest level of care for our patients." "At Siemens Healthineers, we are focused on pioneering innovative healthcare solutions for everyone, everywhere, sustainably. With customer and patient centricity at our core, we've introduced Acuson Origin, a cutting-edge technology designed to empower patients and doctors in managing complex cardiovascular conditions. After this new addition, DDMM Heart Institute is enabling thousands of patients in and around Nadiad to access world-class cardiac care, improving their quality of life and transforming the landscape of cardiovascular treatment in Gujarat”, said Sanjay David - Head of Ultrasound - Zone ASEAN & India, Siemens Healthcare Private Limited  This industry-first technology enhances diagnostic precision and patient outcomes through advanced ultrasound features like 2D and 4D HeartAI, which enable automated contouring and quantification of all four cardiac chambers – even without an electrocardiogram (ECG). ]]> https://biospectrumindia.com/news/91/26281/medtronic-unveils-next-generation-micra-av2-and-micra-vr2-leadless-pacemakers-in-india.html https://biospectrumindia.com/news/91/26281/medtronic-unveils-next-generation-micra-av2-and-micra-vr2-leadless-pacemakers-in-india.html Tue, 24 Jun 2025 00:00:00 +0530 Medtronic, a global leader in medical technology, has announced the launch of the Micra™ AV2 and VR2, the world’s smallest leadless pacemakers, in India. These are designed to last longer, work better, and make life easier for patients with slow heart rhythms.   The Micra™ AV2 and VR2 are the latest innovations in the Medtronic Micra leadless pacemaker family. They do not have leads or require a chest incision, which helps avoid potential complications, like infections, that can happen with traditional pacemakers with leads. The Micra AV2 also has smart technology that adjusts to each person’s heartbeat, helping the heart stay in sync even when the person is moving around.   These new pacemakers are enhanced with extended battery longevity and streamlined implant procedures. They last longer with a median projected battery lifespan of 15.6 years for the Micra AV2 and 16.7 years for the Micra VR2, over 80% of patients will only need one for their whole life. They are also compatible with smartphone-enabled remote monitoring, which can help with care.   Chandrashekhar Jaiman, Director Cardiovascular at Medtronic India commented, “At Medtronic, our mission is to alleviate pain, restore health, and extend life. With the launch of the Micra AV2 and VR2 in India, we are proud to advance that mission by redefining what’s possible in cardiac care. These next-generation leadless pacemakers represent a significant leap forward—combining miniaturization with intelligent pacing technology to deliver a superior experience for both patients and clinicians. This innovation is especially meaningful in India, where the growing burden of cardiovascular disease calls for scalable, accessible, and clinically advanced solutions.”   Real-world data from global studies show that the Micra leadless pacemakers significantly reduce major complications—by as much as 53% compared to traditional pacemakers. These leadless devices can help patients to recover from the procedure with minimal signs of a visible implant. ]]> https://biospectrumindia.com/news/91/26273/esthetic-clinics-unlocks-new-era-for-txa-in-cosmetic-surgery.html https://biospectrumindia.com/news/91/26273/esthetic-clinics-unlocks-new-era-for-txa-in-cosmetic-surgery.html Fri, 20 Jun 2025 00:00:00 +0530 The Esthetic Clinics, one of India’s leading multi-speciality centres for cosmetic and reconstructive surgery, dermatology, and aesthetic medicine, has spearheaded a landmark systematic review and meta-analysis published in the Journal of Plastic, Reconstructive & Aesthetic Surgery (Impact Factor: 2.5), the official journal of the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS). The study spotlights Tranexamic Acid (TXA) as a game-changing adjunct in facial aesthetic surgery, consolidating data from 22 high-quality studies with data from over 9,000 patients across a 20-year span, making it the most comprehensive review of TXA’s role in aesthetic surgery to date. Originally used in trauma care and orthopaedic surgeries — and more widely known for treating heavy menstrual bleeding — TXA has now shown significant promise in enhancing outcomes in facial cosmetic procedures such as rhinoplasty, rhytidectomy (facelift), and blepharoplasty (eyelid surgery). The study revealed that TXA administration — whether intravenous, topical, oral, or through local infiltration — consistently resulted in reduced intraoperative blood loss; shorter surgical duration; lower postoperative swelling (oedema); decreased bruising (ecchymosis); and reduced drain output. The study further highlights the synergistic benefits of combining TXA with local anaesthetic agents such as lidocaine and epinephrine. This combination was found to not only enhance hemostasis and reduce operative time but also prolong the duration of local anaesthesia. While results were promising across all included studies, the authors have called for standardised dosing regimens and outcome grading systems to support consistent and safe implementation globally. ]]> https://biospectrumindia.com/news/91/26264/s-l-raheja-hospital-unveils-ai-enabled-digital-pet-ct-3t-mri-and-advanced-nicu-picu-units.html https://biospectrumindia.com/news/91/26264/s-l-raheja-hospital-unveils-ai-enabled-digital-pet-ct-3t-mri-and-advanced-nicu-picu-units.html Thu, 19 Jun 2025 00:00:00 +0530 S.L. Raheja Hospital, a Fortis Associate, has strengthened its commitment to delivering state-of-the-art diagnostic care with the launch of artificial intelligence (AI)-enabled Digital Positron Emission Tomography – Computed Tomography (Digital PET CT) scan and 3 Tesla Magnetic Resonance Imaging (3T-MRI) services.  These additions mark a milestone in the hospital’s journey toward providing precision-driven diagnostics and critical paediatric care in Mumbai. This is the second digital PET CT scan facility of its kind in Mumbai, bringing world-class imaging capabilities closer to patients. In addition, the hospital introduced advanced Neonatal Intensive Care Unit (NICU) and Pediatric Intensive Care Unit (PICU) services to further enhance critical care for infants and children.  The AI-enabled PET CT and MRI facilities, will be headed by Dr Mary Anne Joseph, Head-Nuclear Imaging and Dr Sanjay Bhatia, Consultant-Dept. of Radiology, respectively. The new digital PET CT delivers enhanced resolution, faster imaging time, and improved patient comfort. It is equipped with AI-enabled software to provide better precision in identifying lesions. This technology is used for cancer, neurology, infection, inflammation, and cardiology—for diagnosis, staging, and assessment of treatment response. The state-of-the-art 3 Tesla MRI machine is AI-enabled and will produce sharper more detailed high-resolution images. It has a stronger magnet that allows for faster scans, which reduces patient time in the machine and improves workflow, and comes with enhanced precision which helps in early diagnosis and more accurate treatment planning. The NICU houses seven beds, and is fully equipped with high-frequency ventilators, continuous positive airway pressure (CPAP) units, LED phototherapy systems, and medical-grade sterilisers. The PICU consists of four beds, with one dedicated isolation bed for immunocompromised or infectious cases, ensuring maximum protection and personalised care.  ]]> https://biospectrumindia.com/news/91/26231/renalyx-launches-worlds-first-indigenous-ai-based-smart-hemodialysis-machine.html https://biospectrumindia.com/news/91/26231/renalyx-launches-worlds-first-indigenous-ai-based-smart-hemodialysis-machine.html Wed, 11 Jun 2025 00:00:00 +0530 Bengaluru-based Renalyx Health Systems has launched RENALYX – RxT 21, world's first fully indigenous, artificial intelligence (AI) and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility.   Price starting at Rs 6.7 lakh - significantly lower than the imported machines - RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions.   Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues.   RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification.   Renalyx has plans to invest Rs 800 crore in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also have plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand.   The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years.   With initial deployments of the machine planned in Maharashtra and Karnataka, Renalyx will go for rapid pan-India distribution of RENALYX – RxT 21 with its partners as well as exports to other countries. The company has successfully penetrated international markets, securing orders from South Africa, the USA, and Europe.   The Indian CDSCO approval of the machine is in its final stages and is expected by July 2025, while the US FDA approval process is underway and anticipated by March 2026.   Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people.    The company, in collaboration with its partner, will set up franchise centres across India and in international markets.   In addition, Renalyx has awarded manufacturing license to Bharat Electronics Ltd. (BEL) to produce 6,000 RENALYX – RxT 17 in the next three years. RENALYX – RxT 17 is a previously launched dialysis machine by Renalyx which comes with standard features and facilities.  ]]> https://biospectrumindia.com/news/91/26219/zimmer-biomet-introduces-latest-orthopaedic-innovations-in-india.html https://biospectrumindia.com/news/91/26219/zimmer-biomet-introduces-latest-orthopaedic-innovations-in-india.html Mon, 09 Jun 2025 00:00:00 +0530 US-based Zimmer Biomet has announced the launch of groundbreaking orthopaedic technologies in India at ZB Next. This extensive portfolio, spanning hip, knee, and shoulder segments, is designed to empower surgeons with enhanced precision, optimise patient outcomes, and support the entire continuum of care, from pre-operative planning through post-operative recovery. Featured innovations within this advanced portfolio include: mymobility®, an AI-powered digital care management platform ROSA® Partial Knee and ROSA® Hip, robotic-assisted surgical systems G7® Acetabular System RibFix Blu® Thoracic Fixation System Comprehensive Micro Stems Comprehensive Augmented Base Plate® Signature ONE® Version 2 Planning Software Tricera® System The portfolio was launched during its flagship innovation showcase, ZB Next, with events held in Mumbai and Delhi, bringing together healthcare professionals and other key stakeholders to explore the latest advancements in musculoskeletal health. “At ZB Next, we showcased our extensive portfolio of solutions that are transforming orthopaedic care in India. It’s an opportunity to connect with our customers and clinical partners, share insights, and reinforce our commitment to improving the quality of life for patients,” said Ajay Bagga, Managing Director, Zimmer India. The ZB Next events featured interactive demonstrations and peer-to-peer engagement, highlighting the value of connected technologies and advanced surgical tools in supporting healthcare professionals across India. ]]> https://biospectrumindia.com/news/91/26187/govt-backs-indias-first-indigenous-thrombectomy-device-by-s3v-vascular-technologies.html https://biospectrumindia.com/news/91/26187/govt-backs-indias-first-indigenous-thrombectomy-device-by-s3v-vascular-technologies.html Fri, 30 May 2025 00:00:00 +0530 In a significant boost to India's medtech innovation landscape, the Technology Development Board (TDB), Department of Science and Technology (DST), has extended financial support to S3V Vascular Technologies Limited, Mysuru, for their project titled “Integrated Manufacturing of Mechanical Thrombectomy Kit for Treatment of Acute Ischemic Stroke.” The board has sanctioned assistance to this pioneering initiative aimed at transforming stroke treatment through indigenous innovation. The project envisions the establishment of a state-of-the-art upstream integrated manufacturing facility at the Medical Devices Park, Oragadam, Sriperumbudur (Chennai), to develop and manufacture advanced mechanical thrombectomy kits—a life-saving intervention for patients suffering from acute ischemic stroke due to large vessel occlusion. Compared to conventional thrombolysis, thrombectomy offers significantly improved outcomes, reducing the risk of long-term paralysis and disability. Thus making a difference between “PARALYSIS and RECOVERY” S3V Vascular Technologies is set to become the first Indian company to indigenously design and manufacture the complete suite of neuro-intervention devices, including microcatheters, aspiration catheters, guidewires, and stent retriever systems in an upstream integrated facility. The company also intends to file patents for critical innovations such as the clot retriever head design, braid-over-coil aspiration catheter structures, and several advanced process technologies. Dr. N.G. Vijaya Gopal, Managing Director  of M/s S3V Vascular Technologies said, "Our integrated manufacturing facility will not only reduce dependency on imports of the finished medical devices used in Mechanical Thrombectomy  but also reduces Indias dependency on import of the raw materials used in manufacturing of these critical complex lifesaving medical devices. We have initiated the CE and USFDA approval process for these devices to expand our access to cutting-edge stroke care solutions across India, Asia, Latin America, Europe and USA." ]]> https://biospectrumindia.com/news/91/26084/breach-candy-hospital-introduces-modular-operation-theatres-in-collaboration-with-drger-india.html https://biospectrumindia.com/news/91/26084/breach-candy-hospital-introduces-modular-operation-theatres-in-collaboration-with-drger-india.html Tue, 06 May 2025 00:00:00 +0530 Breach Candy Hospital, one of Mumbai's most renowned healthcare institutions, has unveiled its new state-of-the-art Modular Operation Theatres (OTs) in collaboration with Dräger India, a global leader in medical and safety technology. As part of its continued commitment to providing world-class healthcare services, the modular operating theatres aim to elevate surgical standards and improve patient care. The journey commenced with the installation of three Modular Operation Theatres in the hospital’s new building, marking a significant transition for Breach Candy Hospital towards modern surgical infrastructure. Recognising the potential for further enhancement, the hospital decided to expand it modular operating room theatres further in the coming years. The project posed a unique challenge as the operating theatre complex remained functional throughout the construction, requiring meticulous care to maintain sterility and ensure patient safety. The collaboration between Breach Candy Hospital and Dräger India resulted in a seamless upgrade. The new modular system not only meets international standards but also reflects a shared vision of improving healthcare delivery.  The newly added modular operation theatres at Breach Candy Hospital are equipped with cutting-edge technology, ensuring optimal sterility, performance, and patient safety. Built with high-quality materials, these state-of-the-art OTs minimise infection risks, contributing to better surgical outcomes. Their thoughtful design enhances workflow efficiency and surgical team comfort, while advanced safety standards create optimal conditions for complex procedures.   ]]> https://biospectrumindia.com/news/91/26041/philips-launches-new-ai-enabled-elevate-platform-upgrade-on-epiq-elite-ultrasound-imaging-platform-in-india.html https://biospectrumindia.com/news/91/26041/philips-launches-new-ai-enabled-elevate-platform-upgrade-on-epiq-elite-ultrasound-imaging-platform-in-india.html Fri, 25 Apr 2025 00:00:00 +0530 Royal Philips, a global leader in health technology, has launched its new cutting-edge Elevate Platform upgrade release on the EPIQ Elite ultrasound imaging platform, at UltraFest 2025 in India. This pioneering solution addresses the increasing demand for streamlined workflows and greater diagnostic efficiency, enabling clinicians to deliver timely, confident decisions for a wider range of patients. Elevate platform is equipped with advanced Artificial Intelligence capabilities which have proven instrumental in enhancing diagnostic accuracy and operational efficiency. The platform also incorporates proactive system monitoring, allowing care teams to consult remotely, support diagnosis from a distance, and troubleshoot systems without the need for on-site intervention. Sachin Grover, Head of Ultrasound, Philips Indian Subcontinent commented “Elevate is a powerful example of our commitment to helping healthcare providers address today’s urgent challenges—from rising patient volumes to workforce constraints. With smarter automation, faster diagnostics, and greater clinical precision, we’re enabling clinicians to deliver high-quality care more efficiently. At Philips, we firmly believe in the transformative potential of Artificial Intelligence to make healthcare more effective, accessible, and inclusive bringing us closer to a future where we provide better care for more people.” The latest suite of automation features includes Quick Launch pre-sets to streamline platform setup and routine procedures, reducing imaging optimization time. Other features include automatic adjustment of image brightness and uniformity, as well as CEUS AutoScan, which improves image quality by fine-tuning each pixel and frame. For liver elastography, the system offers Auto ElastQ, which helps measure liver stiffness more easily and quickly, providing a simple, non-invasive way to assess liver health. ]]> https://biospectrumindia.com/news/91/26022/fujifilm-india-unveils-eluxeo-8000-therapeutic-endoscopy-solution-.html https://biospectrumindia.com/news/91/26022/fujifilm-india-unveils-eluxeo-8000-therapeutic-endoscopy-solution-.html Tue, 22 Apr 2025 00:00:00 +0530 Fujifilm India recently introduced its groundbreaking ELUXEO 8000 Therapeutic Endoscopy Solution at 22nd MUMBAI LIVE Endoscopy event hosted by Sir HN Reliance Foundation Hospital, one of the India’s premier international Endoscopy educational event. Previously available only in Japan and Europe, this advanced endoscopic technology is now entering the Indian market with a focus on enhancing image quality, expanding therapeutic capabilities, and streamlining workflow for healthcare providers. The ELUXEO 8000 is equipped with breakthrough technologies including ACI (Amber-red Color Imaging), TNR (Triple Noise Reduction), and E-DRIP (Extended Dynamic Range Image Processing) offering sharp, high-quality images with minimal halation. These innovations make it easier for healthcare professionals to perform more precise, complex therapeutic procedures. The newly launched system includes the next-generation therapeutic endoscopes, the system is particularly suited for navigating narrow luminal areas and ensuring optimal outcomes during challenging procedures. Dheeraj Chaudhri, Head of the Endoscopy Systems Division at Fujifilm India, remarked, “Our robust R&D ecosystem and close collaboration with global clinicians have enabled us to stay ahead in technological innovation. The ELUXEO 8000, paired with our new generation of gastro endoscopes, sets a new benchmark for advanced endoscopic procedures in India.” ]]> https://biospectrumindia.com/news/91/26015/paras-defence-to-manufacture-critical-magnets-for-indias-first-indigenous-mri-machines.html https://biospectrumindia.com/news/91/26015/paras-defence-to-manufacture-critical-magnets-for-indias-first-indigenous-mri-machines.html Mon, 21 Apr 2025 00:00:00 +0530 Mumbai-based Paras Defence & Space Technologies, a leading Indian defence engineering company specialising in advanced Optronic Systems for Defence & Space, Defence Electronics, Electro Magnetic Protection Solutions & Heavy Engineering, has announced its pivotal role in developing India’s first indigenous Magnetic Resonance Imaging (MRI) machine as part of a consortium spearheaded by the Society for Applied Microwave Electronics Engineering and Research (SAMEER), an autonomous R&D institution under Ministry of Electronics and Information Technology (MEITY).  This initiative marks a major step towards self-reliance in high-end medical technology, with Paras Defence playing a key role in reducing import dependency and making advanced diagnostics more accessible and affordable. Paras Defence will be responsible for developing and manufacturing the high-performance magnets that form the core of MRI machines, leveraging its extensive expertise in precision engineering, electromagnetics and advanced materials. Paras Defence has co-developed the MRI magnet technology in close consultation with the Inter-University Accelerator Centre (IUAC) and international experts, ensuring alignment with global performance standards. The magnets are one of the most complex and expensive components in MRI machines. India has traditionally been import-dependent, making Paras Defence’s contribution a breakthrough in India’s quest for technological sovereignty in medical imaging. This collaboration would add Paras Defence to a select global group of companies possessing the capability to manufacture MRI-grade magnets. The manufacturing of these MRI magnets is planned to be done at Ambernath Facilities of Paras Defence, with production scheduled to begin in the next financial year. Paras Defence will employ advanced electromagnetic, cryogenics and superconducting technologies to ensure that these magnets meet global standards in imaging quality and efficiency.   ]]> https://biospectrumindia.com/news/91/26003/worlds-first-usfda-cleared-microneedling-pen-launches-in-india.html https://biospectrumindia.com/news/91/26003/worlds-first-usfda-cleared-microneedling-pen-launches-in-india.html Thu, 17 Apr 2025 00:00:00 +0530 Skinwood Luxury Aesthetic Centre has announced the official Indian launch of SkinPen Precision, the first US FDA-cleared microneedling device, marking a groundbreaking advancement in the field of aesthetic dermatology. This revolutionary treatment is now available exclusively at Skinwood Luxury Aesthetic Centre, reinforcing the clinic as a pioneer of dermatological innovation and patient-first care. Developed by Crown Aesthetics, USA, SkinPen Precision is a state-of-the-art microneedling system that harnesses the body’s natural wound healing process to improve skin texture and tone. It is designed to treat a wide range of skin concerns including acne scars, fine lines, wrinkles, surgical scars, stretch marks, skin laxity, enlarged pores, and uneven pigmentation. It has already earned global trust as the gold standard in microneedling technology. The system is powered by patented Intuitive Speed Control Technology, ensuring optimal performance across varying skin thicknesses while maintaining a consistent 7,000 RPM. The ultrasonically sealed handpiece prevents blood or fluid backflow, reducing any risk of cross-contamination, and its unique Advanced Cartridge Unit features 14 medical-grade stainless steel needles designed for precision and durability. As the first device of its kind to receive this approval, it has undergone rigorous safety and efficacy evaluations, giving both practitioners and patients confidence in its performance. This launch elevates the standard of care in aesthetic dermatology across India, setting a new benchmark for results-driven treatments backed by clinical research.   ]]> https://biospectrumindia.com/news/91/26010/zydus-medtech-and-braile-biomedica-of-brazil-ink-global-licensing-pact-to-commercialise-tavi-technology.html https://biospectrumindia.com/news/91/26010/zydus-medtech-and-braile-biomedica-of-brazil-ink-global-licensing-pact-to-commercialise-tavi-technology.html Thu, 17 Apr 2025 00:00:00 +0530 Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited specialising in medical technology development, has entered into a strategic partnership with Braile Biomédica Indústria, Comércio e Representações Ltda., (Braile Biomedica) - an innovative cardiovascular device manufacturer based in Brazil - to exclusively commercialise its Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other select markets. This agreement marks a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment. The global TAVI market, currently valued at over $6 billion, continues to witness strong growth driven by the increasing incidence of aortic stenosis and the rising demand for minimally invasive cardiac procedures. Zydus MedTech, which is actively building its interventional cardiology portfolio, will introduce Braile Biomedica’s advanced balloon-expandable TAVI system to international markets, leveraging its commercial and regulatory expertise. Braile Biomedica - with a proven track record in cardiovascular innovation, particularly in Latin America - will manufacture and supply the product for these markets. In addition to spearheading commercialisation, Zydus MedTech will also retain rights to manufacture select components of the TAVI system. This collaboration provides operational flexibility while laying the foundation for further product innovation and development. The TAVI procedure is a recognised breakthrough in structural heart care, particularly for elderly patients or those at high surgical risk. By replacing the diseased aortic valve through a catheter-based approach - without the need for open-heart surgery - patients often experience significantly shorter recovery times and reduced procedural risks. The expansion of TAVI indications to all-risk patients has further accelerated its adoption.   ]]> https://biospectrumindia.com/news/91/25987/australias-telemedc-partners-with-indian-startup-and-healthcare-to-expand-ai-based-eye-disease-screening.html https://biospectrumindia.com/news/91/25987/australias-telemedc-partners-with-indian-startup-and-healthcare-to-expand-ai-based-eye-disease-screening.html Tue, 15 Apr 2025 00:00:00 +0530 TeleMedC, an Australia-based leader in artificial intelligence (AI)-powered retinal disease diagnostics is expanding its footprint in India, through a strategic partnership with Mumbai-based startup AND Healthcare Solutions to deliver low-cost, AI-driven eye screening solutions to millions. The move aims to tackle the growing burden of preventable eye diseases by enabling early detection and intervention. Through its AI-powered technology, the company enables early detection of conditions such as diabetic retinopathy, glaucoma, and macular diseases, helping to prevent vision impairment and blindness.  Supported by Trade and Investment Queensland (TIQ), the Queensland Government’s global business agency, TeleMedC and AND Healthcare Solutions will roll out advanced eye imaging and AI-powered diagnostics across India. This initiative is poised to strengthen India’s healthcare innovation ecosystem, making critical eye care more affordable and accessible to all.  TeleMedC aims to screen one billion eyes over the next decade, driving early detection, disease prevention, and affordable access to advanced diagnostics. The company is actively partnering with Indian healthcare institutions, research bodies, and non-profits to accelerate innovation in eye health. Recently, TeleMedC collaborated with leading Indian healthcare institutions, including Aravind Eye Hospital, through the Australia-India Strategic Research Fund. This partnership is advancing AI-driven eye health solutions, reinforcing the company’s commitment to cutting-edge diagnostics. Expanding its impact, TeleMedC is working with SMEs and large corporations to integrate AI-powered eye screening into Corporate Social Responsibility (CSR) initiatives, making preventive healthcare more inclusive in India.      ]]> https://biospectrumindia.com/news/91/25983/us-based-microport-orthopedics-launches-implants-and-technology-in-india.html https://biospectrumindia.com/news/91/25983/us-based-microport-orthopedics-launches-implants-and-technology-in-india.html Mon, 14 Apr 2025 00:00:00 +0530 MicroPort Orthopedics Inc., a US headquartered global medical devices company, has announced the introduction of its flagship second generation solution, the Evolution Medial-Pivot Knee in India. This innovative solution is designed to deliver superior flexion stability, anatomic motion, and wear-limiting design, replicating the natural stability and motion of the knee to allow superior patient outcomes after total knee replacement surgery. The Evolution Medial-Pivot Knee has received positive feedback from surgeons and patients worldwide. This unique design has achieved clinical success worldwide, with documented 98.8% survivorship at 17 years and a 95% patient satisfaction rate. With over 25 years of documented usage, MicroPort Orthopedics’ line of Medial-Pivot products have been used in over 1,000,000 cases in 70 countries worldwide. MicroPort’s in-house international experts recently trained Indian surgeons across many cities with meticulously planned educational sessions and on-site support for surgeries through a professional team. This launch will now allow access for Indian patients to globally renowned cutting-edge technologies, addressing patient concerns like a feeling of instability while climbing up or down the stairs and an overall discontent with the post operative knee feeling unnatural. With this focus on professional training for healthcare professionals, MicroPort Orthopedics actively provides the latest scientific insights and surgical techniques through its online to on- site platform called Joint Academy, which is a global initiative aimed at providing best-in-class medical education through international key opinion leaders. ]]> https://biospectrumindia.com/news/91/25968/drger-announces-launch-of-atlan-a100-anesthesia-workstation-in-india.html https://biospectrumindia.com/news/91/25968/drger-announces-launch-of-atlan-a100-anesthesia-workstation-in-india.html Thu, 10 Apr 2025 00:00:00 +0530 Dräger, a global leader in medical and safety technology, announces the launch of the Atlan® A100 anesthesia workstation in India, an innovative anesthesia workstation engineered to enhance patient care and optimize workflows in the operating room (OR).  The Atlan® A100 system offers advanced lung protective ventilation, low-flow anesthesia, and infection prevention measure, providing medical professionals with the tools they need to optimize patient outcomes and enhance efficiency in the perioperative field. Key features of the Atlan® A100/XL system include:   Adaptive piston control, precise tidal volume delivery, and PEEP compensation to reduce postoperative pulmonary complications. Integrated active warming of the breathing system and fresh gas decoupling function to minimize anesthetic agent consumption and environmental impact. Reprocessing-friendly design with smooth surfaces and quick disassembly/assembly of the breathing system to support infection control. Scalability and flexibility to meet the specific spatial conditions of different ORs, enhancing staff satisfaction and performance.   “At Dräger, we are committed to innovation and excellence in healthcare technology. The Atlan® A100 system is designed to improve patient care and safety through advanced lung protective ventilation and low-flow anesthesia, while focusing on optimizing the entire perioperative process – improving both patient outcomes and operational efficiency,” said Shalin Patel, CEO Asia Pacific, expressing his excitement about the launch in India. The Atlan® A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments. Its sophisticated networking capabilities provide easy access to patient and therapy data, ensuring robust security through encryption and controlled user authentication.  Dhritimay Dhar, Vice President- Sales and Marketing, Medical Business, highlighted the system’s versatility and connectivity, saying, " The Atlan® A100/XL system is incredibly versatile and adaptable to the diverse needs of healthcare professionals. Its seamless integration with hospital networks and therapy devices ensures streamlined data exchange, which ultimately enhances patient care, supports infection prevention, and delivers a high level of performance in acute care settings.” Atlan® A100/XL anaesthesia machine comprises a fully Integrated Workstation Solution together with Dräger Patient monitoring solutions (e.g. Infinity Acute Care System and Vista Patient Monitoring System). This provides ventilation parameters, gas measurements and vital signs data on a single interface for a complete clinical view at the point of care to support decision making for enhanced patient care and efficiency during perioperative care.  Furthermore Atlan® A100/XL when networked with Dräger Connect, our innovative cloud-enabled digital platform, delivers valuable insights via data analytics and digital services. This connectivity streamlines workflows, optimizes costs, and enhances operational efficiency in operating rooms.   The Atlan® A100/XL is manufactured by Drägerwerk AG & Co. KGaA and is now available for use across healthcare facilities in India. ]]> https://biospectrumindia.com/news/91/25801/pm-inaugurates-namo-hospital-in-silvassa-witnesses-indias-first-ai-powered-knee-replacement-robot-misso.html https://biospectrumindia.com/news/91/25801/pm-inaugurates-namo-hospital-in-silvassa-witnesses-indias-first-ai-powered-knee-replacement-robot-misso.html Fri, 07 Mar 2025 00:00:00 +0530 Prime Minister (PM) Narendra Modi inaugurated the first phase of the 450-bedded Namo Hospital in Silvassa, Dadra and Nagar Haveli. The Rs 460 crore facility is a state-of-the-art healthcare institution, designed to provide advanced medical services to the region. The Prime Minister also launched multiple public welfare projects worth over Rs 2,500 crore, including new hospitals, schools, and critical infrastructure initiatives aimed at enhancing public services and healthcare accessibility. During his visit, PM Modi reviewed the 3D model of the upcoming hospital, appreciating its modern medical infrastructure. A significant highlight of the event was the demonstration of Misso, India’s first indigenously developed AI-powered robotic system for knee replacement surgery, presented by Meril’s CEO, MVivek Shah. This cutting-edge technology is poised to revolutionise orthopaedic surgeries in India, offering greater precision and improved patient outcomes. The Prime Minister expressed keen interest in the innovation and technological advancements driving India’s healthcare sector. He emphasised the importance of indigenous medical technology in making high-quality healthcare more accessible. The launch of Namo Hospital marks a crucial step in strengthening India’s medical ecosystem and reaffirms the country’s commitment to world-class healthcare infrastructure. ]]> https://biospectrumindia.com/news/91/25782/apollo-hospitals-iba-to-introduce-proteus-one-proton-beam-therapy-to-india.html https://biospectrumindia.com/news/91/25782/apollo-hospitals-iba-to-introduce-proteus-one-proton-beam-therapy-to-india.html Tue, 04 Mar 2025 00:00:00 +0530 Apollo Hospitals has inked a landmark partnership with Ion Beam Applications (IBA), the global leader in Proton Beam Therapy (PBT) solutions, to introduce Proteus One system in India.  The new Proteus One system includes the DynamicARC beam delivery technology, subject to statutory approvals. The signing was officiated by Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd (AHEL) and Olivier Legrain, Chief Executive Officer, IBA, in the distinguished presence of Her Royal Highness Princess Astrid of Belgium, Representative of His Majesty King Philippe. Apollo Hospitals Enterprise Ltd introduced Proton Therapy to India in 2019 at Apollo Proton Cancer Centre, its futuristic cancer centre in Chennai—becoming the first and only Proton Therapy facility in South Asia and the Middle East. Since its inception, over 2,000 patients from 147 countries have benefited from this cutting-edge technology. Proton therapy is an effective treatment of tumours of the Central Nervous System, head and neck tumors, paediatric and urological, and complex cancers. According to the studies, the global burden of cancer is projected to increase to 21.4 million incident cases by 2030. As per the study published in The Lancet Regional Health, worldwide in terms of absolute incidence number, following China and the US, India ranks third, contributing 7.5% of all new cancer incidences and is expected to grow to 1.5 million this year. Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd, highlighted, “Cancer care is evolving rapidly, and at Apollo, we remain steadfast in our mission to stay ahead of this evolution. The introduction of the Proteus One system is a significant leap towards personalized, precise, and highly effective treatment for cancer patients."   ]]> https://biospectrumindia.com/news/91/25747/medtronic-and-philips-partner-to-upskill-300-clinicians-in-structural-heart-imaging-in-india-.html https://biospectrumindia.com/news/91/25747/medtronic-and-philips-partner-to-upskill-300-clinicians-in-structural-heart-imaging-in-india-.html Thu, 27 Feb 2025 00:00:00 +0530 Medtronic, a leader in medical technology, and Philips, a leader in health technology, have announced the signing of a Memorandum of Understanding (MoU) in India, to educate and train cardiologists and radiologists on advanced imaging techniques for structural heart diseases. This partnership aims to upskill 300+ clinicians in multi-modality imaging such as echocardiography (echo) and Magnetic Resonance Imaging (MRI), especially for End-Stage Renal Disease (ESRD) patients. The training programme will combine didactic sessions with hands-on experience delivered on Philips’ cutting-edge ultrasound and MRI systems, under the guidance of renowned international and Indian experts. 15 key medical institutions have been identified specialising in structural heart procedures for these educational workshops. Speaking on the collaboration Mandeep Singh Kumar, Managing Director and Vice President of Medtronic India said, “This collaboration represents a significant step forward in our ongoing commitment to improving patient outcomes, particularly for those with chronic kidney disease and ESRD. By providing specialised training and advanced imaging solutions, we aim to equip healthcare professionals with the tools they need to enhance the precision of TAVI (Transcatheter Aortic Valve Implantation) procedures and ultimately improve patient care." “At Philips, every effort we make is centered on providing better care for more people and this partnership with Medtronic is another step towards our goal. By focusing on innovation and education in structural heart imaging across India, we aim to address the rapid advancements in multi-modality imaging through continuous learning. Our objective is to empower clinicians with advanced techniques such as echocardiography and MRI, leading to more accurate diagnoses and improved care outcomes, especially for ESRD patients”, said Bharath Sesha, Managing Director, Philips Indian Subcontinent. ]]> https://biospectrumindia.com/news/91/25662/johnson-johnson-unveils-new-intraocular-lens-tecnis-puresee-in-india.html https://biospectrumindia.com/news/91/25662/johnson-johnson-unveils-new-intraocular-lens-tecnis-puresee-in-india.html Tue, 11 Feb 2025 00:00:00 +0530 Johnson & Johnson, a global leader in eye health, has announced that its TECNIS PureSee purely refractive intraocular lens (IOL) for individuals with presbyopia is now available in India. The TECNIS PureSee IOL features a purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-category contrast and low-light performance, comparable to a monofocal IOL. “Cataract surgery is the most common surgery performed globally, with 28 million procedures each year. But only 10-15% of patients are getting advanced optical IOLs specifically designed for addressing issues of astigmatism and presbyopia, said Burzin Shahana, Country Manager, Surgical Vision India & South Asia, Johnson & Johnson MedTech. While choosing any IOL, surgeons and patients have to consider many factors. For example, a lens that offers clear sight at all distances without spectacles, may not be able to remove glares and halos. The purely refractive design of TECNIS PureSee lens addresses these issues and therefore improves the overall outcomes for both patients and surgeons. With its purely refractive design, the TECNIS PureSee IOL ensures surgeons’ ease of use in providing high tolerance to refractive error.  By 2050, the number of people aged over 60 years old is expected to more than double to 2.1 billion, and Asia Pacific will account for 65% of the global increase for this age group. Cataracts are the leading cause of treatable blindness in the world. Medical science and technology have advanced today such that a qualified eye surgeon can remove a cataract and replace it with an IOL, and patients typically experience improved eyesight the very same day. The TECNIS PureSee IOL is now available in India. ]]> https://biospectrumindia.com/news/91/25606/terumo-india-unveils-advanced-models-for-simulation-based-training-to-strengthen-its-skill-lab.html https://biospectrumindia.com/news/91/25606/terumo-india-unveils-advanced-models-for-simulation-based-training-to-strengthen-its-skill-lab.html Wed, 29 Jan 2025 00:00:00 +0530 Terumo India, the Indian subsidiary of Terumo Corporation, a global leader in medical technology, has taken a significant step forward in its group mission of ‘contributing to society through healthcare’ with the advancement of its Terumo India Skill Lab (TISL). This state-of-the-art facility, designed to enhance the clinical skills of healthcare professionals (HCPs), has been upgraded recently to offer specialised simulation-based training. The advanced Terumo India Skill Lab (TISL) includes the latest cutting-edge equipment to enhance simulation training for complex cardiovascular and interventional procedures. The facility includes the Mentice computer-based simulator and physical training models, designed to simulate various interventional procedures. These tools enable healthcare professionals to better prepare for real-world scenarios and achieve optimal patient outcomes. Notably, a Beating Heart Model has been introduced to simulate the movement of the heart as it beats, while a Liver Flow Model and Iliac Model have been added to train interventional radiologists for minimally invasive procedures. Dr Anudeep Sandhu, Director of Medical Affairs and Clinical Affairs, said, “By advancing Terumo India Skill Lab, we are directly addressing the critical need for enhanced HCP training in India, where complex procedures like percutaneous coronary interventions (PCI) are becoming increasingly vital. Our state-of-the-art facility equips healthcare professionals with the advanced skills needed to manage complications effectively." With over 1,500 HCPs trained every year, TISL aims to expand its reach and support more professionals by 2025. The new training room at TISL, which can accommodate up to 32 people, is equipped with audio and video conferencing capabilities to facilitate remote learning and collaboration.  ]]> https://biospectrumindia.com/news/91/25601/abbott-introduces-next-generation-of-heart-valve-technology-designed-to-treat-aortic-stenosis-in-india.html https://biospectrumindia.com/news/91/25601/abbott-introduces-next-generation-of-heart-valve-technology-designed-to-treat-aortic-stenosis-in-india.html Tue, 28 Jan 2025 00:00:00 +0530 Abbott, the global healthcare company, has announced the launch of Navitor Vision in India for the treatment of patients with symptomatic severe aortic stenosis who are at high or extreme surgical risk. The device is the latest iteration of the company’s Navitor transcatheter aortic valve implantation/replacement (TAVI/TAVR) system. The Navitor platform, known for its stable delivery, remarkable performance, and future readiness, has been enhanced with three large Vision markers for improved visibility and easier valve deployment during a TAVI/TAVR procedure. These markers help interventionists implant the device more accurately, while making the TAVI valve easier to see during the procedure. Aortic stenosis is one of the most common and life-threatening heart valve diseases. Prior to TAVI, the standard of care for severe aortic stenosis was surgical aortic valve replacement, but not all patients were candidates for open-heart surgery. Neeraj Singh, country manager for Abbott’s structural heart business in India said, “For some people, open-heart surgery is considered a high-risk procedure due to the potential complications stemming from age, frailty or having multiple other diseases or conditions. TAVI serves as a less invasive alternative to surgical aortic valve replacement and can reduce symptoms and improve the life expectancy of patients with this condition. Abbott’s Navitor Vision valve is an important addition to our range of treatments for structural heart issues, particularly for heart valve disease and offers hope to people who may not have other treatment choices.” The Navitor Vision valve comes in different sizes to fit heart openings (annulus) ranging from 19 mm to 27 mm and thereby fits almost all patients in need of TAVI. The device also has a dynamic sealing cuff that reduces the leaking of blood back to the heart. Navitor is implanted with Abbott's FlexNav delivery system, which offers a slim design, allowing treatment of people with vessels as small as 5.0 mm. The FlexNav catheter can accommodate different aortic anatomies for stable, predictable and accurate valve delivery and placement. ]]> https://biospectrumindia.com/news/91/25599/royal-philips-launches-ai-enabled-ct-5300-at-asian-oceanian-congress-of-radiology-in-chennai.html https://biospectrumindia.com/news/91/25599/royal-philips-launches-ai-enabled-ct-5300-at-asian-oceanian-congress-of-radiology-in-chennai.html Mon, 27 Jan 2025 00:00:00 +0530 Royal Philips, a global leader in health technology, has launched the artificial intelligence (AI) enabled CT 5300 at the 23rd Asian Oceanian Congress of Radiology (AOCR) 2025. Philips CT 5300 system, equipped with advanced AI capabilities, is designed for diagnosis, interventional procedures and screening. The flexible X-ray CT system increases diagnostic confidence, streamlines workflow efficiency, and maximises system up-time, helping to improve patient outcomes and department productivity. With cutting-edge AI features like AI reconstruction, AI cardiac motion correction & AI smart workflows, CT 5300 is designed to enhance diagnostic accuracy coupled with high speed.  Philips also celebrated the installation of 1500+ Helium Free 1.5T wide Bore (70 cm) MRI systems worldwide. The revolutionary MRI with BlueSeal magnet technology is the industry's first wide bore 1.5T fully sealed magnet, which relieves healthcare providers from helium-related complications and unpredictability. BlueSeal magnet requires only 0.5% of helium compared to a conventional MRI system. Based on a decade of innovation, Philips BlueSeal is a fully sealed magnet designed to simplify MRI installations, reduce lengthy and costly disruptions in MRI services, and help healthcare departments transition to sustainable helium-free operations. This revolutionary magnet operates with only seven liters of liquid helium and is fully sealed – freeing up the minds of healthcare providers from potential helium complications. With BlueSeal magnet, Philips aims to help MRI facilities overcome potential helium-related issues of classic magnet design and eliminate the radiology department's dependency on scarce helium supply.    ]]> https://biospectrumindia.com/news/91/25584/siemens-healthineers-unveils-latest-medtech-breakthroughs-at-asian-oceanian-congress-of-radiology.html https://biospectrumindia.com/news/91/25584/siemens-healthineers-unveils-latest-medtech-breakthroughs-at-asian-oceanian-congress-of-radiology.html Fri, 24 Jan 2025 00:00:00 +0530 Siemens Healthineers, a leading medical devices company, showcased a comprehensive range of diagnostic imaging solutions at Asian Oceanian Congress of Radiology (AOCR) 2025 in Chennai. Highlighting the importance of informed clinical decision-making across the entire healthcare continuum, the company introduced its innovative portfolio in MRI, CT, digital X-ray, and ultrasound, reinforcing its commitment to advancing precision medicine. The showcase features a range of cutting-edge solutions, including the helium-free 1.5T Magnetom Flow MRI with Dry Cool technology, the advanced Dual Source CT scanner Somatom Pro.Pulse, and locally manufactured Digital X-ray systems Multix Impact E. Additionally, the AI-powered ultrasound systems Acuson Maple and Acuson Sequoia offer versatility and precision in imaging capabilities. MAGNETOM Flow is a latest AI-based 1.5 Tesla magnetic resonance imaging (MRI) platform based on innovative dry cool technology. This innovative design reduces liquid helium requirements from 1,500 liters to just 0.7 liters, enabling sustainability in the healthcare. SOMATOM Pro.Pulse is a cutting-edge Dual Source CT scanner designed to accommodate patients with high or irregular heart rates or limited breath-hold capabilities. AI assisted myExam Companion enhances the scanning experience for users and patients.  The MULTIX Impact E is a floor-mounted Digital Radiography X-ray system featuring the necessary tools for easy, intuitive system operation and allows for the detection of anatomical details at low doses of radiation, thereby ensuring patient safety and quality imaging.  ACUSON Maple is a powerful and versatile ultrasound system designed to address the growing diagnostic needs of healthcare providers in India and around the world. The Acuson Maple is equipped with AI-powered tools that enhances clinical ACUSON supporting clinicians in urban hospitals, rural clinics, and smaller healthcare centers across the country. ACUSON Sequoia is a cutting-edge diagnostic ultrasound system that leverages AI-powered technology to enhance accuracy and efficiency in various clinical settings.  The 23rd Asian Oceanian Congress of Radiology hosted by Tamil Nadu and Pondicherry chapter of Indian Radiological and Imaging Association (IRIA) is the largest radiology conference in Asia. ]]> https://biospectrumindia.com/news/91/25434/fujifilm-unveils-medical-training-simulator-designed-to-revolutionise-endoscopy-education.html https://biospectrumindia.com/news/91/25434/fujifilm-unveils-medical-training-simulator-designed-to-revolutionise-endoscopy-education.html Tue, 10 Dec 2024 00:00:00 +0530 Fujifilm India, a leader in medical technology, has unveiled the groundbreaking mikoto Colon Model, a cutting-edge endoscopy simulation technology, during the Indian Association of Gastrointestinal Endosurgeons (IAGES) Prof. Dr. B Krishna Rau Simulation Training Programme, a hands-on endoscopy workshop, in Chennai. The mikoto Colon Model is a state-of-the-art medical training simulator designed to revolutionise endoscopy education. Compact and portable, it combines advanced sensor technology with artificial intelligence to provide realistic feedback, evaluate procedures, and score performance. With four levels of difficulty, it enables self-paced learning for practitioners of varying expertise. This innovative simulator enhances skills, builds confidence, and ensures greater precision in real-world applications, ultimately contributing to improved patient outcomes and advancing the standards of endoscopic care. Prof. Masashi Fujii, MD, Ph.D., CEO of R Zero Inc., Japan, highlighted the significance of this innovation, stating "The mikoto Colon Model represents a leap forward in medical training. By combining technology with education, it allows healthcare professionals to refine their skills in a controlled, realistic environment, ensuring better patient outcomes." The mikoto Colon Model sets a new standard in endoscopy training. This state-of-the-art, portable medical simulator utilises advanced sensors and artificial intelligence to evaluate and score procedures, offering four levels of difficulty for self-guided learning. The unveiling of the mikoto Colon Model marks a transformative moment in medical training, underscoring Fujifilms dedication to advancing endoscopy education. By combining cutting-edge simulation technology with practical learning, it empowers healthcare professionals to enhance their skills and achieve better patient outcomes. ]]> https://biospectrumindia.com/news/91/25422/meril-life-sciences-launches-myval-octapro-transcatheter-heart-valve.html https://biospectrumindia.com/news/91/25422/meril-life-sciences-launches-myval-octapro-transcatheter-heart-valve.html Sun, 01 Dec 2024 00:00:00 +0530 Vapi-based Meril Life Sciences, a leading global medtech company specialising in cardiovascular and structural heart solutions, marked a significant milestone with the launch of its Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024. These esteemed scientific events provided an ideal platform for Meril to showcase its commitment to advancing structural heart care. The Myval THV series, known for its innovative contributions to transcatheter aortic valve replacement (TAVR) procedures, continues to set new benchmarks with the Myval Octapro THV. This latest iteration introduces low frame foreshortening, enhancing operator control and enabling precise deployment for improved procedural predictability. Additionally, its comprehensive size matrix, which includes conventional, intermediate, and extra-large valve sizes, ensures optimal valve selection tailored to diverse patient anatomies. At PCR London Valves 2024, Meril presented key findings from the LANDMARK trial subset analysis and comparative studies, further establishing the safety and efficacy of the Myval Transcatheter Heart Valve (THV) series. Published in EuroIntervention Journal, the findings confirmed the Myval THV’s non-inferiority to both Sapien and Evolut valve series at 30 days post-implantation, solidifying its position as a reliable solution for structural heart interventions. The results highlighted comparable composite safety and effectiveness outcomes between Myval and Sapien (24.7% vs. 24.1%), with Myval demonstrating a lower rate of permanent pacemaker implantation (15.0% vs. 17.3%) and superior hemodynamic performance. Similarly, the Myval THV series performed on par with Evolut in composite endpoints (24.7% vs. 30%), while showing advantages in reducing pacemaker implantation rates and moderate/severe valve regurgitation. Effective orifice areas were also comparable between 26 and 29 mm of Myval THV series and Evolut THV series, underscoring its strong performance in key clinical measures. ]]> https://biospectrumindia.com/news/91/25390/medtronic-launches-us-fda-approved-therapy-for-bladder-control-and-bowel-control-in-india.html https://biospectrumindia.com/news/91/25390/medtronic-launches-us-fda-approved-therapy-for-bladder-control-and-bowel-control-in-india.html Tue, 26 Nov 2024 00:00:00 +0530 Medtronic, a global leader in healthcare technology, has announced the India launch of the InterStim X Sacral Neuromodulation (SNM) system for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention. The InterStim X system offers personalized sacral nerve stimulation therapy. Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that regulate bladder functions, which may reduce symptoms of incontinence – such as frequent trips to the bathroom and accidents. Patients can try the InterStim X system with an evaluation phase before they decide to have the system implanted, and it's reversible if they change their Sacral neuromodulation procedure is performed in two stages. During the first stage, the lead is implanted and connected to an external stimulator to check therapeutic response for a period of 3-5 days. In stage II, the lead is connected to a subcutaneous implantable pulse generator (IPG) which is like a pacemaker. The IPG sends electrical signals via the lead which then signals the brain for voiding and control.  The InterStim™ X device and systems features: Proprietary 5th generation battery that offers more than 10 years of battery life without the need to recharge; the smart programmer is a device that resembles a common smartphone and has the capability of allowing patients to discreetly and independently adjust their choice of 11 therapy settings at home or on-the-go. SureScan™ technology enables full body 1.5T and 3T MRI scans under certain conditions, which means that the latest imaging techniques can be availed when needed to diagnose disease, plan treatment, and monitor treatment progress. The MRI mode can be easily activated or deactivated by the patient using the smart programmer under the guidance of their physician.   ]]> https://biospectrumindia.com/news/91/25387/smt-expands-global-footprint-with-launch-of-hydra-tavi-system-in-hungary.html https://biospectrumindia.com/news/91/25387/smt-expands-global-footprint-with-launch-of-hydra-tavi-system-in-hungary.html Mon, 25 Nov 2024 00:00:00 +0530 Surat-based Sahajanand Medical Technologies (SMT), a global leader in innovative vascular solutions, has announced the launch of its Hydra Transcatheter Aortic Valve Implantation (TAVI) system in Hungary, debuting with promising results at Szegedi Tudományegyetem Szent-György Albert Klinikai Központ. Under the leadership of Dr Ruzsa Zoltán and Dr. Szücsborús Tamás, the Hydra TAVI system has demonstrated positive initial outcomes, marking a significant milestone in advancing minimally invasive treatments for aortic stenosis.The Hydra TAVI system is crafted to address critical clinical needs by offering precise implantation and simplified coronary access, enabling safe and efficient procedures for aortic valve replacement. With an adaptable and robust design, Hydra offers healthcare professionals an advanced solution designed to enhance patient outcomes in cardiac care.With Hydra TAVI now available in 20+ countries, SMT’s global expansion strategy reflects its commitment to making high-quality cardiovascular solutions accessible worldwide. This availability emphasizes SMT’s mission to enhance patient outcomes by providing advanced, minimally invasive options for cardiac care globally.Hydra is re-sheathable, re-positionable and retrievable self-expanding transcatheter aortic valve ensuring patient safety and good results during deployment. It has advanced features like markers on the frame for accurate guidance while deploying the frame. Hydra has a supra-annular design which helps in larger aortic valve area and best-in-class hemodynamic performance post procedure. ]]> https://biospectrumindia.com/news/91/25358/lubrizol-and-polyhose-sign-mou-to-manufacture-medical-tubing-expand-capacity-in-chennai.html https://biospectrumindia.com/news/91/25358/lubrizol-and-polyhose-sign-mou-to-manufacture-medical-tubing-expand-capacity-in-chennai.html Fri, 15 Nov 2024 00:00:00 +0530 Lubrizol, a global leader in specialty chemicals, and Polyhose, global leader in fluid conveyance system, have signed a Memorandum of Understanding (MoU) to empower the Indian medical sector to achieve new levels of innovation. The MoU, which expands a longstanding partnership between the two organisations, was signed in the presence of Dr. T.R.B. Rajaa, Minister for Industries, Tamil Nadu and V Arun Roy, Industries Secretary, Tamil Nadu. Lubrizol leadership called on Thiru.N.Muruganandam, IAS. Chief Secretary, Tamil Nadu after the MoU signing. As part of the collaboration, Lubrizol and Polyhose aim to create a medical manufacturing site in Tamil Nadu. The site will increase Lubrizol’s local medical tubing volume five-fold, creating easier access to life-saving medical tubing in India and in markets around the world via export. High-quality medical tubing produced via the partnership will be used in neurovascular and cardiovascular medical applications, such as balloon catheters and minimally invasive procedure catheters. Groundbreaking of the new manufacturing site is expected in 2025 with operations going live in 2026.  The medical tubing will be produced with Lubrizol’s advanced medical-grade thermoplastic polyurethane (TPU) along with other thermoplastic polymers, which offer biocompatibility and high performance while ensuring patient comfort. The new manufacturing facility will be ISO 13485 compliant, ensuring safe, high-quality medical tubing. Lubrizol has committed more than $350 million in Indian investments over the last year. This year, Lubrizol opened a Global Capability Centre (GCC) in Pune and announced the purchase of a 120-acre plot land in Aurangabad to construct Lubrizol’s largest manufacturing facility in India and second largest globally to support the region’s growing transportation and industrial markets. Just a year ago, Lubrizol broke ground in the first phase of a 100,000 metric-ton CPVC resin plant in Vilayat, Gujarat, the largest single-site capacity for CPVC resin production globally.  The collaboration between Lubrizol and Polyhose will utilize Lubrizol’s strengths in India to cater to both local and global customers. ]]> https://biospectrumindia.com/news/91/25350/yashoda-group-partners-with-medtronic-to-revolutionise-patient-care-with-advanced-surgical-robotics.html https://biospectrumindia.com/news/91/25350/yashoda-group-partners-with-medtronic-to-revolutionise-patient-care-with-advanced-surgical-robotics.html Wed, 13 Nov 2024 00:00:00 +0530 Yashoda Group of Hospitals, based in Ghaziabad, has signed a Memorandum of Understanding (MoU) with Medtronic, a global leader in healthcare technology to expand its capabilities for robotic-assisted surgery.   Through this collaboration, the Yashoda Group designates Medtronic as its Preferred Robotics Partner and will integrate Medtronic's advanced robotic systems across its hospitals and also partner for surgical robotics training programmes.   The surgical robot Hugo Robotic Assisted Surgery (RAS), already installed in Yashoda Group’s Sanjay Nagar unit, is being used to facilitate surgeons in performing complex surgeries with precision and ease. With the expansion of the surgical robotics programme, Yashoda Group is poised to achieve a new milestone that will revolutionise the way surgeries are performed.   Robotic surgery, with its advantages over conventional open and laparoscopic surgeries such as faster recovery time, lesser blood loss, reduced chances of infection, shorter hospitalization, and the ability to perform the most complicated surgeries, is fast becoming the need of the hour.   Medtronic's Hugo RAS is a cutting-edge robotic-assisted surgery solution featuring an open console, modular arms, and a universal system tower. Its best-in-class vision system allows surgeons to view minute anatomical details. The rotation multiplier aids in fast suturing, while the tilt feature and pistol grip controllers enhance motion range and ease of complex procedures, minimizing complications. Hugo is integrated with Touch Surgery, which safely records and stores surgical data, accessible from anywhere, anytime.     Photo Caption: From left to right - Dr Rajat Arora, Group Director of Yashoda Group of Hospitals, and Mandeep Singh Kumar, Managing Director and Vice President of Medtronic India   ]]> https://biospectrumindia.com/news/91/25324/esaote-group-expands-production-of-ultrasound-systems-in-india.html https://biospectrumindia.com/news/91/25324/esaote-group-expands-production-of-ultrasound-systems-in-india.html Wed, 06 Nov 2024 00:00:00 +0530 Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance imaging and information technology for healthcare – strengthens its presence in India with a new manufacturing site in Noida, Uttar Pradesh, created and managed by the subsidiary Esaote Asia Pacific Diagnostic Private Limited. The new Esaote manufacturing site will produce, for the Indian market, a full range of advanced ultrasound series - My Lab™ A, My Lab™ E series and Compact Portable Ultrasounds - as "Made in India", which will be marketed shortly after completion of regulatory and quality assurance processes by the relevant local bodies. For Esaote, the new production plant is a strategic choice to increase its presence in a market with strong growth prospects, where the Italian company has been operating for over 20 years. These ultrasound systems are the latest results of Esaote's R&D efforts. They integrate the Augmented Insight™ functions and provide users with an innovative touchscreen control panel to significantly increase workflow. In addition, they also meet most demanding healthcare professionals' needs with their compact footprint, battery-operated, lightweight and mobile design. The combination of artificial intelligence (AI)-based features and advanced imaging technology is aimed at empowering Indian healthcare professionals to make confident, informed decisions, ensuring accurate diagnostic outcomes. ]]> https://biospectrumindia.com/news/91/25302/nephro-care-to-develop-prototype-of-remote-monitoring-ai-enabled-smart-heamodialysis-machine.html https://biospectrumindia.com/news/91/25302/nephro-care-to-develop-prototype-of-remote-monitoring-ai-enabled-smart-heamodialysis-machine.html Tue, 29 Oct 2024 00:00:00 +0530 In a pioneering move, Nephro Care India Limited (NCIL) is developing a prototype remotely monitored artificial intelligence (AI)-enabled smart haemodialysis machine to make renal care more 'accessible and affordable' to masses. The company, which has received a grant from the Department of Science and Technology and Biotechnology, West Bengal, is collaborating with the National Institute of Technology, Silchar to develop the prototype. Once ready, it is likely to bring down the cost of these machines by nearly 70-75 per cent to Rs 2 lakh from the current Rs 7.5-8 lakh. According to Dr Pratim Sengupta, Founder and MD & CEO, Nephro Care India, currently a majority of the haemodialysis machines in India are imported and hence the cost is significantly higher. Indigenous manufacturing of these machines can bring down cost thereby translating into lower cost of treatment for patients suffering from advanced renal failure. Haemodialysis machine filters wastes, salts and fluids from the blood of a person whose kidneys are not healthy enough to do this work efficiently.  The prototype, which is being developed, will enable distant monitoring of these machines thereby making dialysis more accessible and affordable in the semi-urban and rural locations. NCIL, which successful completed its initial public offering (IPO) earlier this year, recently inaugurated a 100-bedded multispecialty hospital - Vivacity Multispecialty Hospital at Madhyamgram in Kolkata at an estimated investment of Rs 36.51 crore. Founded in the year 2014 by one of the leading nephrologists in India, Dr Pratim Sengupta, the institution provides comprehensive medical services for renal patients.   ]]> https://biospectrumindia.com/news/91/25282/medprime-technologies-secures-pre-series-a-funding-to-propel-growth-and-ai-innovations-in-health-tech.html https://biospectrumindia.com/news/91/25282/medprime-technologies-secures-pre-series-a-funding-to-propel-growth-and-ai-innovations-in-health-tech.html Mon, 21 Oct 2024 00:00:00 +0530 Medprime Technologies, a leading medical device company at the forefront of developing cutting-edge healthcare solutions in diagnostics, has announced the successful closing of its Pre-series A funding, with investment from renowned investor Ashish Kacholia, Co-founder of Hungama Digital and one of India's top 10 investors. The funds will drive Medprime’s growth, with a particular focus on establishing an international market for CILIKA. Additionally, the investment will accelerate the launch of advanced AI modules to enhance its MICALYS platform in India. The funding will also enable significant improvements in Medprime’s manufacturing capabilities, boosting both efficiency and production capacity to meet rising global demand. Medprime has established a strong presence in digital microscopy, with its devices already being utilized by leading medical colleges and research institutions across India. Renowned institutions such as the All-India Institute of Medical Sciences (AIIMS), Maulana Azad Medical College, Grant Medical College, Banaras Hindu University, IIT Delhi, IIT Madras, Dr. Lal Path Labs, Apollo Diagnostics, and Dr. Rajendra Prasad Central Agricultural University have adopted Medprime's cutting-edge digital microscopes, underscoring the company’s commitment to excellence. Medprime’s MICALYS is a pioneer in AI-driven healthcare solutions, and the soon-to-be launched AI modules will further accelerate the company’s mission to enhance medical diagnostics through advanced technology. "The future of healthcare lies in the convergence of technology and medicine. With Medprime’s approach and their commitment to improving lives, I believe this partnership will lead to significant advancements in medical diagnostics,” said Ashish Kacholia. Beyond AI innovations, Medprime is focused on upgrading its manufacturing processes to increase efficiency and scale production. This strategic shift will allow the company to expand its operations and meet the growing needs of healthcare providers worldwide. Founded in 2014 by four biomedical engineering postgraduates from IIT Bombay, Medprime has grown with the support of prominent Indian and global entities. The company is backed by USAID-supported SAMRIDH, managed by IPE Global, and has received BIG and SBIRI grants from BIRAC. Medprime also benefits from a robust support network, including government agencies such as MeitY and industry associations like NASSCOM. Its growth has been further bolstered by partnerships with academic institutions like IIT Bombay, incubators such as SINE and Venture Centre, and organizations like Social Alpha. Venture capital firms such as Lavni Ventures, Riso Capital, Mumbai Angels, and Keiretsu Forum have also recognized and invested in Medprime’s potential. ]]> https://biospectrumindia.com/news/91/25184/stryker-launches-1788-next-generation-of-advanced-surgical-camera-in-india.html https://biospectrumindia.com/news/91/25184/stryker-launches-1788-next-generation-of-advanced-surgical-camera-in-india.html Wed, 25 Sep 2024 00:00:00 +0530 US-based Stryker, a global leader in medical technologies, has announced the launch of its groundbreaking 1788 Advanced Imaging Platform in India, continuing its legacy of excellence in surgical visualisation. The 1788 platform is Stryker’s most comprehensive and sophisticated surgical visualisation system to date, designed for use across multiple specialties and providing surgeons with enhanced imaging capabilities for improved patient outcomes. Building on decades of innovation in surgical camera systems, the 1788 platform delivers vibrant, 4k high-resolution images that enable surgeons to visualise critical anatomy with greater clarity. The platform features advanced fluorescence imaging capabilities, offering clearer perfusion imaging and detailed visualisation of complex anatomical structures. Aman Rishi, Vice President and General Manager – India, said, “Fluorescence-guided surgery is emerging as a promising solution, enabling surgeons to better visualize perfusion, tumors and critical anatomy intraoperatively. The 1788 imaging platform is a new benchmark for surgical imaging with enhanced user experience and most advanced fluorescence imaging capabilities, helping bring our mission of making healthcare better with our customers to life. We are excited about the launch and making this technology accessible to surgeons in India." The 1788 platform is compatible with the currently marketed imaging agents and adaptable to new agents and fluorescence modes as they become available. Notable features of the 1788 platform include wider colour gamut for 62.5x more visible colours; improved fluorescence imaging with better consistency; high dynamic range and new tone mode for more balanced lighting; CSF mode (Color Segmented Fluorescence) shows a colour map based on ICG intensities, especially useful for perfusion assessment and lymph node mapping. This platform is future-ready, supporting imaging agents like CYTALUX, and is paired with an all-new OLED display for a truly premium 4K experience.     ]]> https://biospectrumindia.com/news/91/25179/aiims-delhi-and-intuitive-sign-mou-to-establish-surgical-robotics-training-centre.html https://biospectrumindia.com/news/91/25179/aiims-delhi-and-intuitive-sign-mou-to-establish-surgical-robotics-training-centre.html Tue, 24 Sep 2024 00:00:00 +0530 All India Institute of Medical Sciences (AIIMS) New Delhi, a premium medical institute in India and US-based medtech company Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, have signed a Memorandum of Understanding (MoU) to establish an innovative new training centre for robotic-assisted surgery (RAS) at AIIMS, New Delhi. The AIIMS da Vinci RAS training centre will focus on equipping surgeons and care teams with the skills and technology training necessary to perform robotic-assisted surgery across specialities including urology, gynaecology, general surgery and more. This industry-academia collaboration will advance the adoption of robotic-assisted surgery in India by providing state-of-the-art technology training for more surgeons. While signing the MoU, Gary S. Guthart, CEO, Intuitive, said, "For Intuitive, this MoU with AIIMS represents a significant milestone in our shared commitment to advancing surgical training and improving patient outcomes. We believe the AIIMS da Vinci RAS training centre will also serve as a beacon of excellence, fostering training, skill, and knowledge development for the next generation of surgeons.” While commenting on this, Dr Srinivas Director of All India Institute of Medical Sciences Delhi, said, "With the rising disease burden in India-cancers, urologic, and gynecological conditions requiring soft tissue surgery-the demand for advanced technologies like robotic-assisted surgery is growing. The need for associated training is clear in India. The da Vinci system offers enhanced precision, flexibility, and control, leading to improved surgical accuracy, reduced recovery times, and better patient outcomes. As an early adopter of robotic surgery, AIIMS has a pool of experienced robotic surgeons who will mentor and train new surgeons nationwide. This centre will play a crucial role in advancing surgical skills and elevating patient care standards across India.” As part of Intuitive's continuing effort to establish strong robotics programs across India, the company has already established three training centres in different parts of the country. More than 850 surgeons in India have been trained on da Vinci technology to date and are helping drive the significant increase in its adoption.   ]]> https://biospectrumindia.com/news/91/25156/iit-m-develops-indigenous-portable-ultrasound-scanner-for-sports-injury-diagnosis.html https://biospectrumindia.com/news/91/25156/iit-m-develops-indigenous-portable-ultrasound-scanner-for-sports-injury-diagnosis.html Tue, 17 Sep 2024 00:00:00 +0530 A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-Care-Ultrasound (POCUS) Scanner for sports injury diagnosis and management. They have already been granted several patents for technologies that went into this device and are working towards productisation. This research from the Center of Excellence in Sports Science and Analytics (CESSA) at IIT Madras could potentially allow for on-field diagnosis of injuries, immediate assessment of the extent of injury that will allow for medical professionals to take a call on whether to permit the sportsperson to continue playing. This Artificial Intelligence-powered POCUS scanner has a wide range of applications in sports medicine, and it has the benefits of safety (no radiation) and sufficient resolution compared to other modalities. A working POCUS prototype for Musculoskeletal (MSK) imaging, developed at the Biomedical Ultrasound Imaging Lab (BUSi) is currently ready. The researchers are targeting to complete the product prototype development by 2024. Subsequently, testing and collection of pilot data from the field are also being planned in coordination with Sports Authorities.     ]]> https://biospectrumindia.com/news/91/25140/accuray-addresses-indias-escalating-cancer-burden-with-latest-configuration-of-radixact-system.html https://biospectrumindia.com/news/91/25140/accuray-addresses-indias-escalating-cancer-burden-with-latest-configuration-of-radixact-system.html Fri, 13 Sep 2024 00:00:00 +0530 US-based medtech firm Accuray is stepping up to support the efforts of cancer care with the introduction of Accuray Helix, a configuration of the Radixact Treatment Delivery System, a groundbreaking technology built on TomoTherapy helical platform to help transform cancer treatment in India. Accuray Helix brings flexibility and versatility and is intended to drive improvements in personalisation and patient care, while simultaneously facilitating treatment of more patients each day, boosting productivity for clinics and enabling them to efficiently manage the growing demand for cancer care. It allows healthcare providers to address a broad range of cancer types, making it a game changer for clinics in smaller cities. It is estimated that 50-60% of patients with cancer will need radiotherapy. Radiotherapy provides excellent local tumour control and is used to cure localized disease, palliate symptoms, and control disease in incurable cancer. In 2020, 70% of almost 10 million cancer-related deaths worldwide were in low-and-middle-income countries. This striking inequality underscores the urgent need for more equitable access to early detection and advanced treatment options, both globally and within India, where similar gaps in care exist.  Vidhi Prasad, Managing Director – India & Subcontinent, Accuray, said, "We are actively working with healthcare providers all across India to deliver precision technology for cancer care. We strive to empower healthcare professionals to manage increased patient loads without compromising the quality of care, helping to ensure that no patient is left behind." ]]> https://biospectrumindia.com/news/91/25121/nanavati-max-hospital-offers-revolutionary-advancement-in-cancer-care-for-western-india.html https://biospectrumindia.com/news/91/25121/nanavati-max-hospital-offers-revolutionary-advancement-in-cancer-care-for-western-india.html Fri, 06 Sep 2024 00:00:00 +0530 Nanavati Max Hospital, in Mumbai, has taken a significant step forward in the fight against cancer by introducing the Varian's EDGE radiosurgery system, one of India's most advanced cancer treatment technologies, complemented by HyperArc, a cutting-edge stereotactic radiosurgery solution. This marks a revolutionary advancement in cancer care for Western India. The Edge Radio Surgery System was formally inaugurated by Amitabh Bachchan in the presence of Abhay Soi, Chairman and Managing Director of Max Healthcare. The EDGE system, represents a significant leap in the delivery of radiosurgery and radiotherapy treatments. The system allows clinicians to treat a wider array of cancers with unmatched precision, flexibility, and efficiency. The EDGE system’s ability to deliver sub-millimetre accuracy in treatment, coupled with the efficiency of HyperArc’s automated radiosurgery, significantly reduces treatment times and enhances patient comfort. EDGE can treat malignant tumours of the brain, prostate, lung and pancreas and metastatic tumours like bone and lymph nodes It is specifically efficient in managing metastatic tumours through the single isocentre. Hyperarc is one of the most advanced tools to treat brain tumours benign and malignant. It is a powerful tool for radiosurgery and Stereotactic Body Radiation Therapy (SBRT). The cost of an EDGE HyperArc machine typically ranges from approximately Rs 40 crore to Rs 60 crore. The treatment on the EDGE HyperArc machine may involve an approximately 15-20% cost increase. However, the enhanced efficiency, reduced number of appointments, and improved patient experience and outcomes provided by this advanced technology can justify the investment and make it a valuable choice for those seeking the highest quality of care.  ]]> https://biospectrumindia.com/news/91/25025/stryker-launches-first-of-its-kind-biodegradable-subacromial-balloon-implant-in-india.html https://biospectrumindia.com/news/91/25025/stryker-launches-first-of-its-kind-biodegradable-subacromial-balloon-implant-in-india.html Tue, 13 Aug 2024 00:00:00 +0530 Stryker, a global leader in medical technologies, has announced the launch of InSpace, the first balloon implant for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs), in India. MIRCTs are one of the most common causes of shoulder dysfunction. InSpace provides a new option for surgeons in their shoulder continuum of care that allows them to better meet the needs of their patients. The InSpace balloon implant is designed to restore the subacromial space without requiring sutures or fixation devices and has been demonstrated to improve shoulder motion and function. “InSpace is a groundbreaking, first-of-its-kind technology, offering a new, minimally invasive surgical option for surgeons, addressing their unmet needs in MIRCT and potentially providing early functional recovery and pain relief for patients,” said Aman Rishi, Vice President and General Manager for Stryker in India. On an average, patients showed an increase in range of motion compared to partial repair patients following surgery. It has demonstrated comparable long-term safety and effectiveness results (compared to partial repair) out to two years. ]]> https://biospectrumindia.com/news/91/25015/terumo-india-launches-treo-abdominal-stent-graft-system.html https://biospectrumindia.com/news/91/25015/terumo-india-launches-treo-abdominal-stent-graft-system.html Sat, 10 Aug 2024 00:00:00 +0530 Terumo India, the Indian subsidiary of Japan-based Terumo Corporation, a global leader in medical technology, has announced the launch of the TREO Stent-Graft System, an advanced solution for Endovascular Aneurysm Repair (EVAR). Designed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomies, the TREO Stent-Graft System stands out as the only EVAR graft featuring both suprarenal and infrarenal active fixation. Shishir Agarwal, President and Managing Director of Terumo India, commenting on the launch said, “In India, the prevalence of abdominal aortic aneurysms is rising, with an estimated 1 in 10,000 people affected annually, underscoring the significant need for advanced treatment options.” TREO is a three-piece design featuring in situ limb adjustability and provides a wide range of aortic device configurations to specifically address the anatomy of each individual patient. It features enhanced proximal sealing for improved stability and leak prevention, superior lock stent technology that offers robust fixation to reduce migration risks, and a flexible design that adapts to challenging and angulated anatomy. This enhances treatment flexibility, ensuring long-term performance and patient safety. Recent clinical studies show lower sac shrinkage and re-intervention rates. By bringing this innovative EVR, Terumo India continues to set new standards in providing solutions to challenging endovascular aneurysm repair. ]]> https://biospectrumindia.com/news/91/25000/apollo-cancer-centre-launches-cyberknifes7-fim-robotic-radio-surgery-system-with-an-academia.html https://biospectrumindia.com/news/91/25000/apollo-cancer-centre-launches-cyberknifes7-fim-robotic-radio-surgery-system-with-an-academia.html Mon, 05 Aug 2024 11:00:00 +0530 The CyberKnife S7 FIM System is a non-invasive treatment for cancerous and non-cancerous tumors and other conditions where radiation therapy is indicated. It is used to treat conditions throughout the body including brain, lung, spine, prostate and abdominal cancers, and may be an alternative to surgery for patients who have inoperable or surgically complex tumors. Patients previously treated with radiation, who have metastatic lesions or with recurrent cancers, can also benefit from CyberKnife treatment. The CyberKnife System is the only radiation delivery system that features a radiation delivery device, called a linear accelerator, directly mounted on a robot to deliver the high-energy X-rays or photons used in radiation therapy. It uses real-time image guidance and a robot to deliver doses from thousands of beam angles, setting a new standard for delivery precision anywhere in the body. Mr. Dinesh Gundu Rao, State Minister for Health and Family Welfare, Govt. Of Karnataka, said, “It is equally commendable by Apollo Cancer Centers to introduce the CK Academia thereby benefitting a larger ecosystem of cancer warriors. We are indeed proud that both the latest technology and the future practitioners/adopters of this technology, will originate from our state.” Dr Sridhar PS,  Dr Vinay Ural , Dr Vikram Maiya, radiation oncologists, stated “The CyberKnife S7 FIM System redefines the future of radiation therapy, combining speed, precision and Synchrony AI-driven, real-time target tracking with dynamic delivery to deliver precise hypo fractionated SRS/SBRT treatments for a wider range of indications which include benign brain tumors, brain metastases, select medically refractory functional indications: trigeminal neuralgias, cluster headaches, tremors, lesional epilepsy & select extra cranial inoperable cancers of lung,  pancreas, liver, prostate, recurrent Head and neck cancers and metastatic directed therapy to oligomets.”   ]]> https://biospectrumindia.com/news/91/24995/idex-afms-sign-mou-for-developing-cutting-edge-medical-technologies-for-armed-forces.html https://biospectrumindia.com/news/91/24995/idex-afms-sign-mou-for-developing-cutting-edge-medical-technologies-for-armed-forces.html Mon, 05 Aug 2024 00:00:00 +0530 Innovations for Defence Excellence-Defence Innovation Organisation (iDEX-DIO), the flagship initiative of Ministry of Defence, has signed a Memorandum of Understanding (MoU) with Armed Forces Medical Services (AFMS) for the launch of Medical Innovations and Research Advancement (MIRA). The MoU was signed by Additional Secretary (Defence Production) & CEO, DIO Anurag Bajpai, and Director General of Armed Forces Medical Services Lt Gen Daljit Singh in New Delhi. The MoU aims to foster innovation and research in developing novel medical technologies and their induction into the Armed Forces. The initiative will be propelled by the launch of the Defence India Start-up Challenge (DISC), targeting the critical medical challenges faced by the Armed Forces. It will leverage the unique strengths and expertise of both organisations to foster cutting-edge advancements in medical technologies. The Additional Secretary (Defence Production) & CEO, DIO termed the partnership with AFMS as a testament to the Ministry’s commitment to fostering innovation in every aspect of defence and security. “Together, we will work towards creating a robust healthcare ecosystem that not only meets the current needs of the Armed Forces but also anticipates future challenges,” he said. The DG, AFMS stated that the collaboration with DIO marks a significant milestone in the ongoing efforts to provide the highest quality of medical care and induct new cutting-edge medical technologies. “By harnessing the innovative capabilities through iDEX, we are poised to make substantial advancements in medical science and technology,” he said. ]]> https://biospectrumindia.com/news/91/24958/mahajan-imaging-labs-introduces-ai-enabled-ct-scanner.html https://biospectrumindia.com/news/91/24958/mahajan-imaging-labs-introduces-ai-enabled-ct-scanner.html Sun, 28 Jul 2024 00:00:00 +0530 Mahajan Imaging & Labs has announced the addition of a state-of-the-art Dual Energy Spectral CT Scanner, to its Gurugram centre. The Dual Energy CT Scanner is equipped with exceptional technology designed to guarantee precise and accurate diagnoses across a diverse spectrum of medical conditions with a remarkable rotation speed of just 0.3 seconds. This means patients can get their scans done quickly without compromising the quality of the images. One of the key benefits for patients is the low radiation exposure. The scanner uses ultra-low-dose protocols, which are especially beneficial preventive cardiac scans and for scanning for children, minimizing exposure to radiation during scans. It also features artificial intelligence or AI-enabled advanced software that enhances early disease detection, particularly notable in cardiac screening. The CT Scanner reduces the radiation dose for cardiac patients by up to 85%, making it much safer for individuals undergoing heart-related scans. The unique ultra-fast, high-definition Dual-Energy CT scan provides spectral analysis of body tissues and disease states, adding a new dimension to routine CT imaging. This leads to better lesion characterization and tissue analysis non-invasively. While addressing the launch, Dr Harsh Mahajan, Chairman & Founder & Chief Radiologist, Mahajan Imaging & Labs, said, "Leveraging Artificial Intelligence, the scanner promises improved diagnostic accuracy and efficiency, aiming to improve patient outcomes and healthcare delivery. The CT Scanner offers superior image quality with high-definition ultra thin images and the best spatial resolution, enabling doctors to make more accurate diagnoses. This is particularly crucial for detecting and analysing even the smallest details in the body."   ]]> https://biospectrumindia.com/news/91/24906/fujifilm-india-expands-national-footprint-with-new-endoscopy-centre-in-mumbai.html https://biospectrumindia.com/news/91/24906/fujifilm-india-expands-national-footprint-with-new-endoscopy-centre-in-mumbai.html Mon, 15 Jul 2024 00:00:00 +0530 Fujifilm India’s Endoscopy Division has significantly enhanced its service infrastructure by opening its second largest service centre in Mumbai. This new facility is dedicated to the rapid repair of its gastroscopes, bronchoscopes, and high-end processors, ensuring quicker turnaround times and improved service delivery across India. Over the past six years, the company has established five major service centres in key regions and cities across India, along with two satellite centres designed to accelerate endoscope repairs and accommodate an increasing installation base. The newly launched Mumbai service centre is equipped with state-of-the-art repair tools and technology, aimed at reducing service turnaround times and ensuring the swift delivery of repaired scopes. Fujifilm India plans to further expand its service centres with advanced tools, technology, and increased manpower to reach both small and large cities. Dheeraj Chaudhri, Head of the Endoscopy Division said, “We are pleased to reach this important milestone of increasing our after-sales service capabilities to more than 20 states now. We have developed a high-class repair centre with all the facilities and directly doing repairs of endoscopes in 8 different service centres located in various locations of the country. In addition to infrastructure and manpower expansion, we are also investing in training and education of the paramedic and technicians of the hospital through various trainings and education programmes in collaboration with many hospitals." ]]> https://biospectrumindia.com/news/91/24891/maharashtra-gets-first-mr-fusion-biopsy-machine-at-sir-h-n-reliance-foundation-hospital.html https://biospectrumindia.com/news/91/24891/maharashtra-gets-first-mr-fusion-biopsy-machine-at-sir-h-n-reliance-foundation-hospital.html Thu, 11 Jul 2024 00:00:00 +0530 With an aim to uplift cancer care in Maharashtra, Sir H N Reliance Foundation adds Maharashtra’s First MR Fusion Prostate Biopsy Equipment.  This state-of-the-art MR Fusion Biopsy Equipment offers MRI blended biopsy creating a pathway for an accurate treatment and care. Compared to conventional machines with 30% to 40% accuracy, the MR Fusion biopsy equipment has 90% accuracy is detecting prostate cancers at an early stage. Prostate cancer accounts for 3-7 per cent of all cancers in India, with an estimated 33,000-42,000 new cases diagnosed annually. With MR Fusion Biopsy, the previously done MRI image is combined with the ultrasound equipment. During the process, the abnormal area (the target for biopsy) is marked with AI technology, offering greater chance of cancer detection. "An MR Fusion prostate biopsy detects cancer at a greater rate than the standard approach. There is no risk of rectal bleeding, and it covers entire prostate gland which is often inaccessible as part of the standard approach. There is no risk of damaging rectum, therefore radical prostate ectomy can be performed within days." said Dr Santoshi Janardan Nagaonkar, Director Urology, Urological Oncology & Robotic Surgery, Sir H.N. Reliance Foundation Hospital. As per reports, prostate cancer incidence in India are expected to double to about 71,000 new cases per year by 2040. Therefore, it becomes imperative for India to have a technology that can help detect and treat prostate issues efficiently. This technology has already been embraced by Western World since a few years. ]]> https://biospectrumindia.com/news/91/24894/amrita-vishwa-vidyapeetham-initiates-production-of-innovative-technology-for-speech-impairment.html https://biospectrumindia.com/news/91/24894/amrita-vishwa-vidyapeetham-initiates-production-of-innovative-technology-for-speech-impairment.html Thu, 11 Jul 2024 00:00:00 +0530 Amrita Vishwa Vidyapeetham is all set to commence production of Netravaad, an innovative device designed to revolutionise patient care for individuals with speech impairments. This groundbreaking technology is being developed by T2HInnovations, a healthtech startup incubated under SCTIMST TIMED (TBI for Medical Devices and Biomaterials). Named Netravaad, the device is developed and tested rigorously at Amrita Hospital in Kochi. Netravaad utilises innovative eye gesture-based technology to enable patients to communicate their needs effectively. T2HInnovations, a Kerala-based startup established under the AI and Robotics research center, HuT Labs of Amrita University, specialises in biomedical and healthcare robotics. It operates in close collaboration with Amrita University’s research facilities, leveraging the university’s expertise in engineering and technology to develop impactful solutions such as Netravaad.  Dr. Rajesh Kannan Megalingam, Director, HuT Labs, Amrita Vishwa Vidyapeetham, and Founder, T2H Innovations, said, “We're now in the production phase of Netravaad and all set to bring this transformative technology to a wider audience. Netravaad's ability to enable communication through eye gestures represents a major leap for individuals with speech impairments." ]]> https://biospectrumindia.com/news/91/24884/siemens-healthineers-announces-local-manufacturing-of-multix-impact-e-digital-radiography-x-ray-system.html https://biospectrumindia.com/news/91/24884/siemens-healthineers-announces-local-manufacturing-of-multix-impact-e-digital-radiography-x-ray-system.html Tue, 09 Jul 2024 00:00:00 +0530 Siemens Healthineers, a leading medical technology company, has announced that the Multix Impact E digital radiography X-ray machine will now be manufactured in India, marking a significant milestone in the company's commitment to providing better access to care for patients in the country. According to the Institute for Health Metrics and Evaluation (IHME) 2022 data, Chronic Obstructive Pulmonary Disease (COPD), Tuberculosis (TB), and road injuries continue to be among the leading causes of death in India. An X-ray is one of the primary diagnostic tools instrumental in diagnosing bone fractures in trauma and emergency, anomalies in the chest including infectious diseases like TB and certain tumors.  The Multix Impact E is a floor-mounted system featuring all the necessary tools for easy, intuitive system operation and allows for the detection of anatomical details at low doses radiation, ensuring patient safety and quality healthcare. Commercial availability of Multix Impact E, a locally manufactured digital radiography X-ray system for the Indian market, will enhance the general provision of secondary care for which digital X-ray is a crucial requirement. The Multix Impact E will be manufactured in the Bengaluru factory, leveraging several years of experience in local-for-local manufacturing of mobile C-arms, CT, and MRI systems.   Image caption- Hariharan Subramanian, MD Siemens Healthcare India and Michael Zeus- Head of Global Marketing & Sales - X-ray Products  ]]> https://biospectrumindia.com/news/91/24842/philips-india-partners-with-star-imaging-to-launch-first-mri-training-school-in-india.html https://biospectrumindia.com/news/91/24842/philips-india-partners-with-star-imaging-to-launch-first-mri-training-school-in-india.html Tue, 02 Jul 2024 00:00:00 +0530 Philips, a global leader in health technology, has partnered with Star Imaging, Pune to launch a first-of-its-kind MRI Training School in India. This school will provide international standard training on MRI technologies across 17 sub-specialties. Renowned physician, Dr Ashish Atre, Chief Radiologist, Star Imaging and Research Center, has designed the curriculum for this programme in association with Philips. The first batch of this programme was recently concluded at Star Imaging’s center in Pune. The two-week residential programme, designed to provide advanced theoretical knowledge and practical training, focuses on organ-based sub-specialty reporting and hands-on training. It also involves application training, clinical case study discussions, scanning, and workflow observation across multiple anatomies such as Head and Neck, Musculoskeletal, Body, Neuro, etc. This programme is open to radiologists who wish to upskill themselves with international standard training on MR specialties. By leveraging Philips' cutting-edge technologies and Star Imaging’s clinical expertise, they will gain valuable insights and hands-on experience in the field. This initiative is part of Philips’ endeavor to continuously enhance the skills and expertise of healthcare professionals in India. In July 2023, Philips announced its partnership with Narayana Institute of Cardiac Sciences (NICS) to set up a first-of-its-kind and the only dedicated Centre of Excellence for Echo training in the country. Known as the ELiTE programme, the course offers extensive hands-on training, led by national faculties using Philips ultrasound systems. ELiTE is accredited by Karnataka Medical Council and endorsed by the Indian Academy of Echocardiography, Karnataka.     ]]> https://biospectrumindia.com/news/91/24800/meril-introduces-advanced-surgical-robotic-technology-misso.html https://biospectrumindia.com/news/91/24800/meril-introduces-advanced-surgical-robotic-technology-misso.html Thu, 20 Jun 2024 00:00:00 +0530 Vapi-based Meril, a global medical device company, has announced the launch of its advanced surgical robotic technology, MISSO. MISSO is a high-quality robotic system entirely made in India that provides surgeons with real-time assistance during knee replacement procedures with unparalleled accuracy. Indian hospitals currently depend on imported robotic technology for knee replacement surgeries which requires a significant investment. MISSO will reduce this investment by ~66%, making these surgeries more accessible and affordable. The versatile technology of MISSO can be adapted for other joint surgeries in the near future. Knee replacement surgery is necessary for patients who suffer from severe osteoarthritis. This condition is highly prevalent in India, occurring in around 22 to 39 percent of the population. Today about, ~5.5 lakh people undergo total knee replacement in India every year, which is 2.5 times the number of such procedures conducted annually about five years ago.  Although its adoption is on the rise, the need for knee replacement surgeries annually is 7-8 times higher than the current number of surgeries performed in India. Currently, only 20% of surgeons perform 80% of knee replacement surgeries (approx.). MISSO has received approval from CDSCO and is queued up for CE and USFDA approvals in times to come.  Dr Chandrashekar P, Director of Orthopedics, Sakra World Hospital, Bengaluru, says, “MISSO will help bring cutting-edge technology even to smaller hospitals so that maximum patients get the benefit of robotic surgery. Knee replacement procedures using robotic systems significantly reduce post-operative pain and help patients get back on their feet rapidly as compared to conventional procedures. MISSO, the indigenous robotic system will certainly change the landscape of robotic surgery in India and is a proud moment for our country.”   ]]> https://biospectrumindia.com/news/91/24770/ss-innovations-unveils-most-advanced-ssi-mantra-3-robotic-surgery-system.html https://biospectrumindia.com/news/91/24770/ss-innovations-unveils-most-advanced-ssi-mantra-3-robotic-surgery-system.html Thu, 13 Jun 2024 00:00:00 +0530 Gurugram-based SS Innovations, the developer of India’s first Indigenous surgical robotic system- SSI Mantra, dedicated to making advanced robotic surgeries cost-effective and accessible to a global population, has launched SSI Mantra 3, which is the next generation, most advanced version of the Mantra surgical robot system. Alongside, it has achieved a historic feat in Indian medical science by completing the nation’s maiden human trial in telesurgery, signifying a monumental leap in surgical robotics. The new SSI Mantra 3 is highly advanced and is designed to enhance surgical precision, efficiency, and patient outcomes by integrating the latest advancements in robotic surgery,  featuring 5 slimmer robotic arms and an immersive 3D HD headset which provides surgeons with unmatched optics and a vision cart that provides 3D 4K vision to the entire team for precision and control. Additionally, the cost-effective pricing of SSI Mantra 3 aims to make advanced surgical technologies more accessible to healthcare institutions across all regions of India and the world.  In a momentous stride forward, SS Innovations has successfully conducted India’s first human trial in telesurgery using the SSI Mantra Surgical Robot. This groundbreaking, flawless surgery was a robotic cholecystectomy that took place between the World Laparoscopy Hospital and the SSI Headquarters over a distance of 5 kilometres using the seamless connectivity of Airtel’s fiberoptic network with no perceptible delay. The telesurgery trial signifies a major step forward in providing quality healthcare to remote areas, further aligning with the Make in India initiative by showcasing Indigenous innovation on a global stage.  In a notable step forward, Dr Fredric Moll, widely regarded as the father of surgical robotics, and the visionary founder of Intuitive Surgical, has joined SS Innovations International Inc., as a Board Member and Vice Chairman. Dr Moll has been a pivotal force in advancing robotic surgery and contributed significantly to the development of various groundbreaking robotic technologies that have contributed to the evolution of robotics in medicine.   ]]> https://biospectrumindia.com/news/91/24723/wipro-ge-healthcare-installs-advanced-imaging-equipment-at-tmc-for-brain-surgeries.html https://biospectrumindia.com/news/91/24723/wipro-ge-healthcare-installs-advanced-imaging-equipment-at-tmc-for-brain-surgeries.html Tue, 04 Jun 2024 00:00:00 +0530 The neurosurgery department at Tata Memorial Centre (TMC), Mumbai, recently procured a state-of-the art intraoperative ultrasound (iUS) machine, by Wipro GE Healthcare, for performing complex brain tumour surgeries. iUS is cost -efficient and with appropriate training, can become an important adjunct in the neurosurgeon’s armamentarium. The bKActiv machine, which was recently acquired by the department is the first installation of this advanced iUS system in the country. Intraoperative imaging is crucial for safely and accurately removing intrinsic brain tumours. Combined with navigational aids (which is like a surgical GPS system), the iUS machine allows neurosurgeons to precisely track tumour remnants. Further, when combined with brain mapping techniques like awake surgery, they enable removal of tumours radically, even near critical functioning brain regions.  Dr Aliasgar Moiyadi, Chief of Neurosurgery, Tata Memorial Centre believes this advanced tool is likely to help his team and benefit the large number of brain tumour patients operated at the centre, many of whom are unable to access state-of-the-art care at subsidised rates elsewhere. ]]> https://biospectrumindia.com/news/91/24711/rnt-health-insights-receives-us-fda-breakthrough-device-designation-for-early-gastric-cancer-detection-tool.html https://biospectrumindia.com/news/91/24711/rnt-health-insights-receives-us-fda-breakthrough-device-designation-for-early-gastric-cancer-detection-tool.html Mon, 03 Jun 2024 00:00:00 +0530 Chandigarh-based RNT Health Insights, a clinical stage medical diagnostics startup, has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for their Early Gastric Cancer detection tool. The innovative solution is designed to detect lesions present in the upper gastrointestinal tract indicative of Early Gastric Cancer, as well as gastric malignancy, inclusive of gastric atrophy, nodules, polyps, masses and growths present in the stomach, in real-time during standard endoscopy examinations.Gastric cancer is the fourth leading cause of cancer related mortality across the globe, with a five-year survival rate of less than 40%. However, it is reported that the early accurate detection of gastric cancer can increase the 5-year survival rate to 90%. Despite gastrointestinal endoscopic procedures being the gold standard method for the diagnosis of this disease, the current miss rate for the diagnosis of Gastric cancers during these procedures stands at 4.6-25.8%, depending upon the endoscopists’ experience and visual observations. RNT Health Insights’ Early Gastric Cancer detection technology can be used in real-time during endoscopic procedures to detect these pathologies, and currently displays a detection accuracy of 96% in accordance with the preclinical validation conducted. With the Breakthrough Device Designation, RNT Health Insights will benefit from an expedited review pathway to obtain the necessary permits for marketing their device. The company anticipates this will accelerate the timeline for bringing their innovative tool to market, ultimately benefiting patients and healthcare providers. ]]> https://biospectrumindia.com/views/91/24712/upes-to-enhance-mobility-for-elderly-with-hand-gesture-device-based-wheelchair.html https://biospectrumindia.com/views/91/24712/upes-to-enhance-mobility-for-elderly-with-hand-gesture-device-based-wheelchair.html Mon, 03 Jun 2024 00:00:00 +0530 Tell us about the genesis of this idea and what made you work on developing the wheelchair? The genesis of this idea came into being as we aimed to implement our previously system based on the principles of a previously developed home automation system. We recognised the increasing popularity of Inertial Measurement Units (IMUs) due to their exceptional capability to accurately detect orientation and motion and how they could be implemented in a wide range of application with proper degree of calibration. Not only this a huge driving factor of our project remains to be the social impact that this device can have on people with mobility impairments, congenital mobility issues and accident victims. This device provides a new prospect to the traditional manual as well as joystick wheelchairs as it not only provides more independence to the user but also comes in a much more feasible range. For patients with high limbic mobility issues, this wheelchair can be highly assistive as it can be controlled using the palm and finger movements of the hand alone. Moreover, the implementation of a differential axle to a wheelchair to distribute power efficiently, incorporated with a hand gesture device is not yet available in documentation and therefore adds rarity and significance to our endeavour.   What’s the technology behind developing this product and how exactly does the product solve mobility problem for the elderly people efficiently? Our project introduces a cost-effective solution for enhancing electronic wheelchairs with improved Human-Machine Interaction (HMI). We utilise an open-differential axle and a rack and pinion mechanism to enable directional movement, powered by servo DC motors. Hand gestures replace traditional joystick controls, enhancing user independence. An embedded IMU sensor on a glove detects real-time gestures, wirelessly transmitting commands to the wheelchair's motors via Bluetooth modules. Safety features include an emergency SOS system triggered by a flex sensor and touch sensor, ensuring user security in case of emergencies. This comprehensive system prioritises user comfort, safety, and autonomy.   Are you looking to apply for a patent or is already applied? Yes, the team has recently applied for a patent.   Tell us about the team and students behind this project. How much time did it take to develop the product? Our team consists of two final year students from electronics and communication engineering namely, Kriti Chauhan and Anubhav Tyagi. They have been highly motivated individuals eager to acquire practical knowledge and expertise in the design and development of embedded systems, encompassing sensor calibration, microcontroller programming, and assistive automation applications. The entire project was finalised in eight months from ideation to final testing and implementation.   What are your future plans for this innovation? Do you plan to upgrade this in other stages? It is possible to upgrade this project in various ways in accordance with industry standards, compactness and further optimisation like implementing advanced power monitoring to optimise usage and extend battery life, ensuring reliability, creating sophisticated battery management systems to improve performance. Further, optimised current consumption by assessing and adjusting current draw for various loads to enhance energy efficiency and minimise consumption.   How do you plan to commercialise this product? After much refinement and upgradations in terms of long-term use and industry standards, this project can be commercialised for mobility assistance. As of now, it is a lab prototype.   Are you looking for industry partners? No   How much was invested in the R&D? Any grants that were used? About Rs 60,000 were invested in the development of this project, of which 48% was funded by the university as part of a departmental project (Electrical Cluster), while the rest was invested by the students.   How is the technology unique from what is already available in the market? Our technology revolutionises conventional mechanical wheelchairs by seamlessly transitioning them into electronic counterparts capable of responding to electronic sensory inputs. Unlike existing market offerings, our system incorporates an open differential and rack and pinion mechanism, enabling efficient execution of electronic commands. Through the integration of motors with these mechanisms, we empower users with a more versatile and responsive mobility solution. What sets us apart is our intuitive control system, allowing users to effortlessly navigate using simple hand gestures.   Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/news/91/24663/new-study-supports-efficacy-of-robotic-assisted-partial-nephrectomy-in-renal-mass-surgery.html https://biospectrumindia.com/news/91/24663/new-study-supports-efficacy-of-robotic-assisted-partial-nephrectomy-in-renal-mass-surgery.html Sat, 25 May 2024 00:00:00 +0530 Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, has announced the findings of India’s largest collaborative and multi-institutional study on robotic-assisted partial nephrectomy (RAPN) using the da Vinci surgical system. In collaboration with 14 government and private centres across India, the study supports the use of robotic-assisted partial nephrectomy (RAPN) in surgery for renal masses. This retrospective study utilised data from 800 patient cases spanning the last 12 years, marking a significant milestone in India's landscape for urological care.  The aim of this study, the first of its kind in India, was to validate the value and benefits of using the da Vinci surgical system in RAPN in India, providing comprehensive insights into the procedure's efficacy and safety across diverse patient demographics and tumor complexities. "In India, there has been a need for robust and high-quality data on robotic-assisted partial nephrectomy outcomes tailored to our population," said Dr. Sudhir Rawal, Director, and Head of Department of Genito Uro Oncology Services, at Rajiv Gandhi Cancer Institute and Research Centre. "Our study results help fill this gap by providing insights into the efficacy and safety of robotic-assisted partial nephrectomy across diverse patient demographics and tumor complexities. This will help provide trained surgeons the confidence in choosing robotic-assisted surgery for renal masses, for better clinical outcomes, said Dr Rawal."  "The results of this study are significant,” said Swati Gupta, Marketing Director at Intuitive India. "The data demonstrates the potential of the da Vinci system in improving patient outcomes for robotic-assisted partial nephrectomy in India and lays the groundwork for further advancements in robotic surgery nationwide. Collaboration with leading Indian institutions and surgeons has provided valuable insights specific to the Indian patient population. Going forward, this knowledge will be crucial in refining surgical techniques and expanding access to minimally invasive robotic surgery for more patients," she added.   ]]> https://biospectrumindia.com/news/91/24616/fujifilm-unveils-lung-navigation-synapse-3d-technology-in-kochi.html https://biospectrumindia.com/news/91/24616/fujifilm-unveils-lung-navigation-synapse-3d-technology-in-kochi.html Mon, 13 May 2024 00:00:00 +0530 Fujifilm India has introduced its latest innovation in lung navigation, Synapse 3D, during the Amrita Bronchoscopy & Interventional Pulmonology event held in Kochi on 12th of May. Synapse 3D represents a groundbreaking advancement in pulmonary imaging and diagnostics. Leveraging state-of-the-art 3D technology, this device offers unparalleled precision and insight into pulmonary conditions, empowering healthcare professionals with the tools they need to deliver optimal patient care. The Amrita Bronchoscopy & Interventional Pulmonology (ABIP) event served as a prominent platform for industry leaders, healthcare professionals, and innovators to convene and exchange insights on the latest advancements in pulmonary care. With a focus on interventional techniques and emerging technologies, the event facilitated discussions, workshops, and live demonstrations, providing attendees with valuable opportunities to enhance their knowledge and expertise in the field. Synapse 3D is equipped with specialised technology that identifies three optimal paths leading to a lung lesion. With the help of radial EBUS, the doctor can have better yield which ultimately helps in precise diagnosis for timely intervention. A bronchoscope simulation is performed along the path, helping to visualize difficult procedures before performing an invasive exam. This will not only help in navigating the right path in lungs, but also save time and less discomfort to the patient with better diagnosis.   ]]> https://biospectrumindia.com/news/91/24572/abbott-unveils-next-generation-xience-sierra-stent-in-india.html https://biospectrumindia.com/news/91/24572/abbott-unveils-next-generation-xience-sierra-stent-in-india.html Thu, 02 May 2024 00:00:00 +0530 Abbott, the global healthcare company, has announced the launch of XIENCE Sierra Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. For interventional cardiologists, it brings unparalleled safety to the most complex cases. Abbott has developed several tools and devices that have improved the angioplasty procedure over the years. Percutaneous coronary intervention (PCI), also called coronary angioplasty, is a nonsurgical, minimally invasive procedure that improves blood flow to the heart. Physicians use PCI to open blood vessels to the heart that are narrowed or blocked by plaque. Often, a small mesh tube called a stent is placed to keep the artery open. XIENCE is one of the most-used drug-eluting stents in the world.  XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.  XIENCE Sierra has the same highly specialised coating that lowers the likelihood of the artery becoming re-blocked, found in other XIENCE stents. The stents collectively have an unparalleled safety record from more than 120+ clinical trials involving 120,000 patients. As per published data, the stent has proved efficacy in difficult to treat, narrowed lesions and patients with complex conditions.   ]]> https://biospectrumindia.com/news/91/24551/iit-roorkee-and-univlabs-collaborate-to-develop-biodegradable-ureteral-stents.html https://biospectrumindia.com/news/91/24551/iit-roorkee-and-univlabs-collaborate-to-develop-biodegradable-ureteral-stents.html Fri, 26 Apr 2024 00:00:00 +0530 The Indian Institute of Technology (IIT) Roorkee, and Gurugram-based UnivLabs Technologies have joined hands to translate research findings into real-world applications. Through a Technology Transfer Agreement and a Memorandum of Agreement (MoA), the collaboration aims to develop and commercialise technology related to biodegradable ureteral stents, a breakthrough innovation poised to transform urological care. The patented technology, titled 'A biodegradable polymeric composite with enzymatic degradation for ureteral stent and its methods of preparation,' holds immense promise in addressing challenges associated with conventional ureteral stents. These stents are commonly used to maintain fluid drainage from the kidney to the bladder in cases of ureteral obstruction caused by various clinical conditions. Unlike non-degradable stents currently in use, the biodegradable stents developed by a team of researchers from IIT Roorkee and UnivLabs Technologies offer several advantages. These include reduced discomfort, decreased risk of complications such as urinary tract infections and encrustation, and the elimination of the need for a second surgery for removal.   ]]> https://biospectrumindia.com/news/91/24533/fujifilm-announces-launch-of-endoscopic-submucosal-dissection-device-in-india.html https://biospectrumindia.com/news/91/24533/fujifilm-announces-launch-of-endoscopic-submucosal-dissection-device-in-india.html Tue, 23 Apr 2024 00:00:00 +0530 Fujifilm, a leading innovator in endoscopy solutions, has announced the launch of Tracmotion, the red dot award-winning Endoscopic Submucosal Dissection (ESD) device, at Endocon 2024 in Delhi recently. Endocon, an esteemed platform for gastroenterology advancements, witnessed the unveiling of Tracmotion alongside leading-edge procedures and discussions shaping the future of endoscopic medicine. Endocon serves as a prominent forum for medical professionals, researchers, and industry leaders to converge and exchange insights on the latest trends and innovations in gastroenterology. This year's event, held between 19 and 21 April, showcased groundbreaking procedures, including Endoscopic Ultrasound performed on the Arietta 850, alongside sessions exploring the potential of Artificial Intelligence in gastroenterology. Endoscopic Submucosal Dissection (ESD) is a minimally invasive procedure crucial for removing precancerous and cancerous lesions in the gastrointestinal tract. It offers a targeted approach, sparing healthy tissue and enabling early intervention. Tracmotion, Fujifilm's latest innovation, marks a paradigm shift in ESD techniques. Designed for single-operator use, its 360° rotatable retraction capability empowers precise tissue manipulation independent of the endoscope's movement. With no locking mechanisms required, Tracmotion promises enhanced flexibility and manoeuvrability, potentially streamlining procedures. By facilitating easier, faster interventions with improved visualisation, Tracmotion holds the promise of advancing therapeutic ESD outcomes, ultimately benefiting patient care and treatment efficacy.     ]]> https://biospectrumindia.com/news/91/24527/medtronic-launches-advanced-neurosmart-portable-mer-navigation-system-in-india-for-parkinsons.html https://biospectrumindia.com/news/91/24527/medtronic-launches-advanced-neurosmart-portable-mer-navigation-system-in-india-for-parkinsons.html Mon, 22 Apr 2024 00:00:00 +0530 India Medtronic, a wholly owned subsidiary of Medtronic plc has announced the launch of India’s first NeuroSmart Portable Micro Electrode Recording (MER) Navigation system for Parkinson’s treatment. Deep brain stimulation (DBS) is a treatment for symptoms of Parkinson's disease, including tremors, stiffness, and difficulty walking. DBS is a therapy in which a small pacemaker-like device sends electrical signals through very thin wires, known as ‘leads’, to a targeted area in the brain related to the symptoms. Advanced DBS implants are designed to capture brain signals using the implanted DBS system. The NeuroSmart Portable MER Navigation system revolutionises DBS (Deep Brain Stimulation) therapy by enhancing precision during surgery.  The NeuroSmart Portable MER Navigation system, developed by Alpha Omega Engineering, is a groundbreaking treatment for neurological and psychiatric diseases. Featuring advanced neurophysiological navigation mapping, it enables accurate electrode placement while recording neural activity. Its advanced capabilities for enhanced target localisation, based on HaGuide automatic navigation, help identify the most effective target for the patient, ensuring optimum symptom relief.  The Neurology team at Fortis Hospital, Bengaluru, comprising of Dr Raghuram G, Additional Director Neurosurgery and Dr Guruprasad Hosurkar, Additional Director Neurology, became the first to use this technology for Parkinson’s patients. The case in point was a 68-year-old patient who had been suffering from Parkinson’s for over a decade. The condition led to restrictions in movement, causing challenges in performing daily chores. It also became challenging for the patient’s family to take care of him. While initially medications provided relief, over time these became ineffective, calling for alternative management options. With the implications of new advancement in NeuroSmart, doctors were able to identify the right target that was stimulated to manage this patients’ uncontrolled symptoms with minimal side effects. ]]> https://biospectrumindia.com/news/91/24510/drger-unveils-vista-300-in-india-new-patient-monitoring-system-revolutionizes-hospital-wide-information-.html https://biospectrumindia.com/news/91/24510/drger-unveils-vista-300-in-india-new-patient-monitoring-system-revolutionizes-hospital-wide-information-.html Tue, 16 Apr 2024 00:00:00 +0530 The Vista 300 system offers continuous end-to-end data transfer from the patient's bed to the Hospital Information System (HIS), providing medical professionals with access to critical clinical care information along the entire patient pathway, from the Emergency Room (ER) to the Intensive Care Unit (ICU) and Neonatal Intensive Care Unit (NICU).   Key features of the Vista 300 system include:   Seamless integration of patient data, vital signs, and therapy device data into clinical workstations. Easy configuration and intuitive user interface for clear display of information from multiple sources. Extended data manag ement capabilities with additional components such as the Vista spot check monitor, central monitoring station, gateway software, and viewer stations. Shalin Patel, Managing Director of Draeger India Group, expressed excitement about the launch, stating, "At Dräger, we are committed to innovation and excellence in healthcare technology. The Vista 300 system represents a significant advancement in patient monitoring, enabling medical professionals to provide optimal care while optimizing workflows."   "The Vista 300 system is designed to meet the diverse needs of medical professionals in acute care settings. Its seamless integration with therapy devices and hospital networks ensures efficient data exchange and enhances patient care,” said Dhritimay Dhar, Vice President - Sales and Marketing, Medical business, highlighting the system's versatility and connectivity.   The Vista 300 system for adults, pediatric patients, and neonates provides not only data from connected devices but also supports cross-departmental workflows within the hospital. Its advanced networking capabilities allow for easy access to patient and therapy information, while ensuring data security through encryption and controlled user authentication.   The Vista 300 is manufactured by Drägerwerk AG & Co. KGaA.  ]]> https://biospectrumindia.com/news/91/24487/warburg-pincus-invests-in-ophthalmic-equipment-and-intraocular-lenses-brand-appasamy-associates.html https://biospectrumindia.com/news/91/24487/warburg-pincus-invests-in-ophthalmic-equipment-and-intraocular-lenses-brand-appasamy-associates.html Wed, 10 Apr 2024 00:00:00 +0530 Appasamy Associates, a leading Indian manufacturer of ophthalmic equipment and devices in India, has announced that US-headquartered Warburg Pincus, a leading global growth investor has acquired a stake in the company. This is the largest investment in the healthcare sector by the firm in India. Based in Chennai, Appasamy is the largest Indian manufacturer of ophthalmic equipment and intraocular lenses (IOLs). The company is present across the entire value chain of ophthalmic devices, diagnostic, surgical equipment, and IOLs. Its vertical integration into manufacturing and its strong R&D capabilities allow the company to offer products that meet global standards at comparatively affordable prices. Appasamy will continue to be led by the recently appointed CEO, Senthil Kumar who will drive the business going forward with the support of the promoter family and in partnership with Warburg Pincus.  Narendra Ostawal, Head of India Private Equity, Warburg Pincus said, “Over 40 years, the promoters of Appasamy have built a robust enterprise that has emerged as a leading provider of affordable, high-quality offerings across the complete spectrum of ophthalmic products spanning equipment, lenses, pharmaceuticals and surgical instruments."  Warburg Pincus' investments in the Indian healthcare sector include Meril Life Sciences, MedPlus, Laurus Labs, and Metropolis Healthcare.  ]]> https://biospectrumindia.com/news/91/24424/in-med-prognostics-launches-oncohield-ct-tool-for-liver-and-pancreatic-cancers.html https://biospectrumindia.com/news/91/24424/in-med-prognostics-launches-oncohield-ct-tool-for-liver-and-pancreatic-cancers.html Tue, 26 Mar 2024 00:00:00 +0530 Pune-based startup In-Med Prognostics has announced the launch of Oncoshield CT tool for clinical decision support in diagnosing and treating liver and pancreatic cancers.  In-Med Oncoshield software automatically detects and quantifies lesions in liver and pancreas in CT scans. It automatically calculates volumes and identifies locations of lesions. This significantly enhances diagnostic capabilities and improves patient care especially in preparing for surgery. These insights are produced with over 90% accuracy and very speedily in a matter of minutes. In-Med’s Oncoshield assists radiologists in the early detection of liver lesions. Early detection is crucial for prompt medical intervention and improved patient outcomes. The product is currently deployed at the Madras Medical College and the company is offering 30-day free trial to prospective customers and 90-day free trials to its current customers who may be using Neuroshield. This new product follows the pathbreaking Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer's, Parkinson's, and Epilepsy and Neuroshield CT TBI products already operational in over 280 sites in India, Africa, and the Middle East. Neuroshield MRI Volumetry recently received the US FDA 510 clearance for sales in the US market.  ]]> https://biospectrumindia.com/news/91/24423/fujifilm-india-installs-first-ever-open-mri-machine-in-hyderabad-at-vijaya-diagnostic-centre.html https://biospectrumindia.com/news/91/24423/fujifilm-india-installs-first-ever-open-mri-machine-in-hyderabad-at-vijaya-diagnostic-centre.html Sat, 23 Mar 2024 00:00:00 +0530 Expanding access to advanced diagnostic imaging, Fujifilm India has announced the installation of its groundbreaking Open MRI machine “APERTO Lucent” at Vijaya Diagnostic Centre, Hyderabad. The event was attended by Koji Wada, MD of Fujifilm India and Chander Shekhar Sibal, Sr. Vice President & HOD – Healthcare Business -Fujifilm India, along with Sheshadri Vasan, Chief Operating Officer of Vijaya Diagnostic Centre. This partnership marks a significant step towards advancing patient-centric imaging technology. The APERTO Lucent is a new age, Prime open MRI device which is equipped with IP-RAPID - a modern day technique that reduces scan times while maintaining high image quality by employing under sampling and image reconstruction with iterative processing which will result in improved image quality with higher spatial resolution. The design of APERTO Lucent will provide high speed solutions combined with better patient experience. Revolutionising diagnostic centres and healthcare facilities, this state-of-the-art machine boasts a groundbreaking 0.4T static-field-strength permanent magnet and a sleek gantry, propelling Magnetic Resonance Imaging into a new era of sophistication. Provides swift scans with accelerated speeds, all at a low running cost and an attractive initial investment with no additional infrastructure required. Its simplified installation process and reduced construction needs expedite setup, ensuring operational readiness in record time. Taking patient friendliness to a notch high, APERTO Lucent’s single-pillar MRI structure provides a panoramic open view, significantly reducing patient anxiety. It also features a wide, lateral table with a soft sound operation to create a comfortable examination environment. Moreover, the True OPEN Bore design of the system reduces the risk of claustrophobia while accommodating patients of diverse body types.  ]]> https://biospectrumindia.com/news/91/24417/stryker-unveils-two-new-products-for-cardiac-care-and-emergency-patient-evacuation.html https://biospectrumindia.com/news/91/24417/stryker-unveils-two-new-products-for-cardiac-care-and-emergency-patient-evacuation.html Thu, 21 Mar 2024 00:00:00 +0530 Stryker, a global leader in medical technologies, recently participated at the Criticare National Conference (2024), held at the ITC Royal Bengal in Kolkata, India. During the event, Stryker launched and showcased two new products– 'LIFEPAK CR2 automated external defibrillator (AED) for cardiac care' and 'Evacuation Chair' for emergency patient evacuation. The LIFEPAK CR2 is a revolutionary defibrillator designed to empower rescuers in providing high-quality CPR and delivering instant shock during sudden cardiac arrest (SCA) emergencies. This innovative device incorporates QUIK-STEP electrodes which peel directly off the base for faster placement on patient chest and a Shock Advisory System which is an ECG analysis system that advises whether a shock is appropriate. The CPR coaching technology provides instructions for adult and pediatric CPR, including feedback when no CPR is detected, rate and depth guidance, a metronome, and instructions on hand placement for CPR. LIFEPAK CR2 also detects whether chest compressions are being performed and adjusts the voice prompts, if needed, to help the responder resume CPR and provide life-saving care. Stryker also showcased its new evacuation chair, designed to facilitate the safe and efficient evacuation of patients with limited mobility during emergencies. Additionally, the chair's maneuverability allows for easy navigation in tight spaces, and its compact storage capability maximizes space efficiency when not in use.   ]]> https://biospectrumindia.com/news/91/24393/vygon-spearheads-neonatal-safety-in-india-with-groundbreaking-nutrisafe2-system.html https://biospectrumindia.com/news/91/24393/vygon-spearheads-neonatal-safety-in-india-with-groundbreaking-nutrisafe2-system.html Fri, 15 Mar 2024 00:00:00 +0530 In an innovative leap forward, Vygon, a frontrunner in the manufacturing and distribution of specialised medical devices, has unveiled Nutrisafe2. This cutting-edge enteral feeding system, designed for neonates, ensures feeding precision and safety in neonatal intensive care unit (NICU). With its launch, Vygon addresses the critical challenge of tubing misconnections, a prevalent risk in neonatal care that leads to adverse events, including fatalities. Neonates within healthcare settings receive medication and other therapies through a variety of tubes and catheters.The connectors of these different delivery systems are often compatible and can be connected to each other. Adverse events, and even deaths, have occurred when medicines, liquid feeding formulas or air have been accidentally delivered through the wrong tube. These errors are called tubing misconnections. Speaking during the launch, Pavan Choudary, Managing Director of Vygon India, said, “Misconnections in enteral nutrition has been a crucial concern internationally. 40% of all misconnections are attributed to enteral clinical area, and the consequences are often serious and sometimes fatal." The device's launch comes in response to the critical healthcare issue, underscored by a 2014 Sentinel Event Alert from The Joint Commission. The alert shed light on the severe consequences of tubing misconnections, including enteral feeding solutions mistakenly introduced into IV lines, leading to several reported fatalities. Nutrisafe2 emerges as an effective safeguard against such risks, engineered specially for neonates to ensure safety in neonatal enteral feeding.   ]]> https://biospectrumindia.com/news/91/24385/mitra-introduces-triple-chambered-peritoneal-dialysis-bag-for-improved-patient-care.html https://biospectrumindia.com/news/91/24385/mitra-introduces-triple-chambered-peritoneal-dialysis-bag-for-improved-patient-care.html Thu, 14 Mar 2024 00:00:00 +0530 Faridabad-based Mitra Industries, a renowned name in India's healthcare industry, has unveiled its latest innovation- a triple chambered peritoneal dialysis (PD) bag with a near-neutral pH and low glucose degradation products (GDPs). This groundbreaking product aims to revolutionise patient care for those undergoing peritoneal dialysis, a crucial therapy for Chronic Kidney Disease (CKD) patients. Traditional PD solutions typically have acidic pH levels, which can adversely affect the functionality of the peritoneal membrane, essential for PD treatment. Mitra Industries' triple chambered PD bag addresses this issue, offering a solution with a near-neutral pH, thus potentially improving outcomes for CKD patients. With CKD posing significant challenges to India's healthcare infrastructure due to its rapid growth and associated risk factors like diabetes and hypertension, innovations like Mitra Industries' PD bag are crucial. The scarcity of donor kidneys for transplants further emphasises the importance of dialysis as a life-sustaining option for many patients.   ]]> https://biospectrumindia.com/news/91/24376/antara-senior-care-signs-mou-with-iit-d-to-design-innovative-mobility-aid-solutions-for-seniors.html https://biospectrumindia.com/news/91/24376/antara-senior-care-signs-mou-with-iit-d-to-design-innovative-mobility-aid-solutions-for-seniors.html Wed, 13 Mar 2024 00:00:00 +0530 Antara, an integrated service provider for all lifestyle and lifecare solutions for seniors, a part of the $4 billion Max Group, has signed a Memorandum of Understanding (MoU) with the Indian Institute of Technology Delhi (IIT-D) announcing a collaboration for senior specific offerings. As per Antara, in recent decades, India has witnessed a notable increase in life expectancy due to improved living conditions and advancements in healthcare. Consequently, the proportion and size of the elderly population have risen steadily. Mobility associated disabilities are almost inevitable after attaining a certain age, followed by hearing and visual impairments. This partnership will encompass diverse projects, ranging from mobility-assisting physical products to cognitive enhancement games aimed at delaying the onset of dementia. The collaboration includes knowledge transfer, research consultancy, EDPs, and the sharing of laboratories. It focuses on developing inclusive design solutions to enhance safety, independence, cognition, and communication issues for the geriatric population at large. One such project is designing a walking aid for the elderly.   ]]> https://biospectrumindia.com/news/91/24363/alcon-launches-clareon-presbyopia-correcting-lenses-in-india.html https://biospectrumindia.com/news/91/24363/alcon-launches-clareon-presbyopia-correcting-lenses-in-india.html Tue, 12 Mar 2024 00:00:00 +0530 Alcon, the global leader in eye care, has announced the launch of the Clareon Family of intraocular lenses (IOLs) in India. Utilising Alcon’s most advanced IOL material in its 20+ years of IOL innovation, Clareon delivers consistent visual outcomes and exceptional clarity that lasts. Clareon’s clarity is born out of a glistening-free§ IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs), compared to leading competitor IOLs. Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch IV Delivery System, which provides precise and controlled implantation and that was designed specifically for the new Clareon material. More than 28 million cataract surgeries are performed each year in the world. With the ageing population and increased life expectancies, these surgeries are expected to increase 3-4% per year for the next 30 years, leading to an estimated 60 million global cataract surgeries annually by 2045. The Clareon platform is available in India in two PCIOL technologies- Clareon PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%; and Clareon Vivity with wavefront-shaping X- WAVE technology, offering clinically proven exceptionally low rate of visual disturbances and unsurpassed clarity. ]]> https://biospectrumindia.com/news/91/24334/hmd-develops-revolutionary-dispojekt-to-help-reduce-needle-stick-injuries.html https://biospectrumindia.com/news/91/24334/hmd-develops-revolutionary-dispojekt-to-help-reduce-needle-stick-injuries.html Thu, 07 Mar 2024 00:00:00 +0530 Hindustan Syringes and Medical Devices (HMD) has launched first-of-its kind Dispojekt single use syringes with safety needle, which further strengthens India's position in becoming global powerhouse in medical devices. With the revolutionary Dispojekt safety syringes, HMD aims to reduce prevalence of accidental Needle Stick Injuries (NSIs) among health workers, reduction of infection control cost and that of disposal and training, offering a long term positive financial impact on the healthcare sector. Domestic manufactured, technologically advanced products will provide India a global edge in the realm of R&D and leapfrog indigenous players to meet the highly demanding global market for sharp injury prevention syringes.  The use of safety needles in healthcare settings offer numerous cost benefits. They reduce healthcare worker injuries, lowering costs from potential disease treatment and potential long-term health issues. By minimising needle stick injuries, they also decrease expenses for post-exposure prophylaxis and associated healthcare costs. Moreover, safety needles mitigate compensation claims, absenteeism, and can lead to lower health insurance premiums, while also reducing product and packaging footprints for cost and environmental savings. They assist in creating a safer and more reliable workplace environment for healthcare workers.  According to research, the prevalence of NSIs among healthcare workers in India is between 57% and 73%. In fact, approximately 54% of NSIs are reported because of using hypodermic needles. Many instances of NSIs go unreported, making it a way more serious problem than it appears.   ]]> https://biospectrumindia.com/news/91/24312/fujifilm-unveils-echelon-synergy-mri-machine-in-india.html https://biospectrumindia.com/news/91/24312/fujifilm-unveils-echelon-synergy-mri-machine-in-india.html Mon, 04 Mar 2024 00:00:00 +0530 Fujifilm India, the leading total healthcare imaging solutions provider, has launched its newest cutting-edge Echelon Synergy MRI Machine at its CT & MRI User Conclave held at Hotel Novotel, Mumbai on 2nd and 3rd March 2024.  Organised by Fujifilm India, the CT & MRI User Conclave is an industry meet exploring the future of Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) technologies, nurturing excellence in the radiology field. The latest advancement was unveiled in the presence of Chander Shekhar Sibal, Vice President and HOD, Healthcare Business, Fujifilm India and Shunsuke Honda, Business Advisor Healthcare Business, Fujifilm India. Fujifilm’s next generation 1.5T magnetic resonance imaging (MRI) system, Echelon Synergy, marks a significant leap forward in healthcare technology. Engineered for unparalleled performance and affordability, the system features sitting flexibility, low power consumption and ultra-fast exam times, all contributing to a remarkably low total cost of ownership.  With Echelon Synergy, Fujifilm’s Deep Learning Reconstruction (powered by Artificial Intelligence) delivers noise reduction with exceptional image quality, resulting in a 50 percent scan time reduction compared to previous-generation MRI systems.   ]]> https://biospectrumindia.com/news/91/24287/royal-philips-launches-image-guided-therapy-mobile-c-arm-system-9000-for-surgeons-in-india.html https://biospectrumindia.com/news/91/24287/royal-philips-launches-image-guided-therapy-mobile-c-arm-system-9000-for-surgeons-in-india.html Thu, 29 Feb 2024 00:00:00 +0530 Royal Philips, a global leader in health technology, has announced the launch of Philips Image Guided Therapy Mobile C-arm System 9000 – Zenition 90 Motorized, designed to help surgeons deliver high-quality care to more patients. The new mobile C-arm with expanded capabilities is designed to meet complex vascular needs and a range of clinical procedures such as cardiac interventions, pain management and urology. Zenition 90 Motorized will be commercially available from Q2 2024. Zenition 90 Motorized is an intuitive C-arm that allows the surgeon to control it from the table-side with user-friendly controls and time-saving features – empowering the surgeon with greater flexibility and independence. It delivers state-of-the-art image quality for the most challenging procedures and is designed to meet complex vascular needs. The system allows greater clinical efficiency thanks to its automated workflows, the image controls via the Touch Screen Module and the advanced software solutions. "Zenition 90, the latest in the Zenition series, builds on this tradition of innovation and has been designed, developed, and manufactured in India. We believe Zenition 90’s superior capabilities across a range of procedures will not only empower doctors and hospitals but also reinforce our role as a trusted partner in India’s healthcare ecosystem” said Peeyush Kaushik, VP and Head of the Philips Healthcare Innovation Center, Pune. The launch of the Zenition 90 Motorized follows the recent launch of the Philips Zenition 30 C-arm, and is the latest innovation in the renewed portfolio of the company’s advanced Zenition C-arm systems. ]]> https://biospectrumindia.com/news/91/24278/foldax-signs-manufacturing-agreement-with-dolphin-life-science-india.html https://biospectrumindia.com/news/91/24278/foldax-signs-manufacturing-agreement-with-dolphin-life-science-india.html Tue, 27 Feb 2024 00:00:00 +0530 US-based medical devices firm Foldax Inc., a pioneer in the development of innovative, polymer heart valves, has announced a manufacturing agreement with Dolphin Life Science India to enable in-country manufacturing of the TRIA polymer mitral surgical heart valve outside of the US for the first time. The TRIA mitral valve is designed specifically to accommodate the anatomy and pressures of the mitral position. It combines the company’s proprietary polymer LifePolymer, with an innovative valve design intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. The novel LifePolymer material and computer-designed valve help to democratise the manufacturing process, minimizing the people and processes associated with animal-based tissue valve manufacturing, enabling manufacturing in any location, and improving product variability, precision, repeatability, and quality. Surat-based Dolphin Life Science India is an expert in manufacturing medical devices. The company is registered with the Drugs Controller General of India (DCGI), and the Central Drugs Standard Control Organization (CDSCO). ]]> https://biospectrumindia.com/news/91/24243/iit-m-thsti-develop-first-india-specific-ai-model-to-determine-foetus-age.html https://biospectrumindia.com/news/91/24243/iit-m-thsti-develop-first-india-specific-ai-model-to-determine-foetus-age.html Mon, 26 Feb 2024 00:00:00 +0530 Researchers at Indian Institute of Technology Madras (IIT-M) and Translational Health Science and Technology Institute (THSTI), Faridabad, as part of ‘Interdisciplinary Group for Advanced Research on Birth Outcomes – DBT India Initiative’ (GARBH-Ini) programme, have developed the first India-specific Artificial Intelligence (AI) model to determine the age of a foetus in a pregnant woman in the second and third trimesters precisely. Accurate ‘Gestational Age’ (GA) is necessary for the appropriate care of pregnant women and for determining precise delivery dates. Called ‘Garbhini-GA2’, this is the first late-trimester GA estimation model to be developed and validated using Indian population data. This GA model can improve the care delivered by obstetricians and neonatologists, thus reducing maternal and infant mortality rates in India. The researchers used genetic algorithm-based methods to develop Garbhini-GA2, which, when applied in the second and third trimesters of pregnancy, was more accurate than the current Hadlock and recent INTERGROWTH-21st models. This study was conducted in partnership with Gurugram Civil Hospital, Gurugram, Safdarjung Hospital, New Delhi, Christian Medical College Vellore, and Pondicherry Institute of Medical Sciences, Puducherry. The GARBH-Ini programme is a flagship programme of the Department of Biotechnology (DBT), Govt of India. Once validated in prospective pan-India cohorts, this Garbhini-GA2 can be deployed in clinics across India, improving the care delivered by obstetricians and neonatologists, thus reducing maternal and infant mortality rates in India. ]]> https://biospectrumindia.com/news/91/24230/fujifilm-launches-advanced-endoscopic-ultrasound-machine-aloka-arietta-850-in-india.html https://biospectrumindia.com/news/91/24230/fujifilm-launches-advanced-endoscopic-ultrasound-machine-aloka-arietta-850-in-india.html Mon, 19 Feb 2024 00:00:00 +0530 Fujifilm India, a pioneer in diagnostic imaging and information systems, has launched the ground breaking ALOKA ARIETTA 850 Diagnostic Ultrasound System in India with its first-ever installation at Fortis Hospital in Bengaluru. Representing a remarkable advancement in endoscopic technologies, the high-tech ultrasound system aims to enhance diagnostic precision and image clarity for gastrointestinal diseases in the region. In India, contemporary lifestyles and changing dietary choices are leading to the deteriorating digestive health of the population, adding to the growing prevalence of gastrointestinal (GI) conditions. Addressing this, Fujifilm India’S ALOKA ARIETTA 850 Endoscopic Ultrasound Machine at Fortis Hospital, Bannerghatta Road, Bengaluru is a significant step in providing world-class diagnostic and therapeutic services for patients against these GI-related diseases, performing targeted treatments such as Pancreatic pseudo cyst drainage (without surgery), targeted delivery of treatment in Pancreatic cancers.  Endoscopic Ultrasound (EUS) is a minimally invasive method for assessing malignancies affecting the digestive (gastrointestinal) tract and neighbouring organs or tissues. With this high degree of accuracy in both diagnostic and therapeutic capacities, it allows doctors to precisely examine organs like the lungs, pancreas, gallbladder, liver, lymph nodes and nearby affected areas. EUS also facilitates the extraction of tissue or fluid samples through a thin needle, eliminating the need for a separate biopsy procedure. Additionally, it improves the staging of cancers with accurate sampling provided by Fine Needle Aspiration (FNA) and Fine Needle Biopsy (FNB). Furthermore, EUS proves valuable in cases of altered anatomy and among cancer patients for various therapeutic procedures. ALOKA ARIETTA 850 stands out from conventional endoscopic ultrasound machines with a range of superior features. The machine generates image quality with 7 million digital channels in its B mode. This system also incorporates HD-THI for deeper penetration, ensuring accurate diagnoses, along with combi-elastography, pure symphonic architecture and CHI-TIC and Inflow Time Mapping for clearer visibility by reducing noise and enhancing the completeness and continuity of tissue boundaries.   ]]> https://biospectrumindia.com/news/91/24204/fujifilm-installs-advanced-dexa-machine-in-delhi-to-support-diagnosis-of-bone-related-diseases.html https://biospectrumindia.com/news/91/24204/fujifilm-installs-advanced-dexa-machine-in-delhi-to-support-diagnosis-of-bone-related-diseases.html Mon, 12 Feb 2024 00:00:00 +0530 Fujifilm India, a pioneer in diagnostic imaging solutions, has announced the installation of its powerful Dual-Energy X-ray Absorptiometry (DEXA) machine “FDX Visionary-DR” at the grand inauguration of the Center for Sports Injury in Delhi. The event took place on 11th February. The Center for Sports Injury specialises in Orthopedics, Sports Surgery, Sports Medicine, Sports Imaging, Sports Physiotherapy, Rehabilitation, Fitness and Counseling. The initiative aims to deliver high-quality and fast bone-density scans, commonly known as DEXA scans, to diagnose bone-related health conditions or evaluate the risk of developing such problems.  Bone-related health diseases such as osteoporosis are widespread in India, with estimates indicating that 61 million individuals suffer from this condition. Furthermore, the incidence of osteoporosis tends to occur 10 - 20 years earlier here, in comparison to Western countries. Tackling this, the bone densitometry scan serves as an effective tool to accurately predict the chances of fractures or abnormalities in the upcoming years. Fujifilm India’s FDX Visionary-DR machine delivers a complete diagnostic experience with a wide range of applications and routine examinations for Orthopedics, Pediatrics, Lateral Spine, Morphometry and Whole Body. It features a breakthrough 3D-DXA technology that uses routine bone-mineral-density images to create 3D models of the femur, bringing in new information about bone structure for accurate diagnosis and adapted treatment procedures. Based on a 4-line, 64-element multi-array detector, the machine’s 2D Fan Beam is designed to provide the highest image resolution for a precise diagnosis and perform quick 15-second assessments per site, making it one of the most powerful solutions available in the market. Additionally, it offers advanced fat, muscle and lean medical parameters through its body composition tool which is essential in sports medicine, weight management and medical practice fields.      ]]> https://biospectrumindia.com/news/91/24195/in-med-develops-neuroshield-ct-ai-tool-to-help-reduce-mortality-rates-in-neurotrauma.html https://biospectrumindia.com/news/91/24195/in-med-develops-neuroshield-ct-ai-tool-to-help-reduce-mortality-rates-in-neurotrauma.html Fri, 09 Feb 2024 00:00:00 +0530 In-Med AI has announced the launch of its new product, 'Neuroshield CT TBI, an artificial intelligence (AI) based neurotrauma screening and quantification tool. Grounded in robust research and built on extensive imaging data, NeuroShield CT will aid neuro-critical teams in identifying and quantifying pathologies related to Traumatic Brain Injury (TBI) cases. Leveraging AI, NeuroShield CT automates manual image processing, ensuring accurate results on timely basis. This state-of-the-art technology empowers radiologists, neurologists, and neurosurgeons with accurate data, facilitating rapid, informed decision-making around workflow prioritisation, acute triage management, and developing effective treatment plans in the case of neurotrauma. TBI is the primary cause of hospitalisation, disability, and post-injury mortality worldwide, often referred to as a "silent epidemic". Globally between 64 and 74 million people experience traumatic brain injuries (TBI) every year. According to the Indian Head Injury Foundation (IHIF), India leads the world in brain injury rates, with one in six TBI patients succumbing to their injuries. Early diagnosis is crucial, as 50% of associated mortalities occur within the first 24 hours.  Serving as a decision support tool, Neuroshield CT promptly alerts neurologists to the presence of critical pathologies, offering quantifiable insights. NeuroShield CT provides crucial information, arming neurologists with the knowledge necessary for targeted interventions and improved patient outcomes. This tool is particularly essential for early intervention, a necessity during the "Golden Hour," a critical post-trauma period. The software automatically detects and quantifies bleed (Intracranial Haemorrhage), Fracture, and Midline Shift, and Fracture.   This new product follows the pathbreaking Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer's, Parkinson's, and Epilepsy. It is currently operational in over 280 sites in India, Africa, and the Middle East and recently received the US FDA 510 clearance for sales in the US market. ]]> https://biospectrumindia.com/news/91/24187/aster-cmi-hospital-set-to-revolutionise-nerve-ultrasound-diagnostics.html https://biospectrumindia.com/news/91/24187/aster-cmi-hospital-set-to-revolutionise-nerve-ultrasound-diagnostics.html Thu, 08 Feb 2024 00:00:00 +0530 Aster CMI Hospital charges ahead as a healthcare artificial intelligence (AI) patron with its groundbreaking innovative technology, which supports the health experts on various aspects of treatment such as analysing vast amounts of data that could lead to earlier and more accurate diagnoses of diseases, developing new treatment options, and immediate monitoring of vitals for various specialties. AI Carpal Tunnel syndrome (CTS) is one such technology that is developed by the Neurology Department which is poised to revolutionise nerve ultrasound diagnostics.  This technology redefines, diagnoses, and screens efficiently. It can identify the median nerve in ultrasound videos and detect CTS with the highest accuracy (95%) marking a significant leap in healthcare innovation. The AI tool signifies a transformative stride towards precision and efficiency in CTS diagnosis, marking a new era in healthcare. “As we witness the healthcare landscape evolve from a prescriptive to a predictive model, AI emerges as the catalyst for this transformative journey. Our close collaboration with government bodies underscores our commitment to ethical AI practices, rigorous regulatory compliance, and the highest standards of data privacy and security. This transformative, technology-enabled tool marks a new dawn in healthcare”  says Dr Nitish Shetty, CEO, Aster DM Healthcare. Commenting on the occasion, Dr Lokesh Bathala, Lead Consultant Neurology said, "This lab is an exemplification to the unlimited potential of AI in healthcare. We are pushing the boundaries of medical science, designing AI tools that will transform the future of diagnosis, treatment, and prevention. These AI tools can prevent long-term complications and improve the quality of life. It can also minimize the need for repetitive examinations and invasive procedures, reducing patient’s discomfort and anxiety. While the AI tools significantly reduce the inference time, it is important to note that the final diagnosis will always be carried out by the physician.”   Left To Right:  SGS Lakshmanan, Chief Operating Officer Aster CMI Hospital; Ramesh Kumar S, CEO, Aster Hospitals; Dr Lokesh Bathala, Lead Consultant Neurology; Prof. Phaneendra Yalavarthy Dept. of Computational and Data Sciences, Indian Institute of Science at the unveiling of AI technology at Aster CMI Hospital ]]> https://biospectrumindia.com/news/91/24129/stryker-introduces-tornier-shoulder-arthroplasty-portfolio-in-india.html https://biospectrumindia.com/news/91/24129/stryker-introduces-tornier-shoulder-arthroplasty-portfolio-in-india.html Fri, 26 Jan 2024 00:00:00 +0530 American med tech firm Stryker has introduced the Tornier shoulder arthroplasty portfolio in India and launched its first new Tornier product, the Perform Humeral Stem at Shoulder Conclave in Pune. On the occasion, Aman Rishi, Vice President and General Manager of Stryker India said, “The precise and personalised approach offered by Tornier Perform shoulder implants and Blueprint will redefine shoulder care and set Stryker apart in the shoulder market in India." Elevated by Blueprint planning software and the Tornier Perform anatomic and reverse glenoid, the new Tornier Perform Humeral Stem offers clinical solutions for the simplest to most complex shoulder arthroplasty cases. It is intended for use in anatomic, reverse and hemiarthroplasty of the shoulder. It also allows for conversion from an anatomic to a reverse shoulder prosthesis in the case of revision. The Tornier Perform Humeral Stem was designed with four collar diameters and is available in multiple lengths to optimise humeral fit and give surgeons the power to perform and the options to choose. The focus on smaller stem options makes it ideal for addressing smaller patient anatomies that present unique challenges. ]]> https://biospectrumindia.com/news/91/24092/ss-innovations-organises-maiden-global-multispecialty-robotic-surgery-conference.html https://biospectrumindia.com/news/91/24092/ss-innovations-organises-maiden-global-multispecialty-robotic-surgery-conference.html Sun, 21 Jan 2024 00:00:00 +0530 Amidst rising popularity of robotic surgeries in India, which is still at its nascent stage, Gurugram-based SS Innovations, the makers of India’s first and only homegrown Surgical Robotic System – the SSI MANTRA – organised a 2-day Global Multispecialty Robotic Surgery Conference (on 19th and 20th January, 2024) which witnessed participation from 150+ world renowned doctors from around the world coming together on a single platform to discuss the future landscape of robotic surgery globally, integration of Artificial Intelligence in surgery and the pursuit of sustainable tele-surgery. The highlight of the 2-day event was the Live surgeries, conducted by renowned robotic surgeons with SSI Mantra, which will showcase the system's practical applications across various surgical specialties including cardiac surgery, providing attendees with real-time insights and valuable learning experiences. In a video message, Dr Bharati Pravin Pawar, Union Minister of State for Health & Family Welfare and Tribal Affairs, said, “SS Innovations has taken upon itself the responsibility of bringing together like minded professionals who share a common vision about Robotic Surgery and chart a clear roadmap for the future ahead while also demonstrating the immense potential and the endless possibilities the technology has in store for the betterment of mankind and to bring about a paradigm shift in surgical healthcare in the country”. Dr Sudhir Srivastava, Founder, Chairman & CEO, SS Innovations, “The first global SS Innovations Multispecialty Robotic Surgery Conference 2024 aims to foster collaboration, knowledge exchange, and innovation in the realm of robotic surgery by uniting thought leaders, practitioners, and industry experts." The conference turned out to be a transformative event with gathering of global medical experts, technological innovators, and visionaries to explore the future of robotic surgery, with a special focus on the SSi Mantra Robotic Surgical System. ]]> https://biospectrumindia.com/news/91/24061/bramhansh-technologies-introduces-wearable-biofeedback-device-for-mind-monitoring.html https://biospectrumindia.com/news/91/24061/bramhansh-technologies-introduces-wearable-biofeedback-device-for-mind-monitoring.html Fri, 12 Jan 2024 00:00:00 +0530 In a groundbreaking move towards holistic well-being, Bengaluru-based startup BramhAnsh Technologies has announced the launch of SOONYAM, a wearable biofeedback device revolutionising the way we understand and monitor our mental states. SOONYAM is not just a device but a personal companion that offers real-time insights into psychological arousals, stress levels, mental effort, and more. Utilising the Galvanic Skin Response (GSR) method, SOONYAM captures and interprets the electrodermal resistance of the skin, providing a comprehensive understanding of our mind's activity. Unlike other wearable devices that focus solely on heart rate variability (HRV), SOONYAM goes beyond by tracking electrodermal activity, offering a more spontaneous and sensitive measurement of psychological arousal.  The science behind SOONYAM is rooted in the correlation between mental and physiological reactions. By measuring the electrical conductance of the skin, the device becomes a supersensitive emotion detector, akin to a lie detector. The device is powered by a sophisticated software algorithm, providing live emotional feedback during counseling sessions and facilitating a deeper understanding of one's mental state. Priced at Rs 4599, SOONYAM's tracking guide enables users to evaluate their emotional states by calculating positive and negative points. The bar graph visually represents performance, aiding users in making informed decisions to enhance their mental well-being.   ]]> https://biospectrumindia.com/news/91/24066/qure-ais-ai-driven-chest-x-ray-solution-gets-us-fda-clearance-for-enhanced-lung-nodule-detection.html https://biospectrumindia.com/news/91/24066/qure-ais-ai-driven-chest-x-ray-solution-gets-us-fda-clearance-for-enhanced-lung-nodule-detection.html Fri, 12 Jan 2024 00:00:00 +0530 Mumbai-based startup Qure.ai has announced its 13th US FDA clearance for its artificial intelligence (AI)-enabled solutions. Qure’s chest X-ray based qXR-LN uses artificial intelligence to identify and localise lung nodules, marking another significant milestone for the organisation, strengthening its standing as a pioneer in the realm of AI-powered advancements for plain film radiography and medical imaging. This also marks the 6th FDA clearance for Qure’s chest X-ray based solutions. Notably, this is the only FDA-cleared solution for detecting and localising lung nodules utilising computer vision to have Radiologists, Pulmonologists and ER physicians as intended users.  The introduction of AI solutions, such as qXR-LN, presents a remarkable opportunity to cast a wider net to identify potentially malignant pulmonary nodules, thereby boosting the fight against lung cancer.  qXR for Lung Nodule (qXR – LN) is a cutting-edge computer-aided detection software designed to identify and highlight regions indicative of suspected pulmonary nodules ranging from 6 to 30 mm in size. Tailored for use in the incidental adult population, this innovative device is a game-changer in diagnostic technology. It can also serve as a crucial second reader for physicians, assisting in the review of frontal (AP/PA) chest radiographs of adults acquired on digital radiographic systems.   ]]> https://biospectrumindia.com/news/91/24041/medtronic-and-cardiac-design-labs-bring-advanced-heart-rhythm-monitoring-technology-in-india.html https://biospectrumindia.com/news/91/24041/medtronic-and-cardiac-design-labs-bring-advanced-heart-rhythm-monitoring-technology-in-india.html Thu, 04 Jan 2024 00:00:00 +0530 India Medtronic, a wholly owned subsidiary of Ireland-headquartered Medtronic plc, has announced a strategic collaboration with Cardiac Design Labs (CDL) to launch, scale up, and expand access to CDL’s novel diagnostic technology, Padma Rhythms, an external loop recorder (ELR) patch designed for comprehensive, long-term heart monitoring and diagnosis. As part of the collaboration, Medtronic will become the exclusive distributor of Padma Rhythms in India, while both Medtronic and CDL will jointly develop training and education programmes to expand reach of the ELR technology across the country. The ELR device combines the convenience of an external patch with the advanced capabilities of a Holter, ensuring accurate and insightful data for the monitoring period. It has been designed and manufactured in India by CDL and is powered by a first-of-its-kind connected platform for managing tests, data, algorithms, analysis, review, and reporting. CDL’s innovation includes wearables designed for use in sweat inducing conditions with dependable workflows and minimal interventions for use of devices. An automated data transfer mechanism allows physicians and technicians to access real-time test management dashboards and full disclosures on-demand.   According to Dr Devi Shetty, Chairman of Narayana Health, “It is initiatives like these that will help address the growing burden of cardiovascular diseases in the country."   Image caption- L-R- Michael Blackwell, Vice President and Managing Director of Medtronic India; and Anand Madanagopal, Founder and Chief Executive Officer at CDL     ]]> https://biospectrumindia.com/news/91/23999/iit-m-develops-3d-printed-face-implants-for-patients-suffering-from-black-fungus.html https://biospectrumindia.com/news/91/23999/iit-m-develops-3d-printed-face-implants-for-patients-suffering-from-black-fungus.html Tue, 26 Dec 2023 00:00:00 +0530 Researchers at the Indian Institute of Technology Madras (IIT-M) have developed 3D-printed face implants for patients suffering from Black Fungus, which has been reported in COVID-19 patients as well as those with uncontrolled diabetes, HIV/AIDS and other medical conditions. Around 50 implants have already been done on patients from economically-weaker sections. The Institute has partnered with ZorioX Innovation labs, a startup founded by dental surgeons in Chennai, to implement this initiative, which is based on metal 3D printing or additive manufacturing. The outbreak of black fungus disease, also known as ‘Mucormycosis’, has been a cause of great concern in India. One of the most devastating effects of this disease is the loss of facial features, which can have a profound impact on the patient’s mental and emotional well-being. Therefore, the reconstruction of faces lost due to black fungus is the need of the hour. Reports suggest that about 60,000 mucormycosis cases have been registered in India post-COVID. Reconstructive surgery is a viable solution for patients who have lost their facial features due to black fungus disease. However, patient-specific implants and procedures are expensive, rendering them inaccessible for people from weaker sections. Dr Murugaiyan Amirthalingam, Associate Professor, Department of Metallurgical and Materials Engineering, IIT-M, said, “Extensive research activities are already being carried out in IIT Madras to commercialise this technology for printing patient-specific implants in stainless steel, Ti-6Al-4V and Co-Cr-Mo alloys. Using unique in-house algorithms, a patient’s MRI/CT data is converted to printable CAD format and custom implants are printed from medical-grade titanium using an indigenously-built laser powder bed facility in IIT Madras." IIT-M researchers are also identifying patients who cannot afford costly imported implants and giving these implants free of cost under the campaign called #Right2Face.   ]]> https://biospectrumindia.com/news/91/23991/medtronic-launches-renal-denervation-system-in-india-for-treating-high-blood-pressure.html https://biospectrumindia.com/news/91/23991/medtronic-launches-renal-denervation-system-in-india-for-treating-high-blood-pressure.html Fri, 22 Dec 2023 00:00:00 +0530 India Medtronic, a wholly owned subsidiary of Ireland-headquartered Medtronic plc, has announced the launch of the Symplicity Spyral renal denervation system (RDN) for treating high blood pressure. RDN is a minimally invasive therapy that targets nerves near the kidneys that can become overactive and cause high blood pressure. Medtronic recently announced the US Food and Drug Administration’s (FDA) approval of the system which is a culmination of ten years of clinical research and development, and the system has approval of the Indian regulatory authorities too. In India, nearly 1 in 4 adults have hypertension. Hypertension is the single largest contributor to cardiovascular death; it dramatically increases risk of heart attack, stroke, heart failure, and kidney failure.   The Symplicity Spyral blood pressure procedure has demonstrated clinical efficacy in reducing high blood pressure which can lower serious health risk. It is a minimally invasive procedure that targets nerves near the kidneys that can become overactive and cause elevated blood pressure. After sedation, the doctor makes a small incision and inserts a very thin tube (catheter) into the artery leading to the kidney. The doctor then uses the catheter to calm the excessive activity of the nerves connected to the kidney. The tube is removed, leaving no implant behind. Michael Blackwell, Vice President and Managing Director, Medtronic India said, "With the Symplicity blood pressure procedure, we aim to empower healthcare professionals and offer a comprehensive approach to managing uncontrolled hypertension that supports our patient-centered approach to care." ]]> https://biospectrumindia.com/news/91/23944/fujifilm-india-partners-with-gvn-hospital-for-early-detection-of-gastrointestinal-cancer.html https://biospectrumindia.com/news/91/23944/fujifilm-india-partners-with-gvn-hospital-for-early-detection-of-gastrointestinal-cancer.html Tue, 12 Dec 2023 00:00:00 +0530 Fujifilm India has announced its partnership with GVN Hospital, Trichy to introduce a groundbreaking mobile endoscopy unit called Endo Bus, revolutionising the early detection of gastrointestinal (GI) cancer across India. Starting from December 11, the primary focus of this philanthropic initiative is to facilitate free screening of early-stage GI cancers for economically disadvantaged patients in smaller cities and underserved regions. It will ensure that vital healthcare services are accessible to those in need, irrespective of their socio-economic status or geographical location. Endoscopy is vital for diagnosing gastrointestinal related cancers. The procedure uses an endoscope, a tiny camera on a flexible tube, to check the GI tract by inserting it either through the mouth to see the upper part (esophagus and stomach) or through the anus to examine the lower part (large intestine & small intestines). However, underserved communities face hurdles in availing the benefit of this crucial procedure due to poor endoscopic infrastructure, lack of skilled staff, financial constraints and geographic barriers. With the mobile endoscopy system provided by Fujifilm India in the Endobus, doctors will be able to perform GI endoscopy and colonoscopy using Flexible spectral Imaging Color Enhancement (FICE) technology as part of the screening and it will help in early detection of suspicious lesions.   Once the patients with suspected lesions are screened, at the remote location; they will be moved to GVN hospitals for advanced diagnosis using linked colour imaging (LCI) and blue laser imaging (BLI) technology.    ]]> https://biospectrumindia.com/news/91/23921/opto-semiconductor-chips-manufacturer-unveils-medical-device-for-precise-vein-detection.html https://biospectrumindia.com/news/91/23921/opto-semiconductor-chips-manufacturer-unveils-medical-device-for-precise-vein-detection.html Sat, 09 Dec 2023 00:00:00 +0530 Tamil Nadu-based Polymatech Electronics, at the forefront of semiconductor chip innovation in India, has unveiled its groundbreaking medical device - the Vein Detection Light. This cutting-edge technology promises to revolutionise the healthcare industry, offering a solution to a pervasive problem of accurate vein detection in medical procedures worldwide. The device features high-definition vein detection, delivering real-time full high-definition (FHD) visualisation (1920 X 1080) for unmatched clarity in identifying subdermal veins. Weighing a mere five lbs. and designed for mobility, the Vein Detection Light provides healthcare professionals with unparalleled convenience across various medical settings. According to industry estimates, there are around 174 million veni- puncture failures worldwide every year, with a failure rate of one in five attempts in adults and one in three attempts in paediatrics. Moreover, patient movement during infusion poses the risk of unintended needle punctures, leading to potential complications such as infiltration or extravasation, where the administered medicine leaks from the vein into the surrounding tissue. Polymatech's Vein Detection Light addresses the critical need for accurate vein detection, especially in challenging cases where time is of the essence. ]]> https://biospectrumindia.com/news/91/23845/dr-reddys-rolls-out-usfda-approved-drug-free-non-invasive-migraine-management-device-in-india.html https://biospectrumindia.com/news/91/23845/dr-reddys-rolls-out-usfda-approved-drug-free-non-invasive-migraine-management-device-in-india.html Thu, 16 Nov 2023 00:00:00 +0530 Hyderabad-based Dr. Reddy’s Laboratories has announced the roll-out of Nerivio® in India, a state-of-the-art United States Food and Drug Administration (USFDA) approved wearable therapy device for drug-free management of migraine. Migraine is a global health challenge, affecting around 30% of adults on 15 or more days per month, impacting 1.7% to 4% of the population. Migraines are known to have a disproportionate impact on women, who constitute approximately 60% of the 213 million migraine sufferers in India alone. Nerivio® is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migraine with or without aura for adults and adolescents aged 12 years and above. Nerivio® can be worn on the upper arm. Each device has in-built 18 x 45-minute treatment sessions. It is to be used within 60 minutes of onset of headache for acute treatment of migraine or every alternate day for prevention of migraine. The device uses the Remote Electrical Neuromodulation (REN) mechanism to specifically activate conditioned pain modulation by stimulating nerve endings. This initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects the original source of migraine pain in the head. In January 2023, Dr. Reddy’s entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, for the marketing and distribution of Nerivio® in India.  Dr. Reddy’s also recently signed an exclusive agreement for the commercial marketing and distribution of Nerivio® in Germany, Austria, Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Spain, Sweden, Switzerland and the United Kingdom. ]]> https://biospectrumindia.com/news/91/23837/inmed-ai-receives-us-fda-510k-clearance-for-neuroshield-that-quantifies-brain-volumes-.html https://biospectrumindia.com/news/91/23837/inmed-ai-receives-us-fda-510k-clearance-for-neuroshield-that-quantifies-brain-volumes-.html Tue, 14 Nov 2023 00:00:00 +0530 Pune-based startup InMed Prognostics Inc. has received the US Food and Drug Administration (FDA) 510(k) clearance for NeuroShield™, a fully automated brain geometry-based quantifying analytics tool/cloud platform that uses artificial intelligence (AI)/Deep Net/3D Convolutional Networks to support physicians as a clinical decision support tool for neurologists and neuroradiologists. NeuroShield is currently in clinical use in over 220+ sites across the world. In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics. NeuroShield takes 3D MR images as inputs and automatically calculates brain volumes that can assist physicians in devising treatment plans for patients with neurodegenerative diseases such as Dementia, Alzheimer's' Disease, Parkinson's, and Epilepsy. NeuroShield is the first in the world to provide reference ranges that can be adjusted to age, gender, and ethnicity, setting new standards in healthcare and bringing us closer to precision medicine that is relevant for everyone, everywhere. ]]> https://biospectrumindia.com/news/91/23825/terumo-advances-liver-cancer-care-in-india-with-new-tools.html https://biospectrumindia.com/news/91/23825/terumo-advances-liver-cancer-care-in-india-with-new-tools.html Thu, 09 Nov 2023 00:00:00 +0530 Terumo India, the Indian arm of Japan-based medtech firm Terumo Corporation, has recently announced the launch of Occlusafe™ and LifePearl™, intended for use in the management of liver cancer. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with more than 20,000 cases getting added every year in India. HCC can be treated with management approaches ranging from surgical resection to minimally invasive options. Embolisation is one such minimally invasive management option. The most common type of Embolization is Transcatheter Arterial Chemo-Embolization (TACE), a clinical-guideline recommended, minimally invasive management option for intermediate stage liver cancer. For the first time in India, Terumo has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer. With Occlusafe™, Terumo’s B-TACE device, patients benefit from more precise and targeted delivery of chemotherapy drug to the tumour.  Another value addition to be introduced in the area of liver cancer care is LifePearl™. It helps release chemotherapeutic drug in a controlled and sustained manner at the targeted tumour site inside the liver.  Occlusafe™ and LifePearl™ are known to improve clinical outcomes for liver cancer patients treated with TACE.  ]]> https://biospectrumindia.com/news/91/23807/guwahati-refinery-inks-mou-with-tata-cancer-care-for-medical-equipment-supply.html https://biospectrumindia.com/news/91/23807/guwahati-refinery-inks-mou-with-tata-cancer-care-for-medical-equipment-supply.html Mon, 06 Nov 2023 00:00:00 +0530 Guwahati Refinery recently signed a Memorandum of Understanding (MoU) with Tata Cancer Care Foundation for providing special medical equipment to Silchar Cancer Centre, Assam, under its Corporate Social Responsibility (CSR) initiatives. The agreement was signed by GK Goyari, Chief General Manager and Refinery Head, Guwahati Refinery, and Kumar Nandula, CFO, Tata Cancer Care Foundation, in the presence of Gautam Chintey, Director, Assam Cancer Care Foundation, and senior officials from Indian Oil, Assam Cancer Care Foundation, Tata Cancer Care Foundation, and Tata Trust.The MoU between Indian Oil Guwahati Refinery and Tata Cancer Care Foundation establishes a partnership wherein Guwahati Refinery will extend a financial support of Rs 16.39 crore in providing medical equipment like LINAC for delivering external beam radiation therapy, Treatment Planning System, a computer-based software system used in radiation oncology, dosimetry and immobilisation devices, as well as brachytherapy, i.e., internal radiation therapy used to treat cancer. ]]> https://biospectrumindia.com/news/91/23797/bd-introduces-next-generation-needle-free-blood-draw-technology.html https://biospectrumindia.com/news/91/23797/bd-introduces-next-generation-needle-free-blood-draw-technology.html Thu, 02 Nov 2023 00:00:00 +0530 American medtech firm BD (Becton, Dickinson and Company) has launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay."  With 510(k) clearance from the US Food and Drug Administration (FDA), the new PIVO™ Pro Needle-free Blood Collection Device features design improvements to achieve the first and only compatibility with integrated and long peripheral IV catheters, including the new Nexiva™ Closed IV Catheter System with NearPort™ IV Access. This expands on current PIVO™ compatibility with traditional short peripheral IV catheters available since 2017.    The new solution combines the clinical benefits shown for the integrated closed Nexiva™ Catheter System, including longer dwell times and reduced catheter complications, with the ability to draw high-quality blood samples directly from a patient's peripheral IV line with PIVO™ Pro, reducing the need for additional needlesticks. With needle phobia experienced by more than 60 percent of the adult population, this solution helps improve the patient experience by alleviating fear and anxiety associated with repetitive needlesticks. By removing the needle from blood draws and reducing IV replacements, it may reduce the risk of needlestick injury and blood exposure for clinicians while preserving a patient's vessel health. ]]> https://biospectrumindia.com/news/91/23787/noccarc-to-secure-bis-approval-for-revolutionary-ventilator.html https://biospectrumindia.com/news/91/23787/noccarc-to-secure-bis-approval-for-revolutionary-ventilator.html Wed, 01 Nov 2023 00:00:00 +0530 Noccarc, incubated at the Startup Incubation and Innovation Centre of the Indian Institute of Technology (IIT), Kanpur, is on the verge of obtaining Bureau of Indian Standards (BIS) approval for its groundbreaking ventilator. This accomplishment puts Noccarc in direct competition with international products conforming to FDA and CE standards, a remarkable feat considering that over 80% of medical devices in India are typically imported. The company's dedication to research and development, rigorous testing, and adherence to international manufacturing standards has resulted in two granted patents and over 23 patent applications. The ventilator has garnered endorsements from medical institutions such as AIIMS Bhopal and Ruby Hall, Pune. Noccarc has transformed ICU operations by supplying more than 3,600 ventilators, addressing critical issues overlooked by traditional companies. This achievement not only redefines industry standards but also showcases India's untapped potential in producing high-value, high-margin medical equipment. While Noccarc has global aspirations, the company is currently focusing on the domestic market over the next two years to meet the substantial demand in India. Simultaneously, Noccarc is actively working toward obtaining CE and FDA approvals, positioning itself for broader global expansion. Padmaja Ruparel, Founding Partner of the IAN Fund, praised Noccarc's impressive progress, emphasising their dedication to enhancing ICU care. ]]> https://biospectrumindia.com/news/91/23717/deeptek-ai-secures-us-fda-clearance-for-groundbreaking-chest-x-ray-ai-solution.html https://biospectrumindia.com/news/91/23717/deeptek-ai-secures-us-fda-clearance-for-groundbreaking-chest-x-ray-ai-solution.html Tue, 17 Oct 2023 00:00:00 +0530 DeepTek.ai, a Pune-based medical imaging artificial intelligence (AI)-based startup, has received clearance from the US Food and Drug Administration (FDA) for its revolutionary Chest X-ray AI solution - CXR Analyzer. This advanced technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorises, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations.  Unlike traditional point AI solutions identifying a specific pathology, DeepTek's Chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It is compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful.  This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases. In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential. The shortage of radiologists further emphasises the role of AI in addressing this challenge. DeepTek's AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost. Over 500 hospitals and imaging centers are using DeepTek's AI solutions, impacting the lives of 100,000 people monthly. More than half a million people have been screened using DeepTek's Chest X-Ray Analyzer for tuberculosis screening. ]]> https://biospectrumindia.com/news/91/23683/blk-max-hospital-collaborates-with-intuitive-to-launch-robot-assisted-surgery-fellowship-training-programme.html https://biospectrumindia.com/news/91/23683/blk-max-hospital-collaborates-with-intuitive-to-launch-robot-assisted-surgery-fellowship-training-programme.html Tue, 10 Oct 2023 00:00:00 +0530 BLK-Max Super Specialty Hospital along with its knowledge partner, US-based medtech firm Intuitive, have announced the launch of a comprehensive dual console robot-assisted surgery (RAS) fellowship training programme in oncology for surgeons across India.  With BLK-Max Hospital being the first private hospital in the country to have a da Vinci dual surgeon console, the fellowship is being launched to cater to the need for more trained RAS surgeons and it aims to prepare the next generation of surgeons to be equipped in the field of robotic-assisted surgery. The fellowship extends over three months and is designed to acquaint surgeons with robot-assisted surgery from OPD consultations to live operations focusing on its technology, clinical applications, and benefits with hands-on training. The fellowship programme will be led by one of the leading robotic surgeons in the country, Dr Surender Kumar Dabas.  For the duration of three months, the course will include three sections with exposure to a variety of robotic surgery cases in oncology along with practice sessions on robotic port placement and docking, hands-on experience with a robotic simulator, active involvement as assistant in surgeries, and immersion in from outpatient (OPD) to inpatient (IPD) settings. The training will be carried out on the new-age robot-assisted surgical system, da Vinci by Intuitive.  Mandeep Singh Kumar, VP and Country General Manager, Intuitive India, said, "With robotic surgery continuing to gain prominence as the preferred mode of surgery, early exposure to the robotic platform is becoming increasingly important. We are witnessing a rapid increase in the number of healthcare practitioners in India who are keen to adopt advanced surgical technologies to better serve their patients. Programmes like this will help them with the necessary training from the early adopters of RAS, which will eventually lead them to actively use robotic-assisted surgery in their practice." ]]> https://biospectrumindia.com/features/91/23639/making-radiotherapy-accessible-by-leveraging-ai.html https://biospectrumindia.com/features/91/23639/making-radiotherapy-accessible-by-leveraging-ai.html Tue, 03 Oct 2023 00:00:00 +0530 The global market for radiotherapy is expected to increase at a Compound Annual Growth Rate (CAGR) of 6.3 per cent from 2022 to 2031 to reach $11.9 billion. Out of which, the Indian radiotherapy market is projected to increase from $126 million in 2022 to $250 million in 2030, at a CAGR of 9 per cent. Radiotherapy technology has advanced quickly in recent years, and high-income nations now have access to a wide variety of innovative radiotherapy treatment alternatives. Because radiation therapy can damage normal cells, medical imaging such as x-ray, computed tomography (CT) or magnetic resonance imaging (MRI), are being used to help precisely target the radiation dose to the cancer.  Compared to CT-guided radiotherapy, MRI-guided radiotherapy is more expensive. Because an MRI-linear accelerator requires more time per fraction than a standard linear accelerator, as well as more expensive equipment and skilled employees, it can only treat a few patients. The time per treatment fraction is anticipated to decrease as this technology continues to advance. Treatment on the MRI-linear accelerator will likely continue to be more expensive than on a standard linear accelerator, though. The World Health Organisation (WHO) recommends one medical linear accelerator per million population in developing countries.  At present, the key players in the Indian radiotherapy landscape such as Varian Medical Systems, Elekta, Siemens Healthineers, and Accuray, are mostly global but with extensive operations in India. These leading players have recently launched advanced technologies in the Indian market to take radiotherapy to the next level. From linear accelerators (linacs), brachytherapy devices, and Gamma Knife radiosurgery, to oncology informatics, Swedish firm Elekta has been consistently pushing the boundaries of medical technology. The flagship in their lineup is Elekta Unity, an advanced MR-Linac system that seamlessly integrates a high-field MR magnet with a linear accelerator. This game-changing technology enables clinicians to visualise tumours in real-time during radiation therapy, ushering in a new era of precision treatment. Recently, the introduction of the first Elekta Unity MR-Linac in India took place at Yashoda Hospital, Hyderabad. According to Manikandan Bala, Managing Director, India and Senior Vice President, Intercontinental, Elekta, “The changing shape, size and location of tumours and their surrounding structures requires adaptive treatment planning. Through personalised adjustments to treatment plans, advanced technology enhances treatment efficacy while minimising dose spillage.” The company has also recently collaborated with American firm GE HealthCare to expand access to precision radiation therapy solutions in India. Sharing a similar ambition to improve patient accessibility to advanced precision cancer therapy, Mumbai-based startup Karkinos Healthcare has partnered with Elekta to acquire more than ten linear accelerator (linac) systems to be strategically deployed across the country.   Addressing skill gap  Although newer technologies and precision care for cancer treatment are being introduced in India, a critical aspect of skilled labour still remains a challenge. The broad use of cutting-edge therapies is hampered by a lack of qualified radiation oncologists and healthcare specialists educated in cutting-edge radiotherapy techniques. Improving patient outcomes requires addressing the skill gap and funding training programmes for healthcare personnel. A recent initiative in this regard was announced by another Swedish medtech company C-RAD, the global leader in surface-guided radiation therapy (SGRT) solutions, with the establishment of its first-ever Experience Centre in India at Faridabad. Set up as a joint project with its India partner Marrsis Disha, the facility will train and upskill clinical professionals in precision radiotherapy. “SGRT is a tattoo-free alternative for patients who require radiation therapy. The technology uses advanced 3D camera technology to track and monitor patient movements during set-up and treatment. We want to use this Experience Centre as a platform to promote cutting-edge technologies like SGRT. There is a huge unmet demand for radiation therapy equipment in India and not every patient is able to get treatment in time", said Rohan Mehtani, Chief Executive Officer, Marrsis Disha. Elekta has also initiated a similar approach by launching a collaborative educational facility in Mumbai, with Bengaluru-based HealthCare Global Enterprises (HCG). The training centre will focus on providing radiation oncologists, radiotherapy technologists and medical physicists with the necessary skills and training on the latest treatment techniques and technological advancements in radiation therapy (RT).  Dr B S Ajaikumar, Executive Chairman, HealthCare Global Enterprises says, “Through these training programmes we hope to move the needle from basic radiotherapy techniques to high precision radiotherapy treatment strategies such as image-guided radiation therapy (IGRT), adaptive RT, stereotactic ablative body radiotherapy (SABR) and stereotactic body radiation therapy (SBRT). Equipping medical professionals through effective learning solutions can significantly improve efficiency and patient outcomes.” Besides generating a skilled workforce, another issue in India is the lack of knowledge and instruction on radiotherapy as a possible treatment for cancer and other illnesses. Radiotherapy-related myths and misconceptions can be dispelled by promoting public awareness campaigns and carrying out educational programmes. The bulk of modern treatment facilities are concentrated in urban areas, making it difficult to ensure an equitable distribution of radiation facilities and services across the nation's many regions. To ensure that everyone has fair access to healthcare, radiation services must be made more widely available in rural and distant areas.    How would AI help? Adoption of Artificial Intelligence (AI) is a leading trend in the global radiotherapy devices market and is gaining significant popularity. The incorporation of AI innovation in disease care is expected to improve the exactness and speed of analysis, help clinical dynamics, and lead to better results. Ethos therapy is the first AI-powered personalised cancer care delivery system in radiation oncology, developed by US-based Varian Medical Systems, now a part of Siemens Healthineers. Back in 2022, HCG Cancer Hospital, Bengaluru, announced the launch of India’s first Varian Ethos therapy. The Ethos Radiotherapy applies Artificial Intelligence and Machine Learning to generate adapted plans within minutes to guide doctors while the patient is still undergoing treatment. Radixact X9 Tomotherapy by US-based firm Accuray is another advanced AI-based cancer treatment technology available in India. And these adoptions are gradually increasing. But then arises the question that people from low-income families may find it difficult to get treatment because of the expense of sophisticated radiation equipment and procedures. For many people seeking radiation treatment, affordability is still a problem, which causes inequalities in access to high-quality care. On the other hand, the global shortage of radiologists is a pressing concern impacting patient care worldwide. And AI is apparently revolutionising radiology by expediting diagnoses, enhancing efficiency, and serving as valuable decision support. While spending on AI in India is anticipated to reach $11.78 billion in 2025 and add $1 trillion to the country's economy by 2035, AI might be able to offer more than just financial advantages. Access to care can be increased and made more egalitarian with AI-enabled medical technology but in an affordable manner.   ---------------   “PPPs hold immense potential to accelerate AI implementation in radiotherapy across India” Dileep Mangsuli, Executive Director and Head of Development Center, Siemens Healthineers     In 2022, there were an estimated 1,461,427 new cancer cases in India. Artificial intelligence (AI)-driven innovations can make radiotherapy more accessible and efficient, attracting both healthcare providers and patients. It can enhance treatment accuracy, reduce side effects, and optimise resource allocation by harnessing AI for treatment planning, precise dose calculation, and real-time tumour tracking. This technology can also address the shortage of skilled radiation oncologists by assisting in treatment decisions.   Challenges faced by AI applications in the radiotherapy market in India: Infrastructure disparities: Limited access to advanced radiotherapy equipment and expertise, especially in rural areas, hinders the widespread adoption of AI in healthcare. Data privacy and security: Protecting sensitive patient information is crucial, necessitating robust measures against unauthorised access or data breaches. Education and training: Specialised training for healthcare professionals in AI utilisation is essential for effective implementation. Moreover, accurate contouring of organs-at-risk (OAR) is a critical but challenging step in radiation therapy planning. AI and technological advancements offer automated solutions, reducing workload and standardising CT simulation steps. These automated OAR contouring solutions provide clinically usable results, with over 95 per cent of contours being accurate. They enhance efficiency, accessibility, and integration in clinical environments, expediting the treatment process. Private-public partnerships  (PPPs) hold immense potential to accelerate the implementation of AI in radiotherapy across India. Over 95 per cent of cancer centres are concentrated in urban areas, leaving rural regions underserved. While 70 per cent of the population still lives in rural regions, the majority of cancer treatment facilities are located in urban centres. This scenario indicates a critical need for such collaborations. Moreover, AI-driven automation of organs-at-risk contouring, a pivotal aspect of treatment planning, can significantly benefit from technological advancements. AI's ability to process complex data efficiently addresses the challenge of accurate OAR contouring. This, in turn, streamlines the treatment process, making it more accessible and effective. By combining resources and expertise, private-public partnerships can play a pivotal role in revolutionising radiotherapy in India, ultimately leading to improved patient care and outcomes.   ]]> https://biospectrumindia.com/news/91/23658/sigtuples-ai100-with-shonit-receives-us-fda-510k-clearance.html https://biospectrumindia.com/news/91/23658/sigtuples-ai100-with-shonit-receives-us-fda-510k-clearance.html Tue, 03 Oct 2023 00:00:00 +0530 SigTuple, a Bengaluru-based medtech startup that develops Artificial Intelligence (AI) powered digital microscopy solutions, has announced that its path-breaking device AI100 with ShonitTM (Peripheral blood smear application) has received US FDA 510(k) clearance. This is the first integrated hardware and AI medical device, and the first product in AI assisted digital microscopy from India to obtain the coveted clearance and one of the handful of companies in the world to obtain it.  For all haematological disorders like blood cancers, infections, anaemia & allergies, the microscopic examination of the peripheral blood smear (PBS) is the gold standard test, but microscopy today is predominantly a manual process - necessitating a highly skilled pathologist to be present on-site. SigTuple’s AI100 with ShonitTM is the premier solution for AI assisted digital pathology, wherein a physical sample is digitally imaged through a microscopic lens & the AI models extract each cell and then classify it into over 30 different cell types. The pathologists can now review the samples remotely. Further, the AI helps make the pathologist be more efficient, by automating most of the review. Thus, the same pathologist can now handle a much larger number of samples than what she/he can currently, eliminating the need for an additional manual review. ]]> https://biospectrumindia.com/news/91/23646/us-fda-clears-qure-ais-chest-x-ray-solution-as-potential-indicator-for-identifying-heart-failure-risk.html https://biospectrumindia.com/news/91/23646/us-fda-clears-qure-ais-chest-x-ray-solution-as-potential-indicator-for-identifying-heart-failure-risk.html Fri, 29 Sep 2023 00:00:00 +0530 Mumbai-based startup Qure.ai has announced US Food and Drug Administration (FDA) clearance for measuring the cardiothoracic ratio (CTR) utilising its artificial intelligence (AI)-enabled chest X-ray solution, qXR-CTR.  The qXR-CTR is a deep-learning-based computer vision algorithm designed for use by physicians in all inpatient and outpatient settings, to automate the CTR assessment on chest radiographs (CXR). Precisely, it measures the ratio of the maximum transverse diameter of the heart to the maximum inner transverse diameter of the thoracic cavity, providing the most accurate indicator of cardiomegaly on plain film. This cutting-edge technology leverages artificial intelligence algorithms to deliver precise and efficient results, saving time for physicians and improving diagnostic accuracy.   The clearance of qXR-CTR marks the company's 12th FDA-cleared algorithm, solidifying its position as an industry leader. Previous FDA-cleared findings by Qure.ai include Endotracheal Tube location, Tracheostomy tube location, Pneumothorax, and Pleural Effusion identification for CXR; qER for intracranial haemorrhage detection on head CT scans, and qER Quant for quantifying critical abnormalities on head CT scans.   Heart failure is a complex, life-threatening cardiac condition often misdiagnosed due to its nonspecific symptoms. With qXR-CTR now being cleared by the FDA, Qure's chest X-ray algorithm can be deployed to jointly screen for increased cardiothoracic ratio (CTR) and Pleural effusion along with other radiographic markers associated with the presence of heart failure. ]]> https://biospectrumindia.com/news/91/23579/qure-ai-receives-510k-fda-clearance-for-chest-x-ray-solution-for-pneumothorax-and-pleural-effusion.html https://biospectrumindia.com/news/91/23579/qure-ai-receives-510k-fda-clearance-for-chest-x-ray-solution-for-pneumothorax-and-pleural-effusion.html Tue, 12 Sep 2023 00:00:00 +0530 Mumbai-based startup Qure.ai has announced a pivotal 510(k) FDA clearance for its artificial intelligence (AI)-enabled chest X-ray solution – qXR, under two critical findings. Qure’s qXR has now been cleared to triage pneumothorax (PTX) and pleural effusion (PE), which present severe challenges in emergency rooms and intensive care units (ICUs). The newest clearance is an addition to Qure’s existing FDA-cleared product portfolio that includes qXR-BT for breathing tube placement, qER for emergency room head CT scans, and qER-Quant for head CT quantification software.   qXR has shown exemplary clinical accuracy in triaging pneumothorax (PTX), a condition where air collects in the pleural space, causing the lung to collapse. On the other hand, Pleura Effusion (PE) is where fluid accumulates in the pleural cavity. Performance evaluations reveal that qXR-PTX-PE excels in providing rapid passive notifications, taking an average of 10 seconds to alert healthcare professionals. This impressive speed positions qXR-PTX-PE as an indispensable medical tool designed to inform specialists promptly, especially in critical settings like ICUs and emergency rooms, and to complement the expertise of our trained medical professionals. Utilising a globally sourced training dataset, qXR integrates into the existing standard of care workflow and serves as a passive notification system for worklist prioritisation.   ]]> https://biospectrumindia.com/news/91/23562/apollo-hospitals-installs-ophthalmology-laser-machine-femto-ldv-z8-from-ziemer.html https://biospectrumindia.com/news/91/23562/apollo-hospitals-installs-ophthalmology-laser-machine-femto-ldv-z8-from-ziemer.html Thu, 07 Sep 2023 00:00:00 +0530 Apollo Hospitals has unveiled a breakthrough technology in Ophthalmic care, the FEMTO LDV Z8 from Swiss firm Ziemer, a latest generation ophthalmology laser machine, at Apollo Hospitals, Jubilee Hills, Hyderabad.  This is the first of its kind state-of-the-art machine with comprehensive capabilities, in Telangana and Andhra Pradesh. It can perform a wide range of advanced eye procedures, including laser cataract surgery, customised laser refractive surgery (CLEAR - lenticule extraction) and various laser assisted corneal transplantation surgeries, with much greater precision, higher safety and minimal damage to surrounding tissue. This latest generation laser technology enables patients to avail precision based world-class eye care coupled with the expertise of renowned team of ophthalmologists at Apollo Hospitals. The FEMTO LDV Z8, a high end laser machine, uses low energy femtosecond laser technology to create precise incisions in the eye. This allows for greater accuracy and less trauma during surgery, resulting in faster recovery and better outcomes.     ]]> https://biospectrumindia.com/news/91/23567/fujifilm-india-partners-with-yashoda-group-of-hospitals-in-hyderabad.html https://biospectrumindia.com/news/91/23567/fujifilm-india-partners-with-yashoda-group-of-hospitals-in-hyderabad.html Thu, 07 Sep 2023 00:00:00 +0530 Fujifilm India has formalised a partnership with Department of Gastroenterology, Yashoda Group of Hospitals, Hyderabad for establishing training and research facility. The Memorandum of Understanding (MoU) was signed in the presence of Dr A.Lingaiah, Director Medical Services, Yashoda Group of Hospitals; Tatsuhiko Saeki, Global Head of Endoscopy Division, Fujifilm Corporation, Tokyo; Dheeraj Chaudhri, Head of the Department Fujifilm India; and Tomosuke Okada, Japanese Advisor, Fujifilm India. This training facility at one of the most prestigious institutes will help the gastroenterologists enhance their skills in basic and advanced gastrointestinal (GI) endoscopy including Endoscopic Ultrasound procedures. The centre will also provide comprehensive training and observership programmes to doctors from the Asia Pacific Region. The centre actively conducts clinical research in pancreatic and biliary disorders, early detection of pancreatic cancer, advanced imaging modalities, bariatric endoscopy, and novel endoscopic devices. In addition, the programme is committed to the training of GI fellows and advanced endoscopy fellows. This strategic partnership will support training and clinical research activities in collaboration with all the branches of Yashoda Group with a vision of raising patient care standards in the country. Fujifilm India Endoscopy Division aims to strengthen the health standards of the country and empower the healthcare professionals improve patient outcomes with world class training facilities and latest technologies in the country.  ]]> https://biospectrumindia.com/news/91/23494/intuitive-and-max-healthcare-to-launch-observation-centre-for-robotic-assisted-surgery.html https://biospectrumindia.com/news/91/23494/intuitive-and-max-healthcare-to-launch-observation-centre-for-robotic-assisted-surgery.html Thu, 24 Aug 2023 00:00:00 +0530 Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, and Max Healthcare, one of the largest private sector healthcare services companies in India, have signed a Memorandum of Understanding to establish Southeast Asia’s first Total Programme Observation (TPO) Centre, located at Max Super Specialty Hospital in Saket, New Delhi.                  The TPO Centre will provide healthcare professionals with opportunities to observe and learn from multi-disciplinary robotic-assisted surgery (RAS) programmes. In addition to clinical technology training, the TPO Centre will be able to address other important aspects of developing a robotic surgical program, including financial viability, building a robotic steering committee, and sustained investment pathways.  In order to become an Intuitive robotic-assisted TPO centre, a hospital or health system must follow certain criteria, which include having an RAS programme with more than three specialties, serving as a clinical observation site for more than two specialties, and having successfully adopted robotic technology, including advanced instrumentation. Mandeep Singh Kumar, Vice President and General Manager, Intuitive India said, “This collaboration between Intuitive and Max Healthcare is a commitment to foster a resilient RAS ecosystem in India. The introduction of a Total Programme Observation centre in India aligns with Intuitive's global commitment to catalyse patient care, technological innovation, and excellence in patient outcomes utilising robotic-assisted surgery."    ]]> https://biospectrumindia.com/news/91/23467/smithnephew-launches-new-tool-in-india-for-use-in-primary-and-revision-hip-arthroplasty.html https://biospectrumindia.com/news/91/23467/smithnephew-launches-new-tool-in-india-for-use-in-primary-and-revision-hip-arthroplasty.html Fri, 18 Aug 2023 00:00:00 +0530 UK-based medtech firm Smith+Nephew has announced the launch of its OR3O Dual Mobility System for use in primary and revision hip arthroplasty in India. Compared with traditional solutions, dual mobility implants have a small diameter femoral head that locks into a larger polyethylene insert - increasing stability, reducing dislocation risk, and offering improved range of motion. While most hip implants utilise a Cobalt Chrome (CoCr) liner along with CoCr/SST or ceramic head balls, OR3O incorporates Smith+Nephew's latest advanced bearing surface, OXINIUM DH, for its liner and proprietary OXINIUM on XLPE for its femoral head and polyethylene inserts. This eliminates both the modular CoCr liner and/or CoCr head ball from the construct - reducing wear and corrosion risks that have been associated with the alloy.  OXINIUM DH (Diffusion Hardened) is a unique variation of Smith+Nephew's OXINIUM Technology platform that increases the depth of hardening through an additive manufacturing process. The modular dual mobility segment was introduced to India in 2015 and has continued to grow globally. Post-operative dislocation is the second most common reason for revision of a total hip replacement globally and remains a serious concern for surgeons when performing total hip arthroplasty. Studies have shown dual mobility is uniquely positioned to manage dislocation, better than metal-on-metal or ceramic-on-ceramic large head series. Smith+Nephew's OR3O Dual Mobility System is available in India for both primary and revision applications and offers cross-compatibility with the R3 Acetabular System.   Image caption- L-R- Kamesh Teng (Sr. Director, Orthopedics, S+N India) and Damien Ben-L'Amri (Sr. Director, Orthopedics, S+N Asia-Pacific) ]]> https://biospectrumindia.com/news/91/23433/fujifilm-india-installs-first-ever-smart-mri-machine-at-sarvodaya-hospital-greater-noida.html https://biospectrumindia.com/news/91/23433/fujifilm-india-installs-first-ever-smart-mri-machine-at-sarvodaya-hospital-greater-noida.html Fri, 04 Aug 2023 00:00:00 +0530 Fujifilm India, the Indian arm of Japan-headquartered company Fujifilm, has announced the first-ever installation of the new Magnetic Resonance Imaging (MRI) machine Echelon Smart 1.5 Tesla in Sarvodaya Hospital, Greater Noida West (Noida Extension).  Costing Rs 7 crore, the new MRI machine by Fujifilm India provides functions for patient-friendly acoustic noise reduction (Smart Comfort), operator-friendly operation support and environment-friendly low power consumption. The device is a 1.5T Superconductive MRI system with the high image quality of the high magnetic field achieved by Fujifilm technology and with a flexible site layout inherited from a permanent magnet MRI system. The MRI system has a power consumption of 29 kVA under general conditions and comes with smart technologies including SmartECO, SmartSPACE, SmartCOMFORT, SmartSPEED, and SmartQUALITY. While SmartECO reduces heat generation and provides economical running costs, SmartSPACE has a small footprint and flexible layout. SmartCOMFORT features soft sound technology that provides a 94% reduction in noise and offers quiet scanning without any compromise with image resolution and applies to SE, FSE, FIR, GRE, and DWI sequences. SmartSPEED features Autopose for Brain and Spine under a quick scan plan, besides Whole Body Diffusion, IsoFSE –Single volume acquisition to generate isotropic images in all planes and RADAR- Versatile motion artefact Reduction.   ]]> https://biospectrumindia.com/news/91/23424/india-launches-first-indigenously-developed-magnetic-resonance-imaging-mri-scanner.html https://biospectrumindia.com/news/91/23424/india-launches-first-indigenously-developed-magnetic-resonance-imaging-mri-scanner.html Wed, 02 Aug 2023 00:00:00 +0530 Union Minister of State (Independent Charge) Science & Technology Dr Jitendra Singh recently launched India’s first indigenously developed, affordable, lightweight, ultrafast, high field (1.5 Tesla), next generation Magnetic Resonance Imaging (MRI) scanner in New Delhi. Dr Jitendra Singh said that it is indeed a milestone achievement for National Biopharma Mission (NBM), Biotechnology Industry Research Assistance Council (BIRAC) and Department of Biotechnology (DBT) as we unveil the first indigenously developed state-of-the-art MRI Scanner under Public-Private Partnership mode. Under the National Biopharma Mission, Bengaluru-based startup Voxelgrids Innovations Pvt Ltd has developed a compact, lightweight, next generation MRI Scanner to solve the unmet need of the country. The Minister underlined that out of Rs 17 crore spent for developing the world class MRI scanner, Rs 12 Crore was provided by DBT through BIRAC. Dr Jitendra Singh pointed out that 70% of the world’s population has zero access to Magnetic Resonance Imaging (MRI) diagnostic modality. On comparing other imaging modalities such as CT, X-ray and Ultrasound, access to MRI scanners is typically a factor of 3 less. The reason is prohibitively high capital costs which is a problem in developing counties like India. Current estimates in India indicate that the total installed base of MRI is 4800, which is 3X lower than CT, which is possibly due to high cost and import dependency of this product. ]]> https://biospectrumindia.com/news/91/23410/new-specialists-to-provide-surgical-care-for-indias-cataract-blind.html https://biospectrumindia.com/news/91/23410/new-specialists-to-provide-surgical-care-for-indias-cataract-blind.html Mon, 31 Jul 2023 00:00:00 +0530 US-based HelpMeSee has announced a new partnership with the United States Agency for International Development (USAID) American Schools and Hospitals Abroad (ASHA) Initiative to train 100 new cataract specialists to help restore sight to India's cataract blind. Through this agreement, ASHA has provided funding to deploy two HelpMeSee eye surgery simulators to facilitate training at the HelpMeSee Mumbai Centre of Excellence for Simulation-Based Training.  Currently, untreated cataract is the cause of 66 percent of all blindness in India, according to the National Blindness and Visual Impairment Survey. India has approximately 20,000 ophthalmologists, equating to an average of eight for every million people, which is considerably lower in comparison with higher-income economies. This is compounded by the fact that ophthalmologists are not equally distributed throughout the nation. The cataract blind and visually impaired face significant challenges in finding well-trained specialists to treat them. In India, HelpMeSee has established partnerships with LV Prasad Eye Institute in Hyderabad to train government hospital doctors and Aravind Eye Hospitals in Madurai, empowering local communities to restore sight. ]]> https://biospectrumindia.com/news/91/23404/genworks-introduces-mechanical-hysteroscopic-tissue-removal-system.html https://biospectrumindia.com/news/91/23404/genworks-introduces-mechanical-hysteroscopic-tissue-removal-system.html Thu, 27 Jul 2023 00:00:00 +0530 With an aim to make the hysteroscopic procedure minimally invasive and completely simple, Bengaluru-based startup GenWorks, a healthcare solutions provider, has recently announced the introduction of its Mechanical Hysteroscopic Tissue Removal System that uses a simple mechanical approach for removing intrauterine tissues. This is a highly effective solution that offers better access and improved outcomes. The steps followed in the Hysteroscopy procedure include inserting the hysteroscope into the uterus, dissenting the uterus with the saline, locating the intrauterine abnormality, placing the shaver against the pathology, aspirating, and cutting tissue, removing the shaver and the hysteroscope from the uterus finally. It is made to provide direct visualisation of the intrauterine cavity and has efficient tissue removal capabilities. It captures all the tissue needed for pathological analysis. The soft tissue shavers respect pathology down to its base and allow tissue capture for histological confirmation through simultaneous cutting and aspiration.  It offers a safe and gentle resection which is designed to eliminate the risk of energy discharge and the proprietary suction control minimises fluid use. It also comes with a clear operative field with a continuous hysteroscopic outflow so that there is a clear operative field and no tissue floats within the uterine cavity. The process is efficient because it involves a single insertion and a few procedural steps. Moreover, it helps in targeted removal under continuous visualisation.  It is a minimally invasive system that has been demonstrated to be quicker and is also more than likely to completely remove endometrial Fibroids and Polyps. The average procedure time for Polyps and Fibroids removal is relatively lesser when done with a mechanical hysteroscopic tissue removal system. What is more, the system has been used in more than 1,40,000 procedures until now.     ]]> https://biospectrumindia.com/views/91/23373/unrivalled-precision-of-12-lead-ecg.html https://biospectrumindia.com/views/91/23373/unrivalled-precision-of-12-lead-ecg.html Fri, 21 Jul 2023 00:00:00 +0530 The mortality rate related to Cardiovascular Diseases (CVD) is unfortunately very high. CVD refers to conditions that affect the heart and blood vessels, such as heart attacks and strokes. Additionally, lack of awareness about the importance of a healthy lifestyle and delayed medical intervention can contribute to the gravity of the situation. It is crucial for individuals to understand the significance of timely and accurate diagnosis. When a healthcare condition is detected early and accurately with a 12 Lead ECG, or Electrocardiogram it allows for swift intervention and appropriate treatment. Studies published in medical journals, as well as the consensus of cardiologists and medical societies, consider the 12-Lead ECG as the standard tool due to its higher sensitivity and specificity. This means that it is more capable of identifying heart abnormalities, leading to more accurate diagnoses and appropriate treatment plans for patients.   From Labs to Hands: Rise of Portable ECG devices The global market for portable ECG devices has witnessed significant advancements over the years, with various innovative products leading the way. The initial breakthrough came with the introduction of the single-lead ECG patch, providing a portable solution for heart monitoring. However, the challenge of continuous monitoring with Single Lead ECG patch persisted. Even the integration of single lead ECG devices into smartwatches was initially considered a mere gimmick rather than a serious medical tool. Overcoming the challenge of continuous monitoring and the limitations of single lead and six lead portable ECG devices, the industry experienced a revolution with the development of a 12-lead touch-based ECG device. The market for portable 12 Lead ECG devices continues to expand as these technological advancements improve the effectiveness, accessibility, and convenience of monitoring heart health on the go.   Difference Between 12 Lead ECG, 6 Lead ECG and Single Lead ECG When comparing the interpretation of the graph obtained from a Single Lead ECG and a 12-Lead ECG, there are notable differences in the areas of the graph that can be seen. The level of detail measurements of intervals, segments, and amplitudes on the ECG graph empowers healthcare professionals to detect abnormalities that may indicate myocardial infarction, ventricular hypertrophy, electrolyte imbalances, myocardial ischemia, and other critical cardiac conditions. The 12-lead ECG serves as a vital tool in making accurate diagnoses, leading to appropriate treatment strategies. 12 lead can detect ST elevation and depression which corresponds to MI, Hyper-acute T Wave, Ischemia, while Single lead cannot detect ST elevation or depression because readings from minimum 2 precordial leads are required to confirm Myocardial Infraction.   What You need to Know while choosing ECG In the dynamic world of cardiac diagnostics, the 12-lead ECG shines as the pinnacle of accuracy and comprehensive assessment. Its complete limb lead configuration, precise measurements, and ability to differentiate between cardiac conditions make it an indispensable tool in the hands of healthcare professionals. As individuals, we must make informed decisions and prioritise the use of 12-lead ECG devices for prevention and monitoring purposes. Let us move beyond superficial trends and embrace the true essence of care and concern for our own and our loved ones' heart health, extending our dedication beyond special occasions to the regular days that truly matter.   Ojasvi Nirav, Senior Cardiac Analyst, Agatsa Software   ]]> https://biospectrumindia.com/news/91/23380/medtech-life-introduces-heating-pads-in-variable-sizes-for-comfort-and-pain-relief-.html https://biospectrumindia.com/news/91/23380/medtech-life-introduces-heating-pads-in-variable-sizes-for-comfort-and-pain-relief-.html Fri, 21 Jul 2023 00:00:00 +0530 Mumbai-based Medtech Life has launched the Medtech Orthopaedic Heating pad Handypad HP-01. Designed for busy professionals and individuals with hectic lifestyles and desk jobs, this heating pad provides modern, safe, and convenient heat therapy for effective pain relief. Back pain affects a significant number of adults especially during monsoons, with around 80% of individuals over 50 years old experiencing some form of back pain. Additionally, period cramps are a major cause of distress in women.  Medtech Life's heating pad offers a safe and soothing solution to relieve pain. Lined with velvet fabric for a premium look and feel, the heating pads utilise heat therapy, a trusted and effective pain management technique. Unlike other heating pads, Medtech's thermostatic temperature controller maintains the set temperature for longer durations. With dual thermostats for dual safety and three heating levels, users can select their preferred temperature, providing them with flexibility and making it easier to navigate their busy day. These pads are foldable, easy and a must to carry during travel.  Medtech currently manufactures over 40 medical devices, including Nebulizers, Blood Pressure Monitors, Digital Thermometers, Pulse Oximeters and Oxygen Concentrators, among others. The company also exports its products to 70 countries, thereby embodying the motto of "Make in India, Make for the World." The company's Department of Scientific and Industrial Research (DSIR)-approved Research and Development Division focuses on creating superior quality devices for personal healthcare and wellness.   ]]> https://biospectrumindia.com/news/91/23347/trivitron-unveils-indias-first-automatic-radiation-protection-gloves-manufacturing-facility-at-amtz.html https://biospectrumindia.com/news/91/23347/trivitron-unveils-indias-first-automatic-radiation-protection-gloves-manufacturing-facility-at-amtz.html Mon, 17 Jul 2023 00:00:00 +0530 Trivitron Healthcare has unveiled its advanced Radiation Protection Gloves Manufacturing Facility at the Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam. This state-of-the-art facility, equipped with cutting-edge technology and advanced automation, reaffirms Trivitron's dedication to delivering top-notch products in radiation protection.  The newly established plant boasts an impressive annual capacity of over 200,000 units, making it India's first fully automatic radiation protection gloves manufacturing facility.  Dr GSK Velu, Chairman and Managing Director of Trivitron Healthcare, expressed his enthusiasm for this milestone achievement, stating, "The inauguration of our state-of-the-art radiation protection gloves manufacturing facility at AMTZ signifies a significant leap forward in our mission to advance healthcare." The new continuous production line, unparalleled in its capabilities, is set to revolutionise the radiation protection gloves market. By combining innovation and automation, Trivitron Healthcare is at the forefront of addressing the crucial requirement for high-quality radiation protection gloves worldwide.   ]]> https://biospectrumindia.com/news/91/23325/smithnephew-introduces-new-implant-in-india-for-rotator-cuff-repair.html https://biospectrumindia.com/news/91/23325/smithnephew-introduces-new-implant-in-india-for-rotator-cuff-repair.html Tue, 11 Jul 2023 00:00:00 +0530 British medtech firm Smith+Nephew has announced the launch of its REGENETEN Bioinductive Implant in India. With more than 100,000 procedures completed globally since its introduction, the REGENETEN implant has had a transformative impact on the way surgeons approach rotator cuff procedures. The collagen-based REGENETEN Bioinductive Implant supports the body's natural healing response to facilitate the growth of new tendon-like tissue to biologically augment the existing tendon and change the course of disease progression. Delivered arthroscopically through a small incision over the location of the rotator cuff tendon injury, the implant is about the size of a postage stamp and by 6 months, the implant is no longer visible, with new tendon-like tissue and oriented collagen suggestive of functional loading. The REGENETEN Bioinductive Implant arrives in India with more than 10 years of clinically demonstrated results in 18 studies covering the entire spectrum of rotator cuff disease, from partial thickness tears to large (3-5cm) and massive (5cm+) full-thickness tears. The prevalence of rotator cuff disease (a common cause of shoulder pain) in India was estimated to be 150,000 in 2022 with approximately 28,000 patients undergoing rotator cuff repair procedures. The total rotator cuff repair market in India is expected to reach 33,000 cases in 2023 and 39,000 in 2024, with year-over-year growth of 15%.   ]]> https://biospectrumindia.com/news/91/23305/american-oncology-institute-elevates-cancer-care-in-telangana-with-ai.html https://biospectrumindia.com/news/91/23305/american-oncology-institute-elevates-cancer-care-in-telangana-with-ai.html Fri, 07 Jul 2023 00:00:00 +0530 American Oncology Institute (AOI) Hyderabad, has announced the launch of Ethos Radiotherapy, artificial intelligence (AI)-driven holistic solution integrated with Varian’s most advanced surface guidance system, IDENTIFY™ technology. With the implementation of AI-driven Ethos Radiotherapy, AOI sets a new benchmark in cancer care, offering cutting-edge technology and personalised treatment options to patients in Telangana and beyond.   This new solution uses augmented intelligence, a convergence of people and AI working together to adjust cancer treatments in response to patients’ unique and daily changing needs. In the treatment room, IDENTIFY™ helps guide through setup and patient’s position using visual assistance.   Ethos brings in unique capabilities of treatment personalisation by adapting treatment plan in real time based on changing patient anatomy and tumour location. An extension to the technology for precision cancer care, IDENTIFY™ an intuitive interface detecting real-time changes in position of the tumour during the on-going treatment. This enables the team to accurately position the radiation beam allowing only to target the tumour cells.     American Oncology Institute is the leading cancer hospital chain in South Asia operating 16 cancer hospitals in the region. AOI founded in 2012 by a group of physicians and industry experts, is today a wholly owned subsidiary of the largest cancer medical technology company - Varian Medical Systems, a Siemens Healthineers Company.    ]]> https://biospectrumindia.com/news/91/23298/ge-healthcare-collaborates-with-elekta-to-expand-access-to-precision-radiation-therapy-solutions-in-india.html https://biospectrumindia.com/news/91/23298/ge-healthcare-collaborates-with-elekta-to-expand-access-to-precision-radiation-therapy-solutions-in-india.html Thu, 06 Jul 2023 00:00:00 +0530 American multinational medical technology company GE HealthCare extends its collaboration with Swedish brand Elekta, a leader in radiation therapy, to expand access to precision radiation therapy solutions for the Indian market. It aims to provide hospitals with a comprehensive offering across diagnostics and treatment for cancer patients who require radiation therapy. Radiation therapy is an important component of cancer treatment with more than 50% of patients requiring radiotherapy as part of cancer care. The World Health Organisation (WHO) recommends one medical linear accelerator, (a radiotherapy equipment used in treating cancers) per million population in developing countries. India currently only has availability of  0.4 per million people reducing access to quality care necessary to enhance patient outcomes. Combining GE HealthCare diagnostic solutions with Elekta radiation therapy solutions will result in a compelling offering for hospitals and ultimately, their patients. GE HealthCare’s collaboration with Elekta in India is a testament to the company’s commitment to improving cancer outcomes with multiple partners and providers. As a leading innovator of precision radiation therapy solutions, Elekta’s treatment modalities demand superior precision and accuracy in delivering radiation to the tumor while protecting surrounding healthy tissue and organs.      Picture caption (From left to right): Chaitanya Sarawate, President & CEO, GE HealthCare South Asia and Managing Director, Wipro GE Healthcare Manikandan Bala, Senior Vice President, TIMEA & Asia Pacific and Managing Director, India & South Africa, Elekta ]]> https://biospectrumindia.com/news/91/23278/national-institute-of-tuberculosis-and-respiratory-diseases-conducts-first-robotic-bullectomy-surgery-using-ssi-mantra-.html https://biospectrumindia.com/news/91/23278/national-institute-of-tuberculosis-and-respiratory-diseases-conducts-first-robotic-bullectomy-surgery-using-ssi-mantra-.html Fri, 30 Jun 2023 00:00:00 +0530 National Institute of Tuberculosis and Respiratory Diseases (NITRD), a Government of India Institute, under the Directorate General of Health Services, Ministry of Health and Family Welfare is the first Central Government hospital to purchase the indigenous SSI MANTRA Robotic Surgical System, the brainchild of Dr Sudhir Prem Srivastava, a world-renowned robotic cardiac surgeon and pioneer in the field. The SSI MANTRA Surgical Robot system recently executed a flawless Bullectomy surgery which involved the removal of apical bullae within the lung which had developed because of the destruction of the lungs.  The balloons grow and compress the lung, making it hard to breathe.  If bullae rupture, air escapes into the space between the lung and the chest wall, which can cause the lung to collapse, a condition called pneumothorax.  After undergoing multiple episodes of recurrent pneumothorax, the patient had the condition surgically treated. Dr. Sudhir Srivastava, Founder, Chairman & CEO, SS Innovations said, “The success of the Bullectomy Surgery at NITRD using SSI MANTRA further cements the superiority of the system to be able to perform such complex surgeries with utmost precision. This has spurred the team at SS Innovations to scale the next height and take on more challenging surgeries with renewed vigour”.   ]]> https://biospectrumindia.com/news/91/23260/eye-q-introduces-state-of-the-art-advanced-customised-lasik-technology-in-rewari.html https://biospectrumindia.com/news/91/23260/eye-q-introduces-state-of-the-art-advanced-customised-lasik-technology-in-rewari.html Mon, 26 Jun 2023 00:00:00 +0530 Eye-Q, a chain of 32 Super-Speciality Eye Hospitals having presence in Delhi-NCR, Haryana, Uttar Pradesh, Uttarakhand, and Gujarat, has announced the installation of the first-of-its-kind Advanced Customised LASIK machine at its Rewari eye-care facility. This cutting-edge machine will revolutionise laser vision correction and bring advanced treatments closer to patients in the Rewari region, eliminating the need to travel to the Gurugram facility. Through its Rewari eye-care facility, Eye-Q envisions enhancing the quality of life for individuals, especially youth aged 18-35 years who can do away with spectacles forever by availing of world-class eye-care treatments. The Advanced Customised LASIK machine sets a new standard in laser vision correction, catering to a wide range of visual conditions, including mild to severe nearsightedness with or without astigmatism, farsightedness with or without astigmatism, and mixed astigmatism. Eye-Q’s procedure performed using this machine is known for its high reliability, painless experience, exceptional safety, predictability, and remarkable precision. Eye-Q aims to treat approximately 100 patients with this advanced LASIK machine by the end of this calendar year. The machine combines the advanced technologies of the WaveScan WaveFront System and the VISX STAR S4 IR Excimer Laser with Iris Registration (IR). Moreover, the machine has received FDA approval due to its impressive success rate in treating more than 94 percent of eligible patients for laser vision correction.  ]]> https://biospectrumindia.com/news/91/23246/elekta-unity-mr-linac-to-revolutionise-cancer-care-in-india.html https://biospectrumindia.com/news/91/23246/elekta-unity-mr-linac-to-revolutionise-cancer-care-in-india.html Wed, 21 Jun 2023 00:00:00 +0530 Hyderabad-based Yashoda Hospital, in collaboration with Swedish firm Elekta, a leader in precision radiation therapy, has launched the Elekta Unity MR Linac, its ground-breaking technology, in India. This state-of-the-art system combines the power of magnetic resonance imaging (MRI) with precise radiation delivery, marking a significant advancement in cancer treatment. The Elekta Unity MR Linac integrates an MRI scanner directly into the LINAC system, allowing for real-time imaging of the patient's anatomy during radiation treatment sessions. This enables Yashoda Hospital to provide patients with precise, accurate, and adaptive radiation therapy, resulting in improved outcomes and reduced side effects compared to traditional radiation therapy systems. With a conventional LINAC, imaging and radiation delivery are typically separate processes. Patients are imaged using external imaging modalities like CT or MRI, and then the treatment plan is generated based on those images. The Cone beam CT (CBCT) integrated linear accelerator delivers radiation to the patient based on the pre-planned treatment. But this approach has limitations in detailed visualisation of the tumour and surrounding healthy tissues. By harnessing the capabilities of MRI technology and linear accelerator, this innovative machine enables precise, accurate and adaptive radiation therapy in real-time. It allows for the targeting of tumors with unparalleled precision resulting in improved outcomes with reduced side effects.     ]]> https://biospectrumindia.com/news/91/23160/cml-biotech-installs-worlds-first-integrated-blood-collection-tube-manufacturing-machine.html https://biospectrumindia.com/news/91/23160/cml-biotech-installs-worlds-first-integrated-blood-collection-tube-manufacturing-machine.html Sat, 27 May 2023 00:00:00 +0530 Angamaly, Kerala-based CML Biotech, one of the largest manufacturers of blood collection tubes in India, has installed the world's first integrated machine 'HUSKY-ICHOR', for manufacturing blood collection tubes. The integrated machine comprises machine mould, hot runner, dowser, dehumidifier, chiller, temperature controller and dryer. Normally these functions are carried out in different machines. The machine is manufactured by Canada-based Husky Technologies, a global leader in injection moulds and moulding machines.   The machine, set up at a cost of Rs 12 crore, is capable of manufacturing 8 lakh blood collection tubes per day. The company currently has manufacturing capacity of around 120 million vacuum blood collection tubes and 100 million non-vacuum blood collection tubes per annum. Apart from pan India operations, the company's blood collection tubes, microbiology products and lab disposables are exported to more than 60 countries. ]]> https://biospectrumindia.com/news/91/23047/aiims-and-medtronic-partner-to-open-new-surgical-robotics-training-centre-in-new-delhi.html https://biospectrumindia.com/news/91/23047/aiims-and-medtronic-partner-to-open-new-surgical-robotics-training-centre-in-new-delhi.html Wed, 03 May 2023 00:00:00 +0530 All India Institute of Medical Sciences (AIIMS) New Delhi and India Medtronic, a wholly owned subsidiary of Ireland-based Medtronic plc, has announced the opening of a state-of-the-art surgical robotics training centre at AIIMS, New Delhi. The centre will provide surgeons with best-in-class training in robotic-assisted surgery. It is the first such centre at AIIMS utilising Medtronic’s Hugo robotic-assisted surgery (RAS) system, which was first introduced in India in September 2021. RAS is an emerging medical technology that can help standardise surgical procedures and enable surgeons in performing complex surgeries. The training centre will offer a broad spectrum of training to enhance the knowledge and skill set in RAS, ranging from basic skills training to procedural training to more advanced and specialized areas in soft-tissue surgery. The training will help impart procedural knowledge skills using surgical robotics among surgeons, fellows, and residents from across the country.The Hugo robotic-assisted surgery (RAS) system is not cleared or approved in all markets. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability. In the US, the Hugo RAS system is an investigational device not for sale. “Medtronic’s partnership with AIIMS is a cornerstone of our commitment to make the benefits of RAS available to more patients in India. Together, we will make training and education on the latest technology more accessible and enhance the skill sets of both current and the next generation of surgeons,” said Michael Blackwell, Vice President & Managing Director, Medtronic India. ]]> https://biospectrumindia.com/news/91/23034/concept-medical-receives-3rd-ide-approval-from-usfda-for-magictouch-sirolimus-coated-balloon.html https://biospectrumindia.com/news/91/23034/concept-medical-receives-3rd-ide-approval-from-usfda-for-magictouch-sirolimus-coated-balloon.html Mon, 01 May 2023 00:00:00 +0530 Surat-based Concept Medical Inc. (CMI), with presence in The Netherlands, US, Singapore and Brazil, has received its third Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) for its novel Sirolimus-Coated Balloon, Magic Touch SCB, for the treatment of Small Vessels (SV) in Coronary Arteries. This milestone comes after CMI received IDE approvals for Magic Touch SCB to treat Coronary In-Stent Restenosis (ISR) in September 2022 and Magic Touch PTA to treat "Below the Knee" Peripheral Arterial Diseases (PAD) in February 2022. The IDE approval allows Concept Medical to conduct pivotal clinical studies to gather safety and effectiveness data for the Magic Touch Sirolimus Coated Balloon in small vessel coronary disease. This data will support a future pre-market approval (PMA) application in the USA, providing patients and physicians with an alternate product for the treatment of Coronary Artery Disease (CAD). Currently, there are no FDA approved Drug Coated Balloons for the treatment of CAD in the USA, and the patients are limited to the availability of Drug Eluting Stents and uncoated Balloons. MagicTouch has already been widely studied globally in multiple clinical trials, most notably the EASTBOURNE Registry (2123 patients), NANOLUTE, and ongoing trials like the TRANSFORM 1, TRANSFORM 2, GINGER, TITAN, and Hybrid Bifurcation DEB. Sirolimus has already proven to be safer in coronary artery disease treatment. Notably, no Indian company has received IDE approval for a Drug-Coated Balloon in the USA, either in the Peripheral or Coronary indications. This achievement has the potential to be a game changer for the healthcare industry, healthcare professionals, and patients at large, providing an alternate product for the treatment CAD & PAD.   ]]> https://biospectrumindia.com/news/91/22967/siemens-healthineers-launches-new-mri-manufacturing-facility-at-bengaluru.html https://biospectrumindia.com/news/91/22967/siemens-healthineers-launches-new-mri-manufacturing-facility-at-bengaluru.html Tue, 18 Apr 2023 00:00:00 +0530 Taking a lead in the Indian medtech industry, German firm Siemens Healthineers has inaugurated the new manufacturing facility for Magnetic Resonance Imaging (MRI) machines at Bengaluru. The company will currently manufacture MAGNETOM Free.Star, a disruptively simple approach to high-quality MRI in India. Under the Government of India’s Production Linked Incentive (PLI) scheme, the company is dedicated to manufacture Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) devices. The new facility is approved under the Radiology and Imaging Medical devices segment of the PLI Scheme by the Government of India and the Department of Pharmaceuticals.  MAGNETOM Free.Star is a designed-for-purpose scanner that can be deployed to truly improve the lives of people by helping to diagnose and treat the most prevalent diseases. Addressing the need of the hour, it is built on the latest DryCool technology and is virtually helium-free scanner with an ultra-compact footprint that is far easier to install.  The company recently celebrated laying the foundation stone for the new campus in Bengaluru that integrates R&D, manufacturing, innovation hub, and India headquarters making India a core centre of competence for the design and development of entry-level products. The futuristic campus aims to strengthen collaboration and creativity, coupled with environment-friendly, sustainable, energy-efficient solutions. ]]> https://biospectrumindia.com/news/91/22961/iit-m-develops-screening-device-for-blood-vessel-health-assessment.html https://biospectrumindia.com/news/91/22961/iit-m-develops-screening-device-for-blood-vessel-health-assessment.html Mon, 17 Apr 2023 00:00:00 +0530 A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed a novel, non-invasive device to assess the health and age of blood vessels and thereby provide early screening for cardiovascular diseases. Called ARTSENS, it is designed such that it can be used in routine medical examination by even non-experts, to assess and predict vascular health. It is powered by a proprietary non-imaging probe and an intelligent computing platform and is developed by the Healthcare Technology Innovation Centre (HTIC) at IIT-M. The device has been assessed on more than 5,000 human subjects. The technology already has five utility patents in the US, European Union and India, 10 design patents and awaits awarding of 28 patents in various jurisdictions. The product is ready for technology transfer and commercialisation after extensive testing. The IIT-M team intends to deploy this to conduct over a million vascular screenings per year. ARTSENS has been approved for clinical studies in India, US, and Europe. An extensive clinical study is underway at the All India Institute of Medical Sciences (AIIMS), New Delhi. Scientists at Radboud University Medical Center, The Netherlands, are using this device to investigate the association between arterial age, physical (in)activity, and cardiovascular events and AIIMS New Delhi researchers are using it to study and understand the physiological underpinnings of arterial ageing in various disease conditions.   ]]> https://biospectrumindia.com/news/91/22935/yashoda-hospital-ghaziabad-unveils-new-department-for-robotic-surgery-and-ai.html https://biospectrumindia.com/news/91/22935/yashoda-hospital-ghaziabad-unveils-new-department-for-robotic-surgery-and-ai.html Wed, 12 Apr 2023 09:55:00 +0530 Ghaziabad-based Yashoda Super Specialty Hospital has launched a new department for robotic surgery and artificial intelligence (AI). The department was inaugurated by Union Minister of Health and Family Welfare, Dr Mansukh L Mandaviya in the presence of Union Ministers, Hardeep Singh Puri and Gen VK Singh.    The hospital has installed one of the 4th gen robotic surgery programmes, Da Vinci by US-based Intuitive, at the newly opened department. The hospital aims to make RAS affordable and accessible to the public through this initiative, with a focus on driving better patient outcomes.   While inaugurating the department and scientific session, Dr Mandaviya said that it is setting a milestone in the journey of health for all missions of the Government of India. He said that it is not only professional work for them to add this kind of service but they are doing it for the growth of the nation. He said the mindset of the nation has changed since 2014 people were only expecting the government to work for the nation but now private hospitals have started to come in the front with a holistic approach to the growth of the nation.   The hospital also conducted an informative session on the benefits of Robotic surgery and AI in healthcare, with a focus on robotic surgery technology.   Hardeep Singh Puri said that other private hospitals should also come up with such great initiatives as the Yashoda –Kaushambi to take India to a leading position in healthcare globally.     ]]> https://biospectrumindia.com/news/91/22931/ssi-mantra-conducts-first-robotic-assisted-lima-takedown-surgery-in-hyd-.html https://biospectrumindia.com/news/91/22931/ssi-mantra-conducts-first-robotic-assisted-lima-takedown-surgery-in-hyd-.html Tue, 11 Apr 2023 10:00:00 +0530 SSI MANTRA surgical robot system was recently used to conduct Robotic Assisted LIMA (Left Internal Mammary Artery) Takedown surgery on a 35-year-old patient in Continental Hospital, Hyderabad. The procedure – LIMA Takedown with Pericardial Opening is a coronary artery bypass surgery with a single graft. The left internal mammary artery is taken out from the internal wall of the chest and then grafted or bypassed beyond the area of occlusion for the coronary artery in the heart. LIMA is a life-saving coronary artery bypass procedure that involves the left internal mammary artery and the left anterior descending artery. It opens the heart's blood flow, restoring full function to the heart, thus saving the life of the patient. Dr Sudhir Srivastava, Founder, Chairman and CEO, SS Innovations said, "The success of the heart surgery today in Hyderabad using SSI MANTRA further cements the superiority of the system to be able to perform cardiac surgeries with utmost precision. This has spurred the team at SS Innovations to scale the next height and take on more challenging surgeries with renewed vigour." Dr Srivastava was supported by Dr Pradheep K Rachakonda, Senior Consultant Cardiothoracic Surgeon at Continental Hospital. ]]> https://biospectrumindia.com/news/91/22928/indias-first-indigenously-designed-4k-helium-cryostat-for-lowering-cost-of-magnetic-resonance-imaging.html https://biospectrumindia.com/news/91/22928/indias-first-indigenously-designed-4k-helium-cryostat-for-lowering-cost-of-magnetic-resonance-imaging.html Mon, 10 Apr 2023 00:00:00 +0530 Vadodara-based Cryogenic Liquid Storage, Distribution and Re-Gas solutions provider, INOXCVA, has achieved a significant milestone by completing the fabrication of India's first indigenously designed zero-boil-off 4K helium cryostat for a whole-body 1.5T Superconducting Magnetic Resonance Imaging (MRI) magnet system. The fabrication of the MRI cryostat was carried out at their state-of-the-art facilities in Vadodara, Gujarat. The introduction of this technology would lead to lowering of MRI expenses, and therefore making healthcare more affordable in India. With the significant milestone coinciding with the celebration of Amritkaal, commemorating 75 years of independence, the MRI magnet system has been named I-Amrit 1.5, i.e. Indian Advanced MRI Technology 1.5. The cryostat was indigenously designed by a team of scientists, engineers, and research fellows led by Dr. Soumen Kar, Principle Investigator of Indigenous Magnetic Resonance Imaging (IMRI) project at Inter-University Accelerator Centre (IUAC), New Delhi.     ]]> https://biospectrumindia.com/news/91/22860/fujifilm-india-launches-new-cad-eye-tool-to-detect-abnormal-growth-in-gi-tract.html https://biospectrumindia.com/news/91/22860/fujifilm-india-launches-new-cad-eye-tool-to-detect-abnormal-growth-in-gi-tract.html Tue, 28 Mar 2023 00:00:00 +0530 Fujifilm India has launched an upgraded version of CAD EYE, an empowering tool based on Artificial Intelligence (AI) technology which assists gastroenterologists in early detection and characterisation of abnormal growth in gastrointestinal (GI) tract. The product was launched at a national event “GI Update 2023” at Mysuru. Fujifilm has introduced this technology for the first time outside Japan. This is the second chapter to the already existing AI diagnostic technology available for detection in colon. The newly launched AI technology will work on three different visualisation modes: White light, LCI (Linked colour Imaging) and BLI (Blue light Imaging). LCI mode is a combination of light settings which can visually enhance any abnormal lesion and inflammation. BLI mode magnifies the detected growth for better pattern analysis of cells. This technology is designed to solve two major screening problems- Lesion oversight (The lesions are in the view but cannot be detected) and Blind spots (Missing lesions when not in observation range). Landmark Photo Checker is the newest advancement that assists the proper observation of the major landmarks in the stomach. This assists the practitioner to navigate lesions in less time, which might be missed with conventional methods that eventually helps in saving lives.  Speaking about the new launch, Koji Wada, Managing Director, Fujifilm India said, “Fujifilm India has always been at the forefront of healthcare innovation. With the launch of the new CAD EYE Upper GI in India, we are expanding our endoscopy portfolio. The aim is to provide superior technological medical facilities that can help save lives and encourage patients to become more engaged in their personal care." . ]]> https://biospectrumindia.com/news/91/22852/penumbra-picks-smt-as-exclusive-distributor-for-thrombectomy-technologies-in-india.html https://biospectrumindia.com/news/91/22852/penumbra-picks-smt-as-exclusive-distributor-for-thrombectomy-technologies-in-india.html Mon, 27 Mar 2023 00:00:00 +0530 Mumbai-based Sahajanand Medical Technologies (SMT) has been selected as the exclusive distributor of US-based Penumbra’s peripheral and coronary vascular thrombectomy technologies in select domestic geographies in India. Under the terms of the agreement, SMT will provide healthcare providers with Penumbra’s latest Indigo System portfolio, including CAT RX, which recently received India CDSCO (Central Drug Standard Control Organization) approval, and Lightning technologies, upon regulatory approval, to address conditions such as coronary thrombosis, venous thrombosis, arterial thrombosis and pulmonary embolism.  Penumbra’s Indigo System portfolio is designed for single session blood clot removal in peripheral arterial and venous systems, including the treatment of pulmonary embolism, and now with Lightning Aspiration Tubing, is the first and only computer-aided mechanical aspiration technology that can differentiate between clot and blood, which is designed to minimise blood loss. Additionally, Penumbra’s Indigo System CAT RX is designed for safe and efficient blood clot removal from the coronary and peripheral vasculature. ]]> https://biospectrumindia.com/news/91/22748/first-made-in-india-surgical-robot-ssi-mantra-completes-100-surgeries-within-6-months-of-launch.html https://biospectrumindia.com/news/91/22748/first-made-in-india-surgical-robot-ssi-mantra-completes-100-surgeries-within-6-months-of-launch.html Fri, 03 Mar 2023 00:00:00 +0530 Making robotic surgeries affordable has been made possible by Dr Sudhir Prem Srivastava, Founder, Chairman and CEO of SS Innovations with SSI MANTRA, the first and only Made-in-India surgical robot.  What makes SSI MANTRA unique and successful is the fact that within six months of its commercial launch, the surgical robot has successfully completed 100 surgeries validating the supremacy of the home-grown robot and its ability to perform complex surgeries with flawless precision. Dr Sudhir Srivastava, Founder, Chairman and CEO, SS Innovations popularly known as The Robo Doctor says, “achieving 100 successful surgeries by SSI MANTRA is satisfying both emotionally and professionally for me as it marks a significant milestone in India’s quest to redefine the surgical landscape of the country. SSI MANTRA costing just one third of its global competitors has significantly brought down the cost of surgeries making it much more affordable. India can now look forward to high-end medical care and surgeries without having to worry much about the cost factor. It is a reinforcement of our belief in the system and we are greatly thankful to the medical fraternity for putting confidence in our system and our abilities to provide surgical option which is at par with its global counterparts”.   SSI Mantra was first commercially installed at the Rajiv Gandhi Cancer Institute, New Delhi in July 2022. Since its maiden installation at RGCI, the SSI Mantra system has gained acceptance from many quarters of the country and has been installed in Sanjeevani CBCC USA Cancer Hospital, Raipur; Continental Hospital, Hyderabad and Hindustan Hospital, Coimbatore. With only 140 robotic surgery systems installed across 70,000 hospitals in India, Dr Srivastava sees immense potential for SSI Mantra soon gaining acceptance in Tier 2 and 3 cities as well.   ]]> https://biospectrumindia.com/news/91/22727/lifesigns-partners-with-kerala-based-amala-hospital-to-launch-smart-ward-technology.html https://biospectrumindia.com/news/91/22727/lifesigns-partners-with-kerala-based-amala-hospital-to-launch-smart-ward-technology.html Wed, 01 Mar 2023 00:00:00 +0530 Amala Hospital, a leading multi-disciplinary chain of hospitals based in Kerala, has launched a new and innovative smart ward with wearable wireless technology. This smart ward, the first in Kerala, is equipped with advanced technology that provides continuous patient monitoring and aims to improve patient outcomes and reduce the risk of medical errors. The hospital chain has partnered with Chennai based health-tech startup, LifeSigns to implement their iMS technology across cardiology and medicine departments at its hospital based in Thrissur, Kerala. One of the key features of the smart ward is its wireless patient monitoring system, with early warning scores which allows for real-time monitoring of vital signs and other important health indicators. This technology eliminates the need for traditional wired monitoring systems, which can be cumbersome and uncomfortable for patients, and provides a more efficient and effective way to monitor patient health. In addition to the wireless monitoring system, the smart ward is also equipped with monitors at nursing station, and patient information systems for the hospital, all of which work together to improve patient care and streamline the healthcare process.   ]]> https://biospectrumindia.com/news/91/22729/german-medtech-firm-vara-brings-breast-cancer-screening-solution-to-india.html https://biospectrumindia.com/news/91/22729/german-medtech-firm-vara-brings-breast-cancer-screening-solution-to-india.html Wed, 01 Mar 2023 00:00:00 +0530 Vara, a German medical technology company focused on breast cancer screening and detection, has announced its expansion to India. With a mission to improve the lives of women and their families through early detection of breast cancer, Vara will roll out its data-driven breast cancer screening solution with first screening centres in Mumbai through its partnership with Suburban Diagnostics and NM Medical. Through these partnerships, Vara will offer screenings at affordable prices and raise awareness about the importance of breast cancer prevention and early detection. Vara's technology combines Artificial Intelligence (AI) with digital mammography to detect breast cancer at its earliest stages. By using machine learning algorithms to analyse images and identify earliest signs of potential abnormalities, Vara's technology can improve the accuracy of breast cancer screening while reducing the number of unnecessary biopsies. Vara has published its approach and results in The Lancet, one of the most acclaimed medical publications globally, where it demonstrated that Vara-assisted radiologists significantly outperform average radiologists in detecting the earliest signs of breast cancer. In addition to its breast cancer screening services, Vara also conducts awareness campaigns to educate women about breast cancer and the benefits of early detection. It also offers webinars and educational resources to healthcare providers and patients. Vara is a CE-certified machine learning software platform that conforms to the highest quality standards globally. Vara’s expansion to India marks a significant milestone in the company’s mission to empower women with access to early breast cancer detection technologies.  ]]> https://biospectrumindia.com/news/91/22699/ruby-hall-clinic-launches-bi-plane-cath-lab-for-complex-interventional-procedures.html https://biospectrumindia.com/news/91/22699/ruby-hall-clinic-launches-bi-plane-cath-lab-for-complex-interventional-procedures.html Fri, 24 Feb 2023 00:00:00 +0530 Ruby Hall Clinic, based in Pune, has announced the arrival and launch of a new, advanced medical imaging device known as the Bi-Plane Cath Lab. The first of its kind in Pune, the equipment will bring a whole new level of care in the diagnosis and interventional procedures in neuropathy, oncology, vascular pathologies and associated areas. The Cath Lab will be used where complex intervention is required, while at the same time patients prefer minimally invasive treatment. Additionally, it emits “ultra-low” levels of radiation and provides exceptional, multi-dimensional imaging, helping both the doctor and patient at the same time. “Stroke, epilepsy, Parkinson’s disease and dementia, the most common serious neurological conditions prevalent in India, cause almost 900,000 deaths annually. Many of the underlying sub-types of the conditions, as well as their overall mortality rates, are on the rise”, said Dr Lomesh Bhirud, Neurologist & Neuro-Interventionist, Ruby Hall Clinic, speaking about the importance of the lab. “Other ailments like peripheral vascular diseases, complex tumours, vascular aneurysms, complex biliary strictures, etc are on the rise, and this new facility with technologies like Emboguide, XerCT and Aneurysm Flow is of great help to perform interventions for patients with great accuracy. The influx of cutting-edge technology in this area of medicine is thus imperative,” added Dr Yadav Munde, Vascular & Interventional radiologist at the hospital.     ]]> https://biospectrumindia.com/news/91/22665/hcg-collaborates-with-intuitive-to-deepen-accessibility-of-robotic-assisted-surgery-across-india.html https://biospectrumindia.com/news/91/22665/hcg-collaborates-with-intuitive-to-deepen-accessibility-of-robotic-assisted-surgery-across-india.html Mon, 20 Feb 2023 00:00:00 +0530 Bengaluru-based HealthCare Global Enterprises Limited (HCG) has collaborated with Intuitive to augment the accessibility of new-age surgical technology and robotic-assisted surgery (RAS), across India, including non-metro cities. As a part of that, the hospital begins to install the 4th Gen Da Vinci surgical robot by US-based Intuitive in Mumbai, Kolkata, and a few other cities to make this technology accessible to a wider population in India. The leading cancer hospital chain has expanded its network, further yielding fruitful results with better clinical outcomes from their existing robotic-assisted surgery units in Bengaluru and Ahmedabad. Since the inception of HCG’s cancer centre network in 1989, the company has been taking remarkable steps towards breakthroughs in cancer treatment and diagnosis, which includes immunotherapy as well as advanced screening techniques, all to envision a world without the fear of cancer. Now with the collaboration with Intuitive, HCG is striving towards attaining the best possible clinical outcome for patients across the length and breadth of the country. The joint effort of HCG and Intuitive Surgical will not only make this advanced surgical technology available to a larger community of beneficiaries but also drive familiarisation and awareness about RAS to the medical fraternity across India, including Tier 2 and Tier 3 cities. The Da Vinci technology, known for its better patient outcomes, is also associated with lesser pain, less blood loss, shorter hospital stays, and even minimal post-operative complications in certain cases. In addition to that, Da Vinci brings across some innovative features, including voice and laser guidance systems, a lightweight endoscope, and the same control console and 3D optics system that lets surgeons see into the patients as they operate the device.   ]]> https://biospectrumindia.com/news/91/22651/hinduja-group-backed-mindmaze-to-drive-future-of-upper-limb-neural-recovery-in-india.html https://biospectrumindia.com/news/91/22651/hinduja-group-backed-mindmaze-to-drive-future-of-upper-limb-neural-recovery-in-india.html Fri, 17 Feb 2023 00:00:00 +0530 MindMaze, the Hinduja Group backed Unicorn, has launched a first-of-its-kind, FDA-listed and CE-marked smart peripheral for patients with impairment in hand motor function, Izar in the United States and European Union. It aims at introducing this path breaking treatment in India in association with hospitals and medical centres that have adopted MindMaze technology platforms.  As of now, MindMaze technology is deployed at more than 130 top medical centres across the world.  In India, it is deployed in more than a dozen institutions including the apex government hospital AIIMS, New Delhi, and Hinduja Hospital at Mumbai, through wholly owned subsidiary, MindMaze India. In 2019, the largest contributors to the total neurological disorders in India were stroke (37·9%), headache disorders (17·5%), epilepsy (11·3%), cerebral palsy (5·7%), and encephalitis (5·3%), said a Lancet Global Health Survey. Izar is part of a comprehensive omni site approach to the treatment and maintenance of neurological diseases, including Stroke, Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury (TBI), among others. It is a hyper-sensitive controller built from the ground-up to train and assess both dexterity and strength, through capture of the fine grasp forces and wrist movements required to carry out activities of daily living. Izar can detect sub-newton level patient finger and hand forces, enabling treatment in the most impaired patient populations. This simple and highly portable controller is accompanied by proprietary and engaging gaming content that allows patients to self-train, either in-clinic, at bedside, or in the comfort of their home, dramatically enhancing and expanding training opportunities.  Founded in 2012, MindMaze has presence in Lausanne, Baltimore, London, Paris and Mumbai.   ]]> https://biospectrumindia.com/news/91/22595/fujifilm-india-launches-new-range-of-healthcare-imaging-products.html https://biospectrumindia.com/news/91/22595/fujifilm-india-launches-new-range-of-healthcare-imaging-products.html Mon, 06 Feb 2023 00:00:00 +0530 Fujifilm India announced the expansion of its product and solutions portfolio at the at the 75th National Conference of the Indian Radiological and Imaging Association (IRIA). During the four-day long conference, scheduled from 2nd – 5th February 2023 at Amritsar, the company unveiled revolutionary diagnostic machines. The new range includes ultrasound system Arietta 850 DeepInsight and Arietta 650 DeepInsight along with the new MRI machine APERTO Lucent Non DICOM printer APEOS. Additionally, the company also introduced “FUJIFILM Connect” a service & support mobile application to manage the service and support of Fujifilm healthcare products. The APERTO Lucent is a new age, Prime open MRI device which is equipped with IP-RAPID - a modern day technique that reduces scan times while maintaining high image quality by employing under sampling and image reconstruction with iterative processing which will result in Improved image quality with higher spatial resolution.   Launched at IRIA 2023, the Arietta 850 DeepInsight and Arietta 650 DeepInsight are the latest ultrasound technology offering from Fujifilm India.  The FDX Visionary-DR launched at IRIA 2023 is a bone density scanner which will support for a wide range of solutions for Bone Densitometry and Body Composition Analysis. Also introduced at the exhibition was the APEOS medical printer which is a compact multifunction and single-function A4 Laser Printer.    As part of the event, Fujifilm India also displayed its latest healthcare medical devices like Full Field Digital Mammography (FFDM) - Amulet Innovality, Healthcare IT: Synapse PACS, USG - Arietta and FDR: X-air.  ]]> https://biospectrumindia.com/news/91/22579/carestream-health-india-introduces-new-mobile-x-ray-system-for-radiography-examination.html https://biospectrumindia.com/news/91/22579/carestream-health-india-introduces-new-mobile-x-ray-system-for-radiography-examination.html Thu, 02 Feb 2023 00:00:00 +0530 Carestream Health India has launched its high-powered 'Carestream Motion Mobile X-ray system' at the recent Indian Radiology and Imaging Association (IRIA) meeting at Amritsar. The system is fully equipped to carry out a full range of general radiography examination. The new portable imaging system is compact and easy to maneuver into tight spaces. Innovative features such as a tube-head and articulating arm for excellent visibility and easy use. The system includes an eight-inch touch screen intuitive monitor with easy-to-set protocols, hand switch exposure control, a manual light-beam collimator. These allow fast, accurate patient positioning. In addition, a 32 KW capacitor discharge generator supports a full range of clinical applications. An optional dose-area product (DAP) meters information essential for monitoring dose. Edwin Pinto, XRS Business Manager - India Cluster at Carestream Health India said, "The new mobile system is designed to equip imaging facilities of all sizes with the ability to efficiently capture high quality diagnostic images. This system perfectly compliments our high-end premium ‘Revolution Plus’ system, delivering the same high quality images where budget is a constraint." ]]> https://biospectrumindia.com/news/91/22549/fujifilm-india-expands-endoscopy-solution-portfolio-with-new-compact-ultrasonic-probe-system-.html https://biospectrumindia.com/news/91/22549/fujifilm-india-expands-endoscopy-solution-portfolio-with-new-compact-ultrasonic-probe-system-.html Mon, 30 Jan 2023 00:00:00 +0530 Fujifilm India has announced the expansion of its endoscopy solutions portfolio with the new compact ultrasonic probe system PB2020-M2 at the 3rd Annual conference on Interventional Pulmonology – “BRONCHUS 2023”. The two-day conference at Hyderabad, held on 28 and 29 January 2023, was attended by all leading pulmonologists from 18 countries where Fujifilm India showcased its comprehensive range of pulmonology solutions through one of its kind “Experience centre” at the trade exhibition. The newly launched, PB2020-M2 compact ultrasonic probe is designed for a more efficient examination to provide real-time ultrasound imaging of peripheral lung lesions. This small and lightweight system is user-friendly and provides high resolution ultrasonic images. It comes with an outer diameter 1.4-1.9 and it can easily pass through 2mm working channel bronchoscope. Fujifilm India Endoscopy Division also showcased the new slim line Video Bronchoscope EB-710P, which is a thin endoscope equipped with an exceptionally compact CMOS (Complementary Metal Oxide Semiconductor) sensor. With its extremely small diameter and its rotation function, the innovative EB-710P endoscope system increases the safety and comfort of a bronchoscopy. Additionally, Dr Nobuyasu Awano, Department of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan also delivered a lecture on the new slim line bronchoscope EB-710P and its clinical benefits for diagnostic and therapeutic procedures during the event. The product was launched in presence of Dr Harikishan Gonuguntla, Lead Consultant Yashoda Hospitals, Hyderabad, along with practitioners from the medical industry. ]]> https://biospectrumindia.com/news/91/22529/essilor-introduces-stellest-lenses-in-india-to-slow-down-myopia-progression-in-children.html https://biospectrumindia.com/news/91/22529/essilor-introduces-stellest-lenses-in-india-to-slow-down-myopia-progression-in-children.html Wed, 25 Jan 2023 00:00:00 +0530 Essilor, a France-based leader in prescription lenses, has launched Essilor Stellest lens in India, to combat myopia progression in children and help protect their vision for the future. The Essilor Stellest lens, priced at Rs 16,500, has been designed with an exclusive technology called H.A.L.T. technology (Highly Aspherical Lenslet Target) by Essilor’s research and development teams. The H.A.L.T. technology consists of a constellation of 1021 aspherical lenslets spread on 11 rings, enabling the Essilor Stellest lens to correct myopia and sharpen far vision through a single vision zone while slowing down myopia progression. The technology is a culmination of more than 30 years of academic studies, product design, rigorous research efforts in collaboration with the top research institutes and myopia experts. In a recent study, it was observed that myopia prevalence in the age group of 5 -15 years has grown from 4.4% in 1999 to 21.9% in 2019, and which is now observed to be at almost 25%. The COVID-19 pandemic has resulted in children spending fewer hours outdoors and more time (approximately 6 -7 hours) indoors - these factors have had an impact on the vision of many children. Ophthalmologists and eye care professionals across the country are witnessing an increasingly larger number of children walking into their practice with either higher levels of myopia when tested for the first time or with increasing margins in their existing prescriptions. Studies show that any level of myopia may increase the risk of ocular conditions, but the risk increases exponentially once reaching high myopia. Failure to manage myopic progression significantly impacts a child’s productivity due to an increased risk of ophthalmic conditions such as Myopic Maculopathy, Retinal Detachment, Open Angle Glaucoma and Visual Impairment. The clinical trial results show that the Essilor Stellest lens slowed down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day.   ]]> https://biospectrumindia.com/news/91/22495/fortis-hospital-launches-advanced-state-of-the-art-philips-azurion-cath-lab-facility-in-bengaluru.html https://biospectrumindia.com/news/91/22495/fortis-hospital-launches-advanced-state-of-the-art-philips-azurion-cath-lab-facility-in-bengaluru.html Wed, 18 Jan 2023 00:00:00 +0530 Fortis Hospital, Nagarbhavi, Bengaluru has launched an advanced state-of the-art Philips Azurion 7 C12 Cath Lab facility for faster and timely diagnosis and treatment related to interventional cardiology and cardiovascular surgeries. The state-of-the-art Cath Lab was inaugurated by C. N. Ashwath Narayan, Minister of Skill Development, Entrepreneurship and Livelihood of Karnataka. The high-end version of Philips AZURION 7C12 Monoplane Cath Lab has cutting-edge technologies with an integrated Instantaneous Wave-Free Ratio-IFR (a trans-lesion pressure ratio measured during the wave-free period reducing the risk of Hyperemia agents). It also has a unique advanced interventional tool like DYNAMIC CORONARY ROADMAP (DCR), which creates a dynamic, motion-compensated, real time view of the coronary arteries which automatically adjusts on 2D fluoroscopy, providing continuous and specific visual feedback on positioning of wires, catheters and devices during Percutaneous Coronary Intervention, hence reducing contact with patients. The Cath Lab will also provide patients with enhanced care, accurate interventions, effective treatment alternatives and minimal radiation exposure.     Speaking on the launch, Dr C Prabhakar Koregol, Senior Consultant - Interventional Cardiology, Fortis Hospital, Nagarbhavi said, “The necessity for emergency cardiac treatment is on the rise, due to the complexity of patient profiles and changing disease patterns. Thus, we need to be technologically equipped to be able to treat the patients more efficiently and save lives. Our state-of-the-art Azurion Cath Lab is equipped with unique advanced tools that will facilitate fast and accurate interventions in structural heart diseases. Thus, it provides an advantage for surgeons to offer advanced cardiac interventions in minimal time with greater precision and better clinical outcomes.”     ]]> https://biospectrumindia.com/news/91/22477/theranica-and-dr-reddys-bring-nerivio-to-millions-of-people-with-migraine-in-india.html https://biospectrumindia.com/news/91/22477/theranica-and-dr-reddys-bring-nerivio-to-millions-of-people-with-migraine-in-india.html Fri, 13 Jan 2023 00:00:00 +0530 Theranica, a prescribed digital therapeutics company based in Israel developing advanced neuromodulation devices for migraine and other pain conditions, has announced a strategic license and supply agreement with Hyderabad-based Dr. Reddy's Laboratories, for the exclusive marketing and distribution of FDA-approved Nerivio in India, subject to completion of the regulatory approval process in India. Under the terms of the agreement, Dr. Reddy's will be responsible for the regulatory approval of Nerivio in India, after which it will exclusively market Nerivio in India, manufactured and supplied by Theranica. The agreement includes licensing fees for exclusive rights to market Nerivio in India. While the agreement applies only to India, the companies will continue discussions about expanding to additional territories outside the United States and China. Nerivio is the first US FDA-cleared, prescribed, digitally connected, drug-free wearable device for the acute treatment of episodic and chronic migraine in individuals age 12 and older. Worn on the upper arm, Nerivio utilises remote electrical neuromodulation (REN) to trigger an endogenous descending pain inhibition mechanism known as conditioned pain modulation (CPM), which aborts or alleviates migraine headache and associated migraine symptoms. Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options for acute migraine treatment. The company recently published topline results of a pivotal trial demonstrating the efficacy and safety of Nerivio for the preventive treatment of migraine, an indication currently under FDA review.   ]]> https://biospectrumindia.com/news/91/22473/portronics-unveils-new-3mp-otoscope-xlife-for-ear-cleanup.html https://biospectrumindia.com/news/91/22473/portronics-unveils-new-3mp-otoscope-xlife-for-ear-cleanup.html Thu, 12 Jan 2023 13:10:00 +0530 Portronics has announced the launch of its latest and upgraded otoscope XLife. Powerful enough to wirelessly stream a 360° Full HD view of external acoustic meatus (ear canal) on your smartphone and a safe silicone scoop tip to help you clean out the usual/daily build-up of earwax.    Portronics XLife uses a skin-friendly and hygienic screw-furled silicone (scoop) tip for maximum safety, and behind it is a powerful eye that ensures everything is at a safe distance. The 3-megapixel eye (FHD camera) features an ultra-fine 3.5mm lens for a crisp and clear view of everything ahead and around it, with a 6-LED spotlight to keep everything bright. To make things safer and more convenient the otoscope includes a 3-axis gyroscope for a 360° view for better handling.   The product comes with Wi-Fi 2.4GHz connectivity for easily monitoring your ear directly via your smartphone, be it Android or iOS, using the XLife App. Completely wireless, Portronics XLife has an internal rechargeable battery (USB-C port for charging) which on a full charge offers a 30-minute playtime. The product weighs 13 gm.     ]]> https://biospectrumindia.com/news/91/22470/asian-institute-of-medical-sciences-introduces-next-generation-surgical-robot.html https://biospectrumindia.com/news/91/22470/asian-institute-of-medical-sciences-introduces-next-generation-surgical-robot.html Wed, 11 Jan 2023 00:00:00 +0530 Asian Institute of Medical Sciences (AIMS), Faridabad, designed to meet patient care and adapting the advance technologies of the new millennium, enters a new era in surgery with the introduction of its first 3D Advanced Minimal Access Surgical Robot in the region - the Versius Robotic Surgical System. The next-generation advanced surgical robot is set to revolutionise the field of surgery in oncology and urology (Kidney Nephrectomy), thoracic surgery, and general surgical procedures such as gall bladder stone, complex hernia among several other complex procedures. With superior 3D visualisation, the most advanced and efficient robotic solution backed by artificial intelligence and machine learning is designed to empower the surgeon ensuring greater accuracy, precision, and safety offering superior surgical solutions even in inaccessible areas.  The Versius surgical robot enhances surgeon’s skills whilst surgeon errors are negated. Besides less pain to the patient, robotic surgery with Versius adds another component to the safety of the patient via the surgeon’s comfort and by enhancing their skills. ]]> https://biospectrumindia.com/news/91/22437/teleflex-introduces-urolift-system-in-india-for-benign-prostatic-hyperplasia-treatment.html https://biospectrumindia.com/news/91/22437/teleflex-introduces-urolift-system-in-india-for-benign-prostatic-hyperplasia-treatment.html Tue, 03 Jan 2023 00:00:00 +0530 Teleflex Incorporated, based in the US, has announced the commercial launch of the UroLift System in India for treating benign prostatic hyperplasia (BPH), or enlarged prostate.  BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity,  depression, interrupted sleep, and decreased quality of life. The UroLift System is a minimally invasive approach to treating BPH that can be performed as a same-day outpatient procedure. The UroLift System provides rapid symptom relief for men with BPH and allows a quick recovery time for patients.  Arun Kaushik, Managing Director, South Asia,  Teleflex said, “This technology offers clinical benefits in the minimally invasive treatment of BPH and offers physicians more options in how they treat their patients." BPH cases with the  UroLift system have been performed in Max Super Specialty Hospital (Saket), Medanta The Medicity (Gurugram), Manipal Hospital (HAL  Road, Bengaluru,) and CURI Hospital (Chennai).   The UroLift System is a minimally invasive treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50  years and above in India. In India, a  prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management. ]]> https://biospectrumindia.com/news/91/22412/johnson-johnson-brings-new-lens-for-astigmatism-patients-in-india.html https://biospectrumindia.com/news/91/22412/johnson-johnson-brings-new-lens-for-astigmatism-patients-in-india.html Mon, 26 Dec 2022 00:00:00 +0530 Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, has announced the availability of TECNIS Synergy™ Toric II OptiBlue® PC-IOL for patients with astigmatism in India. TECNIS Synergy™ Toric II IOL, is a continuous-range-of-vision lens engineered for rotational stability, which locks in visual performance and provides high-quality vision. Cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes, with more than 90% of people developing cataracts by the age of 65. Most people will develop cataracts at some point in their life, and modern cataract surgery is a safe and effective treatment that has a success rate of nearly 98%. In India, nearly 73% of adults 60 years and older have cataracts and if left untreated, cause vision to deteriorate over time. Astigmatism reduces distance and near visual acuity, vision quality, and depth perception. All cataracts will eventually need to be surgically removed and replaced with an artificial lens, called an IOL (Intraocular lens). In India, TECNIS Synergy™ Toric II OptiBlue® PC-IOL has been approved by the Central Drugs Standard Control Organisation (CDSCO). Burzin Shahana, Country Manager at Johnson & Johnson Vision, Surgical Vision India, said, “TECNIS Synergy™ Toric II OptiBlue® PC-IOL is an advanced IOL solution for cataract patients with astigmatism and gives patients the visual clarity and increased spectacle independence to improve their current lifestyles.” He also added, “The launch will also expand available options physicians have to provide value to their patients with astigmatism.”   ]]> https://biospectrumindia.com/news/91/22405/state-of-the-art-cardiac-centre-opens-at-nlc-india-hospital-tamil-nadu.html https://biospectrumindia.com/news/91/22405/state-of-the-art-cardiac-centre-opens-at-nlc-india-hospital-tamil-nadu.html Fri, 23 Dec 2022 00:00:00 +0530 A new high-end cardiac centre with state-of- the-art cath lab has been inaugurated at NLC India Hospital by Rakesh Kumar, Chairamn & Managing Director, NLC India. This is the only such advanced cath lab in Cuddalore District, Tamil Nadu which provides cardiology outpatient services & inpatient treatment for any cardiac disease for patients referred by NLC India Hospital and stakeholders and is also open to the public. Procedures like coronary angiogram, emergency and elective coronary peripheral angioplasty, pace-maker implantation and other procedures can be carried out here. The Centre will be equipped to handle all medical emergencies. The cath lab is set up with 25 bedded cardiac facility with all amenities (3 Emergency Rooms, 6 Coronary Care Units, 2 Recovery, 5 Wards, 6 semi private and 3 single room beds). The facility will become fully operational by next month.    NLC India is a central public sector undertaking with the administrative control of the Ministry of Coal, Government of India.       ]]> https://biospectrumindia.com/news/91/22399/indias-first-5g-driven-artificial-intelligence-guided-colonoscopy-trial.html https://biospectrumindia.com/news/91/22399/indias-first-5g-driven-artificial-intelligence-guided-colonoscopy-trial.html Thu, 22 Dec 2022 00:00:00 +0530 Communications solutions provider Bharti Airtel and Apollo Hospitals have carried out India’s first 5G driven, artificial intelligence (AI) guided colonoscopy trials. The trial was conducted using AI on Airtel’s 5G technology with ultra-low latency and high processing capabilities that resulted in detection of the colon cancer much faster and with greater accuracy. HealthNet Global, AWS and Avesha are the other three companies that collaborated in these trials. As per current protocol, colon cancer is detected through colonoscopy procedure which is manual and requires great attention and time from medical practitioners for accurate detection. This procedure is performed using a device comprising a light, flexible tube with light, camera and tools at one end, which are used to extract samples to identify an infected polyp. Not only is the procedure long, its discomforting for patients and for the doctors and nurses who have to perform this procedure which takes around 30 to 40 minutes per case.  As a result of AI guided colonoscopy procedure, the image processing happened in real time without any lag even when the physician moved the scope through the colon for it to be overlaid on top of the right element of the colon. The advent of this technology enables an “extra pair of eyes” for physicians and improves the detection rate of polyps, thus saving lives and vastly improving patient care. The data was processed by Avesha edge inferencing applications on AWS platforms in real time which ensured analysis closer to the end points. AI assisted Colonoscopy Polyp Detection trial will help doctors to improve quality of patient care, improve accuracy of detection rates by capturing information correctly and reducing errors.   ]]> https://biospectrumindia.com/news/91/22349/resmed-hosts-obstructive-sleep-apnea-symposiums-across-india.html https://biospectrumindia.com/news/91/22349/resmed-hosts-obstructive-sleep-apnea-symposiums-across-india.html Mon, 12 Dec 2022 00:00:00 +0530 US-based medtech firm ResMed has announced the launch of its Obstructive Sleep Apnea (OSA) Symposium initiative, a knowledge series for healthcare professionals across Indian metros. Developed in continuance with ResMed’s sleep awareness initiative “Awaken Your Best”, the series kickstarted with symposiums in key Indian cities – Delhi, Kolkata, and Hyderabad to further the importance of recognising sleep apnea as a key disorder impacting the well-being of Indians. With participation from over 250 leading sleep specialists as of now, the series also spotlights OSA and associated breathing disorders.   The symposium series, aligned with India’s Digital Health Mission, extends ResMed’s initiative focused on increasing awareness of sleep disorders among healthcare professionals and promoting digital connectivity for real-time access to remote monitoring and out-of-hospital care. With the next leg in Mumbai, Chennai and Bengaluru, the initiative enables attendees to understand and gain hands-on experience with various therapies and innovative technologies. As part of the knowledge series, ResMed is showcasing AirView, the remote patient data monitoring software and Onesleeptest (OST), a revolutionary at-home sleep test kit, facilitating pulmonologists and sleep specialists to access real-time sleep data for diagnostics and sleep care management. These advanced cloud-connected solutions by ResMed redefine and ease the process for caregivers to effectively help patients stay comfortable and receive full benefits of the therapy.     ]]> https://biospectrumindia.com/news/91/22330/stryker-unveils-state-of-the-art-neurovascular-rd-lab-to-accelerate-stroke-care-innovation.html https://biospectrumindia.com/news/91/22330/stryker-unveils-state-of-the-art-neurovascular-rd-lab-to-accelerate-stroke-care-innovation.html Tue, 06 Dec 2022 00:00:00 +0530 US-based medtech firm Stryker has recently opened its Neurovascular (NV) lab, a state-of-the-art lab designed to accelerate stroke-related innovation in Asia Pacific. Located within the Stryker Global Technology Center (SGTC) at International Park, Gurugram, the Keystone Suite will enable collaboration between customers, product development engineers, cross-functional teams, and other key stakeholders. Stroke is a leading cause of death and disability worldwide, with more than 58 million of those cases recorded in Asia. In India, scarcity of professional care and infrastructure are key factors in the country’s treatment rates. This lab offers an ideal environment for medical education, research and development, and customer engagement activities designed to improve patient outcomes. The NV lab has three main components: a neurovascular catheterization lab designed to mimic the hospital treatment experience with the latest imaging and communication equipment; a performance lab with hands-on stations outfitted with flow models, neurovascular simulators and 3D model printing capabilities; and planned space for physician interaction.   ]]> https://biospectrumindia.com/news/91/22333/abbott-introduces-navitor-to-treat-aortic-stenosis-in-india.html https://biospectrumindia.com/news/91/22333/abbott-introduces-navitor-to-treat-aortic-stenosis-in-india.html Tue, 06 Dec 2022 00:00:00 +0530 Global healthcare company Abbott has launched its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in India with severe aortic stenosis who are at high or extreme surgical risk. With the Navitor valve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve. The Navitor TAVI system is the latest addition to the company's comprehensive structural heart transcatheter portfolio that offers physicians and patients less invasive options to treat heart diseases.  Aortic stenosis is one of the most common and life-threatening heart valve diseases. It restricts blood flow through the aortic heart valve to the rest of the body, which can lead to heart failure and, in certain cases, sudden cardiac death.  Prior to TAVI, the standard of care for severe aortic stenosis was surgical aortic valve replacement, but not all patients were candidates for open-heart surgery.  Navitor features a unique fabric cuff (NaviSeal) that works with the cardiac cycle to reduce or eliminate a backflow of blood around the valve frame known as paravalvular leak (PVL), a common complication following TAVI procedures. The new device is the only self-expanding TAVI system with intra-annular (within the native valve) leaflets and large frame cells – features designed to help improve access to critical coronary arteries to facilitate future interventions to treat coronary artery disease (CAD). The new design additionally provides improved hemodynamics, or better blood flow.   ]]> https://biospectrumindia.com/news/91/22245/fujifilm-expands-pulmonology-solutions-portfolio-in-india.html https://biospectrumindia.com/news/91/22245/fujifilm-expands-pulmonology-solutions-portfolio-in-india.html Mon, 14 Nov 2022 00:00:00 +0530 Fujifilm India has expanded its pulmonology solutions portfolio by launching a new slim video bronchoscope called EB-710P, which was unveiled at the National Conference NAPCON (from 10-13 November 2022) at Udaipur. The EB-710P is a thin endoscope equipped with an exceptionally compact CMOS (Complementary Metal Oxide Semiconductor) sensor. This technology means that the tip is a mere 4.1 mm in diameter, so that it may penetrate the periphery of the lung much more easily than a conventional system. In addition, there is a rotation mechanism which allows the user to return the endoscope safely to its original position before the withdrawal. The ergonomic grip and the teardrop-shaped dial used with the rotation function make for smooth handling. With its extremely small diameter and its rotation function, the innovative EB-710P endoscope system increases the safety and comfort of a bronchoscopy.  The new Bronchoscope EB-710P was launched by Dr Hari Kishan Gonuguntla, Lead Consultant Pulmonology at Yashodha Hospitals, Hyderabad, and D. Arjun Khanna HOD; Senior Consultant Pulmonology & Critical Care, Amrita Hospitals Faridabad in presence of many Interventional Pulmonologist.  The new Slim Standard Video Bronchoscope with linked colour imaging (LCI) and blue laser imaging (BLI) technology will help interventional pulmonologists in peripheral biopsies with excellent HD images. This scope will serve as an amazing therapeutic tool for pediatric patients as well.   ]]> https://biospectrumindia.com/news/91/22203/l-v-prasad-eye-institute-to-use-ai-for-prevention-of-avoidable-blindness-in-children.html https://biospectrumindia.com/news/91/22203/l-v-prasad-eye-institute-to-use-ai-for-prevention-of-avoidable-blindness-in-children.html Thu, 03 Nov 2022 00:00:00 +0530 Hyderabad-based L V Prasad Eye Institute and CognitiveCare, a US-based health tech startup and pioneer in the early detection and quantification of health risks, have announced a partnership to jointly pursue efforts that advance the early detection of eye diseases and adverse eye conditions in infants and children. This partnership combines L V Prasad Eye Institute’s world-renowned expertise and research in eye health with CognitiveCare’s artificial intelligent (AI) platform, which incorporates granular insights and patterns that interplay with clinical and social determinants to quantify propensity for health risks at individual and population levels early. Retinopathy of prematurity (ROP) is a leading cause of preventable blindness in infants and children worldwide. India is experiencing an ROP epidemic, significantly impacting rural districts. Furthermore, it is projected that the myopia epidemic will affect 50% of the global population by 2050. The prevalence of myopia in children in India has quadrupled in the past twenty years. Active prevention and mitigation strategies are needed to control and potentially reverse both the ROP and myopia trends currently seen in India. “Alongside our partners at the L V Prasad Eye Institute, our aim is to support healthcare constituents in understanding propensity for eye conditions early enough to prevent adverse outcomes, including blindness in infants and myopia in children,” said Sheena Gill, President and CEO, Americas for CognitiveCare. ]]> https://biospectrumindia.com/news/91/22194/medtronic-launches-new-tool-for-diagnostic-and-operative-hysteroscopy-in-india.html https://biospectrumindia.com/news/91/22194/medtronic-launches-new-tool-for-diagnostic-and-operative-hysteroscopy-in-india.html Tue, 01 Nov 2022 00:00:00 +0530 India Medtronic, a wholly owned subsidiary of Medtronic plc, has announced the launch of the TruClear system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intra uterine abnormalities (IUA). Some of the commonly seen IUA includes fibroids, polyps, retained products of conception, adhesions, malignancies, or hyperplasia. One of the symptoms of IUA is abnormal uterine bleeding (AUB) which is reported to occur in 9-14% women between menarche and menopause. The prevalence varies in each country. In India, the reported prevalence of AUB is around 17.9%.  “TruClear system is a new addition to our GYN and women’s health portfolio and by introducing innovations like these we’re bringing choice, control and confidence to women’s healthcare in India. The system is built to facilitate a less invasive and effective way of treating intra uterine pathologies, giving patients the choice to retain the organ and go back to routine faster. Its precision and enhanced visibility provides gynecologists much needed comfort and helps avoid complications, yielding better patient outcomes,” said Abhishek Bhargava, director, Surgical, Patient Monitoring, Respiratory Interventions & ENT, Medtronic India. TruClear is a next-generation device that provides practitioners with a clear operative field and patients with gentle mechanical resection during procedure to help efficiently execute a hysteroscopy. Unlike other intrauterine abnormality treatment options that use a high-frequency electric current, the TruClear system uses a simple mechanical approach to remove intrauterine tissue. Therefore, there is no scarring of the uterine lining from thermal energy or electrical energy, thus providing more hope of preserving the uterus for the future. ]]> https://biospectrumindia.com/news/91/22187/hcg-unveils-ai-based-adaptive-radiation-treatment-in-bengaluru.html https://biospectrumindia.com/news/91/22187/hcg-unveils-ai-based-adaptive-radiation-treatment-in-bengaluru.html Fri, 28 Oct 2022 00:00:00 +0530 To provide patients access to world-class treatment facilities and with a commitment to offering high-quality clinical care, HCG Cancer Hospital, Bengaluru, has announced the launch of India’s first Varian Ethos therapy, an Artificial Intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot. It uses augmented intelligence, a convergence of people and AI working together for better outcomes. This game-changing radiation therapy personalises cancer care using Adaptive Intelligence based on the patient’s anatomy and the position of the tumour at the time of treatment. Ethos Therapy, the first-of-its-kind in India and a novel technique in the world, provides the ability to alter the treatment plan based on tumour and anatomical changes. This unique technology can capture movements in internal or external anatomy during each treatment and enhance their pre-treatment plans by enabling them to gain insight through the advanced power of AI-enhanced image segmentation and treatment planning. It also applies automated dose accumulation to forecast and monitor treatment progress and enhances the treatment ability by making radiation personalised and targeted that gives better outcomes with minimised side effects.  The system enables clinicians to efficiently deliver an entire personalised treatment in a 15-minute timeslot which is significantly shorter compared with other treatment systems that take more than 40 minutes, often due to the manual reconfiguration of the treatment.     ]]> https://biospectrumindia.com/news/91/22148/rrcat-partners-with-bd-india-to-roll-out-first-batch-of-sterilised-medical-devices.html https://biospectrumindia.com/news/91/22148/rrcat-partners-with-bd-india-to-roll-out-first-batch-of-sterilised-medical-devices.html Thu, 20 Oct 2022 00:00:00 +0530 BD India has partnered with Raja Ramanna Centre for Advanced Technology (RRCAT), a unit of the Department of Atomic Energy, Government of India, for sterilisation of one of its medical devices, Venflon Pro by electron beam (e-beam) technology, at RRCAT’s Indore facility. The e-beam facility is entirely designed and developed by scientists and engineers of RRCAT. It is the only such facility that is approved by regulatory authorities for irradiation of class A and Class B medical devices in India and is also ISO – 13485 certified.This pivotal partnership is a defining step toward medical device manufacturers realising the benefits of e-beam technology in the country. It also will potentially advance India’s local equipment processing infrastructure, thereby enabling the realization of the Prime Minister’s vision of Atmanirbharta.Currently, medical device sterilisation is dominated by two technologies – ethylene oxide (EO) gas and gamma radiation – which account for 48% and 41% of the market, respectively. Electron beam has advantages over both these processes in terms of enhanced safety and security and minimal ecological effects.RRCAT’s unique e-beam sterilization technology ensures a cost-effective, scalable, and efficient platform for processing medical devices and pharmaceuticals in India. With this technology, medical devices can be sterilised in their final packing by using the penetrating power of high-energy electrons. ]]> https://biospectrumindia.com/news/91/22137/butterfly-iq-point-of-care-ultrasound-solution-enters-indian-market.html https://biospectrumindia.com/news/91/22137/butterfly-iq-point-of-care-ultrasound-solution-enters-indian-market.html Wed, 19 Oct 2022 00:00:00 +0530 Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, and Wellesta Holdings, a Singapore headquartered company providing marketing and commercialization support to the healthcare sector in South East Asia, India & partnering in MENA (Middle East & North Africa), have announced an important new agreement for the marketing and distribution of the Butterfly iQ+ point-of-care ultrasound device in India.  As part of its new agreement with Abdul Latif Jameel Health, Wellesta will register Butterfly iQ+ in India and start promoting and selling the product in the country in the fourth quarter of 2022, bringing this technology to a potential 1.2 million registered physicians in the country. This new collaboration will offer greater distribution of Butterfly iQ+ to physicians in India thereby expanding the capabilities of the practitioners in making informed decisions thereby accelerating access to modern medical care for those who need it most.  Butterfly iQ+ is revolutionizing medical imaging. It is a hand-held 4 in 1 single probe whole-body innovative point-of-care ultrasound device powered by the world’s only Ultrasound–on-Chip technology.  Hailed as potentially the ‘stethoscope of the future’, the Butterfly iQ+ transforms what can sometimes be complex processes, into one connected and integrated point-of-care ultrasound (POCUS) system to help collect advanced imaging, perform rapid assessments, and guide critical procedures. It allows the sharing of results seamlessly with doctors across the globe to help read and interpret scans.   ]]> https://biospectrumindia.com/news/91/22131/genworks-launches-braster-pro-for-breast-cancer-screening.html https://biospectrumindia.com/news/91/22131/genworks-launches-braster-pro-for-breast-cancer-screening.html Tue, 18 Oct 2022 08:00:00 +0530 With the rising breast cancer cases among younger women, Bengaluru-based startup GenWorks, originally a Wipro GE invested company, has launched a new device- Braster Pro, for early detection of the disease.  According to the National Institute of Cancer Prevention and Research, for every two women diagnosed with breast cancer, one succumbs to it. And one of the leading causes of mortality is late detection. Existing screening methods, such as mammography and sonography, are mostly for older women, as the former is usually done in women aged 50 and above. Braster Pro uses a technique called liquid crystal thermography. It detects areas of higher temperature in the breast. It helps in the early detection of the disease as tumor development is associated with higher temperatures in the place where the cancer cells are growing. The device looks like a stemless champagne saucer and works by displaying liquid crystal matrix images showing the distribution of temperature in the inner tissues. Those thermographic images are then sent for analysis. The images are analyzed by interpreting and comparing images of both breasts.  Observational studies have shown that combining Braster with other screening devices like mammography can increase efficiency by up to 9%.   ]]> https://biospectrumindia.com/news/91/22119/max-ventilator-rolls-out-new-intelligent-medical-devices.html https://biospectrumindia.com/news/91/22119/max-ventilator-rolls-out-new-intelligent-medical-devices.html Fri, 14 Oct 2022 13:00:00 +0530 After conquering the terrain of ventilator market, leading manufacturer of medical devices from Vadodara, Max Ventilator is all set to expand its niche by rolling out intelligent devices including pulse oxymeter, ECG, and monitors. Sensing the need for smart and innovative devices in the healthcare sector, the company has come up with solutions that offer world-class quality at an affordable cost. “The pulse oxymeter is an economical choice against the usual price range in the market. Having both inbuilt audio and visual alarms, it comes with a keypad that has all functions accessible. With less than 800 g of weight, the unique oximeter has a reliable memory storage of up to 96 hours where graphical trends of SpO2 and pulse rate values could be easily observed. This would greatly help the doctors in decision making when choosing the the course of medication,” said Ashok Patel, Founder and CEO, Max Ventilator. “We are also pleased to announce the launch of two OT/ICU/ICCU grade monitors: M12 and M10. The USP of the former is that it can be remotely monitored using wi-fi. A prominent feature of the latter is the versatility of the device; it is suited for a wider patient base covering neonates in addition to adult and pediatric patients. This also comes with a TFT screen for better visibility,” said Patel. “We also have high hopes for our portable A4 ECG machine: E200. It offers an internal memory storage that can accumulate data of as many as 200 patients", he added.   ]]> https://biospectrumindia.com/news/91/22107/omron-healthcare-upgrades-home-blood-pressure-monitors-into-connected-devices.html https://biospectrumindia.com/news/91/22107/omron-healthcare-upgrades-home-blood-pressure-monitors-into-connected-devices.html Thu, 13 Oct 2022 09:00:00 +0530 OMRON Healthcare, a global leader in home blood pressure (BP) monitoring and solutions for cardiovascular disease management, has upgraded its portfolio of BP monitors by converting them into “connected” devices. This significant upgrade in the portfolio will help users and healthcare practitioners gain seamless, effortless, more real time and accurate control over hypertension management. The devices, now connected, allow the blood pressure data transfer effortlessly through OMRON’s application called as ‘OMRON connect’- India’s one-of-its-kind mobile app in telehealth segment for BP - with the help of inbuilt Bluetooth technology in the devices facilitating real time and convenient tracking both for the users as well as physicians.  To make the application accessible to more people across India who are still using the older variants of OMRON BP Monitors, OMRON has also introduced the Optical Character Recognition (OCR) technology feature which allows to capture & record BP readings of non-connected OMRON devices and transfers it to phone.A unique feature “BP Diary” has also been included in the app which gives an automated and easy way to keep a record and advisory for a person’s BP readings & management in accordance with his lifestyle along with monitoring & medication reminders.   ]]> https://biospectrumindia.com/news/91/22080/healthium-medtech-launches-new-wound-dressing-portfolio-.html https://biospectrumindia.com/news/91/22080/healthium-medtech-launches-new-wound-dressing-portfolio-.html Mon, 10 Oct 2022 08:05:00 +0530 Bengaluru-based Healthium Medtech has launched a new wound dressing portfolio Theruptor Novo for the management of chronic wounds like diabetic foot ulcers and leg ulcers. With the launch of Theruptor Novo, Healthium strengthens its existing portfolio of patented products in the advanced wound dressing segment. The lifetime risk of a person with diabetes having a foot ulcer has been reported to be as high as 25%. India witnesses almost 1 lakh registered amputations today due to complications of unmanaged diabetic foot ulcers. The treatment of foot ulcers is painful and costly.  Theruptor Novo is an anti-microbial and non-toxic wound dressing with technology patented in US, India, EU and Canada. This product works on a physical kill mechanism of attract, bind and rupture formula – a patented technology that minimizes the development of resistant microbes and aids in the healing process. The entire dressing has positively charged cationic sites, which attracts the negatively charged microbes and ruptures their cell walls effectively, thus achieving anti-microbial protection. The anti-microbial technology is non-interfering and it doesn’t enter into the wound bed, making it persistent and effective for up to 7 days. Dr Ashok Moharana, Chief Medical Officer, Healthium Medtech says, “The unique 3-D Hydrocellular substrate enables wicking action facilitating adequate exudate and moisture management and provides an optimal wound healing environment.”   ]]> https://biospectrumindia.com/news/91/22043/us-hearts-to-be-treated-by-made-in-india-sirolimus-coated-balloon.html https://biospectrumindia.com/news/91/22043/us-hearts-to-be-treated-by-made-in-india-sirolimus-coated-balloon.html Thu, 29 Sep 2022 12:00:00 +0530 Concept Medical has announced receiving US Food and Drug Administration (FDA)’s Investigational Device Exemption (IDE) approval for the world’s first & made in India Sirolimus coated balloon- MagicTouch for coronary artery diseases. The Indian company has developed the world’s first Sirolimus-drug Coated Balloon (SCB) and now has IDE approval for the device. US FDA’s IDE approval allows the investigational device to be used in a clinical study to prove the safety and effectiveness of the device. These clinical studies are conducted to support a pre-marketing authorization (PMA) by the USFDA. As of today, no company has IDE approval for a Drug-Coated Balloon in the USA.  US currently follows conventional percutaneous coronary intervention (PCI), which uses stents, and since the newer generation of interventionalists and modern-day PCI are leaning towards Drug-Coated Balloons, considering neither the operator nor the patient would prefer having a permanent metal implant, this moment will be a gamechanger for the fraternity as well as for the company. Surat-based Concept Medical raised funds for the IDE in 2018, and the SCB has so far received two breakthrough device designations and the IDE title to add to it. The IDE approval has been granted for In-Stent Restenosis (ISR), which will help the company to study the device in this indication in the US population. Concept Medical’s MagicTouch SCB is currently the most clinically studied SCB, with more than 7000 patients. Concept Medical has also designed two clinical studies which will soon start enrolling patients in the USA, apart from the already submitted strong pre-clinical and clinical evidence from multiple studies to the FDA.     ]]> https://biospectrumindia.com/news/91/21980/elekta-and-karkinos-healthcare-expand-access-to-modern-cancer-care-treatment.html https://biospectrumindia.com/news/91/21980/elekta-and-karkinos-healthcare-expand-access-to-modern-cancer-care-treatment.html Tue, 20 Sep 2022 02:00:00 +0530 Swedish firm Elekta has announced that Karkinos Healthcare, a Mumbai-based startup, will acquire more than ten linear accelerator (linac) systems to be strategically deployed across the country. The companies share the ambition to improve patient accessibility to advanced precision cancer therapy. The deal will include several Elekta Versa HD linacs, which is designed to treat a spectrum of tumours throughout the body supporting both conventional and highly sophisticated techniques, as well as a number of Elekta Harmony Pro systems, the company’s most productive linac yet, designed to provide the best in-room experience for both patients and healthcare professionals. Although an estimated 2.7 million people in India are living with cancer, with a 12 percent increase by 2025, companies such as Karkinos Healthcare and Elekta are providing hope. Last year, Elekta announced its ACCESS 2025 strategy to make radiotherapy accessible to 300 million more people in underserved markets by 2025. R. Venkataramanan, Founder & Chief Executive Officer, Karkinos Healthcare said, “Cancer services in India have always seen a geographic skew towards big cities and southern India. We hope to play a small catalytic part in bringing greater equity in radiotherapy through our collaboration with Elekta, combining our strengths in technology and clinical expertise. With barely ten percent of the desired radiotherapy capacity as per the recommendations of the World Health Organization in India, radiotherapy access has been a key area of focus for Karkinos.” ]]> https://biospectrumindia.com/news/91/21975/siemens-healthineers-expands-offerings-in-india-with-multidisciplinary-angiography-system.html https://biospectrumindia.com/news/91/21975/siemens-healthineers-expands-offerings-in-india-with-multidisciplinary-angiography-system.html Mon, 19 Sep 2022 17:00:00 +0530 German firm Siemens Healthineers is expanding its offerings in India, with a multidisciplinary angiography system ARTIS icono. The new ARTIS icono system adapts flexibly to the differing needs of cardiovascular interventions, interventional radiology, neuroradiology, and vascular interventions. In addition to the multidisciplinary approach, connectivity and digitalization of interventional labs are becoming increasingly important. The ARTIS icono provides a uniform interface to enable system parameters to be shared easily with devices from other manufacturers with its Third-Party Broker solution. It comes with OPTIQ imaging which enables constant image quality regardless of procedure, patient size, or C-arm angulation.  It uses a contrast-driven technique based on automatic parametrization and intelligent, self-adjusting algorithms ensuring the ALARA dose principle The angiography system is enabled with significantly superior 2D and 3D imaging, improving image quality, and reducing the radiation required. With an enhanced movement of the C-arm with Sine Spin, the cranial base and skull cap can now be depicted with practically no artifacts in a 3D visualization.  As per an independent study on Burden of Strokes in India, stroke burden in India is quite high. One of the major reasons for this is restricted physical activity, higher intake of processed food and increase workplace stress leading to development of type-2 diabetes, hypertension, obesity, and hyper-lipedema. Timely and accurate diagnosis of neurological disorders will help provide the best treatment to patients. ARTIS icono Biplane will help stroke centers deal with dual challenge of treating more patients, faster with greater accuracy.   ]]> https://biospectrumindia.com/news/91/21960/genworks-health-develops-new-technology-to-improve-newborn-care.html https://biospectrumindia.com/news/91/21960/genworks-health-develops-new-technology-to-improve-newborn-care.html Thu, 15 Sep 2022 04:00:00 +0530 Bengaluru-based startup GenWorks has launched Billicare, a non-invasive (there are no needles or pins to draw blood) technology that measures bilirubin levels by placing a clip on the baby's ears. Newborn jaundice is a medical condition that can lead to brain damage if not identified and treated immediately. The condition is so common in India that doctors declare a ‘yellow alert’ (as the skin of babies with jaundice turns yellow) as soon as a baby is born to ensure regular monitoring for the first two weeks. Babies suspected of jaundice are measured using Billicare and then placed under a blue light for a specific period of time as a part of the treatment. The procedure is known as phototherapy. The best thing about Billicare is that it gives the most accurate results after a phototherapy session on whether there is any change in the texture of a baby’s skin. The accuracy of Billicare is much higher than any other competitive brand. A study published in the Journal of Maternal-Fetal and Neonatal Medicine to find out the accuracy of Billicare showed “good performance with positive bias for the screening of jaundice in healthy late preterm or term infants.”       ]]> https://biospectrumindia.com/news/91/21930/terumo-india-unveils-sterile-pen-needle-for-insulin-injections.html https://biospectrumindia.com/news/91/21930/terumo-india-unveils-sterile-pen-needle-for-insulin-injections.html Fri, 09 Sep 2022 05:00:00 +0530 Terumo India, the Indian arm of Japan-based Terumo Corporation, has announced the launch of FineGlide, a sterile pen needle for patients requiring regular insulin injections or other self-medication.   Designed to be compatible with the most commonly available pen devices in India, Fineglide raises the bar for patient comfort and thereby, drug compliance.   FineGlide is the first product from the Life Care Solutions division of Terumo Medical Care Solutions to be launched in India. Designed as a 3-bevel super sharp needle with a high-grade silicone surface, Fineglide is gentle and more comfortable for patients. It’s built with Thin Wall Technology to ensure a greater flow rate and provides better penetration requiring lesser injection force when compared with other alternatives in the market.   Compatible with the most commonly available pen devices in India, Fineglide is available in multiple sizes ranging from 4 mm to 12.7 mm in length and 29-32 gauge thickness to suit varied applications.     ]]> https://biospectrumindia.com/news/91/21923/allurion-technologies-unveils-medical-device-for-weight-loss-management-in-india.html https://biospectrumindia.com/news/91/21923/allurion-technologies-unveils-medical-device-for-weight-loss-management-in-india.html Thu, 08 Sep 2022 10:10:00 +0530 US-based Allurion Technologies has launched its weight management solution Allurion swallowable capsule to treat obesity in India. The device has been recently approved by the Central Drugs Standard Control Organisation (CDSCO). The swallowable capsule is paired with the Allurion Virtual Care Suite, a remote patient monitoring solution powered by the IRIS AI platform that includes a mobile app, connected scale and health tracker.The capsule contains a deflated gastric balloon that can be inflated with 550 ml of liquid by a healthcare professional. The inflated balloon remains in the stomach for around four weeks, reduces the feeling of hunger and automatically deflates and passes out of the body naturally. The procedure sans surgery, endoscopy and anaesthesia. Though present in around 58 countries and has treated more than 100000 patients worldwide, the device took time to reach India due to stringent regulatory mechanisms. Says Dr Shantanu Gaur, Founder and CEO, Allurion, “The entire treatment costs Rs 3 lakhs in India. We plan to tie up with doctors and healthcare players. There are also plans to set up a metabolic research institute in India.” Regarding the regulatory issues, he mentioned that it was a long process. Dr Ram Chuttani, Chief Medical Officer and Founding Partner, Allurion, opines, “Studies have confirmed the proven efficacy and safety of the Allurion programme, helping patients lose an average 10-15 per cent of their body weight in approximately 16 weeks.”Dr Mohit Bhandari of Mohak Bariatrics mentions, “I think the weight management needs to be normalised rather than stigmatised and the Allurion programme is a positive step.”   Sanjiv Das sanjiv.das@mmactiv.com   ]]> https://biospectrumindia.com/news/91/21892/carestream-health-india-unveils-drx-compass-.html https://biospectrumindia.com/news/91/21892/carestream-health-india-unveils-drx-compass-.html Tue, 30 Aug 2022 21:35:00 +0530 Carestream Health India recently unveiled the newly launched DRX Compass DR system at Delhi Medical Association Conference. The Carestream DRX Compass offers diagnostic quality with the least amount of patient dosage and ease of operation for technicians, improving the diagnostic capabilities and productivity of the diagnostic facility. With the DRX Compass DR system, customers can configure their system based on their needs and budget, with a focus on improved workflow and easy upgrades for the future.   Commenting about the DRX Compass launch Mr. Niraj Srivastava, General Manager- Sales North Carestream India said, “Carestream has invested significant expertise, time and resources in building this digital radiology solution and am sure customers in North India can ‘Navigate & Accelerate’ their radiology practice with this ‘Personalized, Powerful & Partner technology’.”   ]]> https://biospectrumindia.com/news/91/21864/medtronic-unveils-sensight-directional-lead-system-for-dbs-therapy-in-india.html https://biospectrumindia.com/news/91/21864/medtronic-unveils-sensight-directional-lead-system-for-dbs-therapy-in-india.html Fri, 26 Aug 2022 11:25:00 +0530 Medtronic has launched SenSight directional lead system for Deep Brain Stimulation (DBS) therapy in India, as treatment of symptoms associated with movement disorders and epilepsy. DBS is a treatment for symptoms of Parkinson's disease, including tremors, stiffness, and trouble walking.    With collaboration and insights from clinicians, Medtronic engineers have designed every component of the SenSight system to meet customer and patient needs while working seamlessly with Medtronic neurostimulators, including the recently approved Percept PC neurostimulator.   This system will enhance the detection of local field potentials (LFPs) which are 1 million times smaller than DBS stimulation pulses and offers directional stimulation to provide individualized and patient-specific data as well as additional programming features to tailor therapy for patients. ]]> https://biospectrumindia.com/news/91/21857/smartcardia-launches-one-of-its-kind-cardiac-monitoring-patch.html https://biospectrumindia.com/news/91/21857/smartcardia-launches-one-of-its-kind-cardiac-monitoring-patch.html Thu, 25 Aug 2022 00:00:00 +0530 With presence in Switzerland, EU and India, SmartCardia has launched 7L patch, their 7-lead Cardiac Monitoring Patch in India. This state-of-the-art patch monitor combines medical wearable technology with artificial intelligence (AI) to provide predictive and personalized patient insights through remote monitoring. The 7L patch is tracked by SmartCardia’s AI platform which is developed from millions of ECG segments interpreted by cardiologists and certified cardiac technicians and performs real-time detection of important arrhythmia events at cardiologist level accuracy. The platform also presents a real-time dashboard for clinicians to view full-disclosure ECG at any instance and detect early deterioration of patient conditions. The patch measures parameters including seven lead Electrocardiogram (ECG), heart rate, pulse rate, respiration rate, oxygen saturation (SpO2), skin temperature, activity and posture from a single miniaturized unit at clinical accuracy. The 7L patch and cloud platform present a single unified solution to replace holter recorders, event monitors, mobile cardiac telemetry systems and ward monitors. It is easy-to-wear, water resistant and can be used for up to 14 days without requiring a battery recharge. ]]> https://biospectrumindia.com/news/91/21845/fujifilm-india-to-install-latest-medical-devices-at-hospitals-owned-by-paras-healthcare.html https://biospectrumindia.com/news/91/21845/fujifilm-india-to-install-latest-medical-devices-at-hospitals-owned-by-paras-healthcare.html Tue, 23 Aug 2022 15:25:00 +0530     Paras Healthcare has signed a partnership agreement with Fujifilm India. As part of the partnership, Fujifilm India will provide innovative medical and screening devices by installing its cutting-edge machines at the Hospitals of Paras Healthcare.   Under the agreement, Fujifilm will supply a wide range of high-end and sophisticated medical devices including AI-based machines to the network of hospitals run by Paras Healthcare. The healthcare departments at different Paras Hospitals which are particularly likely to benefit from this collaboration are Healthcare IT, Radiology devices like X-ray Imaging Devices, Ultrasound Systems, MRI & CT, Endoscopy, specialised In-vitro diagnostics, among others. Fujifilm India will be installing its Artificial Intelligence modules of medical imaging, 128 slice cardiac CT, 1.5 T MRI, 32 Slice CT, Full-Field Digital Mammography (FFDM), Smart X, Arietta 65, EUS EBUS system, Video endoscope, Mobile DR, etc at the hospitals of Paras Healthcare, and with these new and innovative medical devices, Fujifilm India is supporting the vision of making India a healthier country.  ]]> https://biospectrumindia.com/news/91/21822/hbot-india-unveils-medical-grade-hyperbaric-oxygen-therapy-in-gurugram.html https://biospectrumindia.com/news/91/21822/hbot-india-unveils-medical-grade-hyperbaric-oxygen-therapy-in-gurugram.html Fri, 19 Aug 2022 13:35:00 +0530 HBOT-India has launched one of the first medical-grade hyperbaric oxygen therapy in Gurugram, Delhi NCR. Adding hyperbaric oxygen therapy to the standard of care reduces the risk of major amputation by approx 20-30 per cent and increases wound healing rate by 9-10 times. Further benefits of hyperbaric oxygen are not just limited to diabetic foot ulcer treatment but stretch wider into many diseases and conditions.Dr Mandeep Singh Malhotra, Surgical Oncologist (Clinical Lead & Mentor – Art of Healing Cancer- AOHC) suggests as per research that in a single hour of HBOT treatment, the body takes in approximately about 2.4 pounds of oxygen into the tissue and this increased oxygen benefits by   Increase oxygen delivery to tissues with compromised blood flow such as diabetic foot ulcers, stroke, trauma, flaps, necrotic tissue in cancer, etc. Decreases swelling and inflammation by deactivation of toxins; Increases the ability of the body’s immune cells to fight off infections. Stimulates new blood vessels and capillary growth that aid in wound healing and also removal of toxins and waste products. Increases the active firing of nerve cells thus helping in neural recovery.Hyperbaric Oxygen Therapy has documented benefits in many diseases like:     Diabetic foot ulcers Wound healing Severe anaemia Delayed radiation injury or radiation necrosis Traumatic Brain Injury Gangrene Compromised Grafts & Flaps  Vision loss or sudden hearing loss Brain Abscess There are certain other conditions in which HBOT is likely to benefit:  Brain stroke Brain-related disorders like Alzheimer, Paralysis, Parkinson’s, Brain Fog, etc Refractory cancers which do not respond to chemotherapy.  ]]> https://biospectrumindia.com/news/91/21813/aster-medcity-medtronic-build-deep-brain-stimulation-programme-for-parkinsons-patients.html https://biospectrumindia.com/news/91/21813/aster-medcity-medtronic-build-deep-brain-stimulation-programme-for-parkinsons-patients.html Wed, 17 Aug 2022 20:15:00 +0530 Aster Medcity and India Medtronic have partnered to build a comprehensive and advanced Deep Brain Stimulation (DBS) programme for Parkinson’s patients in India. The partnership supports the Aster Centre for Parkinson’s and Movement Disorder by bringing together Aster's teams with their medical and surgical expertise in DBS therapy and Medtronic’s complete suite of DBS technologies along with technical expertise and support. It marks introduction of the latest version of Microelectrode recording system for DBS surgeries – NeuroNav MER system (Alpha Omega) from Medtronic at Aster Medcity Kochi, making it the first centre in South Asia to bring in this technology. The partnership aims to increase the outreach of the programme to all the Parkinson’s and movement disorder patients who need the treatment, especially those with relatively early onset (under 45 years) or young- onset of Parkinson’s disease so that they get back their mobility and functional capacity in the most productive years of their lives.50 patients with Parkinson’s have benefitted from the partnership programme in the last 15 months, making Aster Medcity the most active DBS Centre in Kerala. ]]> https://biospectrumindia.com/news/91/21796/hyderabad-holds-first-ever-national-conference-on-robotic-gynaecological-surgery.html https://biospectrumindia.com/news/91/21796/hyderabad-holds-first-ever-national-conference-on-robotic-gynaecological-surgery.html Sun, 14 Aug 2022 21:45:00 +0530 Telengana governor, Dr Tamilisai Soundararajan, inaugurated the first-ever national conference on robotic gynaecological surgery in India, RoboGynlndia2022, in Hyderabad.   This conference was jointly conducted by the Association of Gynecological Robotic Surgeons (AGRS), the national organisation of surgeons practising the art of robotic gynaecological surgeries, along with Intuitive Surgical, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS).    The two-day-long conference was aimed at familiarising surgeons and residents with the clinical application of the latest techniques in treating gynaecological disorders. The conference provided a unique opportunity for surgeons to interact with eminent international and Indian faculty to get insights into making this technology clinically relevant to their practice.     Apart from master class sessions on robotic myomectomy, robotic hysterectomy for malignancy, complex hysterectomy, endometriosis excision and neuropelveology, there were keynotes and panel discussions on topics relevant to robotic-assisted surgery, its applications, future, and about the need to include RAS in insurance policies.    More than 100 surgeons and residents from across India were a part of this two-day-long conference. The organising committee is planning to conduct this conference in the coming years as well. Apart from that, AGRS will conduct live robotic-assisted surgery sessions in various parts of the country in the coming months.    ]]> https://biospectrumindia.com/news/91/21779/medtronic-launches-ai-powered-gi-genius-module-for-colonoscopy-in-india.html https://biospectrumindia.com/news/91/21779/medtronic-launches-ai-powered-gi-genius-module-for-colonoscopy-in-india.html Tue, 09 Aug 2022 15:15:00 +0530 India Medtronic has launched innovative computer-aided polyps detection system powered by artificial intelligence (AI) — the GI Genius intelligent endoscopy module. A transformative solution that leans on deep learning algorithms and real-time data, the module empowers physicians to detect and treat colorectal cancer by offering enhanced visualisation during colonoscopy. AIG hospital, Hyderabad becomes the first hospital in India to utilise the enhanced screening feature with GI Genius.The GI Genius module uses advanced AI software to highlight suspicious polyps of various sizes, shapes, and morphologies with a visual marker in real-time. It serves as the gastroenterologists’ ever-vigilant second observer, with a sensitivity rate per lesion of 99.7 per cent and less than 1 per cent of false positives. ]]> https://biospectrumindia.com/news/91/21765/fujifilm-india-focuses-on-early-detection-of-breast-cancer-in-meerut.html https://biospectrumindia.com/news/91/21765/fujifilm-india-focuses-on-early-detection-of-breast-cancer-in-meerut.html Fri, 05 Aug 2022 19:05:00 +0530 Fujifilm India with Dr OP Gupta Imaging Center, Meerut, recently organised a programme to raise awareness about the early detection of breast cancer. As part of the partnership with the centre, Fujifilm India has installed its cutting-edge Amulet Innovality, a highly advanced breast cancer diagnostic tool which enables women to experience early detection of breast cancer. The company held a seminar addressing the main problems and potential solutions in digital mammography breast imaging while also highlighting the clinical relevance of technology. In India, breast cancer cases are on the rise. The country has the sixth highest breast cancer rates in Asia and the tenth highest in the world compared to other population registries. One in 22 women get breast cancer at some point in their lifetime. Despite the innovations in treatment, the risks associated with breast cancer continue to rise. The biggest reason for this is lack of awareness amongst patients, and only reaching the doctor during their last stage of the disease. Understanding this problem, Fujifilm strives to educate people and take the early detection technology across India to save lives. ]]> https://biospectrumindia.com/news/91/21758/new-state-of-the-art-radiation-oncology-facility-opens-at-narayana-health-city-bengaluru.html https://biospectrumindia.com/news/91/21758/new-state-of-the-art-radiation-oncology-facility-opens-at-narayana-health-city-bengaluru.html Thu, 04 Aug 2022 18:25:00 +0530 The radiation oncology department of Narayana Health City has introduced Elekta Synergy with Agility - multileaf collimator head along with the Monaco planning system (version-5.51.10).   The upgraded facility will help doctors to provide not only the traditional treatments (3DCRT, IMRT and VMAT) but also stereotactic treatments (SRS, SRT, SBRT) with more precision, reduced treatment time on the couch and faster and better treatment planning.    The stereotactic treatment will have the ability to treat tumours as small as 5mm and also some non-malignant functional disorders (like trigeminal neuralgias) with more precision. The facility was inaugurated by Dr Devi Prasad Shetty, Founder and Chairman of Narayana Health.   The Brachytherapy system which is used to treat the breast cancer has also been upgraded to Varian’s Brachy-vision with Eclipse planning software and new applicators. Other improvements include greater dose delivery accuracy and better contouring software solutions helping the team to offer better outcomes.     ]]> https://biospectrumindia.com/news/91/21732/allergan-aesthetics-strengthens-presence-in-medical-aesthetics-market-in-india.html https://biospectrumindia.com/news/91/21732/allergan-aesthetics-strengthens-presence-in-medical-aesthetics-market-in-india.html Mon, 01 Aug 2022 00:00:00 +0530 Allergan Healthcare India, Bangalore has launched Juvéderm VOLUX in India under its business unit of Allergan Aesthetics. Allergan Aesthetics has obtained all the necessary approvals from the Central Drugs Standards Control Organization (CDSCO) office before launching this product in India.   Juvéderm VOLUX is a combination of Hyaluronic acid 25 mg + Lidocaine hydrochloride 3 mg and is an injectable implant intended to restore and create a volume of the face.   "The launch of Juvéderm VOLUX in India further strengthens our commitment to provide state-of-the-art options in the medical aesthetics market in India,” said Rahul Choudhary, GM, Allergan Aesthetics in India. “There is an increasing need for medical aesthetics globally and in India due to patients’ desire to empower their confidence. Allergan Aesthetics is strongly committed to the patients who are treated with our products. As part of our continuing medical education via the programmes offered by Allergan Medical Institute (AMI), healthcare professionals can be trained on the use of this new treatment," he added. ]]> https://biospectrumindia.com/news/91/21714/karnataka-hospital-conducts-50-robotic-surgeries-since-june-2022.html https://biospectrumindia.com/news/91/21714/karnataka-hospital-conducts-50-robotic-surgeries-since-june-2022.html Thu, 28 Jul 2022 11:30:00 +0530 Karnataka-based AASRA Group of Hospitals has completed over 50 robotic surgeries since its launch in June 2022 using robotic surgery. MAKO smart robotics and CMR surgical robotic system have been used to perform various surgeries conducted across various specialisations including gynaecological, urological, gastrointestinal, thoracic and many more.Precision-based surgical services lead to reduced morbidity and improved recovery time in all the surgeries done.  ]]> https://biospectrumindia.com/news/91/21711/goitre-patient-treated-using-made-in-india-near-infrared-imaging-tech.html https://biospectrumindia.com/news/91/21711/goitre-patient-treated-using-made-in-india-near-infrared-imaging-tech.html Wed, 27 Jul 2022 18:10:00 +0530 A 59-year-old male patient was treated for large thyroid swelling (goitre) using Made in India technology of Near-Infrared Imaging (NIFI) manufactured by Bengaluru-based Irillic. The patient was operated at CK Birla Hospital.   NIFI uses Infrared technology to identify and preserve the parathyroid glands during thyroid surgery. The use of NIFI offers significant benefits to patients by reducing the post thyroid surgery calcium derangement to <1 per cent. The use of a nerve monitor helps in identifying and preserving the voice nerve. Near-Infrared imaging is an effective technology for identifying the parathyroid gland during surgery.    ]]> https://biospectrumindia.com/news/91/21691/genworks-health-partners-with-medtronic-for-intrauterine-care.html https://biospectrumindia.com/news/91/21691/genworks-health-partners-with-medtronic-for-intrauterine-care.html Mon, 25 Jul 2022 15:20:00 +0530 Bengaluru-based startup GenWorks Health has partnered with Medtronic to redefine how intrauterine abnormalities are treated. The TruClear system by Medtronic offers a complete technology platform for the removal of a range of intrauterine abnormalities. Doctors in the West have now moved on to innovations like Mechanic Hysteroscopic Tissue Removal (MHTR) systems, in which pathology removal, including fibroids or polyps are being treated in the outpatient setting without any need for general anaesthesia or the use of any heat energy, a risky procedure which was previously used. MHTR also enables surgeons to see and treat at the same setting using a single insertion apart from removing as much as 98 percent of the diseased tissues. Ganesh Prasad Founder, MD and CEO GenWorks Health said, "While the last 2 decades have brought great focus on adoption of technology to save lives, tech adoption for women’s wellness is almost non-existent. We serve the maximum women’s health specialists in our country and hence are able to put together solutions from early screening to safe treatment.’’ Prasad further said, "The addition of TruClear is a huge opportunity for safe treatment and almost freedom from archaic practices that affect the wellbeing of our women.’’   ]]> https://biospectrumindia.com/news/91/21685/patient-undergoes-midline-redo-open-heart-surgery-using-oftilatting-saw-by-stryker.html https://biospectrumindia.com/news/91/21685/patient-undergoes-midline-redo-open-heart-surgery-using-oftilatting-saw-by-stryker.html Fri, 22 Jul 2022 20:20:00 +0530 Doctors at Jaslok Hospital & Research Centre, Mumbai successfully performed midline redo open heart surgery on a 48-year-old heart failure patient. The patient was suffering from advanced heart failure and successfully underwent a heart transplant four years after being operated upon for PTCA and Coronary artery bypass surgery at another hospital.   Dr Hemant P Pathare, Additional Director, Department of Heart & Lung Transplant surgery and his team used Oftilatting Saw by Stryker to treat the patient who was suffering repeated episodes of breathlessness, and swelling of the entire body, puffy face, and loss of appetite. ]]> https://biospectrumindia.com/news/91/21682/aimed-urges-govt-to-neutralise-12-15-per-cent-disability-factor-in-manufacturing-med-devices-.html https://biospectrumindia.com/news/91/21682/aimed-urges-govt-to-neutralise-12-15-per-cent-disability-factor-in-manufacturing-med-devices-.html Fri, 22 Jul 2022 11:45:00 +0530 The Commerce Ministry data analysed by the Association of Indian Medical Device Industry (AiMeD) has shown that the imports of medical devices are up by a record 41 per cent at Rs 63,200 crore in 2021-22 from Rs 44,708 crore in 2020-21. Speaking on the rise in imports of medical devices, Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD) said, “NITI Aayog and the Department of Pharmaceuticals recognises that Indian manufacturers have a 12-15 per cent disability factor in manufacturing medical devices in India. We urge the government to neutralise this disability for reduction of medical device imports in India as was in the case of consumer electronics, including mobile phones and even in the toy industry. At present, the duty on Chinese imports ranges mostly from zero to 10 per cent, but the bulk of the items are in the 7.5 per cent category and one item at 25 per cent. Nath urged Department of Science & Technology (DST) & Department of Biotechnology (DBT) to seek correction of the tariff to a nominal 15 per cent because then only entrepreneurs can survive and have a productive relationship with academic institutions for innovations in process and product development or incremental improvements in performance to become competitive."We on behalf of the Indian Medical Devices industry request the Govt. to expedite steps to end the 80 per cent import dependence forced upon us and an ever-increasing import bill of over Rs 63,200 crore, expedite steps for patients’ protection, stronger quality and safety regulations, price controls to make medical devices and quality treatment accessible and affordable and ethical indigenous manufacturing viable The Healthcare Security of India is at very Risk. It’s a very alarming situation as the increase has been five-fold over six years as India imported Rs 12,866-crore worth of medical devices in 2016-17,” said Nath. a ]]> https://biospectrumindia.com/news/91/21673/maxivision-introduces-teneo-317-model-2-excimer-laser-for-vision-correction.html https://biospectrumindia.com/news/91/21673/maxivision-introduces-teneo-317-model-2-excimer-laser-for-vision-correction.html Thu, 21 Jul 2022 15:30:00 +0530 MaxiVision Eye Hospital has introduced Technolas Teneo 317 Model 2 (Teneo M2). The Teneo M2 is an advanced, high-performance excimer laser, designed with expert German engineering design.   It provides customised treatments for a wide range of patients, correcting presbyopia, myopia and hyperopia, and astigmatism. Unique to the TENEO M2, the SUPRACOR treatment is a true varifocal LASIK for presbyopic patients looking for improved quality of vision without glasses for most daily activities.   MaxiVision is the first hospital in Telangana to launch such an advanced device. With integrated technology for precise treatments, the Teneo M2 has features such high-speed eye tracking and an ergonomically designed bed for patient comfort and seamless, fast surgical procedures. ]]> https://biospectrumindia.com/news/91/21668/terumo-india-partners-with-sensible-medical-innovations.html https://biospectrumindia.com/news/91/21668/terumo-india-partners-with-sensible-medical-innovations.html Thu, 21 Jul 2022 10:15:00 +0530 Terumo India, the Indian arm of Japanese firm Terumo Corporation, has signed a partnership with Israel-based Sensible Medical Innovations, a market leader in medical radar monitoring and imaging technology (ReDS), that grants it exclusive distribution rights for ReDS Pro and knowledge-sharing of ReDS technology in India.   ReDS Pro is used to measure the absolute lung fluid volume in patients, which has strong correlation with symptoms of Coronary Heart Failure (CHF). It is a non-invasive method that takes only 45 seconds to measure. Lung fluid assessment with ReDS Pro is proven to be as accurate as that measured by a CT scan.    Periodic monitoring through ReDS Pro and titration of medicines in heart failure patients can potentially reduce hospitalization rates by 30%. ReDS technology has been adapted for medical use from an Israeli military application where it was used to see through walls. ]]> https://biospectrumindia.com/news/91/21631/rgci-installs-made-in-india-surgical-robotic-system-ssi-mantra.html https://biospectrumindia.com/news/91/21631/rgci-installs-made-in-india-surgical-robotic-system-ssi-mantra.html Thu, 14 Jul 2022 18:10:00 +0530 Rajiv Gandhi Cancer Institute and Research Center, New Delhi (RGCI) have installed the first-ever Made-in-India Surgical Robotic System, SSI-Mantra, devised by the new-age Indian med-tech start-up SS Innovations. The ingenious SSI Mantra is the brainchild of robotic cardiac surgeon Dr Sudhir P Srivastava.   The robot is will provide an advanced method of surgery, which will be accessible to the general public at a much lower cost. The cutting-edge SSI Mantra is modular, flexible, and versatile in comparison to leading global surgical systems. ]]> https://biospectrumindia.com/news/91/21626/aakash-healthcare-sets-up-cure-c-3d-lab-at-dwarka-headquarters.html https://biospectrumindia.com/news/91/21626/aakash-healthcare-sets-up-cure-c-3d-lab-at-dwarka-headquarters.html Thu, 14 Jul 2022 13:10:00 +0530 Aakash Healthcare has established a 3D printing facility in its Dwarka headquarters. The lab, known as Cure c 3D, will assist surgeons and clinicians in developing 3D models of complex clinical cases for patient education, surgical treatment planning, and the creation of patient-specific jigs and other medical devices that will enable accurate and safe surgical interventions, such as those in complex spinal deformities.    The lab has a cutting-edge Polyjet printer called the STRATASYS J5 that can create models in several colours and materials. The revolutionary 3D printing technology will produce high-quality models for patient education, resident lectures, and in vitro/outside OT practice of complex surgeries. ]]> https://biospectrumindia.com/news/91/21599/dr-lh-hiranandani-hospital-installs-384-slice-cardiac-ct-scan-machine.html https://biospectrumindia.com/news/91/21599/dr-lh-hiranandani-hospital-installs-384-slice-cardiac-ct-scan-machine.html Mon, 11 Jul 2022 12:10:00 +0530 Mumbai-based Dr LH Hiranandani Hospital has recently installed the most sophisticated 384 Slice Cardiac CT scan machine. The advanced, AI-based CT scanner makes CT procedure and its diagnosis three times better in accuracy (as compared to the older 128 slices for cardiac) leading to more clarity for cardiologists/cardiac surgeons on the further line of treatment to the patients.     The new ‘384 Slice Cardiac CT scanner’ stand out in advanced CT procedures, with high-quality diagnostic imaging results; improve the patient experience with a wide bore of CT scan machine, which reduces fear of any claustrophobia; enhances efficiency with AI-based patient positioning and remote scanning assistance for technologists; increase standardisation with GO technologies powered by artificial intelligence; Enhancing patient safety by ultra-low radiation dose and low breath and less contrast for patients; fully automatic cardiac assessment thereby enhancing diagnostic confidence. ]]> https://biospectrumindia.com/news/91/21598/first-triple-valve-replacement-surgery-in-india-using-minimally-invasive-technique.html https://biospectrumindia.com/news/91/21598/first-triple-valve-replacement-surgery-in-india-using-minimally-invasive-technique.html Mon, 11 Jul 2022 00:00:00 +0530 In the first of its case in India, doctors at HCG Hospitals successfully conducted the complex triple valve replacement surgery using a minimally invasive technique.  The specialists replaced three valves of the heart with mechanical valves of a woman patient aged 61-year suffering from severe narrowing of the mitral, aortic valve, and tricuspid valve disease of the heart. Mechanical heart valves by the global firm Abbott were used in the surgery. The Masters Series Mechanical Heart Valves are rotatable, bileaflet valves designed for implantation in the aortic or mitral position. Abbott minimizes valve bulk with the sleek pivot guard design paired with sewing cuff options that maximize implantability without extraneous material. "The healthcare industry is constantly evolving, and HCG is transforming to adapt and implement the latest equipment and inventive surgical procedures to suit the required needs", said Birsingh Chaudhari, Chief Operating Officer, HCG Hospitals Ahmedabad.  ]]> https://biospectrumindia.com/news/91/21581/tavr-procedure-conducted-to-treat-74-yr-old-for-dextrocardia.html https://biospectrumindia.com/news/91/21581/tavr-procedure-conducted-to-treat-74-yr-old-for-dextrocardia.html Wed, 06 Jul 2022 18:45:00 +0530 Fortis Escorts Heart Institute, Okhla, New Delhi has successfully performed a TAVR (Transcatheter Aortic Valve Replacement) procedure on a 74-year-old man with a rare condition of Dextrocardia (heart on the right side). At Fortis Escorts Heart Institute, Okhla the cardiology team led by Dr Atul Mathur, Executive Director, Interventional Cardiology successfully carried out the complex procedure of TAVR wherein his abnormal heart valve was replaced using a cardiac catheter through skin puncture, thus avoiding a risky open surgery. This is the first reported case of TAVR in the right-sided heart in India and only the fourth worldwide. ]]> https://biospectrumindia.com/news/91/21572/apollo-hospitals-navi-mumbai-conducts-tmvr-using-transcatheter-technique.html https://biospectrumindia.com/news/91/21572/apollo-hospitals-navi-mumbai-conducts-tmvr-using-transcatheter-technique.html Tue, 05 Jul 2022 18:15:00 +0530 Apollo Hospitals Navi Mumbai successfully performed a minimally invasive procedure using a transcatheter technique. A 64-year-old woman successfully underwent a trans-catheter mitral valve replacement (TMVR). The procedure using a balloon-expandable valve was performed over two hours by the doctors of Apollo Hospitals Navi Mumbai.    A TMVR is a mitral valve replacement procedure that allows a cardiologist to replace a diseased previously surgically implanted mitral valve with a new valve without surgery. During this procedure, the cardiologist inserts a catheter (a thin flexible tube) into the vein using advanced imaging and guides it along with a new valve to the heart. It has benefits such as lesser pain and a shorter recovery period.  ]]> https://biospectrumindia.com/news/91/21567/ethiopian-patient-with-kyphoscoliosis-treated-at-sims-hospital-chennai.html https://biospectrumindia.com/news/91/21567/ethiopian-patient-with-kyphoscoliosis-treated-at-sims-hospital-chennai.html Tue, 05 Jul 2022 14:45:00 +0530 An expert group of surgeons from SIMS Hospital, Chennai recently conducted a high-performance surgery to cure a severe case of Kyphoscoliosis on a 15-year-old Ethiopian patient. The surgery was conducted by Dr K Appaji Krishnan, Senior Consultant Spine Surgeon, Asian Orthopaedic Institute, SIMS Hospital. The procedure was facilitated by a pre-operative model of the spine which was prepared by in-house 3D printing technology.    It was decided to treat with a halo gravity traction by hanging 13-14kg of weight to the patient's head for a continual four weeks time period to stretch the Anaconda Spine and straighten the deformity.        ]]> https://biospectrumindia.com/news/91/21556/medica-group-of-hospitals-conducts-gynae-robotic-surgery-with-da-vinci-surgical-system.html https://biospectrumindia.com/news/91/21556/medica-group-of-hospitals-conducts-gynae-robotic-surgery-with-da-vinci-surgical-system.html Mon, 04 Jul 2022 17:10:00 +0530 Medica Group of Hospitals cured a 53-year-old lady who was diagnosed with a large uterine fibroid, which was growing outside her uterus using da Vinci surgical system. Despite the huge fibroid, the patient successfully underwent gynae robotic surgery with hysterectomy and BSO (A bilateral salpingo-oophorectomy is a surgery to remove both of your ovaries and fallopian tubes) through small holes without any blood transfusion. The team put in their combined efforts under the leadership of Dr Arunava Roy, Senior Consultant & Head- Gynecologic Oncology & Women Cancer Initiative, Medica Superspecialty Hospital. ]]> https://biospectrumindia.com/news/91/21549/fourth-generation-pinless-computer-navigation-system-to-aid-in-joint-replacement.html https://biospectrumindia.com/news/91/21549/fourth-generation-pinless-computer-navigation-system-to-aid-in-joint-replacement.html Fri, 01 Jul 2022 22:35:00 +0530 Fortis Bone & Joint Institute, Shalimar Bagh today launched a dedicated state-of-the-art joint replacement care centre. The centre is backed by advanced technological equipment and will cater to personalised care and rehabilitation of patients. The institute will be backed by an advanced fourth-generation pinless computer navigation system, which will help in knee surgery using the latest cutting-edge technology to make the implants placed last longer, reduce complications and aid in faster recovery. The newly launched Institute will also cater to fast-track knee replacement surgeries, including painless and stitch-less procedures. ]]> https://biospectrumindia.com/news/91/21522/indraprastha-apollo-hospitals-conducts-bariatric-surgery-using-intuitive-da-vinci-tool.html https://biospectrumindia.com/news/91/21522/indraprastha-apollo-hospitals-conducts-bariatric-surgery-using-intuitive-da-vinci-tool.html Wed, 29 Jun 2022 21:00:00 +0530 A US lady recently underwent robotic bariatric surgery at Indraprastha Apollo Hospitals, New Delhi for being abnormally overweight and diabetic. Intuitive da Vinci tool was used to conduct the surgery. Dr Arun Prasad, Senior Consultant, GI, Bariatric and Robotic Surgery, Indraprastha Apollo Hospitals, said, "It is a type of robotic surgery in which specialised robotic staplers for a seamless surgery are used. This procedure could be less painful with fewer cuts and wounds and promises better recovery in comparison to other traditional modalities." ]]> https://biospectrumindia.com/news/91/21521/pd-hinduja-hospital-mrc-introduces-fdg-labelled-leukocyte-pet-ct-scan.html https://biospectrumindia.com/news/91/21521/pd-hinduja-hospital-mrc-introduces-fdg-labelled-leukocyte-pet-ct-scan.html Wed, 29 Jun 2022 20:50:00 +0530 PD Hinduja Hospital & MRC has introduced ‘FDG-labelled Leukocyte PET-CT scan for early detection of infection in occult and difficult cases. The 'FDG Labelled Leukocyte PET-CT scan’ imaging procedure has higher specificity whilst maintaining high sensitivity and resolution, has functional + anatomical information, and can easily be a whole-body survey wherever required, so higher yield to diagnose/detect more accurately, and can even be performed in patients where the conventional imaging modalities are not possible, making this scan a powerful tool in the clinical setting.    Dr Natasha Singh, Consultant & Head of Nuclear Medicine & PET-CT, PD Hinduja Hospital & MRC shared, “It is a safe procedure even in patients with kidney dysfunction where contrast-enhanced CT and MRI studies are contraindicated.”      ]]> https://biospectrumindia.com/news/91/21505/manipal-doctors-use-cor-knot-tech-to-treat-systemic-lupus-erythematosus-.html https://biospectrumindia.com/news/91/21505/manipal-doctors-use-cor-knot-tech-to-treat-systemic-lupus-erythematosus-.html Tue, 28 Jun 2022 10:15:00 +0530 Doctors at Manipal Hospitals, Delhi, successfully treated a 27-year-old female patient from Iraq with advanced robotic mitral valve repair. The patient was suffering from Systemic Lupus Erythematosus (SLE) and cardiac problems.   The doctors chose to proceed with a robotic MVR as robotic surgeries have proven to be one of the most effective methods and are beneficial for the patient. The doctors also used a Cor-Knot technology, which allows them to tie the knot in as little as two to three minutes, avoiding any unnecessary delays. As robotic surgeries are minimally invasive procedures, the pain is very minimal because such a procedure does not require spreading the ribs or cutting any bones for the surgery. Therefore, a patient can recover within 2-3 weeks from the surgery, and the chances of infection are also minimal. ]]> https://biospectrumindia.com/news/91/21499/instashield-bags-award-for-virus-attenuation-electron-device.html https://biospectrumindia.com/news/91/21499/instashield-bags-award-for-virus-attenuation-electron-device.html Mon, 27 Jun 2022 17:20:00 +0530 Medical device Instashield has received the ‘WCDM-DRR Award.’ The award was given by G Kishan Reddy, Union Minister of Tourism, Culture and Development of the North Eastern Region of India recently in Delhi. Instashield received the award for its significant contribution in the field of research in virus attenuation electron devices for its product that disables all kinds of viruses including SARS-COV2. ]]> https://biospectrumindia.com/news/91/21497/da-vinci-surgical-system-aids-to-conduct-robot-assisted-live-kidney-transplant-.html https://biospectrumindia.com/news/91/21497/da-vinci-surgical-system-aids-to-conduct-robot-assisted-live-kidney-transplant-.html Mon, 27 Jun 2022 16:55:00 +0530 Fortis Hospital, Bannerghatta Road recently conducted a one-of-its-kind live surgery demonstration on a robot-assisted kidney transplant in association with Intuitive, developer of the Da Vinci Surgical system. The three-hour live session on robot-assisted living donor transplant was led by Dr Mohan Keshavamurthy- Chairman - Renal Sciences Specialty Council, Fortis Hospitals, India & Director- Urology, Uro oncology, Andrology, Robotic Surgery & Transplantation, Fortis Hospitals, Bengaluru and Dr Sreeharsha Harinatha- Consultant - Urology, Robotic Surgery & Transplantation, Fortis Hospitals, Bengaluru.  The educative session demonstrated various skills and expertise required for a robot-assisted kidney transplant and explained the evolution of minimally invasive kidney transplantation, with a specific focus on robot-assisted kidney transplant and the benefits it offers to specific patient groups. ]]> https://biospectrumindia.com/news/91/21503/aims-faridabad-adopts-cobas-platform-by-roche-diagnostics.html https://biospectrumindia.com/news/91/21503/aims-faridabad-adopts-cobas-platform-by-roche-diagnostics.html Sun, 26 Jun 2022 22:40:00 +0530 Asian Institute of Medical Science (AIMS) in Delhi NCR has installed Roche Diagnostics’ fully automated latest state-of-the-art technology- cobas pro e801 and cobas pure e402 to enhance healthcare delivery and patient experience. The technologies offer a wider assay menu including thyroid, fertility, cardiac, cancer, infectious, vitamins others.    Using the cobas solutions will enable the institute to further enhance testing in the realms of endocrinology, immunology, and metabolic diseases. These instruments can facilitate the smallest sample volume in the industry on immunology with a shorter Turnaround Time (TAT). Through automation, Roche Diagnostics’ new solutions are designed to simplify workflows and improve the productivity of lab personnel whilst also supporting the delivery of better patient care.   ]]> https://biospectrumindia.com/news/91/21487/shri-anandpur-trust-installs-carestreams-1st-drx-compass.html https://biospectrumindia.com/news/91/21487/shri-anandpur-trust-installs-carestreams-1st-drx-compass.html Fri, 24 Jun 2022 17:25:00 +0530 Shri Anandpur Trust – Charitable Diagnostic Centre, Krishna Nagar in the NCR has added the Carestream DRX Compass to its diagnostics portfolio. Carestream’s DRX-Compass is the latest technology solution that helps NAVIGATE and ACCELERATE towards superb performance with a solution that grows with its customers. DRX Compass is US-FDA, EU cleared and compliant with ALARA principle. It offers customers the flexibility to customise their fully-featured digital radiography room as per the floor space, workflow and budget. ]]> https://biospectrumindia.com/news/91/21479/doctors-perform-vein-of-galen-malformation-embolization-procedure-on-one-yr-old.html https://biospectrumindia.com/news/91/21479/doctors-perform-vein-of-galen-malformation-embolization-procedure-on-one-yr-old.html Thu, 23 Jun 2022 15:15:00 +0530 A bone-year-old baby girl from Yemen was successfully operated on for an extremely rare condition called ‘Vein of Galen Malformation’, a blood vessel abnormality inside the brain. A vein of Galen malformation (VOGM) is a type of rare congenital brain blood vessel abnormality. In VOGM, misshapen arteries in the brain connect directly with veins, instead of connecting with capillaries, which help slow down blood flow. Dr Bhaskar MV, Chief Interventional Neuro-Radiologist, SPARSH Hospital, said, “A team of doctors treated the baby girl with a minimally invasive advanced neuro-interventional procedure called ‘Vein of Galen Malformation Embolization’, an advanced and delicate procedure to stop the fast flow of the blood flowing into the vein of galen. A microcatheter was introduced from the groin through the internal carotid artery (an artery in the neck that supplies blood to the brain) and passed up to the point of malformation. A high concentration glue is then injected into the catheter to the site of malformation under the cath lab fluoroscopy guidance. The glue sticks there and prevents high blood flow into the vein." ]]> https://biospectrumindia.com/news/91/21454/bpl-medical-technologies-partners-with-ayurythm.html https://biospectrumindia.com/news/91/21454/bpl-medical-technologies-partners-with-ayurythm.html Sat, 18 Jun 2022 21:50:00 +0530 BPL Medical is joining hands with AyuRythm, an IAN-backed innovative startup to simplify healthcare while enabling access to the most ancient and time-tested vedic sciences.   The collaboration will enable users to experience wellness on a much deeper level that allows for a more joyful and truly healthy and preventive way of living.   With the integration of AyuRythm app with the BPL pulse oximeter, BP meters and weighing machine, AyuRythm not only blends modern measurement techniques with Ayurvedic assessments (Naadi Pariksha), but also helps BPL customers to get personalised Ayurvedic wellness solutions.   "This partnership is truly ‘Samasya se Samadhaan tak’ providing a holistic approach in bringing access to smart and modern diagnostic healthcare solutions to the fingertips of the users” says Abhilesh, CEO of AyuRythm.     ]]> https://biospectrumindia.com/news/91/21435/c-camp-selco-foundation-to-support-neonatal-health-in-tribal-areas-of-karnataka.html https://biospectrumindia.com/news/91/21435/c-camp-selco-foundation-to-support-neonatal-health-in-tribal-areas-of-karnataka.html Tue, 14 Jun 2022 17:30:00 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has joined hands with SELCO Foundation, a sustainable technology foundation, to launch the pilot deployment of a long-supported portfolio technology in maternal and neonatal health monitoring. The technology’s USP is non-invasive diagnosis and management of neonatal sepsis.   The deployment of this technology developed by C-CAMP startup and former incubatee Spotsense in the tribal majority Sargur, Mysore district, Karnataka is expected to significantly improve these numbers and make quality healthcare accessible to socially and economically vulnerable communities.   Vivekananda Memorial Hospital, the site of the deployment is a 100-bed rural-tribal hospital catering to the primary and secondary healthcare needs of HD Kote and three other Taluks, covering a population of approx. 4 lakhs that comprises mainly Soliga, Jenukuruba, Yarava and Betta Kuruba (Kadu Kuruba) communities.   The platform technology by Spotsense called VIEWDx is a frugal, all-in-one essential diagnostic device that, through universal photometry analysis, is capable of performing multiple platform tests on blood, saliva and other bodily fluids. VIEWDx is suitable even for low-resource satellite diagnostic labs and unskilled manpower as it is intuitive for users and helps in the easy interpretation of results.   SELCO Foundation, with C-CAMP, will support Spotsense for pilot deployments with seven different partners providing healthcare services to vulnerable communities.    ]]> https://biospectrumindia.com/news/91/21413/gufic-biosciences-unveils-dual-chamber-iv-bags-.html https://biospectrumindia.com/news/91/21413/gufic-biosciences-unveils-dual-chamber-iv-bags-.html Fri, 10 Jun 2022 17:30:00 +0530 Pharma player Gufic Biosciences has targeted to capture a major share of Rs 3000-crore lyophilised antibiotics antifungal market in India. The company has launched New Drug Delivery System: Dual Chamber Bags at an affordable price first time in India.   Gufic Biosciences has collaborated with its French counterpart to manufacture this new technology indigenously in India. The dual-chamber bags launched by Gufic Biosciences are 2-Chamber IV Bags made up of polypropylene (DEHP free) with a peelable aluminium foil allowing the storage of unstable drugs which need a reconstitution just before the administration to the patient. The peelable seal separates lyophilised (or powder) drugs and the diluent. Moreover, the product complies with the US and EU pharmacopoeias and it is manufactured in ISO7 clean room under cGMP.  ]]> https://biospectrumindia.com/news/91/21400/robotic-urology-forum-ties-up-with-intuitive-india-to-conduct-rufcon22.html https://biospectrumindia.com/news/91/21400/robotic-urology-forum-ties-up-with-intuitive-india-to-conduct-rufcon22.html Thu, 09 Jun 2022 17:45:00 +0530 Robotic Urology Forum, a national organisation of surgeons practising the art of robotic urological surgeries, has joined hands with Intuitive Surgical, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), to conduct their 4th annual conference. The three-day-long conference named RUFCON’22 was aimed at familiarising surgeons, nurses and other healthcare professionals with the clinical application of the latest techniques in the treatment of urological disorders. The conference, organised at Muljibhai Patel Urological Hospital, Nadiad was attended by experts of Urology from across the country.  The organising committee had formulated comprehensive sessions to ensure an extensive knowledge sharing experience for the attendees. Apart from comprehensive sessions on the evolution of robotic-assisted surgery in India, there were detailed sessions on the application of RAS in uro-oncology, reconstructive urology, kidney transplant, pediatric urology and female urology. Another motive of the conference was to establish the guidelines for the best ways to manage urological cancers in this rapidly evolving treatment landscape to make sure that patients receive ideal care. Dr Arvind Ganpule, Organising Secretary, RUFCON’22 and Chief, Division of laparoscopy and robotic surgery, Muljibhai Patel Urological Hospital said, “This year we had around 150 uro-surgeons share their knowledge with others. We also demonstrated 10 live surgeries from MPUH Nadiad and HCG Hospital Ahmedabad by using Da Vinci RAS system during the conference." ]]> https://biospectrumindia.com/news/91/21385/strykers-global-technology-centre-opens-in-gurugram.html https://biospectrumindia.com/news/91/21385/strykers-global-technology-centre-opens-in-gurugram.html Tue, 07 Jun 2022 16:45:00 +0530 Medical tech company Stryker has opened a new research and development facility, Stryker’s Global Technology Centre (SGTC), at the International Tech Park, Gurugram. The 150,000 sq ft facility will help accelerate innovation in India and globally, and further support the company’s mission to make healthcare better. The centre is designed to connect with healthcare professionals and develop new technologies to meet their needs. Customers can access a range of Stryker’s products and learn more about the engineering behind the company’s life-changing technologies and innovations. Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. ]]> https://biospectrumindia.com/news/91/21356/medtronic-launches-fourth-generation-flow-diverter-to-treat-brain-aneurysms.html https://biospectrumindia.com/news/91/21356/medtronic-launches-fourth-generation-flow-diverter-to-treat-brain-aneurysms.html Wed, 01 Jun 2022 15:50:00 +0530 India Medtronic has launched CE marked fourth-generation flow diverter, Pipeline Vantage with Shield Technology for endovascular treatment of brain aneurysms. Pipeline Vantage with Shield Technology is a new flow diverter with enhanced design features for both the delivery system and implant. These features allow physicians to deliver, deploy and treat brain aneurysms and intracranial aneurysms with greater ease and reliability while providing a scaffold that promotes the growth of cells in the inner lining of the target blood vessel. Medtronic is also introducing a first-of-its-kind warranty programme called the PED Warranty Program. Through the warranty programme, patients treated with Medtronic’s Pipeline Embolization Device (Pipeline Flex Embolization Device with Shield Technology/ Pipeline™ Vantage with Shield Technology) will receive warranty coverage. ]]> https://biospectrumindia.com/news/91/21340/omron-healthcare-india-supports-worlds-largest-free-public-bp-screening-programme.html https://biospectrumindia.com/news/91/21340/omron-healthcare-india-supports-worlds-largest-free-public-bp-screening-programme.html Mon, 30 May 2022 15:45:00 +0530 OMRON Healthcare India has announced support towards the #THEBIGSQUEEZE movement to bolster the ongoing ‘May Measurement Month (MMM)’ global campaign in India.  The movement aims to encourage people of all ages to get their blood pressure (BP) checked in the world’s largest free blood pressure screening campaign. The objective is to heighten awareness about the dangers posed by elevated BP and hypertension and the importance of monitoring blood pressure regularly in India.  The MMM global campaign is led by the ‘International Society of Hypertension’. This annual programme focuses on educating people about the impact of hypertension on their cardiovascular and cerebrovascular health. It also provides insights into diet and lifestyle advice for hypertensives and for facilitating improved follow up for sufferers. Volunteers in more than 85 countries will screen people in cities, towns, and rural villages as part of this largest free public blood pressure screening programme in the world this year, till August 31, 2022.  ]]> https://biospectrumindia.com/news/91/21322/medtronic-davita-announce-kidney-health-tech-company.html https://biospectrumindia.com/news/91/21322/medtronic-davita-announce-kidney-health-tech-company.html Thu, 26 May 2022 19:15:00 +0530 Medtronic and DaVita announced the intent to form a new, independent kidney care-focussed medical device company NewCo to enhance the patient treatment experience and improve overall outcomes.   NewCo will be uniquely positioned to advance the development of differentiated therapies for patients with kidney failure. The company will focus on developing a broad suite of novel kidney care products and solutions, including future home-based products, to make different dialysis treatments more accessible to patients.   Under the terms, NewCo will be co-owned by Medtronic and DaVita, each with equal equity stakes, and led by an independent management team. Medtronic will contribute its Renal Care Solutions (RCS) business including the current product portfolio (renal access, acute therapies, and chronic therapies), product pipeline, and global manufacturing R&D teams and facilities. No other Medtronic products or portfolios, including those in the AV access portfolio in the Peripheral Vascular Health business, are included. Both companies will provide an initial investment to fund NewCo and future certain operating capital.   NewCo, which will be renamed and rebranded at close, will operate as an independent company governed by a six-person board of directors composed of two directors each from Medtronic and DaVita, and two independent directors.   ]]> https://biospectrumindia.com/news/91/21316/govt-invests-rs-4-87-cr-in-high-powered-magnetron-tech-for-cancer-radiation-therapy.html https://biospectrumindia.com/news/91/21316/govt-invests-rs-4-87-cr-in-high-powered-magnetron-tech-for-cancer-radiation-therapy.html Wed, 25 May 2022 00:00:00 +0530 Union Minister of State (Independent Charge) Ministry of Science and Technology; Minister of State (Independent Charge) Ministry of Earth Science; MoS of Prime Minister's Office and Ministry of Personnel, Public Grievances & Pensions, Atomic Energy and Space, Dr Jitendra Singh has said that the government is supporting indigenous development of high-powered Magnetron technology used mainly for cancer radiation therapy.                            Dr Jitendra Singh presided over the signing of a MoU between Technology Development Board (TDB) of DST and Panacea Medical Technologies, Bangalore to provide financial support for development and commercialisation of “S Band Tunable Magnetron for Particle Accelerators". TDB has agreed to provide loan assistance of Rs 4.87 crore, out of the total project cost of Rs 9.73 crores to the company. "High-powered Magnetron developed by CSIR-CEERI (Central Electronics Engineering Research Institute), Pilani for commercial use will be a pathbreaking technology for oncologists to treat even 2 mm diameter brain tumour with precision radiation with very little side-effects", said the Minister. ]]>